The innate immune kinase IKKε as a novel regulator of PSAT1 and serine metabolism by Jones, William Edward
 
 
 
 
 
 
The innate immune kinase IKKε as a novel regulator of 
PSAT1 and serine metabolism 
  
William Edward Jones 
 
A PhD thesis submitted in partial fulfilment of the  
requirements of the Degree of Doctor of Philosophy 
 
 
 
Principal Supervisor: Dr Katiuscia Bianchi 
Secondary Supervisor: Dr Tyson Sharp 
 
Barts Cancer Institute 
Barts and the London School of Medicine and Dentistry 
Queen Mary University of London 
 
May 02, 2018 
i 
 
Statement of Originality 
 
I, William Edward Jones, confirm that the research included within this thesis is my own work 
and that where it has been carried out in collaboration with, or supported by others, that this is 
duly acknowledged below, and my contribution indicated. Previously published material is also 
acknowledged below. 
I attest that I have exercised reasonable care to ensure that the work is original and does not, to 
the best of my knowledge, break any UK law, infringe any third party’s copyright or other 
Intellectual Property Right, or contain any confidential material. 
I accept that the College has the right to use plagiarism detection software to check the 
electronic version of the thesis. 
I confirm that this thesis has not been previously submitted for the award of a degree by this or 
any other university. 
The copyright of this thesis rests with the author and no quotation from it or information derived 
from it may be published without the prior written consent of the author. 
 
Signature:  
 
Date: 2nd May 2018 
 
Details of collaboration and publications: 
• The work presented throughout this thesis is currently under peer review at The EMBO 
Journal in advance of publication.  
 
• Work presented in this thesis was selected for presentation in poster form at Cell Symposia: 
Hallmarks of Cancer 2016 in Ghent, Belgium 
 
 
 
Contents 
ii 
 
• Collaborations: 
 
• Labelled metabolite analysis was performed in collaboration with Dr Ruoyan Xu 
(Barts Cancer Institute, London, UK) who prepared the samples, and Dr Christian 
Frezza and Dr Sofia De Costa (MRC Cancer Unit, Cambridge, UK) who performed 
mass spectrometry analysis and provided the heat-maps of significantly modified 
results presented in Figures 3.5 and 3.6. This author contributed to the subsequent 
analysis of these results. 
 
• Phosphoproteomic analysis was performed in collaboration with Dr Ewa Wilcz-
Villega (Barts Cancer Institute, London, UK) who prepared the samples, and Dr Pedro 
Cutillas and Dr Vinothini Rajeeve (Barts Cancer Institute, London, UK) who 
performed mass spectrometry analysis and the KEGGs pathway analysis of the 
results. This author contributed to the subsequent analysis of these results. 
 
• The in vitro kinase assay was performed in collaboration with Dr Pedro Cutillas and 
Dr Vinothini Rajeeve. This author prepared the samples, and Dr Cutillas and Dr 
Rajeeve performed the mass spectrometry analysis. 
 
• The promoter analysis investigating the presence of transcription factor binding 
sites in the promoter regions of PHGDH, PSAT1 and PSPH genes was performed in 
collaboration with Professor Claude Chelala and Dr Ai Nagano of the bioinformatics 
team at Barts Cancer Institute, London, UK. This author contributed to the analysis 
of these results. 
 
• The investigations into the effect of siRNA-mediated suppression of ATF4 in breast 
cancer cell lines were performed with the support of Miss Sheila Olendo Barasa, a 
masters degree student under this authors supervision in the lab. Miss Barasa 
performed two replica for the experiments presented in Figure 5.8. 
 
• The data describing analysis of oxygen consumption rate was kindly provided by Dr 
Ruoyan Xu. 
 
• Analysis of mitochondrial membrane potential by TMRM staining was performed in 
collaboration with Professor Gyorgy Szabadkai (University College London, London, 
UK) who imaged mitochondrial staining following preparation of cells by Dr Ruoyan 
Xu and this author. 
iii 
 
Acknowledgements 
 
My first and foremost thanks must go to my supervisor, Katiuscia, who made what I can only assume was 
a significant gamble and took on a relatively unproven young student, giving him the opportunity to learn 
and thrive amongst a fantastic group of people. Thank you for your patience with all the failed westerns, 
for helping me to become a capable and confident scientist, for offering me the freedom to drive my own 
project and work in a dynamic and exciting field, but ultimately, for taking a chance on a nervous young 
undergraduate student who wore a tie for his preliminary Skype interview. 
My thanks also go to both Ruoyan and Ewa. The Bianchi lab membership has fluctuated over 3 and a half 
years, as masters and undergraduate students have come and gone, but our core group of 3 has remained. 
Thank you both for your perpetual willingness to help. Your endless endurance against my steady flow of 
questions and requests for assistance has not gone unappreciated and it has been a genuine pleasure 
working alongside you both.  
I would also like to thank both Tyson, my secondary supervisor and our centre lead, for his support and 
guidance and, of course, all the collaborators on this project, who have provided crucial assistance at key 
points in the work presented within. Thank you to Christian Frezza and Sofia De Costa for the labelled 
metabolite analysis, to Pedro Cutillas and Vinothini Rajeeve for the various mass spectrometry work, to 
Claude Chelala and Ai Nagano for the promoter analysis, to Gyorgy Szabadkai for the TMRM staining and 
to Tencho Tenev for unparalleled assistance with cloning. My gratitude must also go to the Medical 
Research Council for their funding, without which I could not have performed this work in the first place. 
To the members of the KiSS group, both past and present, thank you for making the Barts Cancer Institute 
3rd floor sauna a thoroughly enjoyable place to work. I hope you will continue to cope without mum 
around. Particular thanks must go to the members of the McClelland lab, of whom I am absolutely, 
definitely not a member. Nadeem, Naoka, Alice and Tineke, you all saved me from the eternal threat of 
solitary lunches and provided much-needed social distractions whenever it was most required. I hope the 
newest members of your lab Laura and Sarah will enjoy their time with you as much as I did, and I sincerely 
hope that our paths will continue to cross in the future. 
For their consistent love and care I must thank my family, particularly Mum and Dad. Your invaluable 
wisdom on work, life, the universe and everything have seen me through the ups and downs of my first 
quarter century and a seemingly eternal education. I certainly cannot express the full extent of my 
gratitude with so few words. I love you both.  
Lastly, but most importantly, my thanks go to my fiancée Charlotte. This thesis, which I am sure you will 
find long, dull and tedious, exists because of the love you have given me. To put it simply, I would not 
have achieved everything I have without your support and I owe you everything. As the end of this journey 
draws near, I am excited that our true adventure can finally begin.
iv 
 
Abstract 
 
Induced and activated as part of the innate immune response, the first line of defence against 
bacterial or viral infections, Inhibitor of Kappa-B Kinase ε (IKKε) triggers NF-κB and IFNβ 
signalling. Whilst not expressed at basal levels in healthy cells and tissue, the kinase is 
overexpressed in roughly 30% of human breast cancer cases, driving oncogenesis through 
aberrant activation of NF-κB. 
The impracticality of therapeutic targeting of NF-κB for cancer treatment has led to a 
requirement for greater understanding of IKKε’s oncogenic potential to treat tumours driven by 
the kinase. Considering that IKKε alters cellular metabolism in dendritic cells, promoting aerobic 
glycolysis akin to the metabolic phenotype observed in cancer, it was hypothesised that the 
kinase would play a similar role in breast cancer. 
Using a Flp-In 293 model of IKKε induction and suppressing IKKε expression in a panel of breast 
cancer cell lines using siRNA, IKKε-dependent changes in cellular metabolism were characterised 
using labelled metabolite analysis. IKKε was found to induce serine biosynthesis, an important 
pathway in breast cancer development that supports glutamine-fuelling of the TCA cycle and 
contributes to one carbon metabolism to maintain redox balance. Promotion of serine 
biosynthesis occurred via a dual mechanism. Firstly, PSAT1, the second enzyme of the pathway, 
was found to be phosphorylated in an IKKε-dependent manner, promoting protein stabilisation. 
Secondly, an IKKε-dependent transcriptional upregulation of all three serine biosynthesis 
enzymes, PHGDH, PSAT1 and PSPH, was observed, induced by the inhibition of mitochondrial 
activity and the subsequent induction of ATF4-mediated mitochondria-to-nucleus retrograde 
signalling.  
These data demonstrate a previously uncharacterised mechanism of metabolic regulation by 
IKKε and highlight new potential therapeutic targets for the treatment of IKKε-driven breast 
cancer in the form of the enzymes of the serine biosynthesis pathway.
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1.1 Inflammation and immunity 
 
The activation of cellular immunity and the induction of an inflammatory response signify the 
key aspects of an organism’s response to infection or injury of endogenous tissue. The induction 
of inflammation represents the afflicted organism’s initial attempts to clear the insulting 
stimulus and eventually promote the repair of damaged tissue. There are two main types of 
inflammatory response, namely acute and chronic, classified by the duration of the response 
and its ability to be resolved. Acute inflammation is the classical inflammatory response induced 
by an infection or tissue injury and is mediated by host cell recognition of pathogen-associated 
molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) by a special 
receptor type, pattern-recognition receptors (PRRs), found either intracellularly or on the 
membranes of tissue resident immune cells or on cells of the damaged/infected tissue 
themselves1.  
Innate immunity 
Signalling via the PRRs induces the activation of innate immunity, the first line of defence against 
invading pathogens, which acts to recruit immune cells such as macrophages and neutrophils to 
the site of infection or injury via the production of an acute inflammatory response2. The initial 
activation of PRRs induces the production of pro-inflammatory lipid mediators such as 
prostaglandins, which control blood flow and vessel dilation in the vasculature surrounding the 
inflammatory site; cytokines like interleukin 1β (IL-1β) and tumour necrosis factor α (TNFα), 
which activate immune cells like macrophages and neutrophils locally; and chemokines like 
CCL2, which recruit additional myeloid cells to the inflammatory site, aided by the release of 
cytokines that activate endothelial cells to increase vascular permeability and allow easier 
immune cell infiltration. These endothelial factors also trigger vasodilation of the vasculature, 
leading to the characteristic redness of inflamed tissue3,4. Recruited neutrophils are activated by 
interferon γ (IFNγ) that is produced from T-helper cells at the inflammatory site and 
subsequently attempt to kill the invading pathogen through secretion of toxic reactive oxygen 
species (ROS) and reactive nitrogen species4 and by phagocytosis. Cytokines produced by the 
innate immune response also signal to activate the complement system, which leads to an 
enzymatic cascade that promotes the opsonisation of cells, in which antigens belonging to the 
invading pathogen are “tagged” for recognition by phagocytes, enhancing phagocytosis and 
immune clearance5. 
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If the infecting pathogen is successfully killed the acute inflammatory response shifts into the 
next phase, in which inflammation is resolved and tissue repair begins. Due to the indiscriminate 
nature of the cytotoxic compounds that are produced to kill infecting agents, substantial 
collateral damage can occur during an inflammatory response. An off switch is therefore crucial 
to ensure that the host tissue is protected from further damage than is necessary. Pro-
inflammatory signals are replaced by anti-inflammatory ones such as interleukin 10 (IL-10), 
which is produced from regulatory T-cells and inhibits the production of pro-inflammatory 
cytokines3. A group of molecules called lipoxins are also induced. Lipoxins inhibit the recruitment 
of neutrophils to the inflammatory site and reduce vessel permeability. As neutrophil 
recruitment ceases, the resolution phase begins in earnest and clearance of cellular debris and 
infiltrated immune cells is induced. As neutrophils stop arriving at the inflammatory site, those 
already there begin to undergo apoptosis due to their short life span6. Macrophages, which 
mature from lipoxin-recruited monocytes, then phagocytose the apoptotic neutrophils to clear 
them from the site, before being drained from the tissue themselves via the lymphatic vessel 
system, with macrophage levels in the tissue ultimately returning to pre-infection levels6,7. 
Repair signals are also induced to promote the regeneration of damaged tissues.  
In the context of wound healing, an acute inflammatory response primarily promotes the repair 
of damaged tissue. The process remains relatively similar to that which occurs in the response 
to invading pathogens, beginning with the stimulation of DAMPs and the release of chemokines 
from resident immune cells or activated platelets and facilitate the recruitment of neutrophils 
to the wound site, followed by monocytes that mature into macrophages8. In the absence of an 
infecting pathogen, it has been proposed that the cytotoxic agents released by neutrophils may 
be detrimental to rapid wound healing and do more harm than good9, but the neutrophil 
population at an injury site can have some benefit to the reparative process, acting as a source 
of early-stage pro-inflammatory cytokines like TNFα, IL-1α and IL-1β, which can induce 
expression of matrix metalloproteinases (MMPs) and keratinocyte growth factor (KGF) in 
fibroblasts to initiate repair10. The macrophages take the lead in the wound healing 
inflammatory process however, as the driving force behind the clearance of neutrophils from 
the wound site, but also as a source of many different growth factors and cytokines, including 
transforming growth factor β (TGFβ), platelet-derived growth factor (PDGF), insulin-like growth 
factor (IGF) and TNFα, which are essential for inducing the signalling pathways that control tissue 
repair. Macrophages are also the source of factors which stimulate re-epithelialisation of the 
cells at the wound edge and revascularisation post-repair, such as fibroblast growth factor (FGF) 
and vascular endothelial growth factor (VEGF) respectively9,10. 
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Adaptive and trained Immunity 
In the event an infecting agent is not neutralised by the activation of an innate immune response 
and the resultant inflammation, the immune system switches to a more targeted approach with 
the induction of the adaptive immune response. Dendritic cells, recruited to the site of infection 
as part of the innate immune response, are antigen-presenting cells which digest antigens from 
invading microorganisms. Antigen fragments are then displayed via major histocompatibility 
complex (MHC) proteins on the surface of the dendritic cells11. T-cells are activated by dendritic 
cells presenting such antigen fragments, stimulating T-cell differentiation to either cytotoxic T-
cells (CD8+) or T-helper cells (CD4+)12. Cytotoxic T cells act to destroy infected cells and T-helper 
cells activate B-cells, which differentiate into antibody producing cells. B-cell produced 
antibodies target antigens on invading pathogens to target them for immune cell-related 
destruction. Following clearance of the pathogen, memory B-cells remain in circulation, ready 
to rapidly produce the same antibodies upon reinfection of the pathogen11.    
Whilst the accepted understanding of innate immunity versus adaptive immunity has long 
involved the idea that innate responses are non-specific and lack a memory-driven aspect, it is 
worth mentioning that recent work has begun to demonstrate that innate immunity does in fact 
possess an ability to adapt to stimuli and retain a memory. “Trained Immunity” is the term used 
to define the memory of the innate immune response and allows the mounting of a non-specific, 
yet adaptive response to immune challenges. In plants, histone modification at the gene 
promoters of defence genes in response to initial infection has been shown to “prime” genes for 
an amplified response in the event of a recurrent infection13. Evidence of trained immunity in 
mammals has also been observed. Infection of a mouse model with a non-lethal dose of Candida 
albicans has been found to protect mice against infection with a secondary lethal dose up to 
seven days post-initial infection14. It was found that exposure of monocytes to β-glucan, a 
component of the C. albicans cell wall, activated a programme of histone methylation and 
induced changes in cellular metabolism that promoted enhanced cytokine production from 
monocytes upon secondary stimulation of the innate immune response14,15. Whilst this concept 
of “trained immunity” is in its infancy, increasing evidence in multiple models demonstrates that 
the understanding of memory in innate immunity is rapidly evolving and the classical model of 
an un-adaptable response requires some revision. Given the focus of this thesis, discussing this 
subject in detail is beyond the scope of this introduction, but the concept has been extensively 
reviewed by Netea et al16,17.  
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When a stimulus which induces an inflammatory response cannot be cleared, or recurs 
repeatedly over an extended period, chronic inflammation arises due to the inability for acute 
inflammation to be resolved. This essentially results in the inflammatory process continuing 
indefinitely. Chronic inflammation has been linked to many different diseases, including 
rheumatoid arthritis, coeliac disease and colitis, all of which arise due to ongoing or repeated 
cycles of inflammation. Importantly, the continued cycle of tissue damage and repair and the 
dysregulation of growth inducing signalling that arises from chronic inflammation also makes 
the condition a significant risk factor for another major disease: cancer. 
1.1.1 Inflammation in cancer 
 
As far back as 1863, it was recognised that tumour development and inflammation go hand in 
hand. Rudolf Virchow recognised that tissue injury resulted in inflammation of the injury site 
and subsequent proliferation of tissue for repair purposes and inflammatory diseases or 
conditions have repeatedly been recognised to increase the risk of developing various types of 
cancer18. A good example of this is the link between obesity, which is known to cause low-grade 
chronic inflammation, and multiple different cancer types19. In the intervening years better 
understanding of the tumour microenvironment has validated Virchow’s initial observation and 
the link between inflammation and the development of cancers is now widely accepted, with 
inflammation of  the tumour microenvironment fully recognised as a growth supporting feature 
of tumours20. 
In certain cancer types, oncogenes like Myc and Ras have been shown to directly induce 
inflammatory states via the production of cytokines like IL-1β, IL-8 and IL-6 that can support 
cancer progression21-24 and along the same lines, Myc and Ras have been reported to co-operate 
in the tumour microenvironment in a mouse model of lung cancer, promoting the development 
of an inflammatory stroma and supporting tumour progression25. More ubiquitously however, 
it is now accepted that the microenvironment of most, if not all, tumours is heavily infiltrated 
by cells of the immune system26. It has become clear that inflammation facilitates the acquisition 
of properties necessary for tumour progression. Hanahan and Weinberg have described the 
common features of the majority of cancers, describing them as the “hallmarks of cancer”. These 
features are uncontrolled proliferation, resistance to growth suppression, resistance to cellular 
death signals, unlimited replicative potential, invasive and metastatic properties, the ability to 
induce angiogenesis, the ability to evade immune destruction and finally, dysregulated cellular 
metabolism20.  With those characteristics in mind, it is easy to see how inflammation, which 
stimulates cell growth and tissue repair, can drive cancer development in afflicted cells. 
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Akin to chronic inflammation, the heavy immune cell infiltrate in the tumour microenvironment 
produces the same growth factors, cytokines and signalling molecules as it does away from a 
tumour. Macrophages, which infiltrate the tumour site in large populations, are perhaps the 
most important player in this regard. They help the tumour acquire the ability to proliferate 
continuously by secreting growth factors, like epidermal growth factor (EGF). They can help the 
tumour evade the immune system, by secreting immunosuppressive cytokines like IL-10. They 
facilitate invasion and metastasis by promoting the production of MMPs which help to degrade 
the extracellular matrix. Macrophages even support the neovascularisation of the tumour, 
secreting pro-angiogenic factors like VEGF27. 
Furthermore, in addition to the numerous cytokines and growth factors that are provided by 
inflammation, the process also promotes genome instability that is favourable for tumour 
development. If a genome is more unstable, a mutation that favours cell growth and survival, is 
more likely to be selected for. Over time, this can potentially lead to accumulation of enough 
mutations, or just the right mutation, for malignant transformation. Therefore, inflammation 
can promote cancer progression by making conditions in the tumour favourable for such 
mutations to arise. Not only is the constant cycle of tissue damage and regeneration a favourable 
condition for spontaneous mutagenesis28, but inflammation can also promote genome 
instability through the production of various mutagenic factors. The activation of immune cells, 
neutrophils in particular, often goes hand in hand with the production of reactive oxygen or 
nitrogen species which can have deoxyribonucleic acid (DNA) damaging effects and play an 
important part in carcinogenesis29. Inflammation derived ROS have even been suggested to be 
capable of activating the carcinogenic properties of certain environmental agents, 
demonstrating how the process can contribute to cancer development even through exogenous 
mechanisms30. In addition to this, neutrophils are responsible for the production of multiple 
other mutagenic compounds. They can use an enzyme called myeloperoxidase to oxidise uracil 
nucleotides to 5 -chlorouracil or 5-bromouracil, both of which can be mutagenic if incorporated 
into the DNA sequence31. Neutrophils also generate hypochlorous acid from myeloperoxidase 
which, when secreted, can be mutagenic. Hypochlorous acid has been shown to be mutagenic 
by leading to the generation and accumulation of 5-chlorocytosine (5CIC) lesions in the genome 
of exposed cells. 5CIC has intrinsic mutagenic properties and induces C to T transitions, which 
reportedly occur at high frequency in cancer genomes32. Furthermore, the ability of 
hypochlorous acid to generate DNA damage and induce mutagenesis has been demonstrated in 
lung epithelial cells at physiologically relevant conditions, suggesting its natural secretion in 
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inflammation in the lung could be sufficient promote mutagenesis that could lead to tumour 
formation33.  
Outside of the secretion of growth factors and the genome instability which arises from 
inflammation, a major part of the pro-tumourigenic effect of inflammation is the production of 
TNFα from infiltrating immune cells such as macrophages and neutrophils. TNFα can directly 
support cancer progression through the stimulation and activation of a pathway which enhances 
cell proliferation, inhibits apoptosis and induces the expression of genes that promote 
angiogenesis, invasion and metastasis. Indeed, TNFα binds to the TNFα receptor (TNFR) on the 
surface of cancer cells to induce a signalling cascade which culminates in the activation of the 
NF-κB pathway. 
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1.2 The NF-κB pathway 
 
Activated by many different signalling molecules, including TNFα, the NF-κB pathway is one of 
the central regulators of the inflammatory response within the cell and has been extensively 
reviewed since its discovery over 30 years ago (reviews include Gilmore, 200634, Karin, 200935 
and Hayden and Ghosh, 201236). Activation of the NF-κB pathway induces a transcriptional 
program that involves the production of immunity and inflammatory mediators and signals that 
regulate tissue regeneration and cell death. NF-κB signalling itself is initiated by the activation 
of 5 distinct proteins which hetero- or homodimerise to create functional transcriptional 
regulators which bind to the promoters of NF-κB target genes. These 5 transcription factors are 
p65 (RelA), RelB, cRel, p105/p50 and p100/p52 and are all defined by a shared protein sequence 
known as the Rel homology domain (RHD), which mediates the dimerisation of subunits and 
their DNA binding36. p65, RelB and cRel all possess C-terminal transactivation domains (TADs)34, 
allowing them to drive gene transcription. Although p50 and p52 lack such TADs, they can still 
promote transcription through heterodimer formation with other NF-κB subunits. Before they 
can do so however, they need to be processed from their inactive precursor forms, p105 and 
p100 respectively. p105 and p100 precursors both contain long C-terminal ankyrin repeat 
domains (ARDs) instead of TADs, which inhibit their function37. When activated, the longer 
precursors are ubiquitinated and the ARDs are degraded, leaving behind the mature active NF-
κB subunits38 which can then dimerise with other TAD-containing NF-κB subunits to activate 
pathway signalling. 
As active dimers, NF-κB subunits translocate to the nucleus where they induce the NF-κB 
transcriptional program. Importantly, not all dimers are formed under the same circumstances 
and not all dimers activate the same genes. NF-κB dimers bind 9-10 base pair sites on target 
DNA sequences known as κB sites34 and different dimer conformations will bind  a different set 
of κB sites depending on which type of signal induces the pathway. Generally, an NF-κB response 
can be induced via two distinct mechanisms; the canonical pathway, or the non-canonical 
pathway. 
1.2.1 Canonical NF-κB activation 
 
The canonical pathway of NF-κB activation typically involves cellular stimulation with pro-
inflammatory signals, leading to the activation of cytokine receptors such as the TNFR or toll-
like receptors (TLRs)39.  This triggers the activation of specific signalling cascades depending on 
the inciting stimuli. In the context of TNFα-mediated activation of NF-κB, TNFα binds to the TNFR 
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on the cell surface and triggers the binding of tumour necrosis factor receptor type 1-associated 
DEATH domain protein (TRADD) to the intracellular domain of the receptor. TRADD binding 
provides a platform for the recruitment of adaptor protein TNFR-associated factor 2 (TRAF2) and 
subsequently, TRAF2 associates with cellular inhibitor of apoptosis protein (cIAP) 1, cIAP2 and 
receptor-interacting serine/threonine-protein kinase 1 (RIPK1). cIAP1 and cIAP2 are ubiquitin 
ligases that ubiquitinate RIPK1 with lysine 63 (K63)-linked ubiquitin chains, facilitating the 
recruitment and activation of the inhibitor of kappa-B kinase (IKK) complex40.  
NF-κB subunits are typically sequestered in the cytoplasm by inhibitor of kappa-B (IκB) proteins, 
which prevent their nuclear translocation. To date, several IκB proteins have been described, 
including IκBα, IκBβ, IκBε and IκBζ, all of which feature NF-κB inhibiting ARDs36. Recruitment and 
activation of IKK’s leads to phosphorylation and degradation of IκB proteins (discussed in-depth 
below in 1.2.3) which releases active NF-κB subunits from their sequestration. Active NF-κB 
dimers, usually containing either p65 or cRel with p5039, are formed and undergo nuclear 
translocation where they can transcriptionally induce the expression of genes associated with 
inflammation, cell proliferation and inhibition of apoptosis (Figure 1.1). 
1.2.2 Non-canonical NF-κB activation 
 
The non-canonical aspect of NF-κB activation does not involve such extensive signalling cascades 
and instead, revolves primarily around the NF-κB-inducing kinase (NIK) and the processing and 
activation of p100/p52 (reviewed by Sun, 201141).  
In response to signalling mediated by a subset of TNF ligands, such as lymphotoxin-β (LT-β) or 
B-cell activating factor (BAFF), NIK is activated and induces the processing of p10042. Under basal 
conditions, TRAF3 associates with NIK, targeting it for proteasomal degradation43, but 
stimulation of the LT-β receptor (LT-βR) leads to the recruitment of TRAF2 which, with the help 
of cIAPs, induces degradation of TRAF3 to stabilise NIK44. NIK then activates one of the IKKs45 
(see 1.2.3.1), which phosphorylates p100 to target it for ubiquitination, in turn leading to 
proteasome-mediated degradation of the ARD of p100 and leaving behind the mature active 
p52 subunit. p52, dimerised with RelB, then translocates to the nucleus where it activates NF-
κB target genes involved in secondary lymphoid organogenesis, T-cell differentiation and B-cell 
maturation (reviewed by Sun, 201246) (Figure 1.1).  
The non-canonical NF-κB pathway therefore primarily differentiates from the canonical by the 
involvement and function of the so-called IKKs. Whilst both pathways involve their activation, 
the canonical pathway activates IKKs to target and degrade IκB proteins, whereas the non-
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canonical pathway activates IKKs to directly target NF-κB subunits. The IKKs and their roles both 
in and out of NF-κB signalling are discussed below. 
 
 
 
Figure 1.1 – The canonical and non-canonical mechanisms of NF-κB activation. The canonical NF-κB pathway is 
induced by activation of cytokine receptors in response to pro-inflammatory signals like TNFα, triggering recruitment 
of TRADD proteins to the intracellular domain of the cytokine receptor. TRADD recruitment facilitates association 
with TRAF2 and subsequently, cIAP1/2 and RIPK1. Ubiquitination of RIPK1 by cIAP1/2 promotes recruitment, 
phosphorylation and activation of the IKK complex, which phosphorylate IκB proteins, targeting them for ubiquitin-
mediated proteasomal degradation, thereby releasing active NF-κB dimers. The non-canonical pathway is activated 
by specific TNF ligands like LT-β. Activation of ligand receptors triggers TRAF2 recruitment which associates with 
cIAP1/2 to ubiquitinate TRAF3 and induce its degradation. Release of NIK from TRAF3-mediated suppression allows it 
to phosphorylate and activate IKKα. In turn, IKKα phosphorylates NF-κB subunit p100, inducing ubiquitin-mediated 
degradation of the p100 ARD, producing the mature p52 subunit which, associated with RelB, translocates to the 
nucleus to trigger NF-κB transcriptional activity.  
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1.2.3 Inhibitor of Kappa-B kinases 
 
As previously covered, NF-κB subunits are typically sequestered in the cytoplasm by IκB proteins, 
only released upon stimulation of the pathway by a wide variety of factors including TNFα.  Upon 
activation of upstream signalling, IκBα is phosphorylated at 2 serine residues; Ser32 and 
Ser3647,48, which subsequently leads to its ubiquitination at lysine residues Lys21 and Lys22, 
resulting in proteasomal degradation of the protein49,50. Degradation of IκBα releases the 
sequestered NF-κB subunits, allowing them to freely translocate to the nucleus and activate 
their transcriptional programmes. The Inhibitor of Kappa-B Kinase (IKK) family of kinases are the 
central regulators of NF-κB activation. This family, consisting of four kinases and one regulatory 
protein, is responsible for the phosphorylation of IκBα in response to activating stimuli. 
Structurally, the 4 kinases are relatively similar, all 4 containing a kinase domain for basic 
function and leucine zipper and helix-loop helix sequences that can facilitate dimer formation 
between IKK’s51. IKKβ, IKKε and TBK1 also contain ubiquitin-like domains (ULDs) that are 
indispensable for their respective kinase activities52,53 (Figure 1.2). Despite considerable 
structural similarities however, all 4 kinases have unique roles, which will be discussed below. 
1.2.3.1 Canonical IKK’s and the IKK complex 
 
IKKα (or IKK1) was originally identified as “conserved helix-loop-helix ubiquitous kinase” (CHUK) 
in 199554,55 and was recognised as one of two integral components of an IκB kinase complex (IKK 
complex) in 1997, alongside IKKβ (or IKK2)56-60. IKKα and IKKβ are each capable of 
phosphorylating both Ser32 and Ser36 residues on IκBα61 and both kinases are necessary for full 
activity of the IKK complex60. A third and final component of the IKK complex is regulatory 
subunit IKKγ (or NF-κB essential modulator – NEMO)62,63. IKKγ function, and the subsequent 
activation of NF-κB, depends on K-63-linked ubiquitination of IKKγ by multiple proteins including 
cIAP1 and TRAF664-67. Upon its activation, IKKγ binds to a NEMO-binding domain (NBD) in IKKβ 
and regulates IKK complex activity62. Notably, although IKKγ is not itself a kinase, it is essential 
for NF-κB activation. Indeed, activation of the NF-κB response can be inhibited by blocking the 
ubiquitination of IKKγ or its interaction with IKKβ65,66,68. Upon stimulation of the TNFα receptor, 
the canonical NF-κB signalling cascade promotes the formation of the IKK complex, which 
phosphorylates IκBα to induce activation of NF-κB transcriptional activity (Figure 1.1). 
Despite sharing 52% sequence similarity59, IKKα and IKKβ do not share all functionality. Instead, 
they have unique roles to play, both in and out of NF-κB regulation. Firstly, their functions differ 
between the canonical and non-canonical pathways of NF-κB activation. IKKβ is heavily involved 
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in the canonical mechanism and is the main phosphorylating kinase for IκBα. Experiments 
performed with mice lacking the CHUK gene (encoding IKKα) provide evidence for its 
redundancy in canonical activation of the NF-κB pathway. It was demonstrated that CHUK -/- 
mice exhibit no impairment of IκBα degradation or induction of NF-κB signalling in response to 
cytokine stimuli. Although CHUK -/- mice do display other significant developmental problems, 
this highlights the redundancy of the kinase in induction of canonical NF-κB activation69,70. On 
the other hand, experiments performed with mice lacking the IKBKB gene (encoding IKKβ) show 
significant apoptosis in the liver, resulting in death before full gestation. Furthermore, IKBKB -/- 
cells are almost entirely defective in the activation of cytokine-induced NF-κB signalling 
demonstrating that, whilst IKKα is redundant in canonical NF-κB activation, IKKβ is indispensable 
in this process71. Comparatively, IKKβ is redundant in the activation of the non-canonical NF-κB 
pathway, where IKKα is the primary kinase involved, activated by stabilised NIK to phosphorylate 
and induce the processing of p10045 (Figure 1.1). 
NF-κB independent roles of canonical IKK’s 
As well as their contrasting roles in activating different branches of NF-κB signalling, the 
canonical IKK’s also have important NF-κB independent roles to play. One such example is an 
important developmental role for IKKα in the skin. In mice, it has been demonstrated that the 
kinase is essential for proper embryonic skin development and, as mentioned above, CHUK -/- 
mice exhibit substantial developmental problems, such as impaired limb outgrowth, “shiny, taut 
and sticky skin” and a significantly thicker epidermis that cannot properly differentiate72. This 
demonstrates a key function for IKKα in promoting the proper differentiation of skin cells, 
particularly keratinocytes, during embryonic development, and although CHUK -/- mice can 
develop to term, they are perinatally lethal, dying shortly after birth69,70,72. Interestingly, as well 
as being independent of NF-κB activation, IKKα-mediated control of proliferation and 
differentiation of the epidermis is also entirely independent of IKKα kinase activity73. Instead, 
IKKα acts within the nucleus. A nuclear localisation sequence within IKKα’s kinase domain 
regulates its entry into the nucleus74 where it begins the differentiation process by inducing 
withdrawal from the cell cycle. Nuclear IKKα acts as a scaffolding protein, interacting with Smad2 
and Smad3 transcription factors to induce Ovol1 and Mad2 expression, which leads to inhibition 
of Myc-dependent proliferation and facilitates keratinocyte differentiation75 
IKKβ is involved in the early phases of an allergic response. When mast cells are stimulated by 
IgE, IKKβ is recruited to membrane lipid rafts where it phosphorylates a protein called 
synaptosomal-associated protein 23 (SNAP-23). Phosphorylation of SNAP-23 promotes 
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degranulation of the mast cell to allow the mounting of an appropriate allergic response and 
accordingly, the suppression of IKKβ in mast cells is reported to inhibit degranulation and reduce 
the anaphylactic response76.  
Both IKKα and IKKβ also play a role in preventing RIPK1-dependent cell death. TNF receptor 
activation induces various signalling activities that regulate cell death. Primarily, these are anti-
apoptotic signals activated by NF-κB in response to TNF receptor activation, but TNF also 
activates RIPK1 which, rather than inhibiting cell death, can enhance it through induction of 
caspase-mediated apoptosis or induction of necroptosis. IKKα and IKKβ can protect cells from 
RIPK1 induced cell death by directly phosphorylating RIPK1 and inhibiting it, ensuring that the 
balance of survival/death signals induced by TNF signalling is firmly tipped into survival in 
inflammatory conditions77 
1.2.3.2 Non-canonical IKK’s 
 
More recently described are the so-called “non-canonical IKK’s”. An inducible IKK, IKKε (or IKK-
i)78, was identified as a member of a wholly separate IκB kinase complex to what had previously 
been described79. The final IKK identified was TANK-binding kinase 1 (TBK1) (or NAK), shown to 
activate NF-κB as a part of a complex with TRAF2 and TANK80 and through activation of the 
“canonical” IKK complex via directly activating IKKβ81. Since their characterisation, a clearer 
understanding of the roles of these “non-canonical” IKK’s in the activation of NF-κB has 
emerged. Although capable of phosphorylating IκBα, IKKε or TBK1 on their own are only able to 
phosphorylate the Ser36 residue of the protein79,81 which, alone, is insufficient to induce 
degradation48. This makes the kinases distinct from IKKα and IKKβ, both of which can 
phosphorylate both required residues, and suggests a minimal role for the “non-canonical” IKK’s 
in the classical mechanism of NF-κB activation. Instead, the roles for IKKε and TBK1 in NF-κB 
regulation appear to be more in support of the activity of the canonical IKK’s, fine-tuning the 
basal and induced activation of NF-κB transcription. Both IKKε and TBK1 can directly 
phosphorylate NF-κB subunits to regulate their activation independently of IκB degradation. The 
cRel subunit is directly phosphorylated by both IKKε and TBK1, facilitating its dissociation from 
IκBα independently of IκBα phosphorylation and allowing its nuclear translocation82. IKKε can 
also directly phosphorylate the p65 (RelA) NF-κB subunit at serine residues Ser468 and Ser536 
to regulate NF-κB activity. Indeed, phosphorylation of Ser468 serves to enhance p65 
transcriptional activity via modulation of transactivation potential upon release of the 
transcription factor from IκBα83. 
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Since their discovery, it has become clear that although the IKK’s show strong sequence 
homology with each other (IKKβ is 52% similar to IKKα59, TBK1 and IKKε show 64% similarity and 
are both 30% similar to IKKβ78,80,84) and certainly share some functional similarity, the division of 
the IKK family into discrete “canonical” and “non-canonical” groups goes beyond their roles in 
NF-κB. Instead, classification can now be based upon well-defined and distinct primary 
functions. Whilst all IKK’s are involved, to a greater or lesser extent, in the regulation of NF-κB, 
the non-canonical IKK’s play unique and important roles in innate immunity and the activation 
of the interferon antiviral response. 
Non-canonical IKK’s and the innate immune response 
Upon stimulation of the toll-like receptors (TLRs) by viral or bacterial products (such as double 
stranded RNA (dsRNA) or lipopolysaccharide (LPS) respectively) a signalling cascade is activated 
that culminates in the induction and secretion of type 1 interferon, interferon-β (IFNβ) (reviewed 
by Chau, 200885). This pathway is dependent on both IKKε and TBK186-88, which directly 
phosphorylate interferon regulatory factor 3 (IRF3) at the serine residue Ser39687 and IRF7 at 
serine residues Ser477 and Ser47989, inducing their activation through dimerisation and nuclear 
translocation87,90-92 wherein they bind to specific DNA sequences on a set of genes known as IFN-
stimulated response elements (ISREs) in the promoters of target genes (reviewed by Honda and 
Taniguchi93). One key genetic target is interferon-β (IFNβ)94, which is induced and secreted from 
signalling cells when IRF3 is activated. IFNβ then signals via the type 1 IFNα/β receptor (IFNAR) 
in an autocrine and paracrine manner, resulting in dimerisation of the 2 IFNAR subunits (IFNAR1 
and IFNAR2). The interaction of IFNβ with IFNAR activates Janus family of protein kinases (JAK) 
Tyk2 and JAK1, resulting in the phosphorylation of signal transducer and activator of 
transcription (STAT) 1 and STAT2 and full activation of the JAK/STAT signalling cascade95-97. This 
signalling cascade culminates with the formation of a protein complex known as the IFN-
stimulated gene factor 3 (ISGF3) complex, which is comprised of a STAT1/STAT2 heterodimer 
interacting with IRF9. The ISGF3 complex then binds to ISREs in the promoters of IFN-stimulated 
genes such as Ifit3 and OAS1 to produce the antiviral effects of the pathway98,99 (Figure 1.3).  
Whilst IKKε and TBK1 share common targets for phosphorylation and can both activate the IFN 
response, it is important to note that their activities do not entirely overlap. Despite IKKε only 
being inducible compared to TBK1’s constitutive expression, IKKε does not act solely for 
redundancy or for the enhancement of an initial TBK1-mediated response. Experiments 
performed in TBK1-, IKKε- or TBK1/IKKε- deficient mouse embryonic fibroblasts (MEFs) show 
that, although TBK1 -/- MEFs exhibit impaired IFNβ and interferon stimulated gene (ISG) 
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induction and IKBKE (IKKε-encoding gene) -/- MEFs do not, combined TBK1/IKBKE -/- MEFs show 
completely abolished activation of the interferon response, indicating that IKKε does have a 
unique function which, whilst comparatively minor, cannot be compensated for by TBK188. 
 
 
Figure 1.3 – IKKε and TBK1-mediated NF-κB and interferon signalling. In response to activation of the toll-like 
receptors, adaptor molecule toll-interleukin receptor (TIR)-domain-containing adapter-inducing interferon β (TRIF) is 
recruited to the TIR domain of the TLRs and acts as a platform for TRAF3 and TRAF6 recruitment. This induces the 
activation of IKKε and TBK1. Whilst neither kinase is capable of phosphorylating both IκBα serine residues necessary 
for degradation and therefore cannot induce the canonical NF-κB signalling pathway, they are able to directly 
phosphorylate specific NF-κB subunits including p65 and cRel, inducing their activation and nuclear translocation 
independently of IκB degradation. The primary function of IKKε and TBK1 involves the phosphorylation of IRF3, 
inducing its dimerisation and subsequent nuclear translocation. This induces the expression and secretion of IFNβ, 
which binds to the interferon receptor on the cell surface to activate the JAK/STAT signalling cascade, culminating in 
the formation of the ISGF3 complex, containing STAT1, STAT2 and IRF9. IKKε can also directly promote the formation 
of this complex via direct phosphorylation of STAT1. The ISGF3 complex translocates to the nucleus to activate 
transcription of IFNβ target genes and drive the innate immune response. 
 
An explanation for this might come from the fact that IKKε plays a secondary role in IFN 
signalling, downstream of IRF3 and the IFNAR. IKKε directly phosphorylates STAT1 at serine 
residue Ser708, an event which dramatically increases ISGF3 binding to ISREs in ISGs. It is 
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thought that this phosphorylation facilitates a tighter, more stable interaction between STAT1 
and STAT2 in the ISGF3 complex which, in turn, allows binding of the ISGF3 to shorter ISREs in 
target gene promoters. In agreement with this, there are a subset of IKKε-dependent ISG’s 
(including ADAR1, an RNA targeting adenosine deaminase that can target viral dsRNA) that 
cannot be induced without expression of IKKε, even if JAK/STAT signalling is activated by TBK1 
or via other means99. 
By the same mechanism, IKKε regulates the balance between type 1 and type 2 interferon 
responses. Whereas the type 1 response culminates with the formation of the ISGF3 complex, 
STAT1 does not always form a STAT1-STAT2 heterodimer ready for incorporation into the ISGF3. 
In response to type 2 IFN signalling (IFNγ), STAT1 can homodimerise to form the gamma-
activated factor (GAF) complex100, which binds to a different subset of genes, containing gamma 
activated sequences (GAS) in their promoter regions101. The same Ser708 phosphorylation of 
STAT1 by IKKε that promotes its incorporation into the ISGF3 also inhibits STAT1 
homodimerisation. IKKε therefore inhibits GAF formation and promotes a type 1 IFN response 
over a type 2 response102. 
Non-canonical IKK’s in metabolism 
Interestingly, a role in various metabolic activities is emerging as a key part of the activities of 
the non-canonical IKK’s. IKKε has been linked with the development of obesity in mice, where 
feeding of animals with a high-fat diet was found to increase expression of the kinase in white 
adipose tissue and the liver. It was found that, compared to wild type mice, mice lacking IKKε 
expression exhibited a reduction in diet-induced weight gain and an increase in energy 
expenditure, attributable to a significant increase in expression of uncoupling protein 1 (UCP1), 
which promotes energy usage through thermogenesis103. Alongside reduced weight gain, loss of 
the kinase in mice was also found to reduce chronic diet-induced hepatic steatosis 
(accumulation of fat in the liver) and obesity-induced chronic inflammation whilst preventing 
development of insulin resistance in response to a high-fat diet, indicating that IKKε might play 
an important role in the establishment of metabolic diseases such as diabetes103. Accordingly, 
anti-inflammatory drug amlexanox, approved for treatment of asthma, allergic rhinitis and 
aphthous ulcers, was found to be an inhibitor of IKKε and TBK1 and was shown to promote 
weight loss and energy expenditure in mice on high-fat diets, as well as restore insulin sensitivity 
and reverse hepatic steatosis104. 
Within the context of immune cells, IKKε and TBK1 have also been recently linked to the 
regulation of intracellular metabolism. In 2010, it was shown that TLR-activated dendritic cells 
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rapidly changed their metabolism, significantly increasing their glycolytic rate105 and in 2014, it 
was demonstrated that this increase in glycolysis was induced by IKKε and TBK1, which 
promoted the association of glycolysis enzyme hexokinase II with the mitochondria. This 
association allowed the glycolytic enzyme to rapidly use mitochondrial adenosine triphosphate 
(ATP), thereby massively increasing the speed of glycolysis to support the production of fatty 
acids necessary for the expansion of the endoplasmic reticulum and Golgi apparatus in dendritic 
cell activation106. This demonstrated that, in addition to their involvement in innate immunity, 
the non-canonical IKK’s have the ability to regulate overall cellular metabolic state. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1. Introduction 
19 
 
1.3 IKK’s in cancer 
 
Given its role in wound healing and tissue repair, as well as the fact that the NF-κB response 
plays important roles in the regulation of cell growth and proliferation, it is unsurprising that 
aberrant activation of the NF-κB pathway is a long-established mechanism of cancer 
development. In fact, NF-κB activation facilitates the acquisition of certain cancer hallmarks20 
(reviewed by Dolcet et al.107 and Xia et al.108). For instance, NF-κB signalling can regulate the 
balance between pro- and anti-apoptotic signals to promote a pro-survival phenotype through 
the induction of anti-apoptotic Bcl proteins109,110 or proteins like cFLIP, a homologue and 
competitive inhibitor of caspase-8111,112. Activation of the pathway can also promote 
proliferation through regulation of cell cycle genes like cyclin D1113 and by inducing the 
production of various factors and cytokines necessary to support growth, such as angiogenic 
factors like VEGF114,115. Indeed, the components of the NF-κB signalling pathway are frequently 
dysregulated in cancer. Haematopoietic tumours often exhibit genetic changes that result in 
hyperactivation of NF-κB subunits. Inhibitory mutations in the NFKBIA gene, which encodes the 
IκBα protein, have been reported in Hodgkin lymphoma patients116-118, and amplification and 
rearrangements of the REL gene, encoding the NF-κB subunit cRel, are common in various 
lymphoid malignancies (reviewed by Courtois and Gilmore119). Whilst mutations that directly 
activate NF-κB are much rarer in solid tumours, some have been reported. IκBα is, again, a target 
of such mutations. For example, the NFKBIA gene is subject to deletion in glioblastoma120. 
Furthermore, genetic gain of function mutations in upstream signalling molecules like K-Ras, EGF 
Receptor (EGFR) and HER2 can lead to enhanced NF-κB activation in a variety of cancers121. The 
predominant way that NF-κB is dysregulated in human cancer however, is from changes that 
occur in the tumour microenvironment, as inflammation and infiltration of immune cells signal 
to activate NF-κB signalling via activation of the IKK’s. 
1.3.1 Canonical IKK’s in cancer 
 
IKKα and IKKβ activity have been implicated in a variety of cancers since the discovery of their 
respective functions. 
IKKα 
Notch-1, a member of the Notch family of receptors which are heavily involved in regulating the 
balance between cellular proliferation and differentiation, has been found to interact with IKKα 
to promote different types of cancer. In cervical cancer, Notch-1 promotes cancer cell survival 
through the NF-κB pathway, interacting with IKKα to enhance IKK activity upon stimulation of 
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NF-κB signalling. It also interacts with IKKα in basal conditions to facilitate nuclear translocation 
of the kinase and promote its association with chromatin. Here IKKα can enhance NF-κB activity 
and contribute to NF-κB-mediated transcription by phosphorylating histone H3 at serine residue 
Ser10, a site associated with positive regulation of gene expression122,123, as well as 
phosphorylating p65 and NF-κB repressor silencing mediator for retinoic acid and thyroid 
hormone receptor (SMRT) to promote p65 transcriptional activity124,125. In estrogen receptor 
(ER) positive (+) breast cancer, Notch-1 interacts with IKKα to form a “Notch transcriptional 
complex” (NTC) and translocate ERα to the nucleus in the absence of estrogen. This facilitates 
ERα recruitment to estrogen response elements (EREs) in the genome and, upon p300 
recruitment, the transactivation of ERα-target genes that drive proliferation in cancer126. 
In ovarian cancer, IKKα is the target of microRNA (miRNA) miR-23a. Previously associated with 
oncogenesis in colorectal cancer127, laryngeal carcinoma128 and other types of cancer, miR-23a 
is also upregulated in epithelial ovarian cancer, where it has been reported to directly upregulate 
IKKα expression whilst simultaneously suppressing suppressor of tumourigenicity 7 protein-like 
(ST7L) via binding to its 3 prime untranslated region (3’-UTR). STL7 supresses tumour growth by 
inhibiting the Wnt/Mitogen-activated protein kinase (MAPK) pathway to prevent cell cycle 
progression and epithelial-mesenchymal transition (EMT). Upregulation of IKKα by miR-23a 
enhances NF-κB pathway activation to promote cell growth and invasion which, when combined 
with the parallel regulation of STL7, leads to increased cancer development129.  
IKKα also plays a large role in the progression of later stage prostate cancer. Generally speaking, 
highly invasive PC3 prostate cancer cells show increased NF-κB activity compared to a less 
invasive PC3 line, attributable to an increase in IκBα phosphorylation and accordingly, 
expression of an IκBα super-repressor, containing an S32/36A mutation that prevents it’s IKK-
dependent phosphorylation and subsequent ubiquitin-mediated proteasomal degradation, 
reduced this highly invasive phenotype, demonstrating involvement of NF-κB activation in 
oncogenesis130. Importantly however, IKKα also promotes prostate cancer via NF-κB 
independent mechanisms. Maspin, a serine protease inhibitor, has been shown to reduce 
tumour metastasis by enhancing cell adhesion to the extracellular matrix, thereby preventing 
migration of tumour cells131,132. When immune cells infiltrate the tumour microenvironment, 
receptor activator of NF-κB ligand (RANKL) expressed on their cell membranes binds to RANK on 
the prostate cancer cells. This activates IKKα and facilitates its translocation to the nucleus, 
where it is recruited to the promoter of the Maspin gene and represses its transcription, thereby 
promoting disease progression. In accordance with this, levels of active, nuclear IKKα in human 
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prostate cancer correlate with metastatic progression133 and suppression of IKKα expression 
reduces pancreatic cancer PC3 cell line migration and invasion134. 
Intriguingly, IKKα appears to have an inhibitory role in squamous cell carcinoma. As previously 
mentioned, IKKα plays an important role in the differentiation of skin cells during embryonic 
development and is crucial for switching off the growth of the epidermal layer. This indicates 
that should the kinase’s role in differentiation become dysregulated, skin cells would begin to 
uncontrollably proliferate and tumours would begin to form. Accordingly, reduced expression 
of IKKα has been observed in squamous cell carcinomas, with missense mutations reported in 
exon 15 of the CHUK gene135 and epigenetic modifications in the CHUK promoter reported to 
silence gene expression in oral squamous cell carcinoma (SCC)136. Indeed, loss of IKKα expression 
has been shown to promote the development of skin cancers and SCC in particular137. In 
agreement with this, an inverse correlation between IKKα expression and disease aggression is 
observed in human SCC135. As indicated by the findings of disrupted skin development in CHUK 
-/- mice, the kinase acts as a tumour suppressor in SCC by enhancing the terminal differentiation 
of the epidermal layer through inhibition of Myc-dependent proliferation (see 1.2.3.1), thereby 
preventing the tumour development and progression of the disease to a metastatic phenotype.  
IKKβ 
IKKβ has also been implicated in various cancers. In the intestine, inflammation-driven colitis-
associated cancer (CAC) was found to be dependent on IKKβ-mediated NF-κB activation in a 
mouse model. Deletion of IKBKB in the enterocytes of said model led to a dramatic reduction in 
tumour incidence due to enhanced apoptosis in the early stages of tumourigenesis, indicating 
that the kinase is important for tumour initiation. Furthermore, IKBKB deletion in the 
macrophages which infiltrate the tumour site caused a decrease in tumour growth, but had no 
effect on apoptosis of the tumour cells, indicating that, in myeloid cells, IKKβ is crucial for the 
production of inflammatory factors that support CAC tumour progression138.  
Interestingly, IKKβ’s role in CAC development is more controversial in the context of 
mesenchymal cells. Two studies, published at the same time in the same journal, proposed two 
alternate hypotheses. The first proposed IKKβ as a tumour promoting kinase, showing that loss 
of kinase expression in these stromal cells reduced colitis in response to inflammatory factor 
dextran sulphate sodium (DSS) and subsequently had a preventative effect on of tumour 
initiation139. It was shown that expression of IKKβ in the mesenchymal cells was important for 
proper infiltration of inflammatory cells and production of cytokines in the intestine and that 
without IKKβ activity, the inflammation that drives CAC initiation cannot occur. The second study 
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presented findings that suggested IKKβ activity in cancer associated mesenchymal cells has 
tumour suppressive properties instead, reporting that loss of IKKβ in fibroblasts led to an 
increase in the size of CAC tumours, attributable to an increase in proliferation of epithelial cells 
and a decrease in tumour cell apoptosis140. It was shown that loss of kinase expression led to a 
reduction in Smad7 expression and a corresponding increase in TGFβ signalling, which ultimately 
increased the secretion of hepatocyte growth factor (HGF) from the fibroblasts and increased 
tumour cell proliferation. Whilst both studies used Cre based systems to knockout IKBKB in the 
mesenchymal cells, the first used a constitutive ColVIcre knockout, whereas the second used a 
tamoxifen inducible Col1a2creER system which targeted a much larger mesenchymal cell 
population than the ColVIcre system. It was therefore suggested that IKKβ’s pro- or anti-
tumourigenic effect in fibroblasts is highly dependent on the level of expression within the whole 
population or on its expression in uncharacterised sub-populations139. It was also noted that the 
ColVIcre knockout of IKBKB primarily affected tumour incidence and the early stages of CAC, 
whereas the Col1a2creER knockout had little impact at that stage, suggesting that the kinase 
might play different roles in the fibroblasts at different time points, enhancing inflammation and 
promoting tumour development in early stage CAC, but preventing progression at later stages. 
Whatever the explanation for this discrepancy, IKKβ clearly plays a highly intricate role in CAC, 
with well-defined pro-tumourigenic function in epithelial and myeloid cells and a more complex 
role in the stroma. 
Similar to IKKα, IKKβ has also been shown to be regulated by miRNA’s in ovarian cancer. miR-
199a has a direct inhibitory effect on the expression of IKKβ. Concurrently, one study found that 
a subset of epithelial ovarian cancer (EOC) cells which showed low levels of miR-199a had 
correspondingly high levels of IKKβ, allowing induction of the NF-κB pathway and increased 
survival in response to chemotherapy drug paclitaxel, low levels of apoptosis in the face of TNFα 
stimulation and secretion of pro-tumour cytokines. Comparatively, a subset of EOC cells with 
high levels of miR-199a had much lower levels of IKKβ, struggled to produce an NF-κB response 
when treated with paclitaxel and, upon treatment with TNFα, exhibited significantly higher 
levels of apoptosis. This indicated that IKKβ expression regulates chemosensitivity and tumour 
aggression in ovarian cancer141.  
IKKβ is also a target of miRNA’s in non-small cell lung cancer (NSCLC), where miR-503 has been 
shown to repress disease progression through the suppression of the oncogenic 
phosphoinositide 3-kinase (PI3K) p85 subunit and IKKβ. In NSCLC, expression of miR-503 
correlates positively with patient survival and the tumour suppressive abilities of miR-503 were 
found to be tightly linked to the reduction of PI3K p85 and IKKβ expression. Ectopic expression 
Chapter 1. Introduction 
23 
 
of the two kinases partially negated the tumour suppressive effects of the miRNA142, which 
suggests an important role for the IκB kinase, and PI3K, in the development of NSCLC. 
Outside of its NF-κB related activities, IKKβ has also been linked to tumourigenesis through 
regulation of the mechanistic target of rapamycin (mTOR) pathway. The tuberous sclerosis (TSC) 
1/TSC2 complex inhibits mTOR signalling, but IKKβ activates the pathway by restricting activity 
of the TSC1/TSC2 complex through direct inhibitory phosphorylation of TSC1 at serine residues 
Ser487 and Ser511. IKKβ-mediated inhibition of the TSC1/TSC2 complex therefore indirectly 
activates the mTOR pathway, which results in the secretion of VEGF and the subsequent 
promotion of angiogenesis to support tumour development. In patient samples, IKKβ 
phosphorylation (indicative of activity) correlated strongly with phosphorylation of TSC1 and 
Kaplan-Meier analysis demonstrated association of phosphorylation of TSC1 with poor survival 
outcome143. 
Joint roles of IKKα and IKKβ 
The two canonical IKK’s also work in tandem in some cancers. In head and neck cancer, IKKα and 
IKKβ are both overexpressed and phosphorylated, and both kinases contribute to nuclear 
activation of the canonical and alternative NF-κB transcription factors. Whilst knockdown of 
either IKKα or IKKβ individually reduced NF-κB activation, combined knockdown of both kinases 
had a synergistically inhibitory effect on NF-κB activity and on cell proliferation and migration144. 
In the same cancer setting, dual knockdown of both IKK’s suppressed a broad gene expression 
program that involved genes associated with the EGFR-activator protein 1 (EGFR-AP-1) pathway. 
The EGFR-AP-1 pathway specifically regulates cell proliferation and migration, indicating that 
the two IKK’s also contribute to head and neck cancer via the activation of such growth factor 
pathways144. In liver cancer, high expression of IKKα and IKKβ has been shown to contribute to 
malignancy. Human hepatocellular carcinoma (HCC) tumour samples exhibited high levels of 
both kinases, along with high levels of c-FLIP and cyclin D1 and reduced levels of Maspin145. As 
previously mentioned, c-FLIP is an anti-apoptotic protein that can be induced by NF-κB 
activation111,112 and reduction in Maspin levels is a phenotype observed in IKKα-driven prostate 
cancer that promotes metastatic progression133. This indicates that in certain liver cancers, both 
NF-κB-dependent and NF-κB-independent functions of IKK’s are active and contributing to 
survival and development of the tumour. Accordingly, in HCC cell lines suppression of both IKKα 
and IKKβ has been shown to increase apoptosis and, in a subcutaneous injection mouse model 
using HCC cell lines, siRNA-mediated suppression of both IKKα and IKKβ reduced tumour 
Chapter 1. Introduction 
24 
 
growth145. Together, these studies demonstrate how both kinases can work together to enhance 
tumourigenesis and disease progression in multiple cancer types. 
1.3.1.1 Therapeutic targeting of canonical IKK’s in cancer 
 
Given the role that NF-κB plays in cancer and the importance of the IKK’s in the variety of cancers 
discussed above, both in and out of the context of NF-κB activation, it is unsurprising that there 
has been much interest in developing IKK inhibitors. Indeed, some of the aforementioned 
studies have demonstrated the efficacy of using such inhibitors to treat breast cancer143. Even 
in some circumstances where a particular IKK inhibitor has had little antiproliferative or pro-
apoptotic effect, treatment with the IKK inhibitors has been shown to improve response to other 
therapeutic agents such as doxorubicin146. Much of the effort to develop inhibitors has focused 
on the development of small molecule inhibitors of the kinases, with most focusing on inhibition 
of IKKβ due to its central role in canonical NF-κB activation.  
One such example is IKKβ inhibitor BMS-345541, which has been shown to sensitise breast 
cancer cells to ionising radiation by inhibiting the cells ability to repair double-strand breaks via 
homologous recombination. This results in an increased DNA damage response, increased cell 
death in vitro and reduced tumour growth in a xenograft mouse model in response to ionising 
radiation147. Efficacy has also been demonstrated in melanoma, where the same inhibitor 
reduced proliferation of human melanoma cells in vitro and in an in vivo xenograft mouse 
model148.  
Another example of an IKKβ inhibitor is PS1145. The effectiveness of PS1145 has been tested in 
prostate cancer cells, where it was shown to effectively reduce NF-κB activity and induce 
apoptosis while simultaneously sensitising cells to TNFα-induced apoptosis. The drug was also 
shown to reduce proliferation and invasion of prostate cancer cells in vitro149. Interestingly, 
when studied in leukaemia, PS1145 was found to not only inhibit cell proliferation, but also 
restore sensitivity to imatinib in resistant cell lines150.  
CHS 828 is another inhibitor with IKK inhibiting properties151. However, whilst this compound 
showed promising effects in lung and breast cancer cell lines in vitro and even in in vivo lung and 
breast cancer xenograft mouse models152, attempts to translate this efficacy to a range of solid 
tumours in the clinic have yielded disappointing results153. 
More disappointing is the fact that most of these IKK inhibitors are still in the preclinical stage, 
so the true efficacy of these compounds in patients remains to be seen. Some promise has been 
shown in the use of IKKγ mimetic peptides (NEMO peptides) however. NBD peptide inhibits the 
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formation of the canonical IKK complex and has been demonstrated to be effective in inhibiting 
the growth of pancreatic cancer both in vitro and in an in vivo xenograft model, whilst also 
sensitising cells to gemcitabine154. Efficacy has also been shown in a phase I clinical trial of 
activated B-cell like diffuse large B-cell lymphoma (ABC-like DLBCL), although this was in a canine 
cohort, not human155. 
However, even if more effective inhibitors are described, the primary aim of inhibition of 
canonical IKK activity is still to block NF-κB activation. Whilst it would be expected that NF-κB 
inhibition would be an effective therapeutic strategy in many cancers, the inhibition of NF-κB 
activation and downstream signalling causes significant negative effects that may ultimately 
limit the therapeutic efficacy of NF-κB inhibitors in the clinic, suggesting that targeting NF-κB 
through the inhibition of the canonical IKKs might not be a particularly effective strategy for 
cancer treatment (see 1.3.3.1). 
1.3.2 Non-canonical IKK’s in cancer 
 
1.3.2.1 TBK1 in cancer 
 
In the years since its identification, TBK1 has frequently been closely associated with lung cancer 
pathogenesis, by a variety of mechanisms. Firstly, TBK1 kinase activity has been shown to be 
induced by Ras signalling156. With mutations resulting in constitutively active, oncogenic K-Ras 
being very common in lung cancer, it is therefore unsurprising that TBK1 would play an active 
role. Indeed, it has been identified that TBK1, through its ability to activate NF-κB, functions as 
a key effector of mutant K-Ras-driven oncogenesis. The kinase has been reported as essential 
for the induction of anti-apoptotic signals from Bcl proteins that arise from the activation of NF-
κB signalling downstream of mutated K-Ras, and it has been shown that suppression of TBK1 in 
K-Ras-dependent human lung cancer cells led to a significant down-regulation in an NF-κB gene 
signature and increased apoptosis, indicating that TBK1 expression and activity is a crucial player 
in K-Ras-driven cancer, without which, cells cannot tolerate mutated K-Ras and will die157. 
Secondly, and independently of NF-κB activity, the direct phosphorylation of AKT by TBK1 has 
been shown to contribute to oncogenic transformation in the lung. Accordingly, inhibition of 
TBK1 in certain lung cancer cell lines has been found to impair AKT signalling. Activation of AKT 
by TBK1 can lead to the inhibition of apoptosis or the promotion of cell growth, thereby 
contributing to tumour development158. In addition to this, TBK1 has been shown to support the 
activation of AKT/mTORC1, not only through the phosphorylation of AKT, but also through 
interaction with mTORC1 subunit Raptor and phosphorylation of mTORC1 effector S6 kinase 
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(S6K)159. TBK1 therefore tightly regulates the mTOR pathway, with involvement at multiple 
stages both early, with phosphorylation of AKT, and late, with phosphorylation of S6K, indicating 
that activation of mTOR signalling may represent a large piece of TBK1’s oncogenic potential. 
A recent phosphoproteomic study also shed light on other mechanisms by which TBK1 
contributes to lung cancer, recognising a subset of lung cancer cells which were highly sensitive 
to TBK1 knockdown. Notably, these cells showed no changes in the basal levels of AKT 
phosphorylation when TBK1 was suppressed, suggesting the activation of AKT is inessential for 
pro-survival signalling mediated by the kinase. Furthermore, TBK1 knockdown impaired cell 
viability in cells where NF-κB and IRF3 signalling was constitutively active, indicating that known 
TBK1-mediated signalling is also not always required for its ability to promote tumour 
development in the lung160. Instead, polo-like kinase 1 (PLK1), a kinase involved in the G2/M 
transition of the cell cycle and previously established to be synthetically lethal in K-Ras mutant 
tumours161, was identified as a direct substrate of TBK1 indicating that the IκB-related kinase 
plays a role in the regulation of mitosis160. Activated during the G2/M transition phase of mitosis, 
TBK1 phosphorylates PLK1 to drive cell cycle progression. TBK1 was also found to indirectly 
induce phosphorylation of metadherin, a protein which enhances angiogenesis and correlates 
with poor prognosis in early-stage lung cancer. Cell sensitivity to pharmacological inhibition of 
PLK1 and suppression of metadherin both correlated strongly with cell sensitivity to TBK1 
knockdown, implicating both PLK1 and metadherin as key effectors of TBK1’s role in lung cancer 
growth160. 
Whilst TBK1 regulates a complex network of signalling in lung cancer, it has also been connected 
to other cancer types. One example is pancreatic cancer. Somewhat paradoxically, autophagy, 
the controlled intracellular degradation of cytoplasmic components, has been shown to be pro-
tumourigenic in K-Ras-driven pancreatic tumours, due to the fact that it helps maintain 
mitochondrial integrity and oxidative metabolism162 whilst detoxifying reactive oxygen 
species163. TBK1 has previously been shown to induce autophagy164,165 and correspondingly, 
impairment of the process has been reported in pancreatic cancer upon the inhibition of TBK1. 
Intriguingly, the same study also demonstrated that TBK1 activity is limited by autophagy166 
suggesting the existence of a tightly-controlled negative feedback loop. Indeed, as it is evident 
that TBK1 is closely involved in the regulation of controlled levels of autophagy within K-Ras-
driven pancreatic tumours, it has been suggested that oncogenic K-Ras induces TBK1 activity to 
promote autophagy to a level at which it is beneficial for tumour growth. In turn, autophagy can 
limit the activation of TBK1, thereby preventing autophagy levels from tipping over the balance 
into the point where it is no longer beneficial166. 
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In human epidermal growth factor receptor 2 (HER2) positive (+) breast tumours, an shRNA 
kinome screen identified TBK1 as a potential therapeutic target. Both knockdown and 
pharmacological inhibition of the kinase suppressed the growth of HER2+ breast cancer cells, 
and pharmacological TBK1 inhibition was synergistic with HER2 targeting drug lapatinib in in vivo 
models. Consistently with its roles in other cancers, TBK1’s role in HER2+ breast cancer appears 
to be more in favour of driving the progression of the cell cycle rather than inhibition of 
apoptosis. Inhibition of TBK1 induced cellular senescence in HER2+ breast cancer cells but 
treatment failed to induce apoptosis, perhaps explaining the synergistic effect of TBK1 inhibition 
and lapatinib. TBK1 inhibition causes cells to arrest, then lapatinib induces apoptosis167. 
Interestingly, TBK1-mediated regulation of the cell cycle in this context is not regulated via the 
phosphorylation of PLK1 as it is in lung cancer160. Instead it is the activation of NF-κB signalling 
that explains TBK1’s pro-tumourigenic effect in this tumour type167. 
Finally, TBK1 has been reported to be involved in the regulation of dormancy and drug resistance 
in advanced prostate cancer. Prostate cancer cells are known to metastasise to the 
haematopoietic stem cell (HSC) niche in the bone marrow168 and TBK1 levels in prostate cancer 
cells are increased following the binding of those cells to osteoblasts in the HSC niche, suggesting 
a role the kinase might play a role in late stage disease progression. Intriguingly, in prostate 
cancer cells in this context, TBK1 inhibits mTOR signalling, rather than promoting it as it does in 
other settings. This has the effect of inducing dormancy in the cells, which confers drug 
resistance to the population and facilitates the development of a prostate cancer stem-like 
cells169.  
1.3.2.2 IKKε in cancer 
 
Like other IKK’s, IKKε has been implicated in a variety of cancer types and has been reported to 
drive tumourigenesis via a variety of mechanisms. 
Recent years have uncovered important roles for IKKε in glioma’s. The kinase has been shown 
to be overexpressed in both human glioma cell lines and patient tissue specimens, where it 
promotes resistance to apoptosis via the NF-κB-mediated induction of anti-apoptotic 
proteins170. Knockdown of the kinase in glioma cell lines also resulted in reduced proliferative 
rates and a reduction in migration and invasion, indicating IKKε also enhances tumour 
development by promoting growth, not just by inhibiting cell death171. Whilst this pro-
proliferation/pro-invasion activity is also mediated by activation of NF-κB signalling, other 
mechanisms of IKKε-induced tumourigenesis in gliomas have been reported. Yes-associated 
protein 1 (YAP1) is a transcription factor that activates the expression of pro-proliferative genes 
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and suppresses apoptotic genes. Its transcriptional activity is typically repressed as part of the 
Hippo pathway, a signalling pathway that regulates organ size by controlling the cellular balance 
between proliferation and apoptosis. Given the pathways tight control over such processes, it is 
understandable that it is frequently a target of dysregulation in human cancers (reviewed by 
Harvey et al.172). In human glioma cell lines IKKε stabilises YAP1 protein and transports it to the 
nucleus to enhance its transcriptional activity. In turn YAP1, as well as inducing its pro-
proliferative transcriptional program, suppresses the expression of microRNA’s miR-let-7b and 
miR-let-7i173, which have previously been shown to inhibit IKKε expression in glioblastoma, 
suppressing  invasion and migration as a result174.  Inhibition of miR-let-7b and miR-let-7i by 
YAP1 therefore sustains expression of IKKε, which can continue to enhance YAP1 activity in a 
positive feedback loop. IKKε therefore promotes the growth of gliomas through both pro-
proliferative NF-κB and YAP1 transcriptional programs and anti-apoptotic NF-κB signalling. 
IKKε is also involved in colorectal cancer, where it has been shown to inhibit β-catenin 
signalling175. Whilst β-catenin is frequently mutated in various cancers and its activation is well 
known to be oncogenic, as it promotes the EMT, it has been proposed that hyper-activation of 
β-catenin signalling can in fact have a negative effect on proliferation. For example, in 
melanoma, β-catenin expression has been shown to be linked with decreased proliferation and 
the upregulation of genes associated with melanocyte differentiation176. IKKε has been shown 
to directly interact with β-catenin and phosphorylate it at multiple serine residues to inhibit its 
signalling activity, and in colorectal cancer cells inhibition of the kinase enhances β-catenin 
transcriptional activity and inhibits proliferation. It has therefore been suggested that IKKε 
contributes to the development of colorectal cancer by phosphorylating β-catenin to limit its 
activation, keeping signalling activity below the threshold where it becomes anti-proliferative175. 
In lung cancer, IKKε has been shown to inhibit forkhead box O3 (FOXO3a)177, a known tumour 
suppressor that is capable of inducing apoptosis178 and promoting quiescence179. The kinase 
directly phosphorylates FOXO3a at serine residue Ser644, leading to inhibition of FOXO3a 
transcriptional activity, sequestration of the transcription factor in the cytoplasm and induction 
of protein degradation, thereby preventing FOXO3a induced apoptosis. Overexpression of IKKε 
has been shown to correlate with phosphorylation of FOXO3a in human lung tumours, indicating 
that the kinase contributes to tumourigenesis in the lung through regulation of FOXO3a 
transcriptional activity177.  
The kinase also supports lung cancers by promoting the development of drug resistance. 
Transcription factor STAT3 is frequently activated by environmental carcinogens like nicotine180 
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and, in NSCLC, activation of STAT3 in response to nicotine has been reported to induce IKKε 
expression. The transcription factor binds directly to STAT3 response elements in the IKBKE 
promoter (encoding IKKε) to induce kinase expression, which supports tumour development by 
conferring resistance to chemotherapeutic agents such as cisplatin, gemcitabine and 
doxorubicin, reducing levels of apoptosis in NSCLC cells upon treatment with such agents181.   
In terms of later stage cancer progression, IKKε has also been reported to promote lung cancer 
metastasis. Experiments performed using murine lung carcinoma cells (M27) have shown that 
IKKε can transcriptionally regulate the expression of MMP3 via regulation of NF-κB and AKT 
signalling182. MMP’s are a group of enzymes that help degrade proteins of the extracellular 
matrix and are frequently dysregulated in many different cancers due to their ability to help 
cancer cells metastasise (reviewed by Gialeli et al.183 and Shay et al.184). For example, increased 
MMP3 expression in M27 cells has been shown to promote lung colonisation. The IKKε-mediated 
upregulation of MMP3 therefore represents a mechanism by which the kinase facilitates 
metastatic tumour growth in the lung. Similarly, in gastric cancer, high levels of IKKε expression 
correlate with worse patient prognosis and suppression of the kinase has been shown to inhibit 
tumour progression and metastasis in a xenograft mouse model using gastric cancer cells185. 
Together, these studies demonstrate a clear role for the kinase in the metastasis of various 
cancers.  
IKKε is therefore linked to a wide variety of different cancer types. On top of those mentioned 
above, it has also been implicated in ovarian cancer, where it is overexpressed and contributes 
to cisplatin resistance186 and invasion and metastasis187, in pancreatic cancer, where its 
expression correlates with poor patient prognosis188 and it enhances glycolytic metabolism to 
support tumour growth189, in renal clear cell carcinoma, where its expression again correlates 
with prognosis190 and in melanoma, where it promotes proliferation via activation of NF-κB, AKT 
and MAPK signalling191.  The main cancer type where IKKε is oncogenic however, is breast cancer, 
where the role of the kinase has recently been closely investigated. 
1.3.3 IKKε in breast cancer 
 
The first indication that IKKε was involved in the development of breast cancer came in 2005, 
when it was reported that expression of the kinase was significantly higher in a range of breast 
cancer cell lines than it was in untransformed MCF-10 breast epithelial cells and was expressed 
in patient tumour samples. Expression of IKKε was reported to strongly correlate with the 
expression of casein kinase 2 (CK2)192, a kinase which has been heavily linked to cancer in the 
past due to the anti-apoptotic effects of its activity and its role in cell cycle progression (reviewed 
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by Trembley et al.193).  CK2 was shown to induce IKKε which, in turn, enhanced degradation of 
IκBα and activation of NF-κB to promote cell growth. In agreement with this, inhibition of IKKε 
kinase activity reduced colony formation in a soft agar assay, indicating that the kinase played a 
part in driving cell proliferation and assisted anchorage independent growth in breast cancer192. 
A subsequent study demonstrated that IKKε regulated basal, constitutive activation of NF-κB in 
breast cancer cells. As previously mentioned, IKKε can phosphorylate NF-κB family member p65 
directly at serine residues Ser468 and Ser536 (see 1.2.3.2). Phosphorylation of p65 at Ser536 has 
been detected in a variety of cancer cells, including a selection of breast cancer cell lines. Whilst 
IKKε was dispensable for cytokine-induced phosphorylation of p65, it’s expression in cancer 
maintained p65 phosphorylation at a level high enough to facilitate some basal NF-κB 
transcriptional activity and maintain induction of NF-κB-mediated pro-proliferative signals194. 
Therein a mechanism by which expression of IKKε in cancer maintains a constant background 
activation of NF-κB to promote tumour formation was proposed. 
These early connections between IKKε and breast cancer were then expanded upon when, in 
2007, Boehm et al. formally identified the kinase as a fully-fledged breast cancer oncogene195. 
Hahn et al. had previously characterised a mechanism of cellular transformation by which they 
could generate bona fide human cancer cells. They showed that human embryonic kidney (HEK) 
epithelial cells expressing human telomerase reverse transcriptase (hTERT) and large and small 
SV40 T antigens (LT and ST respectively) could be tipped over into tumourigenic status by the 
expression of oncogenic, constitutively active H-RasV12 196. Boehm et al. set out to investigate 
which downstream effectors of H-RasV12 would contribute to cellular transformation in this 
model, termed herein as HA1E cells. Initially finding that a combination of constitutively active 
MAPK and PI3K signalling would substitute for H-RasV12, they became interested in kinases that 
could induce PI3K signalling. Expressing a mutated, constitutively active MEKDD to activate MAPK 
signalling, they screened for kinases that could replace constitutively active AKT in the activation 
of PI3K, eventually concluding that IKKε was sufficient to substitute for PI3K signalling and render 
HA1E cells expressing MEKDD (HA1E-M cells) tumourigenic. Subsequently, the IKKε gene, IKBKE, 
was found to be the subject of a genetic copy number gain or amplification at chromosomal 
region 1q32 in 16% of breast cancer cell lines and 30% of human breast tumours, leading to 
overexpression of the kinase. Copy number gain was also found in 4/10 ductal carcinoma in situ 
(DCIS) tumours analysed, which indicated that the amplification of the kinase was an early event 
in breast tumour development and may contribute to early stage growth. Suppressing IKKε 
expression in IKBKE amplified breast cancer cell lines led to a reduction in proliferation and cell 
viability, demonstrating the essential role of the kinase in cells where it is amplified. Importantly, 
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expression of an IκBα super-repressor, which cannot be phosphorylated and degraded, in HA1E-
M cells blocked the transforming effect of IKKε, demonstrating that aberrant activation of NF-
κB was the driving force behind the kinases oncogenic potential. Furthermore, expression of 
IKKε in breast cancer cell lines was linked with expression of NF-κB-induced MMP9 and Bcl2, 
suggesting enhancement of invasive properties and inhibition of apoptosis in cell lines 
expressing the kinase. Notably, the primary function of the kinase, in the phosphorylation of 
IRF3 and the activation of innate immunity, was determined to be redundant for 
transformation195. As previously discussed, IKKε has also been reported to directly activate NF-
κB subunits like cRel82, inducing their nuclear translocation independently of IκBα 
phosphorylation (See 1.2.3.2). Accordingly, Boehm et al. demonstrated that expression of IKKε 
in breast cancer patient tissues correlated with the expression and nuclear localisation of cRel195. 
IKKε can also contribute to the canonical activation of NF-κB in breast cancer. Activation of 
canonical IKK’s and subsequent NF-κB induction involves ubiquitination of various signalling 
components including IKKγ and several upstream factors. CYLD, a tumour suppressor and 
deubiquitinase enzyme, has been shown to inhibit NF-κB activation by removing the conjugated 
ubiquitin from said components. IKKε has been shown to phosphorylate CYLD at serine residue 
Ser418, a modification which restrains CYLD deubiquitinase activity and thereby inhibits the 
tumour suppressor197. Phosphorylation of CYLD by IKKε therefore promotes the activation of NF-
κB signalling and may provide an explanation for how the kinase induces degradation of IκBα in 
spite of the fact that IKKε itself can only phosphorylate one of the two required serine residues 
to do so79. These studies therefore demonstrate how IKKε can activate NF-κB in breast cancer to 
drive disease progression, both by contributing to the degradation of IκBα and by directly 
activating NF-κB subunits to drive breast cancer development. 
1.3.3.1 Downsides of targeting NF-κB in cancer therapy 
 
30% of human breast cancer cases is a substantial fraction for IKKε to be involved in and, with 
no clear association with particular breast cancer subtypes195, the kinase is therefore an 
attractive therapeutic target for a large group of patients.  
For the treatment of IKKε-driven breast cancer, IKKε inhibitors have previously been described. 
3 separate IKKε/TBK1 dual inhibitors, designated SR8185, 200A and 200B, have been shown to 
suppress the proliferation of breast cancer, prostate and oral cancer cells in vitro. 200A was also 
shown to induce apoptosis in the same cells in vitro and suppressed the growth of tumours in a 
xenograft mouse model, demonstrating the effectiveness of IKKε/TBK1 inhibition for cancer 
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therapy198. However, like the canonical IKK inhibitors, these IKKε/TBK1 inhibitors remain at a 
preclinical stage, so have not yet been tested for efficacy in patients. 
One more promising compound is a drug called amlexanox. Already approved for clinical use by 
the US Food and Drug Administration (FDA) in America, amlexanox is an anti-inflammatory 
compound, typically used for the treatment of recurring mouth ulcers and, in Japan, has been 
used to treat other inflammatory conditions such as asthma or rhinitis. Amlexanox was shown 
to selectively inhibit both non-canonical IKK’s104 and has been demonstrated to induce cell cycle 
arrest and apoptosis in glioma cells and suppress glioblastoma growth in xenograft models199. 
However, even though, in this circumstance, amlexanox was shown to exert anti-tumour effects 
by inhibiting IKKε-mediated activation of the Hippo pathway, the drug has still been shown to 
inhibit the activation of the NF-κB pathway200, and therein lies the problem with targeting the 
IKK’s directly. 
Despite the high frequency occurrence of NF-κB dysregulation in cancers, it is not a particularly 
useful therapeutic target. In fact, inhibition of the NF-κB pathway presents several significant 
complications. Given the high number of cellular processes in which NF-κB signalling is involved, 
inhibition is likely to result in many undesirable effects, including immunosuppression.  
Additionally, NF-κB signalling on the whole is remarkably complex and includes various feedback 
mechanisms that can just as easily restrict inflammation as promote it. Indeed, NF-κB inhibition 
has surprisingly been reported to increase the production of pro-inflammatory cytokine IL-1β 
from neutrophils and macrophages. IL-1β precursor pro-IL-1β is produced in response to NF-κB 
signalling, but simultaneously, NF-κB induces expression of serine protease inhibitors in 
neutrophils, which inhibit the processing of pro-IL-1β to IL-1β. Accordingly, suppression of NF-
κB subunit p65 or inhibition of NF-κB via pharmacological inhibition of IKKβ in a mouse model 
was shown to substantially upregulate plasma IL-1β levels due to increased pro-IL-1β processing 
and secretion201. NF-κB has also been reported to upregulate p62, a protein which binds to 
proteins and organelles to target them for autophagy-mediated degradation. In macrophages, 
IL-1β processing is controlled by the “inflammasome”, a protein complex that contains caspase 
1 and processes pro-IL-1β to its mature secretable form. Signals from the mitochondria in 
primed macrophages can activate the inflammasome, but p62, upregulated by NF-κB activation 
in macrophages, can bind to polyubiquitinated mitochondria, degrading them via mitophagy. 
This cuts off the inflammasome activating signals, thereby reducing IL-1β processing and 
secretion202 and again, demonstrating how inhibition of NF-κB can promote inflammation. Such 
mechanisms have been suggested to have developed as an NF-κB independent inflammatory 
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mechanism to ensure appropriate host defence and protective inflammation could be raised in 
response to pathogens that were capable of inhibiting NF-κB signalling201. Importantly, these 
mechanisms suggest that the long-term inhibition of NF-κB necessary for tumour treatment may 
serve to promote an inflammatory environment that could potentially enhance tumour 
formation. 
Furthermore, NF-κB has been suggested to play tumour suppressive roles in certain contexts. In 
epidermal cells, expression of an IκBα super repressor protein and subsequent inhibition of NF-
κB activity was shown to induce hyperplasia, which could be blocked by expression of NF-κB 
subunits203. In endothelial cells, NF-κB reportedly maintains vessel structural integrity, as cells 
expressing the IκBα super repressor showed increased angiogenic potential and the vessels 
formed from those cells demonstrated disrupted tight junction formation, leading to increased 
vessel permeability that is favourable for tumour metastasis204. In liver parenchymal cells, 
deletion of regulatory subunit IKKγ, which is necessary for canonical NF-κB activation, led to 
development of steatohepatitis and spontaneous development of hepatocellular carcinoma in 
a mouse model, indicating a tumour suppressive role for NF-κB in the development of liver 
cancers205. Considering these context specific roles, it is clear that inhibition of NF-κB signalling, 
whilst initially beneficial, might lead to further complications further down the line including, in 
extreme circumstances, giving rise to further tumour development. 
As briefly discussed earlier (see 1.3.1.1), to date there has been little success with the 
development of NF-κB inhibitors, with most attempts stuck firmly in the pre-clinical stages of 
development. One relatively successful compound is bortezomib, a proteasome inhibitor which 
can prevent NF-κB activation by inhibiting the degradation of IκB proteins, thereby maintaining 
the cytoplasmic sequestration of NF-κB subunits206. However, whilst bortezomib has shown 
some efficacy in haematological cancers and has been approved for clinical use in multiple 
myeloma and lymphoma patients207, it has been found to be ineffective in solid tumours. Indeed, 
this story is true of many other compounds. It is likely these disappointing results are down to 
the fact that such inhibitors are very broad therapeutics, failing to target NF-κB specifically and 
having very generalised effects in patients. Accordingly, targeted inhibitors have shown more 
signs of promise (reviewed by Godwin et al.208). NBD peptide, which specifically targets NF-κB 
activation by inhibiting the formation of the canonical IKK complex by binding with IKKγ (or 
NEMO) to prevent its interaction with IKKβ, was mentioned previously. This peptide has been 
shown to reduce cytokine inducible NF-κB-dependent gene expression68 and some efficacy has 
been demonstrated in head and neck squamous cell carcinoma, melanoma and pancreatic 
ductal adenocarcinoma (PDAC) where it inhibited constitutive NF-κB activation, reduced 
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proliferation and migration and induced apoptosis154,209,210. Furthermore, NBD peptide has been 
shown to be efficacious in a phase I clinical trial of ABC-like DLBCL in canines155. 
Despite this, these targeted inhibitors still work to inhibit NF-κB activation and therefore, still 
risk the negative effects described above, meaning the benefits of using such compounds to 
inhibit the pathway for cancer treatment need to be carefully weighed against the drawbacks. 
In the meantime, keeping in mind the context of treating IKKε-driven breast cancers, the 
question remains as to whether therapeutic intervention that avoids targeting NF-κB signalling 
would be possible. To understand the answer to that question, a better understanding of the 
full scope of IKKε’s oncogenic potential is required. As discussed previously (see 1.3.2.2), IKKε 
has been shown to play NF-κB independent roles in the development of various tumour types, 
and that is no different in breast cancer. 
1.3.3.2 NF-κB independent mechanisms of IKKε-driven oncogenesis in breast cancer 
 
Despite Boehm et al.’s findings that IKKε-mediated transformation was dependent on NF-κB 
activity, recent findings have highlighted a selection of other mechanisms by which the kinase 
can support breast tumour development. 
As previously mentioned, IKKε can promote lung tumour development by phosphorylating and 
inhibiting tumour suppressor FOXO3a at serine residue Ser644, resulting in decreased levels of 
apoptosis (see 1.3.2.2). The same phosphorylation also occurs in breast cancer and, as in the 
lung, IKKε expression has been found to correlate with phosphorylation of FOXO3a in breast 
tumours. This indicates that the kinase contributes to breast cancer development by inhibiting 
FOXO3a-induced apoptosis in addition to promoting NF-κB-mediated anti-apoptotic signals177.  
IKKε has also been shown to promote the expression of an alternate variant of ERα in breast 
cancers that are typically classified as ER negative (ER-). ERα-36 is a truncated version of the 
receptor that is primarily cytoplasmic or contained to the cell membrane, having little nuclear 
activity211. IKKε directly interacts with the shortened receptor, inducing its expression in ER- 
breast cancer cells. ERα-36 expression leads to the activation of MAPK signalling and induction 
of cyclin D1 and c-Myc to promote ERα-36-mediated cell growth in ER- breast cancers212. 
Additionally, whilst Boehm et al. described IKKε’s role in innate immunity as dispensable for 
cellular transformation, a subset of triple negative breast cancer cell lines where IKKε activated 
the type 1 interferon pathway and JAK/STAT signalling was identified in 2014. In this study IKKε-
mediated JAK/STAT signalling generated a cytokine network which supported the development 
of the tumour213. These “immunomodulatory” breast cancer cells demonstrated increased 
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secretion of pro-tumourigenic cytokines CCL5 and IL-6, which stimulated cell growth. It was 
shown that simultaneous inhibition of IKKε and JAK signalling abrogated the increased CCL5 and 
IL-6 secretion and reduced proliferation, suggesting therapeutic targeting of the IRF3 branch of 
IKKε signalling might be a valid option for patients with IKKε-driven breast cancer after all.  
Furthermore, it remains to be seen whether any of the NF-κB-independent mechanisms by 
which IKKε promotes tumourigenesis in other cancer types might be at play in a breast cancer 
setting. IKKε has been shown to enhance proliferation of gliomas by stabilising YAP1173, which 
has itself been previously linked to breast cancer, albeit in a somewhat contrasting manner. In 
some instances, it has been shown to be overexpressed and pro-tumourigenic in breast cancer, 
promoting proliferation in cell lines and xenograft tumour formation in a mouse model214. In 
other breast cancer circumstances, YAP1 has been reported to be tumour suppressive, as 
expression was found to be decreased or completely absent in tumour tissues and suppression 
of YAP1 was shown to increase migration and invasion in cells and in a xenograft mouse 
model215. Irrespectively of which side of the fence YAP1 is ultimately shown to fall in breast 
cancer, it is not outside the realms of possibility that if IKKε is promoting glioma formation via 
stabilisation of YAP1, it might also promote breast tumour development in the same way. 
Similarly, IKKε induces MMP3 in lung carcinomas, which helps invasion and metastasis182. MMP3 
is overexpressed in many different types of cancers, including breast, and its elevated expression 
is predictive for poor patient outcome in breast tumours216. It remains to be seen whether IKKε 
also upregulates MMP3 in breast cancer, but it could easily represent another mechanism by 
which the kinase can support the later stage progression of tumours in the breast. 
One area of particularly notable interest is the emerging understanding that IKKε appears 
capable of regulating intracellular metabolism. The role of IKKε in promoting an essential 
increase in glycolytic rate in dendritic cells to support their activation has been previously 
discussed (see 1.2.3.2). Whilst this was the first indication that IKKε could regulate cellular 
metabolic states, the kinase has subsequently been linked with cellular metabolism in pancreatic 
cancer, where it was shown to induce a Myc-mediated upregulation in glucose metabolism to 
support the rapid proliferation of the cancer cells189. 
Given the ubiquitous nature of metabolic reprogramming in human cancers it is now increasingly 
recognised as a key part of tumour formation and a hallmark of cancer20. The increasing evidence 
that IKKε is emerging as a central regulator of metabolism in both immune and cancer settings 
is therefore very exciting, and the question of whether IKKε regulates metabolism in other 
cancers where it is oncogenic, including breast cancer, is a question worth investigating. 
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1.4 Cancer metabolism 
 
1.4.1 Aerobic vs. anaerobic respiration 
 
Respiration describes the process by which the nutrients taken up by a cell are converted into 
energy. The aim of the process is to break down nutrients into useable biological material, so 
that energy held within the nutrients can be stored for future use, or so that the compounds can 
be converted into materials useful for cell growth and proliferation. The most common nutrient 
taken up by cells is sugar in the form of glucose, but while this nutrient uptake is largely the 
same between different cell types, the way in which the nutrients are used within cells is highly 
context-dependent. 
When a source of oxygen is present and readily available, the metabolism of the majority of 
differentiated cells is described as “aerobic”. In aerobic respiration, glucose is used in a process 
called glycolysis, which involves a sequence of biochemical reactions that convert glucose, step-
wise, into pyruvate within the cell (Figure 1.4). The glucose-derived pyruvate then enters the 
mitochondria, where it undergoes decarboxylation by the pyruvate dehydrogenase complex to 
produce a compound called acetyl coenzyme A (acetyl-CoA). Acetyl-CoA is then used as a source 
of acetyl groups to fuel the tricarboxylic acid (TCA) cycle within the mitochondria. As well as 
producing various biosynthetic intermediates, a crucial aerobic product of the TCA cycle is the 
reduced form of nicotinamide adenine dinucleotide (NAD), aka NADH, which is subsequently 
used to fuel oxidative phosphorylation (OXPHOS) by donating electron to an intermembrane 
complex in the inner mitochondrial membrane. These electrons are then passed along a series 
of similar intermembrane protein complexes before being ultimately donated to oxygen, 
reducing it to water. The passing of electrons from complex to complex produces energy which 
is used to pump protons, also donated by NADH, across the inner mitochondrial membrane into 
the intermembrane space. This generates and maintains a proton gradient, which ensures there 
is a pool of H+ protons to fuel the phosphorylation of adenosine diphosphate (ADP) to adenosine 
triphosphate (ATP) via the transportation of the protons back into the cristae through the ATP 
synthase enzyme complex (Figure 1.5). ATP acts as an intracellular energy store and the 
production of ATP via oxidative phosphorylation, fuelled by the electron transport chain (ETC), 
is a highly efficient process, producing a net total of 32 moles of ATP for every mole of glucose 
that is taken into the cell. 
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In the absence of oxygen, the ETC lacks a terminal electron acceptor and therefore cannot 
function, meaning mitochondrial production of ATP ceases. Instead, hypoxic conditions trigger 
a switch in the metabolic activities of cells. Instead glycolysis being used to fuel the TCA cycle 
and subsequently drive OXPHOS, hypoxic cells exhibit “glycolytic” metabolism. Glycolytic cells 
display a significantly increased rate of glycolysis and, instead of producing acetyl-CoA, convert 
glucose-derived pyruvate to lactate via lactate dehydrogenase (LDH). This switch is primarily 
mediated by hypoxia inducible factor 1 (HIF1), a transcription factor complex crucial for the 
intracellular response to changes in oxygen availability217.  
 
 
Figure 1.5 – The electron transport chain. NADH produced in the TCA cycle fuels the ETC to drive OXPHOS through 
the donation of electrons and protons to the inner mitochondrial membrane. The passing of electrons along a series 
of inter-membrane protein complexes provides the energy necessary to pump protons through those complexes and 
into the inter-membrane space of the mitochondria. The maintenance of a proton gradient ensures that the protons 
will pass back into the cristae of the mitochondria via the enzyme complex ATP synthase, providing the energy 
necessary for the complex to phosphorylate ADP and generating one molecule of energy storage unit ATP. The 
electrons that are passed along the membrane are donated to terminal electron acceptor oxygen, hence the term 
oxidative phosphorylation and the requirement of oxygen for mitochondrial respiration. 
 
HIF1 and the balance between aerobic and anaerobic respiration 
HIF1 is a heterodimer complex comprised of the constitutively expressed HIF1β and the post-
translationally regulated HIF1α. The alpha subunit is degraded in the presence of oxygen due to 
the action of oxygen-dependent prolyl hydroxylases (PHDs), which target HIF1α for 
ubiquitination by the von-Hippel-Lindau (VHL) protein and subsequent degradation by the 
proteasome. When cellular oxygen availability is low, the PHDs cannot modify the HIF1α subunit 
which is therefore no longer degraded. Stabilised HIF1α dimerises with HIF1β, facilitating 
nuclear translocation and induction of HIF1 target gene expression218-220. 
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HIF1 induces the anaerobic metabolic state by upregulating glucose transporters like glucose 
transporter 1 (GLUT1) to increase glucose uptake221,222, by upregulating LDH to increase lactate 
production and by inhibiting the mitochondrial uptake of glucose derived carbon through the 
upregulation of pyruvate dehydrogenase kinase (PDK), which phosphorylates and inhibits 
pyruvate dehydrogenase to limit the conversion of pyruvate to acetyl-CoA223,224. This increase in 
glycolytic rate and production of lactate is the key characteristic of “anaerobic respiration”, 
which is significantly less efficient than OXPHOS, producing a net gain of just 2 moles of ATP, 
generated during the main glycolytic process225. Importantly though, as the rate of glycolysis is 
increased by the increase in glucose uptake, the rate of ATP production is much faster which 
allows cells to salvage some overall ATP production despite the lack of oxygen (Figure 1.6).  
 
 
Figure 1.6 – Aerobic vs anaerobic respiration. When oxygen is available, normal differentiated cells will metabolise 
glucose to pyruvate and then convert that pyruvate to acetyl-CoA, which can enter the mitochondria and combine 
with oxaloacetate in the TCA cycle to regenerate citrate to allow continuation of the cycle. NADH is produced in the 
cycle which is used to drive the ETC and OXPHOS, producing large amounts of ATP. This is efficient respiration, 
producing a net gain of about 32 moles of ATP for each mole of glucose consumed. When cells are starved of oxygen, 
the ETC cannot function and the cells enter a state of anaerobic respiration. Transcription factors like HIF1 drive the 
cellular adaptation to hypoxia, by diverting metabolic flux away from the mitochondria. Glucose uptake, glycolytic 
rate and lactate production is elevated, and glucose-derived carbon entry into the mitochondria is inhibited through 
upregulation of pyruvate dehydrogenase kinase, which inhibits pyruvate dehydrogenase to prevent acetyl-CoA 
production. This ensures cells increase their glycolytic rate to maximise production of ATP in hypoxic conditions. 
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1.4.2 The altered metabolic state of tumours 
 
Whilst most differentiated cells only convert pyruvate to lactate in the absence of oxygen, 
rapidly proliferating cells will exhibit “glycolytic metabolism” and preferentially convert glucose-
derived pyruvate to lactate, irrespective of oxygen availability. Indeed, cancer cells, which are 
inherently rapidly proliferative, often, if not always, display this metabolic phenotype in both 
normoxic and hypoxic conditions, exhibiting substantially increased glucose uptake and lactate 
secretion compared to normal differentiated cells. This glycolytic metabolic state, irrespective 
of oxygen availability, is known as “aerobic glycolysis”.  
The observation that cancer cells displayed an altered metabolic state was initially made nearly 
100 years ago in 1924 by German physiologist Otto Warburg226. Warburg hypothesised that the 
reason why cancer cells converted pyruvate to lactate was due to defective mitochondria, 
proposing that mitochondrial dysfunction was an inciting factor in cancer. More recent work, 
and a better understanding of the metabolic state of tumours, has disproven Warburg’s 
hypothesis by demonstrating that cancer cells do in fact exhibit a working TCA cycle227,228 and 
even, in some cancers, intact and functional OXPHOS229,230. However, the aerobic glycolysis 
phenotype, elevated glycolytic rate and the increased conversion of glucose to lactate, is still 
seen as a key hallmark of human cancers and is important for the development of tumours20.  
As mentioned previously, aerobic glycolysis is far less efficient in terms of ATP production than 
classical aerobic respiration via OXPHOS. Therefore, it may seem paradoxical that rapidly 
proliferating cells and cancer cells would preferentially choose a less efficient form of energy 
production. It appears counter-intuitive, especially when one would consider rapid proliferation 
to have higher energy demands than quiescence or senescence. However, sustained aerobic 
glycolysis confers proliferative advantages to cells that go beyond energy production. In order 
to proliferate and generate new cells, certain molecules are required. Lipids are required for 
membrane production, nucleic acids for DNA replication, amino acids for protein production, 
these are the building blocks necessary for creating new cells and rapid proliferation brings a 
high demand for these “anabolic molecules”. Aerobic glycolysis is often accompanied by shifts 
in the fluxes of other intracellular metabolic pathways, mediated by oncogenic activity or 
otherwise, that promote a significant increase in the production of essential anabolic molecules. 
As more glucose is taken up by cells and less pyruvate is taken into the mitochondria, the result 
is an accumulation of glycolytic intermediates available to be diverted into these other 
metabolic pathways for generation of anabolic molecules, allowing cells to meet the high 
anabolic demand and facilitate the continuation of proliferation (Figure 1.7).  
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Altered pathway dynamics in aerobic glycolysis 
One example of this anabolic shift is the enhanced activity of the pentose phosphate pathway 
(PPP) in many cancers. The PPP is a metabolic pathway that branches out from the main 
glycolysis pathway and is fuelled by the glucose-6-phosphate produced in the first glycolytic 
reaction when glucose is phosphorylated by hexokinase. The PPP is one of the body’s main 
sources of reducing agents, producing large amounts of NADPH. NADPH is necessary for 
generating reduced glutathione, a key ROS scavenger within the body, and can also be used in 
biosynthesis reactions including fatty acid synthesis. The pathway also generates ribose-5-
phosphate and other pentose-phosphates essential for the production of nucleotides231. 
Accordingly, the pathway is often aberrantly activated in cancers. Common loss of function 
mutations in tumour suppressor p53 or gain of function mutations in K-RAS have both been 
shown to enhance PPP activity in cancers232,233 and an increase in glucose uptake due to aerobic 
glycolysis results in greater glucose-6-phosphate availability to fuel the PPP in cancer. 
Another example is the altered role that the TCA cycle plays in cancer. When not being used to 
fuel OXPHOS the TCA cycle essentially becomes a biosynthetic hub for anabolic molecule 
production, producing basic components necessary for the synthesis of lipids, proteins and 
nucleotides. The diversion of glucose-derived carbon away from entry into the mitochondria 
means that replenishment of TCA cycle intermediates must be driven by an alternative fuel. In 
most cancers that fuel is glutamine, and accordingly, many cancers exhibit glutamine 
addiction234-236 and overexpress glutamine transporters, resulting in elevated glutamine 
uptake235,237,238. Glutamine can be converted to glutamate by the enzyme glutaminase (GLS) and 
subsequently to TCA cycle intermediate α-ketoglutarate (α-KG) by any of a number of 
aminotransferases. Glutamine-derived α-KG can directly fuel the cycle in the absence of glucose-
derived acetyl-CoA. In agreement with this, 13C-labelled glutamine-based flux analysis, tracking 
the incorporation of glutamine-derived carbon into metabolites, has confirmed the 
incorporation of glutamine-derived carbon into the TCA cycle in cancer227,236. The continued 
replenishment of TCA cycle intermediates, even in the absence of glucose-derived carbon entry, 
allows the cancer cells to continue to take advantage of the biosynthetic products of the TCA 
cycle. For example, oxaloacetate can be used to generate aspartate, which in turn is converted 
to arginosuccinate and subsequently to arginine in the urea cycle. Arginine is an amino acid on 
which rapidly proliferating cells, and many cancers, depend to produce nucleotides, proteins, 
polyamines and more239. Citrate is also an important TCA cycle intermediate for anabolic 
molecule production, as it can be shuttled to the cytoplasm where it is cleaved to acetyl-CoA to 
fuel fatty acid synthesis.  
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Figure 1.7 – Altered tumour metabolism. A schematic overview of some of the key changes that occur in the 
intracellular metabolic network of tumour cells. Similar to anaerobic respiration, tumour cells preferentially exhibit 
glycolytic metabolism and repress mitochondrial respiration. The benefit of this is that the increased glycolytic flux 
allows for increased diversion of glucose-derived carbon into biosynthetic pathways like the pentose phosphate 
pathway or the serine biosynthesis pathway, which allows cells to produce large amounts of anabolic molecules like 
nucleotides and fatty acids to support new cell growth and allows cells to maintain redox balance to avoid oxidative 
toxicities. Cancer cells also utilise glutamine-derived carbon to continue to replenish TCA cycle metabolites in the 
absence of glucose-derived carbon uptake, ensuring the biosynthetic reactions in the cycle can continue. Glucose and 
glutamine-derived carbon atoms are represented as white circles. 
 
Citrate generation within a glutamine-fuelled TCA cycle is not always as straight forward as the 
TCA cycle progressing from α-KG to completion as normal, as lack of glucose-derived carbon 
mitochondrial uptake can mean a lack of acetyl-CoA that can be combined with oxaloacetate to 
regenerate citrate. Instead, generation of citrate from α-KG can require the cycle to run in 
reverse, in a process called reductive carboxylation. In this process, α-KG is oxidised to succinate, 
Chapter 1. Introduction 
43 
 
generating a reducing agent in the form of NADH. The NADH is converted to NADPH by an 
enzyme called nicotinamide nucleotide transhydrogenase (NNT) and then fuels the conversion 
of α-KG to isocitrate by the action of the isocitrate dehydrogenase (IDH) isoform 2 (IDH2). 
Isocitrate can then be converted back to citrate for anabolic use240,241. 
One carbon metabolism represents another pathway that is enhanced in aerobically glycolytic 
conditions. This broad term describes the combined folate and methionine cycles which 
generate one carbon units within cells that are necessary for nucleotide synthesis and DNA 
methylation events. One-carbon metabolism also generates NADPH, which can be used for the 
reduction of glutathione to maintain intracellular redox balance. Enhanced folate and 
methionine cycle activity therefore allows cancer cells to generate more nucleotides to support 
their rapid proliferation and protect against ROS generation to prevent cell death (reviewed by 
Yang and Vousden, 2016242 and Newman and Maddocks, 2017243). As with the PPP, aerobically 
glycolytic conditions support enhanced one carbon flux as accumulation of glycolytic 
intermediates allows diversion of more glucose-derived carbon into the one-carbon cycles via a 
branching biosynthesis pathway that generates the amino acids serine and glycine. The 
contribution of the “serine biosynthesis pathway” to one carbon metabolism and cancer will be 
discussed below (see 1.4.4.1 and 1.4.4.2). 
1.4.3 Oncogene-driven metabolic alterations 
 
With altered metabolism playing such an important role in supporting the development of 
tumours, it is understandable that many different oncogenes have been shown to induce 
metabolic changes or, from another perspective, that many proteins which induce metabolic 
changes have been classified as oncogenes, or effectors of oncogenic signalling. A selection of 
such key regulators is discussed below.  
1.4.3.1 HIF1α 
 
Activation of the aforementioned hypoxia-inducible factor 1 (HIF1) in hypoxic conditions is a key 
mechanism behind how cells switch between aerobic and anaerobic respiration and, 
unsurprisingly, many tumours feature dysregulated HIF1 activation. Overexpression of the alpha 
subunit is common in many cancers, in a manner often predictive of poor patient outcome244-
246. HIF1α is stabilised in cancers in a variety of ways, facilitating its dimerisation with HIF1β and 
activation of HIF transcriptional activity. A common way involves the expansion of a tumour 
beyond the range of oxygen perfusion from the existing vasculature. This results in the centre 
of the tumour becoming hypoxic. The lack of oxygen results in stabilisation of HIF1α and 
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subsequent HIF1 transcriptional activity promotes the revascularisation of the tumour by 
inducing expression of VEGF, which simulates endothelial cell growth and vessel formation247,248. 
As well as stimulation of angiogenesis, HIF1 target genes also promote the adaptation of cancer 
cells to the hypoxic environment by promoting the aerobic glycolysis phenotype, thereby 
reducing the dependency of cells on oxygen to respire. As mentioned earlier, this action comes 
through the regulation of glycolysis at multiple nodes. Firstly, HIF1 increases the amount of fuel 
available for glycolysis, increasing glucose uptake by enhancing expression of glucose 
transporters. The best reported upregulation is of GLUT1222, but HIF1 has been linked with 
upregulation of other GLUT’s in cancer as well. For example, in glioma HIF1 expression correlates 
with GLUT3249. HIF1 also promotes aerobic glycolysis by diverting carbon flux away from the 
mitochondria and toward lactate production through upregulation of pyruvate dehydrogenase 
kinase and lactate dehydrogenase respectively223,224, effectively preventing the mitochondrial 
use of glucose-derived carbon. Additionally, HIF1 has been reported to actively contribute to the 
increased rate of glycolysis by upregulating the expression of glycolytic enzymes hexokinase II250, 
fructose-bisphosphate aldolase, phosphoglycerate kinase (PGK) and pyruvate kinase M 
(PKM)251. HIF1 also induces the expression of a kinase called 6-phosphofructo-2-kinase/fructose-
2,6-bisphosphatase (PFKFB3)252,253. Glycolytic enzyme phosphofructokinase 1 (PFK1) is a key 
enzyme in the glycolytic process, catalysing the irreversible conversion of fructose-6-phosphate 
into fructose-1,6-bisphosphate whilst consuming 1 mole of ATP in the process. PFK1 is itself 
allosterically activated by fructose-2,6-bisphosphate, and PFKFB3 is a bifunctional enzyme which 
promotes both the synthesis and degradation of fructose-2,6-bisphosphate, thereby tightly 
regulating PFK1 activity. Therefore, induction of PFKFB3 and glycolytic enzymes like hexokinase 
II by HIF1 allows hypoxia-mediated regulation of glycolytic rate which, combined with regulation 
of glucose uptake and mitochondrial uptake of glucose-derived carbon, gives HIF1 extensive 
control over the aerobic glycolysis phenotype. 
HIF1 activation in tumours is not solely dependent on hypoxic conditions however, as many 
tumours exhibit “pseudohypoxia”, or the stabilisation of HIF1α even in the presence of oxygen. 
Pseudohypoxia can be induced by a number of factors, including loss of function mutations in 
the gene encoding VHL protein254 or activation of the PI3K/AKT/mTOR pathway which leads to 
an mTOR-mediated increase in the rate of HIF1α synthesis, allowing stable expression of HIF1α 
above what is degraded255. Pseudohypoxia can therefore arise through loss of function 
mutations in PI3K inhibitor PTEN256 or gain of function mutations in mTOR-associated receptor 
tyrosine kinases such as HER2255, both of which are common in cancers. One other example of a 
mechanism by which pseudohypoxia can be induced is through the common mutation of 
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succinate dehydrogenase (SDH) in cancers. SDH catalyses the conversion of succinate to 
fumarate in the TCA cycle, and loss of function mutations or downregulation of expression of 
SDH is common in cancers257,258. This results in an accumulation of succinate which, in the 
context of HIF1 activation, inhibits PHDs in the cytosol to prevent the degradation of HIF1α in 
normoxic conditions259. 
1.4.3.2 Myc 
 
The Myc family of transcription factors, specifically the c-Myc protein, have been extensively 
linked to cancer, and recent studies have demonstrated that aberrant activation of c-Myc 
transcriptional activity is heavily involved in the regulation of cellular metabolism in many 
human cancers.  
Originally identified as a mammalian cell homolog of v-Myc, a retroviral oncogene, in Burkitt 
lymphoma patients (where it is the target of common chromosomal translocations)260, c-Myc is 
transcriptionally activated by various signalling pathways that regulate cell growth and 
proliferation, and acts as a convergence point for pathways like Wnt/β-catenin and ERK/MAPK 
signalling in the downstream induction of genes that promote proliferation. Accordingly, Myc 
dysregulation is a common event in cancer development. In haematological malignancies, it is 
frequently subject to chromosomal translocations which lead to enhanced activation, and 
studies examining genetic amplification in human cancers have repeatedly identified it as one 
of the most frequently amplified genes across a variety of cancer types261-263. 
As understanding of c-Myc’s role in cancer has developed, it has become evident that the 
transcription factor tightly regulates cellular metabolism in a myriad of ways. Firstly, the 
oncogene has been shown to promote enhanced glycolysis, as activation of Myc induces 
expression of glucose transporter GLUT1; glycolytic enzymes like hexokinase II, PFK1, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), PGK and enolase264,265; and LDH266. This 
enhances glucose uptake, glycolysis and lactate production respectively to promote aerobic 
glycolysis. 
As well as regulating glucose metabolism though, Myc appears to play an important role in 
glutamine metabolism in tumours. The importance of glutamine to tumours was discussed 
earlier (see 1.4.2), but briefly, the uptake of glutamine allows cancer cells to continue to fuel a 
truncated version of the TCA cycle in the absence of glucose-derived carbon uptake. Myc 
supports this by enhancing glutamine metabolism. The oncogene has been reported to 
transcriptionally upregulate the expression of glutamine transporters and glutaminase to 
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promote glutamine uptake and the conversion of glutamine to glutamate respectively. The 
oncogene has been shown to bind directly to the promoter regions of genes encoding glutamine 
transporters in order to upregulate them235 and experiments performed using tamoxifen-
inducible c-Myc-expressing MEFs have demonstrated that expression of the oncogene leads to 
an increase in GLS mRNA levels and glutaminase enzymatic activity235. Furthermore, liver 
tumours induced specifically by MYC in a mouse model have been shown to exhibit significantly 
increased GLS mRNA levels compared to normal tissues265. Interestingly, c-Myc has also been 
shown to regulate glutaminase expression indirectly in a Burkitt lymphoma cell line, through 
transcriptional repression of miRNA’s miR-23a and miR-23b, both of which target the 3’ UTR of 
GLS mRNA, demonstrating how the oncogene can regulate glutaminase expression through both 
direct and indirect means. 
Notably, Myc appears to regulate the expression of multiple glutaminase isoforms. GLS1 and 
GLS2 encode tissue-specific glutaminase isoforms (GLS1 encodes kidney-type isoforms and GLS2 
encodes liver-type267, however alternate splice variants of each type have been detected in a 
range of tissues268). Fellow Myc family member N-Myc has been shown to directly bind to intron 
1 of the GLS2 gene and directly induce promoter activation269. A binding site for c-Myc in the 
same intron has been predicted268, indicating that the GLS2 promoter could also be activated by 
c-Myc as well as N-Myc.  
Together, the studies mentioned above demonstrate how c-Myc promotes glutamine 
metabolism by enhancing uptake and processing of glutamine within cancer cells. However, 
increased glutamine metabolism may provide a potential therapeutic exploit for treatment of 
tumours. It has been demonstrated that the enhancement of glutamine metabolism by c-Myc 
triggers glutamine dependency within cancer cells. Indeed, cells which express c-Myc have been 
shown to undergo apoptosis when deprived of glutamine, in a manner that can be rescued by 
delivery of TCA intermediates234,235. Not only does this demonstrate the importance of cancer 
cells continuing to fuel the TCA cycle in the absence of glucose-derived carbon uptake, it 
highlights how blocking the entry of glutamine-derived carbon into the TCA cycle might 
represent an effective therapeutic strategy in cancers which exhibit aerobically glycolytic 
metabolism. 
1.4.3.3 Pyruvate Kinase 
 
Arguably one of the most central regulators of cancer metabolism is glycolytic enzyme pyruvate 
kinase, which catalyses the conversion of Phosphoenolpyruvate (PEP) to Pyruvate, producing 
one molecule of ATP in the process (Figure 1.4). Four distinct isoforms of the kinase exist from 
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two separate genes. Alternative splicing of the PKLR gene generates the PKL or PKR isoforms, 
expressed in the liver or the red blood cells respectively270, whereas alternative PKM splicing 
gives rise to either the muscle type-1 (PKM1) isoform, which is predominantly expressed in most 
adult tissues, or the muscle type-2 (PKM2) isoform, which is usually only expressed during 
embryonic development271,272. 
Most cancers exclusively express the M2 isoform271. It can be transcriptionally upregulated by 
HIF1 activity and c-Myc has been shown to regulate PKM alternative splicing to inhibit the 
generation of the M1 isoform and thus promote M2 expression273,274. Aberrant activation of 
EGFR, which is commonly observed in tumours, has also been demonstrated to induce PKM2 
expression in a range of breast cancer cell line, via the activation of canonical NF-κB signalling275. 
PKM2 also exists in discrete forms which dictate the activity of the kinase. In a tetrameric form 
PKM2 is highly active, whereas in a monomeric or a dimeric form it exhibits very low activity. 
The enzyme is known to be allosterically regulated by fructose-1,6-bisphosphate, 
succinylaminoimidazolecarboxamide ribose-5’-phosphate (SAICAR) and serine which 
dynamically controls the state of PKM2 activity in response to glucose availability and different 
requirements for glucose utilisation276-278. Intriguingly however, the predominant state is one of 
inactivity. This means that cancers preferentially express a variant of pyruvate kinase whose 
basal activity is lower than that of normal tissues. Whilst this seems to go against the idea of a 
rapid aerobic glycolysis phenotype, the restriction of glycolytic flow is in fact beneficial for 
proliferation. 
The reduction in pyruvate kinase activity triggers a build-up of upstream glycolytic intermediates 
as a consequence of reduced conversion of PEP to pyruvate. This actively promotes the anabolic 
phenotype of tumour metabolism, as build-up of glycolytic intermediates significantly increases 
the pool of glucose-derived carbon that is available for use in the biosynthetic pathways that 
branch from glycolysis such as the PPP, hexosamine biosynthesis pathway, or the serine 
biosynthesis pathway, thereby enhancing the production of anabolic molecules in order to 
support the rapid proliferation of tumours. Indeed, the importance of PKM2 for continued 
proliferation of cancer cells and the maintenance of aerobic glycolysis has been demonstrated 
in many cancer models. Examples include human lung cancer cells and xenograft mouse models, 
where suppression of PKM2 reduced cell proliferation, and expression of PKM1 was shown to 
increase OXPHOS and suppress tumour formation in mice compared to PKM2 expression271; 
ovarian cancer cell lines, where PKM2 suppression inhibited proliferation and invasion, and  
induced apoptosis279; and colorectal cancer cells, where suppression of PKM2 reduced lactate 
production, proliferation and invasion, and increased apoptosis280. 
Chapter 1. Introduction 
48 
 
It is important to note however, that the preferentially inactive state of PKM2 does not 
completely abolish pyruvate production in cancer cells. Instead, the expression of PKM2 allows 
cells to respond to the changing demands of proliferation, letting them adapt to ever-changing 
nutrient availability on the fly. In aerobic glycolysis, glucose-derived carbon is either used to 
produce pyruvate (and subsequently lactate) facilitating ATP production, or it is used in 
biosynthesis. Expression of allosterically regulated PKM2 allows cells to recognise when one 
requirement is greater than the other. As mentioned earlier, serine is capable of activating PKM2 
and does so when its intracellular concentration is high enough. This provides the cell with a 
mechanism by which it can respond to biosynthetic needs. If enough glucose-derived carbon is 
being diverted into biosynthesis, intracellular serine production will be elevated and serine 
concentration will rise. In turn, PKM2 will be activated allowing a balance between the use of 
glucose-derived carbon in biosynthesis and in glycolysis. In circumstances where glucose 
availability is low, the amount of glucose-derived carbon being diverted into biosynthesis will 
drop and accordingly, so will serine concentration. PKM2 will subsequently inactivate and the 
progression of glycolysis will be blocked. This will result in build-up of glycolytic intermediates 
and the maximal biosynthetic use of glucose until such a time when nutrient availability 
increases, or biosynthetic demands are met277. Essentially, dynamic regulation of PKM2 
facilitates the carefully controlled balance between energy production and biosynthesis that 
arises from aerobic glycolysis. 
Aside from this dynamic regulation, there is evidence to suggest that inactive PKM2 can enhance 
aerobic glycolysis in other ways as well. Firstly, it has been suggested that PKM2 inactivity allows 
the glycolytic pathway to escape inhibitory feedback loops that normally restrict the rate of 
glycolysis within cells. Key glycolytic enzymes like PFK1 are subject to end-product inhibition by 
ATP281, which helps to slow the rate of glycolysis when ATP concentrations are high. Because 
conversion of PEP to pyruvate by pyruvate kinase produces ATP, the classical glycolysis pathway 
can contribute to cellular ATP concentration and, considering the speed at which glycolysis 
occurs in tumours, could be sufficient to induce such inhibition. PKM2’s lack of activity thereby 
prevents glycolytic production of ATP, allowing the upstream reactions to continue unhindered. 
In accordance with this model, an alternative end to the glycolytic process has been proposed 
in the presence of inactive PKM2, whereby the phosphate group of PEP, which would usually be 
transferred to ADP to make ATP by pyruvate kinase, is instead transferred to a catalytic residue 
on phosphoglycerate mutase (PGAM) (Figure 1.8). This mechanism has been demonstrated in 
both lung cancer cells and prostate and breast carcinoma tissue from mice and represents a 
mechanism by which cancer cells expressing PKM2 can generate pyruvate in glycolysis  
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Figure 1.8 – The alternative glycolytic pathway. In order to avoid ATP-mediated end product inhibition of glycolytic 
flux, an alternative culmination of the glycolytic sequence has been proposed260. As PKM2 is an inactive version of 
pyruvate kinase, it cannot remove the phosphate group from PEP and therefore cannot produce ATP. Instead, the 
phosphate-group from PEP has been shown to be donated to the PGAM enzyme at physiological concentrations, 
phosphorylating PGAM histidine residue His11 when PKM2 is expressed. This allows the production of pyruvate 
without concurrent ATP synthesis and therefore, completion of glycolysis with no net ATP gain, which can allow 
cancer cells to maintain rapid glycolytic rates without end-product inhibition due to accumulation of ATP. White 
circles represent carbon atoms and red circles represent phosphate groups on glycolytic intermediates. 
 
independently of ATP production, thereby uncoupling glycolysis from ATP-mediated end 
product inhibition and allowing glycolysis to progress unhindered282. 
Secondly, the inactive monomer or dimer form of PKM2 is capable of nuclear translocation, 
whereas the tetrameric form is not. Interestingly, nuclear PKM2 has been linked with both HIF1-
mediated regulation of aerobic glycolysis and c-Myc-associated tumourigenesis. Dimeric PKM2 
has been shown to interact with nuclear HIF1α and, in doing so, promote the binding of HIF1 to 
the promoters of HIF-responsive genes, including the glycolytic genes which it regulates283,284. 
Interestingly, treatment of NSCLC cell lines with activators of PKM2, which promote the 
formation of stable PKM2 tetramers, reduced cell proliferation under hypoxic conditions and 
triggered a reduction in lactate production whilst simultaneously increasing oxygen 
consumption rate, both of which are characteristic changes indicative of a metabolic switch from 
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aerobic glycolysis to OXPHOS. Furthermore, activation of PKM2 was shown to reduce tumour 
growth in an NSCLC xenograft mouse model285. This highlights two things. Firstly, the importance 
of PKM2 inactivity for the maintenance of aerobic glycolysis and promotion of tumour formation 
and secondly, that the HIF1-mediated response to hypoxia, and its ability to promote aerobic 
glycolysis, is dependent on inactive PKM2. This therefore further emphasises the benefits that 
can be provided to cells preferentially expressing an inactive form of the kinase.  
Nuclear PKM2 has also been associated with phosphorylation of histone H3 at threonine 11 
(H3T11). Phosphorylation of the histone at this site has been linked with cancer in the past. In 
prostate cancer, increased H3T11 phosphorylation correlated with a higher Gleason score and 
therefore, worse prognosis286, and levels of H3T11 phosphorylation have been shown to 
correlate with malignancy grade and prognosis in gliomas287. Nuclear PKM2 has been reported 
to directly bind to and phosphorylate H3T11, possibly in combination with serine biosynthesis 
enzymes (see 1.4.4.1) and S-adenosylmethionine (SAM) synthetases as part of a serine-
responsive SAM-containing metabolic enzyme (SESAME) complex, although this complex has, so 
far, only been characterised in yeast287,288. Phosphorylation of H3T11 induces the dissociation of 
histone deacetylase 3 (HDAC3) from the promoter regions of CCND1 and MYC genes, encoding 
cyclin D1 and c-Myc respectively. Since histone deacetylases repress gene transcription, 
disassociation of deacetylases from gene promoters can conversely induce gene expression and 
accordingly, phosphorylation of H3T11 by PKM2 has been shown to induce cyclin D1 and c-Myc 
expression, thereby promoting tumour cell proliferation287. 
PKM2 has also been shown to promote tumourigenesis via other non-metabolic mechanisms, 
including protecting cells from oxidative stress and ROS-induced apoptosis through direct 
phosphorylation and stabilisation of Bcl2289, and promoting the phosphorylation and nuclear 
translocation of STAT3 to promote EMT and migration in colorectal cancer290. PKM2 therefore 
plays an important role in tumourigenesis, both by promotion of the aerobic glycolysis metabolic 
phenotype and by other non-metabolism related mechanisms. 
1.4.4 Metabolites as supporters of cancer development 
 
Many different oncogenes and tumour suppressors have repeatedly been shown to be involved 
in the regulation of the aerobic glycolysis phenotype. In addition to those discussed above, 
oncogenic PI3K/AKT/mTOR signalling actively promotes aerobic glycolysis through the 
upregulation of glucose transporters291 and stabilisation of HIF292, and loss of tumour suppressor 
p53 is associated with increased expression of glucose transporters293 and reduced expression 
of cytochrome c oxidase 2, which is  necessary for OXPHOS complex formation294. What is also 
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becoming clearer as our understanding of cancer metabolism develops is how metabolite 
alterations that arise from aerobically glycolytic conditions can themselves support the 
development of cancer outside of anabolic benefits.  
A good example of this is the previously mentioned succinate and its ability to stabilise HIF1α in 
normoxic conditions, resulting in pseudohypoxia and induction of all the pro-tumourigenic HIF1 
target genes. Succinate levels are frequently elevated in cancer as a consequence of SDH 
inactivation or dysfunction but can also be elevated by altered tumour metabolism as a 
consequence of increased glutamine metabolism and feeding of the TCA cycle with glutamine-
derived carbon295. Accumulated succinate can induce HIF1α stabilisation via inhibition of PHDs259 
and, in turn, promote HIF1-mediated angiogenesis, invasion and metastasis to support tumour 
development.  
Another example comes from the role that metabolites can play in the regulation of the 
epigenome in cancer. Recent years have seen an increase in the understanding of the cross-talk 
that occurs between metabolism and the epigenetic regulation of gene expression. Indeed, 
PKM2’s aforementioned ability to modulate gene expression via phosphorylation of H3T11 and 
subsequent modulation of histone acetylation stands as a prime example of that cross-talk. 
Importantly though, recent studies have shown that metabolites themselves can effect changes 
in gene expression through epigenetic regulation. Gain of function mutations in the gene 
encoding TCA cycle enzyme IDH are common in gliomas and leukaemia296-298 and confer cells 
with the ability to convert α-KG into oncometabolite 2-hydroxyglutarate (2-HG)299. 2-HG 
competitively inhibits a class of enzymes called α-KG-dependent dioxygenases. This dioxygenase 
enzyme class includes enzymes that regulate the methylation status of the genome, such as 
histone demethylases and ten-eleven translocation (TET) hydroxylases, which convert 5-
methylcytosine that is used for DNA methylation to 5-hydroxmethylcytosine300. The inhibition 
of these enzymes by 2-HG therefore facilitates increased DNA methylation. Indeed, the 
production of 2-HG in glioma and leukaemia has been shown to induce a state of global DNA 
hypermethylation, which establishes a gene expression programme that supports cancer 
development in a manner which is at least partially attributable to reductions in cellular 
differentiation. Reduced cellular differentiation therefore promotes a more proliferative stem-
like state for the cancer cells301,302.  
Similarly, other TCA cycle metabolites, like fumarate and succinate, have also been shown to be 
competitive inhibitors of histone demethylases and TET hydroxylases and can promote histone 
and DNA hypermethylation in cancers when accumulated. Accordingly, siRNA-mediated 
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suppression of fumarate hydratase (FH) or SDH in vivo, modelling common loss of function 
mutations in cancers, has been shown to induce histone methylation and upregulate the 
expression of genes associated with the regulation of differentiation in a mouse model303. 
Modulation of cellular metabolism is therefore integral to tumour development for several 
reasons. Increasing the production of anabolic molecules allows cells to meet the high 
biosynthetic demands of rapidly proliferating cells, but modulation of intracellular metabolite 
levels can also support cancer development in ways independent of classic metabolic roles, by 
enhancing the transcriptional activity of an oncogene or by tuning the global gene expression 
programme to a state that encourages tumourigenesis. It is therefore easy to understand why 
cancers exhibit these drastically altered metabolic states. From a therapeutic standpoint, the 
benefits of this are clear. There are specific metabolic pathways that exhibit increased activity 
in many cancers that can facilitate all of these pro-tumourigenic activities combined and 
therefore represent possible critical nodes of altered metabolism in tumours which potentiate 
multiple growth benefits. Identification of these key pathways can therefore highlight several 
attractive therapeutic targets, the inhibition of which could significantly destabilise tumour 
metabolism and prevent disease progression. One of the best examples of such a pathway is the 
serine biosynthesis pathway. 
1.4.4.1 Serine biosynthesis and catabolism 
 
Responsible for the de novo production of non-essential amino acid serine inside the cell, the 
serine biosynthesis pathway (SBP) is comprised of three biochemical reactions that sequentially 
convert glycolytic intermediate 3-phosphogylcerate into serine (Figure 1.9). The first enzyme of 
the pathway, phosphoglycerate dehydrogenase (PHGDH) diverts glucose-derived carbon away 
from the main glycolytic process, oxidising 3-phosphoglycerate to produce 
phosphohydroxypyruvate and reducing agent NADH. The second reaction is a transamination 
reaction, catalysed by phosphoserine aminotransferase 1 (PSAT1), which transfers an amino 
group from glutamine-derived glutamate to phosphohydroxypyruvate, converting it to 
phosphoserine as well as converting glutamate to α-KG in the process. The third and final step 
involves hydrolysis of phosphoserine and removal of the phosphate group. This step is catalysed 
by phosphoserine phosphatase (PSPH) and leaves fully synthesised serine.  
Serine can then be catabolised to produce glycine via the action of the serine 
hydroxymethyltransferase (SHMT) enzyme. SHMT catalyses the transfer of a methyl group from 
serine to tetrahydrofolate (THF). This produces methylene-tetrahydrofolate, which is used in 
one-carbon metabolism, and serine-derived glycine. Unlike the other reactions of the pathway, 
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this is a reversible reaction, meaning serine and glycine are readily interconvertible. Indeed, 
serine can also be synthesised within the cell from glycine. However, this yields little benefit for 
cells other than serine production, whereas the forward progression of serine biosynthesis from 
glucose and the subsequent production of glycine from serine support the rapid proliferation of 
cancer cells in various ways. 
 
 
Figure 1.9 – The serine biosynthesis pathway and catabolism to glycine. Serine and glycine production within tumour 
cells represents a key metabolic pathway for support of rapid proliferation. Serine and glycine production benefits 
cells in terms of protein production, but the by-products of the pathway are crucial for supporting anabolic 
metabolism and maintaining redox balance. The second enzyme of the pathway is catalysed by PSAT1, an 
aminotransferase that can facilitate the conversion of glutamate to α-KG, thereby allowing the use of glutamine-
derived carbon in the anabolic reactions of the TCA cycle. The catabolism of serine to glycine involves the donation 
of carbon atoms to the one-carbon pool, which supports rapidly proliferating cells through the production of 
nucleotides and reducing agents essential for maintaining cellular redox states at non-toxic levels. Indicative of the 
importance of the pathway for cancer, PHGDH is an established oncogene and all the other enzymes have been 
implicated in various cancers as well. 
 
1.4.4.2 The serine biosynthesis pathway in cancer 
 
In 2011, near simultaneous publications identified PHGDH as an oncogene, reporting copy 
number gain of the genetic locus wherein the PHGDH gene resides. This copy number gain 
resulted in amplification of the gene, overexpression of the PHGDH enzyme and increased serine 
production as a result in melanoma and breast cancer. It was demonstrated that suppression of 
PHGDH, or other serine biosynthesis enzymes PSAT1 and PSPH, in cell lines where PHGDH was 
amplified resulted in suppression of proliferation, and suppression of PHGDH in a breast cancer 
xenograft mouse model reduced tumour formation. Furthermore, ectopic expression of PHGDH 
in MCF-10A breast epithelial cells promoted lumen filling and loss of cellular polarity in a 3D 
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spheroid formation assay, indicating the enzyme promoted cancer like properties and enhanced 
anchorage-independent growth304,305. Increased PHGDH expression has also been reported in 
pancreatic tumours, where it has been shown to correlate with patient prognosis. Higher PHGDH 
expression correlated with greater tumour size, metastasis and worse staging in pancreatic 
cancer patients. Accordingly, suppression of PHGDH reduced proliferation, migration and 
invasion of pancreatic cancer cells306. PHGDH was also shown to correlate with poor prognosis 
in a subset of lung adenocarcinomas. In this subset, cells exhibited a higher glycolytic rate and 
elevated serine biosynthesis, and suppression of the enzyme induced cell death demonstrating 
dependency on the pathway for cell survival. These cells also displayed higher levels of reduced 
glutathione and PHGDH suppression induced DNA damage, demonstrating a pro-tumourigenic 
role for the enzyme in protection against oxidative stress and DNA damage307. In multiple 
myeloma PHGDH expression and increased SBP activity has also been shown to promote 
resistance to bortezomib due to an increased anti-oxidant capacity308. 
Other enzymes of the pathway have been associated with tumour development as well. PSAT1 
has been implicated in colon cancer, where overexpression of the enzyme increased colon 
cancer cell proliferation and xenograft formation in a mouse model. PSAT1 was also 
demonstrated to induce chemoresistance in colon cancer cells, reducing apoptosis in response 
to therapy. Correspondingly, expression level of PSAT1 in patient tumours negatively correlated 
with tumour regression in response to therapy309. In NSCLC, PSAT1 has been implicated in 
regulation of the cell cycle. Overexpression of PSAT1 in NSCLC has been shown to promote cyclin 
D1 expression and cell cycle progression through a glycogen synthase kinase 3 β (GSK3β)/β-
catenin signalling axis310. Furthermore, overexpression of the PSAT1 also correlates with poor 
prognosis in breast, nasopharyngeal and oesophageal squamous cell carcinoma311-313. The 
enzymes of the SBP have additionally been associated with later stage disease progression. In a 
breast cancer context, PHGDH and PSAT1 were overexpressed in a metastatic breast cancer cell 
line compared to a less metastatic variant, and suppression of PSAT1 reduced cell proliferation 
in the metastatic cell line, suggesting a potential role for the pathway in more aggressive 
metastatic tumours314. 
Although less well studied, recent work has begun to implicate PSPH in cancer as well. It has 
been reported that aberrant expression of  the enzyme correlates with poor outcome in HCC 
patients315 and, in colorectal cancer tissues, overexpressed PSPH has been shown to promote 
resistance to 5-fluorouracil therapy316 and act a prognostic marker, correlating with invasion and 
metastasis in patient samples317. Although not a mainline serine biosynthesis enzyme, SHMT has 
also been associated with cancer development, including in ovarian cancer where the enzyme 
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has been reported to promote tumour growth and migration through the induction of pro-
oncogenic inflammatory cytokines IL-6 and IL-8318; breast cancer, where the expression of the 
enzyme negatively correlated with patient prognosis319; and neuroblastoma, where the enzyme 
was reported to protect against redox imbalance in hypoxia and its expression again correlated 
with poor patient outcome320. 
The repeated overexpression of the SBP enzymes and enhanced SBP activity in so many cancer 
types indicates the importance of the pathway for tumour growth and development. A big 
reason for this importance is likely down to the fact that enhanced de novo production of serine 
and glycine from glucose-derived carbon yields several benefits for proliferating cells. Obviously, 
production of serine and glycine is beneficial to cells in terms of protein production. Moreover, 
increased serine levels can have unexpected benefits for cancers, as the amino acid has been 
shown to induce osteoclastogenesis to stimulate bone resorption, which can contribute to the 
metastasis of primary breast tumours to bone314.  However, most serine and glycine used by 
cells is just taken up from the extracellular environment when it is readily available. Instead, the 
main benefit of increased SBP activity comes from increased flux through the biochemical 
reactions that both produce serine and catabolise it to glycine.  
Serine and glutamine anaplerosis 
As previously mentioned, many cancers exhibit glutamine addiction and feature elevated 
glutamine uptake and glutaminolysis. The benefit of this phenotype is that cancer cells can 
continue to fuel the TCA cycle in the absence of glucose-derived carbon usage, thereby 
facilitating the continuation of the biosynthetic reactions that occur within the cycle (see 1.4.2). 
The PSAT1-catalysed SBP reaction can support this phenotype, as the catabolism of glutamine 
requires its conversion to glutamate by glutaminase and the subsequent removal of an amino 
group from glutamate to generate α-KG ready for use in the TCA cycle. PSAT1 is an 
aminotransferase enzyme and can therefore transfer the amino group from glutamate to 
phosphohydroxypyruvate. In the process, this reaction progresses serine biosynthesis but also 
converts glutamate to α-KG, facilitating the usage of glutamine-derived carbon in the TCA cycle. 
Indeed, when PHGDH’s oncogenic potential in breast cancer was discovered, it was noted that 
a substantial portion of α-KG in PHGDH amplified breast cancer cells was derived from serine 
biosynthesis. It was also recognised that reduced breast cancer cell proliferation resulting from 
PHGDH suppression was not necessarily attributable to reductions in serine production, since 
serine was readily available in the medium, but rather to the reduction in PSAT1-mediated α-KG 
production. Concurrently, suppression of both PHGDH and PSAT1 was shown to significantly 
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reduce incorporation of glutamine-derived carbon into the TCA cycle305. Enhanced activity of the 
SBP is therefore a major contributor to maintaining TCA cycle anaplerosis in aerobic glycolysis 
and is a key supporter of glutamine metabolism. 
Serine and redox balance 
The other major growth benefits of the SBP come from the catabolism of serine to glycine. The 
importance of one-carbon metabolism in aerobic glycolysis and cancer growth has been 
previously mentioned (see 1.4.2) and the breakdown of serine to glycine is a major contributor 
to the one carbon pool. Catalysed by SHMT, the one carbon unit that is removed from serine to 
generate glycine is donated to THF, generating methylene-THF. From this point on, serine-
derived carbon has entered the folate cycle and can support cancer development through 
nucleotide production and the generation of critical reducing agent NADPH. The NADPH 
produced within the folate cycle following the conversion of methylene-THF to 10-formyl-THF, 
is used to produce reduced glutathione, which is an essential ROS scavenger and crucial for 
protecting against oxidative stress. Enhanced SBP flux can therefore benefit cancer cells by 
maintaining intracellular redox balance and protecting against ROS-mediated toxicity320. By 
extension, this also explains why cancers with enhanced SBP activity or serine biosynthesis 
enzyme expression have been shown to exhibit resistance to therapeutics which cause oxidative 
damage307,308,316. 
Serine and epigenetic regulation 
The donation of one carbon units from serine to one carbon metabolism also contributes to 
oncogenic epigenetic regulation via the methionine cycle. After cycling around the folate cycle, 
the one carbon unit from serine is eventually transferred into the methionine cycle, where it is 
combined with homocysteine to regenerate methionine. Methionine is then converted to SAM 
with the addition of an adenosine nucleoside. SAM can then stimulate DNA methyltransferase 
reactions and inhibit the activity of DNA demethylases, thereby promoting DNA 
hypermethylation and the epigenetic regulation of gene expression321. This allows cells to 
maintain regulation of DNA methylation even in the event of methionine starvation.  
Notably however, serine still contributes to the regulation of DNA methylation in a methionine 
rich environment. If serine-derived one carbon units are not used to generate methionine, they 
are still used, along with serine derived glycine, for purine synthesis and de novo ATP production, 
which is used in the conversion of methionine to SAM. This therefore demonstrates that serine 
catabolism to glycine is a crucial step for regulation of DNA methylation in all conditions322.  
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It is important not to understate the importance of serine’s catabolism to glycine in the 
maintenance of cancer cell proliferation. Further demonstrating that the pathway, not the 
product, is the crucial aspect of upregulated SBP activity in cancer, it has been shown that serine 
starvation, but not glycine starvation, has an inhibitory effect on the proliferation of breast 
cancer cells due to a reduction in nucleotide synthesis. This is important as it demonstrates that, 
although serine can be generated from glycine, the serine itself is redundant. Instead, it is the 
donation of serine-derived carbon to the one carbon cycle that is the essential factor for 
maintenance of cell growth323. 
The enzymes of the SBP are also involved in the epigenetic regulation of gene expression. As 
previously mentioned, it has been demonstrated that yeast homologs of the serine biosynthesis 
enzymes PHGDH and SHMT can form a multi-subunit protein complex with the yeast homolog 
of PKM2 (Pyk1) and the SAM synthetases. This protein complex is known as SESAME and 
facilitates Pyk1-mediated phosphorylation of histone H3T11288, which is an important event for 
epigenetic regulation of pro-tumourigenic genes like CCND1 (cyclin D1) and MYC (c-Myc) (see 
1.4.3.3). 
The SBP therefore contributes to cancer in a wide variety of ways and accordingly, various 
mechanisms that upregulate expression of PHGDH, PSAT1 and PSPH in cancer have been 
described. Oncogenic c-Myc signalling has been shown to induce serine biosynthesis enzyme 
expression in HCC315 and in lung cancer, the SBP has been shown to be regulated by the 
transcription factor nuclear factor erythroid-2-related factor 2 (NRF2). NRF2 was reported to 
induce PHGDH, PSAT1 and SHMT expression via the transcription factor activating transcription 
factor 4 (ATF4), in order to support glutathione production and nucleotide synthesis324. The 
pathway has also been shown to be regulated by p73, which indirectly activates serine 
biosynthesis through regulation of glutaminase 2 to promote glutathione production325. 
Importantly however, there is still more to understand about the regulation of these enzymes 
in cancer, and even more to uncover about how, if at all, these enzymes are regulated at a post-
translational level. PHGDH protein level has been shown to be subject to ubiquitin-mediated 
proteasomal degradation and deubiquitinating enzyme Josephin Domain-containing 2 (JOSD2) 
has been reported to regulate PHGDH’s protein stability in this regard307. PHGDH activity has 
also been linked to phosphorylation of two threonine residues, Thr57 and Thr78, by protein 
kinase C ζ (PKCζ)326. Other than this, nothing is known about the post-translational regulation of 
the serine biosynthesis enzymes, which needs to be addressed in order to effectively target this 
hugely important metabolic pathway. 
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1.5 Project aims 
 
Whilst IKKε has been identified as an oncogene in about 30% of human breast cancer cases, its 
characterised mechanism of oncogenesis in breast tissue is via aberrant activation of NF-κB 
signalling. The impracticalities of therapeutic inhibition of the NF-κB pathway mean there is a 
desperate need to develop our understanding of how IKKε overexpression in breast tissue can 
lead to cancer development so that a substantial subset of breast cancer patients might be more 
effectively treated. Some progress has been made into identifying NF-κB-independent 
mechanisms of IKKε activity in tumour formation but generally, little is known about how else 
the kinase can contribute to disease progression in the breast. 
Recent studies have identified a role for IKKε in the rewiring of cellular metabolism. The kinase 
has been shown to promote a metabolic phenotype resembling aerobic glycolysis in dendritic 
cells during their activation in the immune response. More recently, IKKε was demonstrated to 
induce aerobic glycolysis in cancer in pancreatic ductal adenocarcinoma (PDAC). As changes in 
intracellular metabolism in cancer cells are increasingly recognised as critical events in tumour 
formation, the indication that IKKε has a part to play in metabolic rewiring opens up new areas 
of exploration for investigating the full scope of the kinases oncogenic potential. The entry point 
for this project was in data described at the beginning of chapter 3, which details the finding 
that IKKε promotes an aerobic glycolysis like phenotype in a breast cancer cell line setting. This 
project subsequently set out to explore the mechanism of IKKε-mediated metabolic regulation 
in breast cancer, with the hope of identifying new therapeutic targets that might be exploitable 
for the treatment of IKKε-driven tumours. 
The specific aims of this project were therefore; 
1) To outline the mechanism by which IKKε regulates cellular metabolism in breast 
cancer 
 
2) To identify novel IKKε phosphotargets involved in IKKε-driven metabolic rewiring 
 
 
3) To determine what contribution, if any, established IKKε signalling pathways make 
to the altered metabolic phenotype induced by the kinase 
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2.1 Cell culture 
 
2.1.1 Culture medium 
 
Cells were routinely cultured in either Dulbecco’s modified Eagle’s medium (DMEM) - high 
glucose, containing 4.5 g/L glucose, 0.584 g/L L-glutamine and 0.11 g/L sodium pyruvate (Sigma 
Aldrich - #D6429), or Roswell Park Memorial Institute 1640 medium (RPMI-1640), containing 2.0 
g/L glucose and 0.3 g/L L-glutamine (Sigma Aldrich - #R8758). 
For siRNA oligo transfections, Opti-MEM® reduced serum medium, containing L-glutamine, 
Phenol Red and 2.4 g/L sodium bicarbonate, was used (Gibco, Life Technologies – #31985062). 
Serine-free medium experiments were performed using custom DMEM or RPMI-1640 medium 
which were both formulated without glucose, glutamate, glutamine, glycine, serine and sodium 
pyruvate by the Custom Media Production units at either the Institute of Cancer Research, 
London, UK or the Francis Crick Institute, London, UK. When used, custom DMEM was 
supplemented with 4.5 g/L glucose and custom RPMI was supplemented with 2.0 g/L glucose to 
match their respective concentrations in commercial DMEM #D6429 and RPMI-1640 #R8758. In 
addition to glucose, custom DMEM was supplemented with 0.11 g/L sodium pyruvate, custom 
RPMI was supplemented with 0.02 g/L glutamate and both types of media were supplemented 
with 0.3 g/L glutamine and 0.01 g/L glycine. Serine was also supplemented at a concentration of 
0.03 g/L in control conditions. 
All medium was supplemented with 10% (v/v) foetal bovine serum (FBS) (Gibco, Life 
Technologies - #10500) (Serine-free medium was supplemented with Dialyzed FBS (Gibco, Life 
Technologies - #26400044)), 1% (v/v) penicillin-streptomycin (Sigma Aldrich - #P4333) and 0.2% 
Normocin™ (InvivoGen - #ant-nr-1) prior to use, and stored at 4°C.  
2.1.2 Cell lines 
 
All Flp-In 293 cells were maintained in DMEM – high glucose medium. Parental Flp-In 293 cells 
were a gift from Professor Pascal Meier and Tencho Tenev (Institute of Cancer Research, London, 
UK). Generation of inducible Flp-In 293 cells is described in 2.2. Stable inducible Flp-In 293 cell 
lines were selected for using hygromycin (Merck Millipore - #400051-1MU) at a concentration 
of 300 µg/ml. 
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The panel of breast cancer cell lines was cultured in appropriate medium as described in Table 
2.1 and were kindly provided by William Hahn (Dana-Farber Cancer Institute, Boston, US), 
Professor David Sabatini (Whitehead Institute for Biomedical Research, Massachusetts, US), or 
Professor Peter Schmid and Dr Alice Shia (Barts Cancer Institute, London, UK) as indicated. 
 
Table 2.1 – Cell lines used within this project. 
Cell Line Cell Type Culture Medium Original Source 
Flp-In 293 (Parental or 
Dox-inducible) 
Embryonic kidney DMEM + 10% FBS + P/S 
Prof. Pascal Meier 
(ICR) 
    
HA1E-M Embryonic kidney DMEM + 10% FBS + P/S 
Prof. William Hahn 
(Dana-Farber) 
    
HA1E-M F-IKKε Embryonic Kidney DMEM + 10% FBS + P/S 
Prof. William Hahn 
(Dana-Farber) 
    
Cal120 Breast cancer (Basal) DMEM + 10% FBS + P/S 
Prof. Peter Schmid 
(BCI) 
    
HCC1143 Breast Cancer (Basal) RPMI-1640 + 10% FBS + P/S 
Prof. Peter Schmid 
(BCI) 
    
MCF7 Breast Cancer (Luminal-A) RPMI-1640 + 10% FBS 
Prof. Peter Schmid 
(BCI) 
    
MDA-MB-231 Breast Cancer (Basal) RPMI-1640 + 10% FBS 
Prof. David Sabatini 
(Whitehead) 
    
MDA-MB-453 (Parental 
or Dox-inducible PSAT1) 
Breast Cancer (Basal) RPMI-1640 + 10% FBS 
Prof. Peter Schmid 
(BCI) 
    
MDA-MB-468 Breast Cancer (Basal) RPMI-1640 + 10% FBS 
Prof. David Sabatini 
(Whitehead) 
    
SUM44 Breast Cancer (Luminal-A) DMEM + 10% FBS + 1 mM E2 
Prof. Peter Schmid 
(BCI) 
    
T47D Breast Cancer (Luminal-A) RPMI-1640 + 10% FBS 
Prof. Peter Schmid 
(BCI) 
    
ZR-75-1 Breast Cancer (Luminal-A) RPMI-1640 + 10% FBS 
Prof. Peter Schmid 
(BCI) 
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2.1.3 Maintenance of 2D cell cultures 
 
Cells were cultured in a 2D monolayer in 75 cm2 flasks (Corning) and cultures were maintained 
through incubation at a temperature of 37°C with atmospheric conditions of 5% CO2 in a Binder 
incubator. 
Cells were passaged upon reaching 80-90% confluency. Medium was removed from the flask 
using an aspirator and the cell monolayer was washed with 10 ml of sterile autoclaved 
phosphate buffered saline (PBS). PBS was then aspirated and 5 ml of 0.05% v/v Trypsin 
ethylenediaminetetraacetic acid (EDTA) (Sigma Aldrich - #T4299) was added to cells to detach 
the monolayer from the flask surface. For Flp-In 293 cells Trypsin EDTA was aspirated 
immediately to avoid cell loss. For breast cancer cell lines, flasks were incubated with Trypsin for 
up to 5 minutes at 37°C, 5% CO2 in the culture incubator. Flasks were agitated to fully detach all 
adherent cells, after which fresh medium was added to resuspend cells and inactivate residual 
trypsin. The cell suspension was mixed thoroughly by pipetting to ensure complete cell 
separation and generation of as true a single cell suspension as possible. Medium was added to 
a volume necessary for the required passaging ratio, and 1 ml of the cell suspension was added 
to a new flask, i.e. if cells were passaged at a 1:10 ratio, the cells were suspended in a volume of 
10 ml and 1 ml was taken out. Medium in the new flask was topped up to a volume of 15 ml and 
mixed gently to ensure even distribution of cells across the flask surface. The new cell flask was 
then labelled appropriately with the name of the cell line, the date of passage and the passage 
number, then returned to the incubator. 
2.1.4 Freezing and thawing  
 
An 80-90% confluent 75 cm2 flask of cells was processed as in 2.1.3 till trypsin detachment. 
Following detachment of adherent cells from the flask surface, cells were resuspended in 4 ml 
FBS. 0.9 ml of the resulting cell suspension was then aliquoted into 2 ml capacity cryovials 
(Corning) containing 0.1 ml dimethyl sulfoxide (DMSO – Sigma Aldrich - #D5879-500ML), 
achieving a final concentration of 10% v/v DMSO in FBS. Cryovials were then frozen at -80°C and 
later transferred to liquid nitrogen for storage at -185°C long term. 
When thawed, cells were removed from liquid nitrogen and transported on dry ice to maintain 
freezing during transportation. Cells were thawed in a 37°C water bath and cell suspension was 
subsequently added to 24 ml of the appropriate culture medium in a 75 cm2 flask to substantially 
dilute the DMSO in the cell suspension. The flask was placed in a 37°C incubator to allow cells to 
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attach to the flask surface and medium was changed the following day, further diluting the 
DMSO to negligible amounts and removing cells that had died during the freezing and thawing 
cycle. Following thawing, cells were passaged at least once prior to experimental use, to allow 
re-acclimatisation. 
2.1.5 Cell plating 
 
An 80-90% confluent 75 cm2 flask of cells were processed as in 2.13 till cell resuspension in 
culture medium and generation of single cell suspension. 10 µl of cell suspension was mixed 
thoroughly with 10 µl of Trypan Blue Solution, 0.4% (Gibco, Life Technologies - #15250-061) for 
exclusion of dead cells in counting. 10 µl of cell/Trypan Blue mixture was added to a counting 
slide (Bio-Rad - #1450015) so that cell numbers in the suspension could be counted using a 
TC20® Automated Cell Counter (Bio-Rad - #1450102). Cells/ml counts were taken in duplicate 
and an average was calculated to more accurately represent cell numbers within a suspension. 
The volume of cell suspension required for the desired number of cells was calculated and added 
to a 10 cm2 dish (Corning), or a 6-well or 96-well plate (Corning). For experiments involving either 
no treatment of cells or basic drug treatments, cells were plated at densities described in Table 
2.2. For all IncuCyte experiments, or for experiments that required siRNA-mediated suppression 
of mRNA prior to drug treatments, cells were plated at densities described in Table 2.3. 
 
Table 2.2 – Cell plating density for drug treatment of cell lines in 6-well plates or 10 cm dishes. 
 Plating density (Cells per well (CPW)) 
 6-well 10 cm 
Flp-In 293 (Various) 400,000 5,000,000 
ZR-75-1 600,000 - 
T47D 500,000 - 
MDA-MB-453 600,000 - 
MDA-MB-468 400,000 - 
MDA-MB-231 400,000 - 
MCF7 400,000 - 
Cal120 500,000 - 
HCC1143 600,000 - 
SUM44 600,000 - 
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Table 2.3 – Cell plating density for IncuCyte experiments, or experiments involving siRNA transfection of cell lines 
in 6-well or 96-well plates or 10 cm dishes. 
 Plating density (Cells per well (CPW)) 
Cell Line 6-well 96-well 10 cm 
Flp-In 293 (Various) 150,000 5,000 2,000,000 
ZR-75-1 300,000 10,000 - 
T47D 200,000 7,500 - 
MDA-MB-453 300,000 10,000 - 
MDA-MB-468 200,000 4,000 - 
MDA-MB-231 150,000 4,000 - 
MCF7 125,000 3,000 - 
Cal120 150,000 5,000 - 
HCC1143 125,000 3,000 - 
SUM44 300,000 10,000 - 
 
2.1.6 Drug treatments 
 
Doxycycline was used to induce expression of HA-tagged GFP, IKKε wild-type (wt) and kinase 
dead mutant (KD-m) and PSAT1 wt and S>A or S>E mutant variants in corresponding Flp-In 293 
cell lines and PSAT1 wt and S>A or S>E mutants in MDA-MB-453 PSAT1 cell lines. Doxycycline 
was kindly provided by Susana Godinho (originally sourced from Sigma Aldrich - #D9891). 
α-IFNAR blocking antibody (Merck Millipore - #MAB1155) was used to inhibit the activation of 
the IFNAR upon induction of HA-IKKε in Flp-In 293 cells, thereby preventing activation of the 
JAK/STAT signalling cascade and IKKε-mediated IFNβ signalling. 
Dichloroacetate (DCA) (Sigma Aldrich - #347795) is a pyruvate dehydrogenase kinase (PDK) 
inhibitor and was used to activate the pyruvate dehydrogenase complex in the presence of HA-
IKKε induction in Flp-In 293 cells. 
All compounds were stored at -20°C and diluted in water, so no vehicle control was required in 
non-treated cells when used.  
2.1.7 siRNA transfection 
 
Cells were transfected with siRNA oligos detailed in Table 2.4 to suppress the expression of 
specific proteins. AllStars Negative Control siRNA (Qiagen - #SI03650318) was used for non-
targeting transfections to control for the transfection process. 
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For western blotting and quantitative real-time PCR (qRT-PCR) experiments involving siRNA 
suppression of protein expression, Flp-In 293 cells or breast cancer cell lines were plated in a 6-
well plate. For IncuCyte experiments involving siRNA transfection, cells were plated in a 96-well 
plate. For suppression of endogenous PSAT1 in HA-pulldown assays, cells were plated in a 10 cm 
dish. Plating densities for siRNA experiments are indicated in Table 2.4. After incubation of 
plated cells for 24 hours at 37°C to allow cells to attach to the growth surface, siRNA was 
transfected in a total volume of 700 µl in a 6-well plate, 100 µl in a 96-well plate and 4 ml in a 
10 cm dish. 
For one well of a 6-well, 1.75 µl of 20 µM control non-targeting siRNA oligo, or 0.875 µl of each 
oligo in a pool of 4 10 µM targeting oligos (or 3.5 µl for single oligo transfection) was added to 
200 µl Opti-MEM® reduced serum transfection medium in an autoclaved 1.5 ml microcentrifuge 
tube. This mixture was briefly vortexed, following which 2 µl DharmaFECT 4 transfection reagent 
(Dharmacon - #T200402) was added and the mixture was vortexed once again. The transfection 
mixture was incubated at room temperature for 10 minutes, after which 200 µl of the mixture 
was added dropwise to 500 µl of medium in each well of a 6-well plate, giving a final siRNA 
concentration of 50 nM in 700 µl. 16 hours later, the transfection medium was aspirated and 
replaced with 2 ml of fresh DMEM or RPMI-1640 as required. Cells were incubated for 72 hours 
prior to harvesting. In the case of siRNA-mediated suppression of endogenous PSAT1, a pool of 
3 10 µM siRNA oligos targeting the non-coding sequence of the PSAT1 mRNA was used, with 
1.17 µl of each oligo transfected per well. 
For one well of a 96-well plate, 0.25 µl of 20 µM control non-targeting siRNA oligo, or 0.125 µl 
of each oligo in a pool of 4 10 µM targeting oligos was added to 20 µl Opti-MEM® reduced serum 
transfection medium in an autoclaved 1.5 ml microcentrifuge tube and the mixture was 
subsequently vortexed. 0.2 µl DharmaFECT 4 transfection reagent was then added followed by 
a second brief vortex and incubation of the mixture at room temperature for 10 minutes. 80 µl 
of culture medium was then added to give a total volume of 100 µl and a final siRNA 
concentration of 50 nM. Existing culture medium in the plate well was then aspirated and 
replaced with the transfection mixture. The plate was incubated at 37°C for 16 hours, following 
which the transfection medium was replaced with 200 µl fresh culture medium leaving the plate 
ready for growth analysis on the IncuCyte. For IncuCyte experiments involving the suppression 
of endogenous PSAT1, a pool of 3 10 µM non-coding sequence targeting siRNA oligos was used 
and 0.17 µl of each oligo was transfected per well. 
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For a 10 cm dish, 10.1 µl of 20 µM control non-targeting siRNA oligo, or 6.8 µl of each oligo in a 
pool of 3 10 µM PSAT1-targeting oligos was added to 1.16 ml Opti-MEM® reduced serum 
transfection medium in a 15 ml Falcon® tube (corning). The mixture was vortexed and 11.6 µl 
DharmaFECT 4 transfection reagent was then added. Following further vortexing and 10 minutes 
incubation, the siRNA mixture was added dropwise to 2.9 ml of medium in the dish. From here, 
experiments progressed as in a 6-well plate. 
 
Table 2.4 – Qiagen FlexiTube GeneSolution siRNA oligos used for protein knockdown. *PSAT1 oligo Hs_PSAT1_10 
was not used in transfections specifically targeting the non-coding sequence of PSAT1 mRNA. †ATF4 oligo Hs_ATF4_5 
was the single oligo used for ATF4 knockdown prior to use of an oligo pool. 
Target Oligo product name Catalogue Number Oligo target sequence 
IKBKE (IKKε) 
Hs_IKBKE_6 SI02622319 acggcggaacaaggagatcat 
Hs_IKBKE_7 SI02622326 ccgcatcatcgaacggctaaa 
Hs_IKBKE_8 SI02655317 aagaagcatccagcagattca 
Hs_IKBKE_9 SI02655324 caagatgaacttcatctacaa 
    
PSAT1 
Hs_PSAT1_10* SI03019709 aaggaattattagactacaaa 
Hs_PSAT1_12 SI03222142 gtgcattatagcattccatta 
Hs_PSAT1_14 SI04265625 ccaggcgaagggcaaactgta 
Hs_PSAT1_15 SI04272212 tagatcgatctttatgctgtt 
    
ATF4 
Hs_ATF4_5† SI03019345 cagcgttgctgtaaccgacaa 
Hs_ATF4_8 SI03218404 gaggatagtcaggagcgtcaa 
Hs_ATF4_9 SI04236337 aagcctaggtctcttagatga 
Hs_ATF4_10 SI04261614 aggagataggaagccagacta 
    
IRF3 Hs_IRF3_4 SI02626526 cagcctcgagtttgagagcta 
    
RELA (p65) Hs_RELA_5 SI00301672 aagatcaatggctacacagga 
 
 
2.1.8 Cell harvesting 
 
Following the culmination of cell treatment, medium was aspirated from the cells and cells were 
washed with ice cold PBS. PBS was subsequently aspirated, leaving empty wells. Plates or dishes 
were then sealed using parafilm and stored at -80°C till sample processing. 
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2.2 Generation of PSAT1 mutant cell lines 
 
To investigate phosphorylation of the enzyme, PSAT1 serine residue Ser331 was mutated using 
point mutagenesis. To mimic unphosphorylated serine, Ser331 was mutated to an alanine 
residue by changing 1 nucleotide in the DNA sequence. To mimic phosphorylated serine, Ser331 
was mutated to a glutamic acid residue by changing 2 nucleotides in the DNA sequence. 
2.2.1 Point mutagenesis primers 
 
Primers were designed to modify the PSAT1 DNA sequence at nucleotides relevant to the Ser331 
residue within the protein sequence. All primers were manufactured by Sigma Aldrich. Modified 
nucleotides are indicated in red. 
 
PSAT1 S>A mutagenesis primers: 
Forward – 5’-gaactcaatatgttggccttgaaagggc-3’ 
Reverse – 5’-gccctttcaaggccaacatattgag-3’ 
 
PSAT1 S>E mutagenesis primers: 
Forward – 5’-gaactcaatatgttggacttgaaagggc-3’ 
Reverse – 5’-gccctttcaagtccaacatattgag-3’ 
 
2.2.2 PSAT1 point mutagenesis 
 
2.2.2.1 PCR Mutagenesis 
 
PSAT1 cDNA Open Reading Frame (ORF) Clone in the pGEM-T vector (Sino Biological - #HG14187-
G) was used for point mutagenesis PCR.  
Mutagenesis PCR was performed using Phusion® High-Fidelity DNA Polymerase (New England 
Biolabs - #M0530). The PCR was performed in a 50 µl volume in an autoclaved Fisherbrand™ 0.2 
ml Flat-Cap PCR tube (Fisher Scientific - #12174102) as per the manufacturer’s recommended 
instructions with 1 ng of template pGEM-T PSAT1 cDNA (Table 2.5). Reaction mixtures were 
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briefly vortexed, centrifuged and placed on a C1000 Touch™ Thermocycler (Bio-Rad). 
Mutagenesis PCR was performed with the protocol described in Table 2.6.  
 
Table 2.5 – Composition of 50 µl Phusion® High-Fidelity DNA Polymerase PCR reaction for PSAT1 mutagenesis. 
Component In 50 µl 
5x Phusion® HF Buffer 10 µl 
10 mM dNTP mix 1 µl 
10 µM Forward Primer 2.5 µl 
10 µM Reverse Primer 2.5 µl 
DMSO 1.5 µl 
Phusion® High-Fidelity DNA Polymerase 0.5 µl 
Template PSAT1 cDNA 1 ng 
Nuclease-free water (Invitrogen - #AM9915G) Volume to 50 µl total 
 
 
Table 2.6 – Thermocycler program for PSAT1 mutagenesis PCR. 
Temperature Time  
98°C 30 seconds  
98°C 10 seconds  
17 x 51°C 30 seconds 
72°C 3 minutes 
72°C 10 minutes  
4°C ∞  
 
 
2.2.2.2 DpnI digestion 
 
DpnI restriction enzyme (New England Biolabs - #R0176S) was used to digest the wild-type 
pGEM-T PSAT1 plasmid in the S>A and S>E PCR mutagenesis products to ensure the purity of the 
mutated pGEM-T PSAT1 S>A or pGEM-T PSAT1 S>E plasmids. DpnI cleaves methylated sites, 
which are present on the wild-type plasmid but are not maintained during PCR amplification. 
DpnI digestion therefore only cleaves the template plasmid to leave a pure PCR product.  
A 60 µl reaction mixture for DpnI digestion was prepared in an autoclaved Fisherbrand™ 0.2 ml 
Flat-Cap PCR tube as described in Table 2.7 using the PCR product from 2.2.2.1, then incubated 
in a thermocycler at 37°C for 1 hour to allow DpnI-dependent cleavage and at 80°C for 20 
minutes to inactivate the enzyme. 
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Table 2.7 – Composition of 60 µl DpnI digestion reaction for digestion of template pGEM-T PSAT1 plasmid. 
Component In 60 µl 
PCR product 50 µl 
DpnI restriction enzyme 2 µl 
10x CutSmart® Buffer (Included with DpnI) 6 µl 
Nuclease-free water 2 µl 
 
 
2.2.2.3 Bacterial transformation 
 
The pGEM-T vector contains an ampicillin resistance gene, which allows cells expressing the 
vector to survive in the presence of the antibiotic. Therefore, in order to validate successful PCR 
of entire pGEM-T PSAT1 plasmid and eventually confirm mutagenesis, the PCR product was used 
to transform Alpha-Select Gold Efficiency competent cells (Bioline - #BIO-85027). Transformed 
cells expressing a full plasmid were then selected by their ability to grow on LB-agar plates 
containing 100 µg/ml ampicillin.  
Alpha-Select Gold Efficiency competent cells were thawed on ice. 5 µl of mutagenesis PCR 
product was mixed with 45 µl of cells in an autoclaved 1.5 ml microcentrifuge tube. The DNA/cell 
mixture was incubated on ice for 30 minutes, then heat-shocked via incubation at 42°C in a water 
bath for 1 minute. Following heat-shock the cells were returned to ice for 5 minutes, after which 
950 µl of autoclaved LB broth was added to the cells. The cells were thoroughly mixed by 
pipetting, then incubated at 37°C for 1 hour in a shaking incubator at 200 RPM. Cells were 
subsequently pipetted onto the surface of a pre-warmed LB-agar plate containing 100 µg/ml 
ampicillin and spread across the agar surface with a cell spreader. Plates were then incubated 
at 37°C for 24 hours. Cells containing an ampicillin resistance gene, due to successful PCR and 
transformation with the pGEM-T PSAT1 plasmid, formed colonies in the presence of ampicillin, 
whereas untransformed cells failed to grow.  
2.2.2.4 Mini-prep 
 
A mini-prep was performed to amplify pGEM-T PSAT1 S>A and pGEM-T PSAT1 S>E plasmid DNA 
from the transformed bacterial cells. Several colonies from the transformation plates were 
picked and separate colonies were each transferred to 3 ml of LB-broth containing 100 µg/ml 
ampicillin in a 30 ml universal tube. The bacteria were cultured overnight at 37°C in a shaking 
incubator at 200 RPM, allowing amplification of transformed cells and the contained plasmid. 
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DNA from the cultured bacterial cells was then extracted using the QIAprep Spin Miniprep Kit 
(Qiagen - #27104).  
Bacterial cells were pelleted by centrifugation at 7000 g for 3 minutes, resuspended in 250 µl of 
Buffer P1 and transferred to an autoclaved 1.5 ml microcentrifuge tube. Cells were then lysed 
with the addition of 250 µl Buffer P2, followed by thorough mixing through inversion of the tube 
until the solution turned blue due to the presence of pH indicator LyseBlue reagent in Buffer P1. 
Cells were left lysing at room temperature for up to 5 minutes. Following lysis, 350 µl of Buffer 
N3 was added to neutralise the pH, and the LyseBlue-containing mixture turned colourless 
accordingly. Cells were then centrifuged at 18,000 g for 10 minutes and the supernatant was 
transferred to a QIAprep spin column. Centrifugation of the spin column, at 18,000 g for 1 
minute allowed DNA to bind to the membrane within the column. Flow through from the 
centrifugation was collected in a 2 ml collection tube and subsequently discarded. 500 µl of 
Buffer PB was added to the spin column to wash the membrane. The column was again 
centrifuged at 18,000 g for 1 minute, after which the flow through was discarded. 750 µl of 
Buffer PE was then added to further wash the spin column membrane. The spin column was 
centrifuged at 18,000 g for 1 minute and flow through was again discarded. The spin column 
was immediately centrifuged again at 18,000 g for 1 minute, allowing the membrane to dry and 
facilitating removal of residual wash buffer. The QIAprep spin column was then transferred to 
an autoclaved 1.5 ml microcentrifuge tube and 50 µl of Buffer EB was added directly to the 
column membrane. The column was the incubated at room temperature for 1 minute. Finally, 
the spin column was centrifuged a final time at 18,000 g for 1 minute, eluting the DNA from the 
column membrane and collecting it in the 1.5 ml microcentrifuge tube. 
2.2.2.5 Quantification of DNA 
 
Following miniprep extraction of plasmid DNA from the bacterial cells, DNA concentration was 
quantified using a Nanodrop-2000 spectrophotometer (ThermoFisher Scientific - #ND-2000).  
The absorbance of light at a 260 nm wavelength of 1.5 μl of Buffer EB was measured to quantify 
background absorbance in the DNA samples. The absorbance of 1.5 μl of each DNA extraction 
was then quantified. The ng/μl concentration of DNA in each sample was automatically 
calculated by the Nanodrop using the Beer-Lambert Law, which describes the linear correlation 
between absorbance and concentration.  
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2.2.2.6 PSAT1 PCR 
 
To confirm the presence of PSAT1 within the pGEM-T plasmid, a PCR reaction was used to 
amplify the gene from the plasmids extracted from each bacterial colony. The primers for PSAT1 
amplification were the same primers that would later be used for amplification of PSAT1 in 
preparation for cloning of the gene into the pcDNA5.5 vector (see 2.2.3). PCR was performed 
using Q5® High-Fidelity DNA Polymerase (New England Biolabs - #M0491S).  
A 25 µl reaction mixture was prepared in an autoclaved Fisherbrand™ 0.2 ml Flat-Cap PCR tube 
as per the manufacturer’s recommended instructions with 0.5 ng of pGEM-T PSAT1 plasmid DNA 
(Table 2.8). The reaction mixture was briefly vortexed and centrifuged, then placed on a 
thermocycler to run the PCR with conditions described in Table 2.9 
 
Table 2.8 – Composition of 25 µl Q5® High-Fidelity DNA Polymerase PCR reaction for PSAT1 amplification. 
Component In 25 µl 
5x Q5 Reaction Buffer 5 µl 
10 mM dNTP mix 0.5 µl 
10 µM Forward Primer 1.25 µl 
10 µM Reverse Primer 1.25 µl 
Q5 High-Fidelity DNA Polymerase 0.25 µl 
Template PSAT1 cDNA 0.5 ng 
Nuclease-free water Volume to 25 µl total 
 
 
Table 2.9 – Thermocycler program for PCR amplification of PSAT1. 
Temperature Time  
98°C 30 seconds  
98°C 10 seconds  
29 x 60°C 30 seconds 
72°C 45 seconds 
72°C 2 minutes  
4°C ∞  
 
The PCR product from each colony was then analysed on a 1% w/v agarose gel. 0.5 g of agarose 
was dissolved in 50 ml of 1x Tris Acetate EDTA (TAE) diluted from 50x concentrated stock that 
was prepared by Dr Ruoyan Xu (242 g of Tris Base (Sigma Aldrich - #D5879), 57.1 ml of Glacial 
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Acetic Acid (Honeywell - #33209) and 25 ml of 200 mM EDTA pH 8.0 (Severn Biotech - #20-5300-
01) made up to a total volume of 1 L with distilled water). Microwaving in 30 second intervals 
followed by mixing was used to heat the TAE buffer and facilitate dissolving of agarose. The 
agarose/TAE solution was allowed to cool sufficiently to add 1 µl of GelRed® Nucleic Acid Gel 
Stain (Biotium - #41003). GelRed® intercalates with nucleic acids and fluoresces under exposure 
to UV light, thereby allowing visualisation of DNA within the gel. The agarose/TAE solution was 
then poured into a gel mould and allowed to cool enough to set, ready for 2D gel 
electrophoresis. The PCR product was mixed with Gel Loading Dye, Purple (6x) no SDS (New 
England Biolabs - #B7025S) diluting the loading dye to 1x concentration. The PCR 
product/loading dye mixture was loaded to the 1% w/v agarose gel alongside 5 µl of 1 kb DNA 
ladder (New England Biolabs – #N3232S). The gel was run in 1x TAE at 80V till adequate 
separation was achieved. Amplification of PSAT1 was assessed by visualisation of the DNA within 
the gel using an Amersham Imager 600UV chemidoc system (GE Healthcare - #29083463). 
2.2.2.7 Sequencing 
 
Following the confirmation of PSAT1 presence in the plasmid DNA extracted from bacteria, 
pGEM-T PSAT1 S>A and pGEM-T PSAT1 S>E plasmid DNA samples were sent for sequencing to 
confirm successful mutagenesis of the gene sequence. 20 µl of 100 ng/µl dilutions of each 
plasmid was prepared in autoclaved 1.5 ml microcentrifuge tubes. The plasmids were sent for 
Sanger sequencing by GATC Biotech using pre-paid SUPREMERUN Tube barcodes (GATC Biotech 
– #B50100100). 2 samples per plasmid were sent for sequencing to sequence both forward and 
reverse strands of PSAT1 within the pGEM-T multiple cloning region. The forward and reverse 
strands were sequenced using the GATC Biotech in-house M13-FP and M13-RP sequencing 
primers respectively. Sequencing results were analysed using DNADynamo Sequence Analysis 
Software (BlueTractorSoftware Ltd) 
2.2.3 Cloning of PSAT1 into the pcDNA5.5 vector 
 
For generation of Flp-In 293 cells expressing HA-tagged PSAT1 wt or mutant variants, PSAT1 wt, 
PSAT1 S>A or PSAT1 S>E DNA from the pGEM-T vector was cloned into a modified version of the 
pcDNA5 vector which contains 2x human influenza haemagglutinin (HA-) and 2x Strep-tag 
sequences that are added to the N-terminus of coded proteins to generate tagged proteins. The 
vector was also mutated to allow use of the EcoRI restriction site in its multiple cloning region. 
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This modified vector was generated and kindly provided by Tencho Tenev (Institute of Cancer 
Research, London, UK) and is herein termed pcDNA5.5.  
PSAT1 DNA was amplified from the pGEM-T vector via PCR. For eventual cloning into pcDNA5.5, 
amplification primers were designed to insert KpnI and EcoRI restriction sites at the start and 
end of the PSAT1 DNA sequence respectively. The KpnI restriction site is indicated in green and 
the EcoRI restriction site is indicated in blue. Arrows indicate the exact cutting site within the 
sequence. 
 
PSAT1 pcDNA5.5 primers: 
 Forward (KpnI) – 5’-ttggtac˅cagccatggacgcccccaggcag-3’ 
 Reverse (EcoRI) – 5’-gatggatatctgcag˅aattctagctgatgcatctcc-3’ 
 
PSAT1 PCR was performed using the pGEM-T PSAT1 wt, pGEM-T PSAT1 S>A and pGEM-T PSAT1 
S>E plasmids as template DNA, using Q5® High-Fidelity DNA Polymerase as described in 2.2.2.6. 
This generated PSAT1 wt, PSAT1 S>A and PSAT1 S>E PCR products containing KpnI and EcoRI 
restriction sites. The PSAT1 PCR products and pcDNA5.5 vector were then digested with KpnI-
High-Fidelity (HF®) (New England Biolabs - #R3142S) and EcoRI-HF® (New England Biolabs - 
#R3101S) restriction enzymes ready for ligation. Separate digestions for the PSAT1 PCR product 
and the pcDNA5.5 vector were prepared in autoclaved Fisherbrand™ 0.2 ml Flat-Cap PCR tubes 
as described in Table 2.10. 
 
Table 2.10 – Composition of reaction mixtures for digestion of PSAT1 PCR product and pcDNA5.5 vector. 
PCR Product Digestion pcDNA5.5 Digestion 
Component In 50 µl Component In 20 µl 
PSAT1 PCR product 40 µl pcDNA5.5 Vector 5 µl 
CutSmart® Buffer 5 µl CutSmart® Buffer 2 µl 
KpnI-HF® 2 µl KpnI-HF® 2 µl 
EcoRI-HF® 2 µl EcoRI-HF® 2 µl 
Nuclease-free water 1 µl Nuclease-free water 9 µl 
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The digestion reaction mixtures were vortexed and centrifuged briefly and placed on a 
thermocycler for digestion. Reaction mixtures were incubated at 37°C for 2 hours to facilitate 
restriction enzyme cutting, then incubated at 65°C for 20 minutes to inactivate KpnI and EcoRI. 
Following digestion, the digested vector was run on a 1% w/v agarose gel as described in 2.2.2.6. 
The resultant plasmid backbone and cleavage products were then visualised within the gel using 
a UV transilluminator. The section of the gel containing the plasmid backbone was then cut out 
using a scalpel and stored in a pre-weighed, autoclaved 1.5 ml microcentrifuge tube. The 
combined weight of the gel section and the tube was noted and used to calculate the weight of 
the gel section. The digested plasmid backbone was then extracted from the agarose gel using 
the QIAquick Gel Extraction Kit (Qiagen - #28704) as per the manufacturer’s instructions. Using 
a conversion rate where 100 mg of gel is equivalent to roughly 100 µl volume, 3 volumes of 
Buffer QG was added to 1 volume of gel. The gel was then incubated at 50°C in a heat block for 
up to 10 minutes, with periodic vortexing, allowing the section to completely dissolve. 1 gel 
volume of isopropanol was added, and the solution was transferred to a QIAquick spin column. 
The spin column was centrifuged at 18,000 g for 1 minute to allow DNA to bind to the column 
membrane. The flow through was collected in a 2 ml collection tube and discarded. 750 µl of 
Buffer PE was added to the spin column to wash the membrane. The column was centrifuged 
again at 18,000 g for 1 minute and the flow through was discarded. The empty spin column was 
immediately centrifuged again at 18,000 g for 1 minute to remove residual washing buffer. The 
spin column was then transferred to an autoclaved 1.5 ml microcentrifuge. To elute the 
extracted DNA, 50 µl of Buffer EB was added directly to the membrane within the spin column 
and allowed to soak through for 1 minute. The column was centrifuged once more at 18,000 g 
for 1 minute and DNA was collected in the 1.5 ml microcentrifuge. 
Ultimately, the digested PSAT1 PCR products and pcDNA5.5 backbone were ligated to generate 
pcDNA5.5 HA-PSAT1 wt, pcDNA5.5 HA-PSAT1 S>A and pcDNA5.5 HA-PSAT1 S>E plasmids. 
Ligation was performed in a total volume of 10 µl using 80 ng of DNA, with the pcDNA5.5 vector 
and PSAT1 insert used at a molar ratio of 4:1 vector to insert. T4 DNA Ligase (New England 
Biolabs - #M0202S) was used to catalyse the ligation and a 10 µl reaction mixture was prepared 
in an autoclaved Fisherbrand™ 0.2 ml Flat-Cap PCR tube as per the manufacturers 
recommended instructions (Table 2.11). The 10 µl reaction mixture was then incubated at 16°C 
overnight on a thermocycler to facilitate ligation. 
As with pGEM-T, the pcDNA5.5 vector contains an ampicillin resistance gene. Therefore, 
successful ligation was confirmed by transforming competent bacterial cells as described in 
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2.2.2.3 and growing transformed bacterial colonies overnight on LB-agar plates containing 100 
µg/ml ampicillin. Colonies were then mini-prepped as described in 2.2.2.4 to amplify and extract 
pcDNA5.5 HA-PSAT1 wt, pcDNA5.5 HA-PSAT1 S>A and pcDNA5.5 HA-PSAT1 S>E plasmid DNA 
ready for cellular transfection. 
  
Table 2.11 – Composition of 10 µl T4 DNA Ligase reaction. 
Component In 10 µl 
T4 DNA Ligase Buffer (10x) 1 µl 
Vector DNA (4 kb) 40 ng 
PSAT1 DNA (1 kb) 40 ng 
T4 DNA Ligase 1 µl 
Nuclease-free water Volume to 10 µl 
 
The resulting pcDNA5.5 PSAT1 wt, pcDNA5.5 PSAT1 S>A and pcDNA5.5 PSAT1 S>E plasmids were 
also sent for Sanger sequencing as in 2.2.2.7, using GATC Biotech’s in-house CMV-Forward and 
BGH-Reverse sequencing primers to sequence the forward and reverse strands of the gene 
insert site respectively, as an additional confirmation for successful ligation. 
2.2.4 Flp-In 293 HA-PSAT1 cell line generation 
 
The Flp-In™ T-REx™ system allows the generation of stable cell lines expressing single copies of 
gene inserts at a pre-integrated FRT site in the host cell genome. The pcDNA5.5 vector also 
contains an FRT site. When the pcDNA5.5 vector is co-transfected with the pOG44 vector, which 
expresses FLP recombinase under a constitutive CMV gene promoter, homologous 
recombination between FRT sites in the pcDNA5.5 vector and in the host cell genome integrates 
the pcDNA5.5 gene insert into the host cell genome. Flp-In 293 T-REx cells are a variant of the 
human embryonic kidney (HEK)-293 cell line, containing an FRT site and a constitutively 
expressed tetracycline repressor (TetR) protein. TetR protein dimers bind to tetracycline 
operator (Tet Op) sequences in the promoter region that controls the expression of genes in the 
FRT site and represses gene expression. Doxycycline, when present, can bind to the TetR protein 
dimers and trigger a conformational change that inhibits binding to the Tet Op sequences, 
thereby de-repressing gene expression. Flp-In 293 T-REx cells were therefore used to generate 
cell lines expressing doxycycline inducible HA-PSAT1 wt, HA-PSAT1 S>A and HA-PSAT1 S>E genes. 
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Flp-In 293 T-REx cells were plated at a density of 125,000 cells per well in 6-well plates and 
transfected the following day with a combination of pOG44 and one of the three pcDNA5.5 HA-
PSAT1 plasmids. 3.3 µg of DNA was transfected in total, with pOG44 and the pcDNA5.5 HA-PSAT1 
plasmid being transfected in a ratio of 9 pOG44: 1 pcDNA5.5 HA-PSAT1 (i.e. 2790 ng pOG44: 330 
ng pcDNA5.5 HA-PSAT1). For the transfection of Flp-In 293 T-REx cells, 150 µl Opti-MEM® 
reduced serum transfection medium, 3.3 µg of DNA and 9.9 µl of FuGENE® HD Transfection 
Reagent (Promega - #E2311) were mixed together in an autoclaved 1.5 ml microcentrifuge tube 
and incubated at room temperature for 10 minutes. The transfection mixture was then added 
dropwise to the plated cells in 2 ml of medium. In addition to combined transfection of pOG44 
and pcDNA5.5 HA-PSAT1 plasmids, transfection of each plasmid individually (2790 ng pOG44 or 
330 ng of pcDNA5.5 HA-PSAT1) was also performed to control for proper recombination in the 
presence of both plasmids. Recombination of the HA-PSAT1 gene insert from the pcDNA5.5 
vector provides Flp-In 293 cells with a hygromycin resistance gene. Therefore, to select for cells 
in which homologous recombination had occurred, transfected cells were incubated at 37°C for 
48 hours and transfection medium was then replaced with fresh medium containing 300 µg/ml 
hygromycin. 
2.2.5 Cloning of PSAT1 into the pTRIPZ vector 
 
In order to generate MDA-MB-453 breast cancer cell lines expressing inducible PSAT1 wt, PSAT1 
S>A and PSAT1 S>E proteins, PSAT1 wt, PSAT1 S>A or PSAT1 S>E cDNA was cloned from the 
pcDNA5.5 vector into the lentiviral pTRIPZ vector, using methods described in detail in 2.2.3. 
PCR was performed from the pcDNA5.5 vectors using primers that inserted AgeI and EcoRI 
restriction sites at the beginning and end of the PSAT1 DNA sequence respectively, facilitating 
compatible ligation with the pTRIPZ vector following digestion of both insert and vector with 
AgeI-HF® (New England Biolabs - #R3552S) and EcoRI-HF®. The AgeI and EcoRI primer sequences 
used are indicated below. The AgeI restriction site is indicated in green and the EcoRI restriction 
site is indicated in blue. The specific cutting sites within the sequence are indicated by arrows. 
 
PSAT1 pTRIPZ primers: 
 Forward (AgeI) – 5’-ata˅ccggtaccatggacgcccccag-3’ 
 Reverse (EcoRI) – 5’-tgcgcg˅aattctcatagctgatgcatctcc-3’ 
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As with cloning of the PSAT1 wt, PSAT1 S>A and PSAT1 S>E genes into the pcDNA5.5 vector, 
successful ligation was confirmed via Sanger sequencing with GATC Biotech, sequencing the 
pTRIPZ PSAT1 wt, pTRIPZ PSAT1 S>A and pTRIPZ PSAT1 S>E plasmids as described in 2.2.2.7. The 
mutagenesis primers described in 2.2.1 were used as sequencing primers to read from the 
middle of the PSAT1 sequence outwards, checking for alignment with the pTRIPZ vector 
sequence at the beginning and end of the gene. Alignment with the pTRIPZ sequence at the start 
and end of the PSAT1 gene confirmed the gene was contained within the pTRIPZ vector and 
ligation was successful. 
2.2.6 MDA-MB-453 PSAT1 cell line generation 
 
2.2.6.1 Lentiviral generation 
 
For transduction of pTRIPZ PSAT1 vectors into the MDA-MB-453 breast cancer cell lines, a 
strategy of lentiviral infection was used. To generate lentiviruses carrying each pTRIPZ PSAT1 
vector, as well as a control pGIPZ vector which constitutively expresses GFP, Flp-In 293 T-REx 
cells were grown in 25 cm2 flasks to around 60-70% confluency, at which point they were 
transfected with a virus generation transfection mixture. 2.2 µg psPAX and 0.9 µg of pMD2.G, 
the plasmids encoding the components necessary to assemble the virus, were mixed via 
vortexing along with 2.9 µg of the pTRIPZ PSAT1 vector in 600 µl of Opti-MEM® reduced serum 
transfection medium. Transfection was performed using Effectene Transfection Reagent 
(Qiagen - #301425) so, after mixing the DNA plasmids in the Opti-MEM® reduced serum 
transfection medium, 15 µl of Effectene Enhancer Buffer was added to the mixture, which was 
then vortexed once again. Finally, 21 µl of Effectene Transfection Reagent was added to the 
mixture which was vortexed once more to mix thoroughly. The transfection mixture was then 
incubated at room temperature for 5 minutes and added directly into the 25 cm2 flask of Flp-In 
293 T-REx cells in 6 ml of medium.  
Cells were incubated at 37°C for 10 hours to allow transfection of the virus-generating plasmids 
and the pTRIPZ PSAT1 vector. Transfection medium was then changed to 10 ml of fresh medium, 
in which assembled virus was collected for 48 hours (after 24 hours, cells generating the pGIPZ 
virus were checked for green fluorescence to assess successful transfection of DNA and viral 
assembly). Virus containing medium was collected from the flasks and filtered through a Millex-
HP 45 µm pore-size syringe filter unit (Merck Millipore - #SLHP033RS). Filtered viral medium was 
then stored at -80°C till use. 
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2.2.6.2 Lentiviral infection of MDA-MB-453 cells 
 
MDA-MB-453 cells were plated in a 6-well plate at a density of 300,000 cells per well and 
incubated at 37°C for 24 hours. Hexadimethrine bromide (commercially named Polybrene – 
Sigma Aldrich - #H9268), which increases the efficiency of virus infection in receiving cells, was 
diluted to 8 µg/ml in lentiviral medium. 1 ml of lentiviral medium per well was then added to 
the MDA-MB-453 cells and cells were incubated for 72 hours, facilitating infection of the breast 
cancer cells by the virus. Green fluorescence of MDA-MB-453 cells infected with the pGIPZ virus 
was used to assess the efficiency of infection. pTRIPZ contains a puromycin resistance gene so, 
after 72 hours of incubation of MDA-MB-453 cells with the lentiviral medium, the lentiviral 
medium was removed from the cells and replaced with medium containing 3 µg/ml puromycin 
to select for cells where pTRIPZ PSAT1 transduction was successful. The resulting post-selection 
cells were passaged into 25 cm2 flasks and subsequently into 75 cm2 flasks when sufficiently 
confluent, ready for experimental use. 
All virally contaminated materials, including medium, pipette tips, plates and filters were 
decontaminated in 1% w/v Virkon (1x 5 g Rely+On™ Virkon™ tablet (DuPont) dissolved in 500 
ml of water) for at least 24 hours to kill any residual virus prior to disposal. 
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2.3 HA-GFP and HA-IKKε cell line generation 
 
Flp-In 293 cells expressing inducible HA-tagged GFP and IKKε wt or KD-m proteins were 
generated by Dr Ruoyan Xu, using techniques described in detail in 2.2. Similar to the generation 
of PSAT1 mutant variants, an IKKε kinase dead mutant was generated using point mutagenesis 
PCR to mutate the IKBKE gene sequence encoding lysine residue Lys38 on the IKKε protein to an 
alanine residue. This was done by changing 2 nucleotides in the DNA sequence. As with PSAT1 
mutagenesis, IKBKE mutagenesis primers were manufactured by Sigma Aldrich. 
IKBKE K>A mutagenesis primers: 
Forward – 5’-gagctggttgctgtggcggtcttcaacactac-3’ 
Reverse – 5’-gtagtgttgaagaccgccacagcaaccagc-3’ 
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2.4 IncuCyte Growth Analysis 
 
Cells were plated in either a 96-well or 6-well plate at densities described in Table 2.3. In 96-well 
plates, cells were plated in triplicate for each condition. For experiments involving siRNA 
treatments, cells were transfected 24 hours after plating as described in 2.1.7, washed 16 hours 
later and placed on the IncuCyte Zoom system (Essen BioScience). For drug treatments, cells 
were treated 24 hours after plating and placed immediately on the IncuCyte Zoom system.  
Cells were cultured within the IncuCyte Zoom system for up to 7 days at 37°C with 5% CO2. 
Brightfield images at 100X magnification were captured in at least 6 hourly intervals and from 
at least 4 independent locations within the wells, depending on the well size.  
Cell confluency in each image was quantified using an imaging mask programmed to recognise 
cells within the image. An average of the cell confluency from the images in each well was taken 
to calculate cell confluency per well. Delta confluency over 72 hours was calculated by 
subtracting confluency at 0 hours from confluency at 72 hours and was used as a readout to 
compare relative cell growth. Full details of the imaging masks used for analysis of each cell line 
are included as supplementary materials (see Table 7.1). 
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2.5 Western Blotting 
 
2.5.1 Pre-mixed buffers and Reagents 
 
Pre-prepared 1 M Tris HCl (pH 7.4) and 1 M MgCl2 solutions (both from Severn Biotech) were 
used in the preparation of Triton 1% lysis buffer for extraction of proteins from cells. Both 
solutions were stored at room temperature. 
20% w/v Sodium Dodecyl Sulfate solution (Sigma Aldrich - #05030-500ML-F) was used in the 
preparation of 6x loading dye for gel loading. The 20% solution was stored at room temperature 
and would occasionally precipitate when ambient temperature dropped. In this circumstance, 
the solution was warmed to 40°C in a water bath and incubated for 15 minutes to facilitate re-
solubilisation. 
NuPAGE™ MOPS SDS Running Buffer 20x solution (50mM MOPS, 50 mM Tris Base, 0.1% SDS, 1 
mM SDS, pH 7.7) (Life Technologies - #NP000102) was used for SDS-PAGE protein separation. 
The solution was diluted to 1x concentration in distilled water. The 20x solution was stored at 
room temperature and the 1x dilution was freshly prepared when required.  
Tris Glycine 10x solution (250 mM Tris, 1.92 M Glycine) (Severn Biotech - #20-6300-100) was 
used for the preparation of wet transfer buffer. The solution was diluted to 1x in distilled water 
when required. The 10x solution was stored at room temperature. 
Tris Buffered Saline (TBS) 10x solution (1.37 M Sodium Chloride, 200 mM Tris) (Severn Biotech - 
#20-7301-10) was used for the preparation of TBS-T used for preparing immunoblot membrane 
blocking solution, antibody solutions and for washing membranes in between antibody 
incubations. The 10x solution was stored at room temperature. 
2.5.2 Cell lysis 
 
Cell culture plates frozen at -80°C were removed from the freezer and placed on ice. 150 µl of 
Triton 1% lysis buffer (Table 2.12) was added to each well and wells were scraped using a cell 
scraper to suspend cells in the lysis buffer. The cell suspension was then transferred to a 1.5 ml 
microcentrifuge tube and centrifuged at 13,000 g for 15 minutes at 4°C, pelleting unwanted 
cellular debris at the bottom of the microcentrifuge tube. The resulting cell lysate supernatant 
was transferred to a fresh microcentrifuge tube and stored at -80°C when not in use. 
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Table 2.12 – Recipe for Triton 1% lysis buffer. Lysis buffer was stored at 4°C when not in use. 
Component Concentration 
Tris HCl (pH 7.4) 20 mM 
NaCl 135 mM 
MgCl2 1.5 mM 
Glycerol ≥ 99% (Sigma Aldrich - #G5516-1L) 10% v/v 
Triton™ X-100 (Sigma Aldrich - #T8787-100ML) 1% v/v 
cOmplete™ Mini Protease Inhibitor Cocktail (Roche - #11836153001) 1 tablet 
  
 
2.5.3 Protein quantification using DC protein assay (Bio-Rad) 
 
To measure the concentration of the protein content of cell lysates, the Bio-Rad DC protein assay 
was used, utilising a colourimetric reaction to determine unknown concentrations from a curve 
plotted using standards of known concentrations. The assay was performed as per the kit 
manufacturer’s instructions. Briefly, using an 8 µl total volume per well of a 96-well plate, a 
standard curve was generated using a bovine serum albumin standard (BSA (Sigma Aldrich - 
#A2153) dissolved in Triton 1% lysis buffer, stored at -20°C and thawed on ice when required) of 
a known concentration of 1 mg/ml. Wells containing 1 mg/ml, 0.5 mg/ml, 0.25 mg/ml and 0.125 
mg/ml were prepared in triplicate and diluted using water (i.e. 8 µl BSA = 1 mg/ml, 4 µl BSA + 4 
µl water = 0.5 mg/ml, 2 µl BSA + 6 µl water = 0.25 mg/ml, 1 µl BSA + 7 µl water = 0.125 mg/ml). 
For each unknown sample, 2 µl of cell lysate was added to a well of a 96-well plate in triplicate 
and the volume was topped up to 8 µl using water. 3 lysis buffer control wells were also prepared 
using 2 µl of lysis buffer and 6 µl water to control for background absorbance in the lysis buffer 
in the unknown samples (Figure 2.1). 
With 8 µl total volume in each well, the reagents for the colourimetric reaction were prepared 
and added. Reagent S’ was prepared freshly as required, mixing DC Protein Assay Reagent A 
(Bio-Rad - #500-0113) with DC Protein Assay Reagent S (Bio-Rad - #500-0115) at a ratio of 1 ml 
Reagent A : 20 µl Reagent S. Reagent S’ was vortexed briefly to thoroughly mix and 25 µl was 
added to each reaction well. Subsequently 200 µl of DC Protein Assay Reagent B (Bio-Rad - #500-
0114) was added to each reaction well. The quantification plate was then incubated at room 
temperature for at least 20 minutes to allow the colourimetric reaction to occur to completion. 
The absorbance of light at an excitation wavelength of 630 nm was then measured for each well 
using a Victor3 Multilabel Counter plate reader (Perkin Elmer - #1420-050).  
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Figure 2.1 – Example layout for a 96-well protein concentration quantification plate. A standard curve is generated 
using 1 mg/ml BSA dissolved in Triton 1% lysis buffer at a concentration of 1 mg/ml, 0.5 mg/ml, 0.25 mg/ml and 0.125 
mg/ml and a Triton 1% lysis buffer blank for background control as indicated. 2 µl of each sample of unknown 
concentration is diluted in 6 µl H2O as indicated. All samples are assayed in triplicate and 25 µl of DC Protein Assay 
Reagent S’ was added to each well, followed by 200 µl of DC Protein Assay Reagent B. Absorbance of light at a 
wavelength of 630 nm was measured for each well and the concentration of unknown samples was calculated using 
the standard curve. 
 
Microsoft Excel was used to plot a standard curve from the average absorbance values of the 
triplicate BSA samples and generate the curve equation. The average absorbance values for 
unknown samples were fed into the equation to calculate the concentrations of the cell lysates. 
 
2.5.4 Preparation of cell lysates for SDS-PAGE 
 
To facilitate comparison of relative protein expression upon completion of the western blotting 
protocol, cell lysates must be analysed in equal amounts. Therefore, being kept on ice at all 
times, cell lysates were diluted to an equal concentration of 1 µg/µl where possible, or to an 
equal concentration with the most dilute lysate in instances where lysate concentration was too 
low to normalise to 1 µg/µl. 6x concentrated loading dye (Table 2.13) was subsequently added 
to a final concentration of 1x in the lysates. Lysates were then incubated at 95°C for 10 minutes 
in a heat block to ensure full denaturation of proteins, after which, brief centrifugation ensured 
collection of full lysate at the bottom of the microcentrifuge. Lysates were then either placed on 
ice once again, ready for gel loading, or stored at -80°C for use at a later time. 
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Table 2.13 – Recipe for 6x concentrated loading dye. 
Component Concentration 
Glycerol ≥ 99% 40% v/v 
β-mercaptoethanol (Sigma Aldrich - #M3148-25ML) 30% v/v 
20% w/v Sodium dodecyl sulfate (SDS) solution 6% v/v 
Bromophenol blue (Sigma Aldrich - #B8026-5G) - 
 
2.5.5 SDS-PAGE 
 
Sodium dodecyl sulfate – polyacrylamide gel electrophoresis (SDS-PAGE) was used to separate 
lysate proteins based on size. 18 µl of each sample lysate (containing 15 µg protein in 15 µl lysate 
and 3 µl of 6x loading dye) was loaded per well of a 10-well, 12-well or 20-well precast NuPAGE™ 
Novex™ 4-12% Bis-Tris Midi Protein Gels (Life Technologies – #NP0321BOX (10-well), 
#NP0322BOX (12-well), #WG1402BOX (20-well)), which had been inserted into either an XCell 
SureLock™ Mini-Cell (for 10- and 12-well gels, Invitrogen - #EI0001) or an XCell SureLock™ Midi-
Cell (for 20-well gels, Invitrogen - #WR0100) prior to sample loading. In addition to loading the 
lysate samples, one well to the left of the samples was loaded with 8 µl PageRuler™ Plus 
Prestained Protein Ladder (ThermoFisher Scientific - #26619) and one well to the right of the 
samples with 4 µl of ladder. This allowed visualisation of protein molecular weights in the gel 
and orientation of the gel and membrane at later points. Following sample loading, the gel tank 
was filled with NuPAGE™ MOPS SDS Running Buffer (20x) diluted to 1x in distilled water. 120V 
was then run through the gel for 2 hours to resolve the proteins. 
2.5.6 Transfer to PVDF membrane 
 
Following separation of the proteins via SDS-PAGE, proteins were transferred to 0.45 µm pore-
size PVDF membrane (Merck Millipore - #IPVH00010) using either semi-dry or wet transfer 
techniques. 
2.5.6.1 Semi-dry transfer 
 
Semi-dry transfer was performed using a TE77 PWR Semi-Dry Transfer Unit (GE Healthcare - 
#11001342). Completed SDS-PAGE gels were removed from the electrophoresis tank and 
incubated in Kat (-) buffer (Table 2.13) for 20 minutes. PVDF membrane cut to the necessary size 
of the gel used was briefly incubated in methanol to activate the membrane and allow proper 
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binding of proteins. 2 pieces of Grade 17 Chr Cellulose Chromatography paper (GE Healthcare - 
#3017-915) were soaked in Kat (+) buffer (Table 2.14) and placed onto the anode base of the 
transfer unit. The PVDF membrane was washed in Kat (-) buffer to remove excess methanol and 
placed on top of the blotting paper. Following incubation, the completed gel was carefully laid 
on top of the membrane ensuring no air bubbles were present between the membrane and the 
gel. 2 further pieces of blotting paper were soaked in Kat- buffer and placed on top of the gel to 
complete the transfer “sandwich”. A 5 ml pipette was then rolled across the surface of the 
transfer sandwich, with pressure applied to remove any potential bubbles between any of the 
layers. The transfer unit was closed and 20V was applied for 1 hour to allow migration of 
resolved proteins from the gel to the membrane in parallel, maintaining the protein separation 
throughout the process. 
 
Table 2.14 – Recipe’s for Kat (-) and Kat (+) buffers for semi-dry transfer. 
Kat (-) Buffer Kat (+) Buffer 
Component Concentration Component Concentration 
Tris Base 24.8 mM Tris Base 302.1 mM 
E-Aminocaproic Acid  40.4 mM MetOH 20% v/v 
(Sigma Aldrich – #A7824)  Distilled water 80% v/v 
MetOH 20% v/v   
Distilled water 80% v/v   
 
 
2.5.6.2 Wet transfer 
 
Wet transfer was performed using a TE62 Transfer Cooled Unit (GE Healthcare - #TE62), kept in 
the fridge at all times. The tank was filled with transfer buffer (Table 2.15), which was reused for 
multiple transfers and replaced when signs of inefficient transfer began to appear (i.e. low 
running voltage and retention of protein ladder within the gel following completion of transfer). 
As with semi-dry transfer, PVDF membrane was incubated briefly in methanol to activate it. 
Transfer cassettes were assembled in a plastic tray containing transfer buffer. 2 pieces of X50 
chromatography paper (Fisher Scientific - #1156-7393), cut to the size of the cassette and soaked 
in the transfer buffer contained within the tray, were placed on top of a buffer-soaked sponge 
on the grey (positive) side of the cassette. The activated PVDF membrane was washed in the 
transfer buffer and placed on top of the blotting paper. Completed SDS-PAGE gels were removed 
from the electrophoresis tank, gently washed in transfer buffer and carefully laid on top of the 
membrane, again taking care to avoid the trapping of air bubbles between the membrane and 
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the gel. 2 more pieces of thin blotting paper were soaked in the transfer buffer and placed on 
top of the existing layers and a 5 ml pipette was rolled across the gel containing section of the 
transfer sandwich to push out any bubbles present between the layers. Another buffer-soaked 
sponge was laid on top of the transfer sandwich. The cassette was closed and submerged in the 
transfer tank, ensuring correct orientation of the cassette within the tank (grey/positive to 
anode and black/negative to cathode). The transfer was run for 2 hours using 1 Amp. 
 
Table 2.15 – Recipe for Tris Glycine transfer buffer for wet transfer. 
Component Concentration 
Tris Glycine (10x solution) 10% v/v 
MetOH 20% v/v 
Distilled water 70% v/v 
 
2.5.7 Immunoblotting 
 
Following completion of transfer, the membranes were subject to immunoblotting for 
visualisation of specific proteins of interest. Firstly, membranes were incubated in 5% w/v 
skimmed milk powder (Sigma Aldrich - #70166) in TBS-T (a 0.1% v/v TWEEN® 20 (Sigma Aldrich 
- #P1379) solution prepared in 1x TBS buffer) for 1 hour at room temperature on a rocking 
platform. Subsequently, membranes were cut into multiple pieces based on molecular weight 
to facilitate immunoblotting of multiple proteins from a single membrane. Membrane sections 
were then incubated in primary antibody diluted in 5% w/v skimmed milk powder in TBS-T 
overnight at 4°C either in a petri dish on a rocking platform, or in a 30 ml universal tube on a 
rolling mixer depending on membrane size. The following day, membrane sections were washed 
3 times for 15 minutes a piece in TBS-T at room temperature to remove unbound antibody. 
Membranes were then incubated in horseradish peroxidase (HRP)-conjugated secondary 
antibody diluted in 5% w/v skimmed milk powder in TBS-T for 1 hour at room temperature.  Full 
details of both primary and secondary antibodies used in this project are found in 2.5.7.1 and 
Table 2.16. Following secondary incubation, membrane sections were washed again for 15 
minutes, 3 times over at room temperature in TBS-T to remove excess secondary antibody. After 
washing, the immunoblot was developed using an Amersham Imager 600UV chemidoc system 
(GE Healthcare - #29083463) or Fuji Medical X-Ray Film (Fujifilm - #47410 19289). For 
development using the chemidoc system, membranes were placed on the surface of a tray with 
a white plastic insert. Standard strength Pierce™ enhanced chemiluminescence (ECL) Western 
Blotting Substrate (ThermoFisher Scientific - #32106), high strength SuperSignal™ West Pico 
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PLUS Chemiluminescent Substrate (ThermoFisher Scientific – #34577) or maximum strength 
SuperSignal™ West Femto Maximum Sensitivity Substrate (ThermoFisher Scientific - #34094) 
was added to the membranes to induce the HRP-mediated chemiluminescent reaction. The tray 
with the membranes on was then inserted into the chemidoc system for detection of 
chemiluminescent signal. For development to X-Ray film, ECL substrate was added and 
membranes were placed between 2 sheets of clear plastic film inside an autoradiography 
cassette. In a dark room, X-Ray film was inserted in the cassette and exposed to the membranes 
for up to 15 minutes depending on signal strength. X-Ray films were subsequently developed 
using an SRX-101A table-top medical film processor (Konica Minolta) and scanned to digital .jpg 
format using a table-top scanner for figure preparation.  
If membranes were re-probed with additional antibodies following the completion of the 
immunoblot, membranes were stripped by incubation in Restore™ PLUS Western Blot Stripping 
Buffer (ThermoFisher Scientific – #46430) for 10 minutes, followed by 5x 3-minute washes in 
PBS and 1 hour blocking at room temperature. Re-probing was then performed. 
2.5.7.1 Antibodies 
 
Primary antibodies specific to protein of interest and secondary HRP-conjugated antibodies 
were obtained from commercial sources and stored at either 4°C or -20°C as required. Primary 
antibodies were used initially at a dilution of 1:1000 which was then adjusted based on signal 
strength as necessary. Secondary antibodies were used at a dilution of either 1:2000 or 1:5000. 
Specific details of each antibody used are indicated in the Table 2.16. 
2.5.8 Densitometry analysis western blot quantification 
 
In order to quantify differences in protein expression between samples, relative protein band 
density was quantified using NIH’s ImageJ software327. Firstly, relative protein band density of 
the vinculin loading control in each sample was quantified as a percentage of total protein band 
density for vinculin across all samples. Then, the same process was repeated for the protein of 
interest, quantifying the density of each individual protein band as a percentage of total protein 
band density for the protein of interest across all samples. Finally, the percentage density for 
the protein of interest was divided by the percentage density for the loading control for each 
sample, to generate relative values for each protein normalised to loading. Further 
normalisation of density values for proteins of interest was then performed for specific 
experiments and is indicated in such cases throughout the results chapters. All western blots 
were repeated in at least three biologically independent experiments unless otherwise stated. 
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Table 2.16 – Details of antibodies used for immunoblot protein detection. *antibody discontinued. †HRP linked. 
Type Target Company Cat. Number Host  Storage Dilution  
Primary Actin Santa Cruz  sc1615 Goat 4°C 1:1000 
       
Primary ATF4 Cell Signaling 11815 Rabbit -20°C 1:1000 
       
Primary HA-tag Roche 11867423001 Rat -20°C 1:4000 
       
Primary IKKε Sigma Aldrich I4907* Rabbit -20°C 1:1000 
       
Primary IRF3 Cell Signaling 11904 Rabbit -20°C 1:1000 
       
Primary 
IRF3 
pSer396 
Cell Signaling 4947 Rabbit -20°C 1:1000 
       
Primary NF-κB p65 Cell Signaling 8242 Rabbit -20°C 1:1000 
       
Primary 
NF-κB p65 
pSer468 
Cell Signaling 3039 Rabbit -20°C 1:1000 
       
Primary PHGDH Sigma Aldrich HPA021241 Rabbit -20°C 1:4000 
       
Primary PSAT1 
ThermoFisher 
Scientific 
PA5-22124* Rabbit -20°C 1:1000 
       
Primary PSAT1 ProteinTech 20180-1AP Rabbit -20°C 1:1000 
       
Primary PSPH ProteinTech 14513-1-AP Rabbit -20°C 1:1000 
       
Primary SHMT2 Cell Signaling 12762 Rabbit -20°C 1:1000 
       
Primary STAT1 Cell Signaling 9172 Rabbit -20°C 1:1000 
       
Primary 
STAT1 
pTyr701 
Cell Signaling 9167 Rabbit -20°C 1:1000 
       
Primary TBK1 Cell Signaling 3013 Rabbit -20°C 1:1000 
       
Primary Vinculin ProteinTech 66305-1-Ig Mouse -20°C 1:1000 
       
Secondary† Goat IgG Santa Cruz sc2020 Donkey 4°C 1:2000 
       
Secondary† Mouse IgG Cell Signaling 7076 Horse -20°C 1:2000 
       
Secondary† Rabbit IgG GE Healthcare NA934-1ML Donkey 4°C 1:2000 
       
Secondary† Rat IgG Santa Cruz  sc2956 Chicken 4°C 1:2000 
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2.6 Labelled Metabolite Analysis 
 
Samples were prepared for labelled metabolite analysis by Dr Ruoyan Xu and were subsequently 
sent to Dr Christian Frezza and Dr Sofia De Costa (MRC Cancer Unit, Cambridge, UK) for mass 
spectrometry detection of total and labelled metabolites. Flp-In 293 HA-GFP and Flp-In 293 HA-
IKKε cells were treated with 50 ng/ml doxycycline. T47D breast cancer cells were transfected 
with either a single non-targeting control oligo or a pool of 4 IKKε-targeting siRNA oligos to a 
final concentration of 50 nM as described in 2.1.7. 2 hours post-doxycycline induction of Flp-In 
293 cells or 48 hours post-transfection of T47D cells, cells were incubated with either U-13C6-D-
glucose (Cambridge Isotope Laboratories - #CLM-1396-5) or 15N2-L-glutamine (Cambridge 
Isotope Laboratories – #NLM-1328-0.25) for 14 hours to facilitate incorporation of labelled 
carbon or nitrogen into intracellular metabolites. Flp-In 293 HA-PSAT1 cells were transfected 
with a pool of 3 siRNA oligos targeting the non-coding sequence of PSAT1 mRNA to a final 
concentration of 50 nM as described in 2.1.7. 24 hours post-transfection, 50 ng/ml doxycycline 
was added to the cells to induce PSAT1 expression. 24 hours post-doxycycline induction (48 
hours post-transfection) cells were incubated with 15N2-glutamine for 24 hours to measure the 
intracellular synthesis of serine via incorporation of labelled nitrogen. 
Following incubation with labelled glucose or glutamine, cells were washed 3 times in PBS and 
placed on methanol and dry ice for metabolite extraction. At a ratio of 1 ml buffer/106 cells, ice-
cold metabolite extraction buffer (Table 2.17) was added to the cells which were then incubated 
for 15 minutes. After incubation, cells were placed on a rocking platform for 15 minutes at 4°C, 
then incubated for 1 hour at -20°C. The cell/buffer mixture was transferred to autoclaved 1.5 ml 
microcentrifuge tubes and centrifuged at 13,000 RPM for 15 minutes at 4°C, after which the 
supernatant was transferred into autosampler glass vials (ThermoFisher Scientific - #60180-600) 
and stored at -80°C prior to mass spectrometry analysis. 
 
Table 2.17 – Recipe for metabolite extraction buffer for extraction of labelled and unlabelled metabolites for 
mass spectrometry analysis. 
Component Concentration 
MetOH, LC-MS CHROMASOLV® Grade (Honeywell - #34966-1L) 50% v/v 
Acetonitrile, for HPLC, gradient grade, ≥99.9% (Sigma Aldrich - #34851-1L) 30% v/v 
Water, LC-MS CHROMASOLV® Grade (Honeywell - #39253-1L-R) 20% v/v 
HEPES 100 ng/ml 
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For mass spectrometry detection of metabolites, samples were randomised and processed 
blindly to avoid bias. Each sample was subject to liquid chromatography-mass spectrometry (LC-
MS) analysis using a Dionex U3000 UHPLC system (ThermoFisher Scientific) coupled to a Q 
Exactive™ Hybrid Quadrupole-Orbitrap™ mass spectrometer (ThermoFisher Scientific). For high-
pressure liquid chromatography (HPLC), the Dionex U3000 UHPLC system was fitted with a 
SeQuant® ZIC®-pHILIC column (150 mm x 2.1 mm) (Merck Millipore - #150460) and a SeQuant® 
ZIC®-pHILIC guard column (20 mm x 2.1 mm) (Merck Millipore - #150438) and temperature was 
maintained at 45°C. The mobile phase used is described in Table 2.18 and the flow rate was set 
at 200 µl/min at a gradient previously described by Mackay et al.328. The mass spectrometer was 
operated in full MS and polarity switching mode and acquired spectra traces were analysed by 
Dr Christian Frezza and Dr Sofia De Costa using XCalibur™ Qual Browser and XCalibur™ Quan 
Browser software (ThermoFisher Scientific). 
The raw data from all labelled metabolite analysis experiments are provided in the 
supplementary materials (see chapter 7), specifically on the provided CD. 
 
Table 2.18 – Recipe’s for Solvent A and Solvent B comprising the mobile phase for High-Pressure Liquid 
Chromatography separation of metabolites. 
Solvent A Solvent B 
Component Concentration Component Concentration 
Ammonium carbonate 20 mM Acetonitrile 100% 
Ammonium hydroxide 0.1% v/v   
Water To 2 litres total volume   
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2.7 Phosphoproteomic Analysis 
 
The samples for phosphoproteomic analysis were prepared by Dr Ewa Wilcz-Villega. Mass 
spectrometry analysis was performed by Dr Pedro Cutillas and Dr Vinothini Rajeeve (Barts 
Cancer Institute, London, UK). 3 independent single cell clones of Flp-In 293 HA-GFP and Flp-In 
293 HA-IKKε cells were treated with 100 ng/ml doxycycline for 16 hours. Cells were then washed 
twice in PBS containing sodium orthovanadate (Na3VO4) and sodium fluoride (NaF) phosphatase 
inhibitors (kindly provided by Dr Vinothini Rajeeve). 250 µl of phosphoproteomic lysis buffer 
(Table 2.19 - including phosphatase inhibitors, again kindly provided by Dr Vinothini Rajeeve) 
was added to each well. Cells were incubated with lysis buffer on ice for 5 minutes, then scraped 
using a cell scraper and collected in a 1.5 ml microcentrifuge tube. The samples were then 
centrifuged at 13,000 g for 10 minutes at 4°C to pellet cellular debris. The supernatant was 
subsequently transferred to fresh microcentrifuge tubes. The samples were then frozen on dry 
ice and handed over to Dr Vinothini Rajeeve for mass spectrometry analysis. 
After cell lysates were thawed, protein content was digested using trypsin. Phosphopeptides 
were enriched using TiO2 as previously described329 and peptides were then analysed using LC-
MS with an Orbitrap mass analyser. Peptides were identified from MS/MS spectra using the 
Mascot search engine330 and were quantified using Pescal as previously described331. 
 
Table 2.19 – Recipe for phosphoproteomic lysis buffer. 
Component Concentration 
Urea 8 M 
HEPES 20 mM 
Sodium Orthovanadate (Na3VO4) 1 mM 
Sodium Fluoride (NaF) 1 mM 
β-Glycerol phosphate 1 mM 
Disodium diphosphate (Na2H2P2O7) 0.25 mM 
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2.8 qRT-PCR 
 
2.8.1 RNA extraction 
 
RNA was extracted from cells in 6-well plates stored at -80°C following application of 
experimental conditions in tissue culture. The RNeasy Mini Kit (Qiagen - #74104) was used to 
extract RNA from cells by following kit instructions. Cell culture plates were removed from the -
80°C freezer and placed on ice for lysis. In each well of a 6-well plate, 350 µl of RLT buffer was 
added to lyse the cells. A cell scraper was used to collect cells and 350 µl of 70% v/v ethanol was 
added to precipitate nucleic acids. The lysates were mixed thoroughly by pipetting with a p1000 
pipette and transferred to an RNeasy spin column. The spin column was centrifuged at 8,000 g 
for 15 seconds to allow the passing of cell lysate through the column, during which RNA in the 
lysate binds to the membrane within the column. The flow through, containing the majority of 
DNA, proteins and cellular debris was collected in a 2 ml collection tube and subsequently 
discarded. The membrane within the column was then stringently washed with the addition of 
700 µl of RW1 buffer to the spin column, which was then centrifuged again at 8,000 g for 15 
seconds. This removes biomolecules like carbohydrates and fatty acids bound non-specifically 
to the membrane within the column. The flow through was again discarded. Two more washes 
with buffer RPE, a much milder washing buffer than RW1 designed to remove salt traces present 
on the column membrane, were performed. 500 µl of RPE buffer was added to the column, 
followed by centrifugation at 8,000 g for 15 seconds and discarding of the flow through. A 
further 500 µl of RPE buffer was added to the column, which was centrifuged again at 8,000 g, 
but this time for 2 minutes. The RNeasy spin column was then placed in a new 2 ml collection 
tube and centrifuged at 13,000 g for 1 minute to dry the column and remove residual buffers 
soaked within the membrane. Finally, the RNeasy spin column was transferred to an autoclaved 
1.5 ml microcentrifuge tube and 30 µl of nuclease-free water was pipetted directly onto the 
membrane within the column, releasing the membrane-bound RNA. Centrifugation for 1 minute 
at 8,000 g then collected the RNA in the microcentrifuge tube, which was kept on ice or stored 
at -80°C till use. 
2.8.2 Quantification of RNA concentration 
 
The concentration of RNA extracted using the RNeasy Mini Kit was quantified using a Nanodrop-
2000 spectrophotometer as described in 2.2.2.5, using the absorbance of light at a 260 nm 
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wavelength of 1.5 μl of nuclease-free water to quantify background absorbance in the RNA 
samples. The absorbance of 1.5 μl of each RNA sample was then quantified and used to calculate 
the ng/μl concentration of RNA in each sample. 
2.8.3 cDNA synthesis 
 
cDNA was prepared from cellular RNA extracts in Fisherbrand™ 0.2 ml Flat-Cap PCR tubes, using 
the Omniscript® RT Kit (Qiagen - #205111). Per sample, RNA was diluted to 83.3 ͘ng/μl in 12 μl 
of nuclease-free water, using a total of 1000 ng of RNA for cDNA synthesis. A 20 μl cDNA 
synthesis reaction was then prepared in an autoclaved 0.2 ml PCR tube as described in Table 
2.20. The 20 μl reaction mixture was then thoroughly mixed by vortexing and briefly centrifuged 
in a table top centrifuge. The reaction was then incubated at 37°C for 1 hour to facilitate cDNA 
production. Generated cDNA was stored at -20°C till use. 
 
Table 2.20 – Composition of 20 µl Omniscript® RT cDNA synthesis reaction for synthesis of cDNA from cellular 
RNA extracts. 
Component In 20 µl 
Buffer RT (10x) 2 µl 
  
dNTP Mix (5 mM) 2 µl 
  
50 µM Oligo (dT) Primer (Invitrogen - 
#AMG5730G) 
2 µl of 10 µM dilution, diluted prior to use in 
nuclease-free water 
  
40 units/µl RNase Inhibitor (New England Biolabs 
- #M0307S) 
1 µl of 10 units/µl dilution, diluted prior to use in 
1x Buffer RT (diluted in nuclease-free water) 
  
Omniscript RT 1 µl 
  
RNA extract (83.3 ng/µl) 12 µl (1000 ng total) 
 
2.8.4 PCR reaction 
 
The qRT-PCR reaction was performed in a MicroAmp™ Optical 96-Well Reaction Plate (Applied 
Biosystems - #N8010560) using either the 7500 Real-Time PCR System (Applied Biosystems - 
#4351105) or the QuantStudio™ 5 Real-Time PCR System (Applied Biosystems - #A28569). cDNA 
samples were run in triplicate, along with a single no cDNA control for each mRNA probe used. 
Chapter 2. Materials and Methods 
94 
 
In each sample well, a 20 µl TaqMan™ reaction mixture was prepared as detailed in Table 2.21. 
The Optical 96-Well Reaction Plate was then sealed with a MicroAmp™ Optical Adhesive Film 
(Applied Biosystems - #360954) and centrifuged for 1 minute at 2000 g to collect the whole of 
the reaction mixture at the bottom of the plate well. The qRT-PCR reaction was then run using 
one of the PCR machines. The PCR programme used involved a 10-minute incubation at 95°C to 
activate the polymerase, followed by 40 cycles of 15 seconds incubation at 95°C and 1-minute 
incubation at 60°C to facilitate TaqMan™ probe primer annealing and DNA amplification. Full 
details of TaqMan™ Gene Expression probes used within this project are detailed in Table 2.22. 
Relative gene expression was quantified by using the Ct values from the qRT-PCR run (the 
number of cycles necessary for fluorescence from gene probes to pass a pre-determined 
threshold). Ct values were used for ΔΔCt analysis to calculate gene expression relative to a 
control value arbitrarily defined as “1”. Gene expression in treated samples was normalised to 
ACTB (β-Actin) mRNA level, to control for differences in plate loading. 
 
Table 2.21 – Composition of 20 µl TaqMan™ PCR reaction for quantitative analysis of mRNA expression. 
Component In 20 µl 
TaqMan™ Universal PCR Master Mix (2x) 10 µl 
TaqMan™ Gene Expression Probe 1 µl 
Nuclease-free water 8 µl 
Sample cDNA (Or nuclease-free water in no cDNA control) 1 µl 
 
 
Table 2.22 – Details of TaqMan™ Gene Expression Probes used for qRT-PCR analysis of mRNA expression. 
mRNA Target Product Name/Assay ID Source 
Company 
Catalogue 
Number 
Reporter 
Dye 
Quencher 
Dye 
PHGDH Hs00198333_m1 ThermoFisher 
Scientific 
4331182 6-FAM™ NFQ-MGB 
PSAT1 Hs00795278_mH ThermoFisher 
Scientific 
4331182 6-FAM™ NFQ-MGB 
PSPH Hs00190154_m1 ThermoFisher 
Scientific 
4331182 6-FAM™ NFQ-MGB 
ACTB (β-Actin) Human ACTB (Beta Actin) 
Endogenous Control 
Applied 
Biosystems 
4310881E VIC® TAMRA™ 
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2.9 HA-Pulldown assays 
 
Flp-In 293 cells expressing HA-PSAT1 wt, S>A or S>E were plated in 10 cm dishes at densities 
described in Table 2.2 (or Table 2.3 for pull-down assays in which siRNA was used to suppress 
endogenous PSAT1). Following necessary treatment, cells were washed twice with 1 ml of ice 
cold PBS and frozen at -80°C till use.  
Cells were lysed on ice for 30 minutes with 1 ml of Triton 1% lysis buffer, then centrifuged at 
13,000 g for 30 minutes at 4°C. Protein concentration was quantified as described in 2.5.3 and 1 
mg of protein was diluted in 1 ml of Triton 1% lysis buffer. The protein sample was then 
incubated with 20 µl Monoclonal Anti-HA-Agarose Beads (Sigma Aldrich - #A2095) in a 1.5 ml 
microcentrifuge tube on a rotator mixer for 1 hour at 4°C. Samples were centrifuged in a table 
top centrifuge at 4500 RPM for 30 seconds to pellet the Anti-HA-Agarose beads and the 
supernatant was aspirated. 1 ml of lysis buffer was added to wash the beads. This washing step 
was repeated 3 more times.  
A glycine elution was then performed to detach bound protein from the beads. 90 µl of 0.2 M 
glycine pH 2.5 (Severn Biotech) was added to the bead pellet and the samples were incubated 
at room temperature for 30 minutes. A final centrifugation at 4500 RPM for 30 seconds in a table 
top centrifuge was performed and the 90 µl glycine elution was pipetted away from the beads 
and added to 10 µl of 1 M ammonium bicarbonate (NH4HCO3) pH 8.8 (Severn Biotech) in a fresh 
1.5 ml microcentrifuge tube. 6x loading dye was diluted to 1x in the elution and western blotting 
was performed to analyse protein pulldown. 
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2.10 in vitro kinase assay 
 
Flp-In 293 cells expressing HA-IKKε wt or HA-IKKε KD-m were plated in 10 cm dishes at densities 
described in Table 2.2. 24 hours post-plating, cells were treated with 100 ng/ml doxycycline for 
16 hours to induce HA-tagged kinase expression. Following doxycycline treatment, cells were 
washed with ice cold PBS containing Na3VO4 and NaF phosphatase inhibitors and frozen at -80°C 
till use. Cells were thawed and lysed on ice for 30 minutes with Triton 1% lysis buffer 
supplemented with HALT™ Phosphatase Inhibitor Cocktail (ThermoFisher Scientific - #78428). 
Cell lysates were centrifuged for 30 minutes at 13,000 g and lysate protein concentration was 
quantified as described in 2.5.3. HA-IKKε was purified from 1 mg of protein lysates using an HA-
Pulldown as described in 2.9 up to the washing steps. After 2 washes in lysis buffer, Anti-HA-
Agarose beads were washed twice in kinase buffer (Table 2.23 - as with the phosphoproteomic 
analysis, all phosphatase inhibitors were kindly provided by Dr Vinothini Rajeeve).  
Following washes, the beads were resuspended in 40 µl of kinase buffer. 5 µl of 1 picoMol/µl 
recombinant His-tagged PSAT1 (Creative Biomart - #PSAT1-1328H) was added to the bead 
suspension, along with 5 µl of 10 mM ATP (New England Biolabs - #P0756S) to trigger the 
phosphorylation reaction. The reaction was incubated at room temperature for 20 minutes, 
after which the reaction was halted by adding 24 mg of solid urea (to a final 8M concentration 
in 50 µl) and vortexing till the urea had completely dissolved. The samples were then stored at 
-80°C till mass spectrometry analysis by Dr Pedro Cutillas and Dr Vinothini Rajeeve as described 
in 2.7. Phosphorylation of recombinant PSAT1 was analysed by integrating the peak areas of 
extracted ion chromatograms of the phosphorylated and un-phosphorylated PSAT1 derived 
peptides. 
 
Table 2.23 – Recipe for kinase buffer for in vitro kinase assay. 
Component Concentration 
Tris HCl (pH 7.8) 25 mM 
MgCl2 10 mM 
EGTA 0.5 mM 
DTT 1 mM 
Na3VO4 1 mM 
Na2P2H2O7 2.5 mM 
β-glycerophosphate 20 mM 
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2.11 Analysis of Mitochondrial Function 
 
For evaluation of oxygen consumption rate (OCR) in doxycycline-treated Flp-In 293 HA-IKKε cells 
and IKKε-siRNA-transfected breast cancer cells, Dr Ruoyan Xu prepared cells as described below 
and measured OCR using either an Oroboros O2k-FluoRespirometer (Oroboros - #10002-02) 
(Flp-In 293 cells) or a Seahorse XFe96 Analyzer (Agilent) (breast cancer cells). 
For Flp-In 293 cells, cells were plated in 6-well plates and subsequently treated with 50 ng/ml 
doxycycline for 16 hours. Following treatment, cells were resuspended in Seahorse XF Assay 
Medium (Agilent - #102365-100) containing 4.5 g/l glucose, 1 mM pyruvate and 25 mM HEPES 
and OCR was measured at 37 °C using an Oroboros O2k-FluoRespirometer. 
For breast cancer cell lines, cells were plated in 6-well plates and 24 hours later, were 
transfected with IKBKE-targeting siRNA as described in 2.1.7. 24 hours post-transfection, cells 
were trypsinised and re-plated in Seahorse XF Assay Medium in a Seahorse XF96 cell culture 
microplate (Agilent - #101085-004). 48 hours later, OCR was measured using the Seahorse XFe96 
Analyzer. 
Measurement of mitochondrial membrane potential was performed in collaboration with 
Professor Gyorgy Szabadkai at (University College London, London, UK). Flp-In 293 HA-GFP and 
HA-IKKε cells were plated in 96-well Black Clear Thin Bottom tissue culture plates (BD Falcon - 
#353219) at a density of 4000 cells per well and incubated at 37°C for 24 hours before use. 
Experimental conditions were applied as described in specific experiments and prior to imaging, 
1 µg/ml Hoechst 33342 (Sigma Aldrich) and 30 nM tetramethylrhodamine, methyl ester (TMRM) 
(Molecular Probes) was added to the cells for 30 minutes. TMRM was also present in the 
medium (DMEM w/o phenol red) throughout imaging. Images were acquired by Dr Szabadkai 
using the ImageXpress Micro XL (Molecular Devices) high content wide field digital imaging 
system using a Lumencor SOLA light engine illumination with ex377/50 nm and em446/60 nm 
filters for detection of Hoechst staining or ex562/40 nm and em624/40 nm filters for detection 
of TMRM staining and a 60x, S PlanFluor ELWD 0.70 NA air objective, using laser based 
autofocusing. 16 fields were acquired per each well and images were analysed with the 
granularity analysis module in the MetaXpress 6.2 software (Molecular Devices) which identified 
mitochondrial (TMRM +) and nuclear (Hoechst +) objects. Average TMRM intensity per cell was 
calculated and averaged for each well and the mean from each well was used as individual data 
for statistical comparison of TMRM staining intensity between conditions. 
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2.12 Statistical Analysis and Figure Preparation 
 
All statistical tests were performed in either GraphPad Prism version 5.04 or version 7.03 for 
Windows (GraphPad Software) using data from at least 3 biologically independent experiments, 
unless otherwise stated in figure legends. Specific tests on an experiment by experiment basis 
are detailed in figure legends. GraphPad Prism was also used to prepare graphs and Adobe 
Illustrator version 16.0.3, purchased as part of the Adobe Creative Suite 6 software package 
(Adobe Systems), was used to generate western blot figures. The heat map presented in Figure 
3.8 B was generated using R and RStudio software with the ggplot2 package332-334. Schematics 
were prepared using a combination of Adobe Illustrator and Microsoft® PowerPoint® 2016 
(Microsoft).
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IKKε directly phosphorylates PSAT1 to promote protein stability 
 
Disclaimer: Whilst such instances are clearly indicated previously in the materials and 
methods and again in the following text and figure legends, the samples sent for labelled 
metabolite analysis and phosphoproteomic analysis with collaborators (Dr Christian Frezza 
and Dr Sofia De Costa at the MRC Cancer Unit in Cambridge, UK and Dr Pedro Cutillas and Dr 
Vinothini Rajeeve at Barts Cancer Institute in London, UK respectively) were prepared for 
analysis by other members of the Bianchi Lab group. The samples for labelled metabolite 
analysis (data presented in Figures 3.5, 3.6 and 3.18) were prepared by Dr Ruoyan Xu and the 
samples for phosphoproteomic analysis (data presented in Figure 3.8 and Table 3.2) were 
prepared by Dr Ewa Wilcz-Villega. In both cases, the author assisted with the post-run analysis 
of this data and the data was included with the intention to provide context for the work 
performed in this study as key cornerstones in the basis of the project, not as an attempt to 
suggest the work was performed by the author. 
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3.1 IKKε expression models 
 
3.1.1 The Flp-In 293 system 
 
As evidence emerges of a link between IKKε and regulation of cellular metabolism106,189, this 
project set out to examine that link in a breast cancer setting. In order to investigate the effects 
of initial upregulation of IKKε on cellular metabolism, a model of IKKε induction was utilised, to 
reflect the early changes that will occur when the kinase is first overexpressed in cancer. 
Untransformed human embryonic kidney (HEK) cell line Flp-In 293 was used to generate a cell 
line in which HA-tagged IKKε could be induced via treatment with doxycycline. The Flp-In 293 
system can generate stable cell lines expressing gene inserts via homologous recombination, as 
FRT sites flanking a gene insert are recombined with FRT sites in the host cell genome (see 2.2.4). 
In each parental Flp-In 293 cell line there is only one FRT gene insert site in the host cell genome 
meaning genes can only be inserted at a single location. When generating multiple cell lines, this 
means different genes are always inserted at the same location in the genome and are always 
expressed equally under the control of the same promoter. This allows comparison of proteins 
based on protein function rather than expression level, which makes the Flp-In 293 system a 
particularly effective system for comparing the activity of mutant versions of the same protein. 
Doxycycline-inducible HA-IKKε and, for control purposes, HA-green fluorescent protein (GFP) 
Flp-In 293 cell lines were generated by Dr Ruoyan Xu to evaluate the effect of kinase induction 
on cellular metabolism. Consistent with the fact that IKKε is an inducible kinase, typically not 
expressed in basal conditions in most tissues78, IKKε expression was undetectable in Flp-In 293 
HA-IKKε cells prior to doxycycline treatment, but treatment with doxycycline resulted in stable 
expression of HA-tagged IKKε (Figure 3.1 B). A Flp-In 293 cell line expressing a HA-tagged kinase-
dead mutant variant of IKKε was developed simultaneously with the HA-GFP and HA-IKKε wild-
type (wt) cells. Introduction of a K38A point mutation in the kinase domain of IKKε is well known 
to ablate kinase activity79. An HA-tagged IKKε K38A mutant was generated by Dr Ruoyan Xu using 
point mutagenesis and, akin to GFP and IKKε wt, was expressed under a doxycycline inducible 
promoter in Flp-In 293 cells.  The discrete cell lines will be termed Flp-In 293 HA-GFP, Flp-in 293 
HA-IKKε wt and Flp-In 293 HA-IKKε KD-m from here on (Figure 3.1 C). To validate lack of HA-IKKε 
KD-m kinase activity, HA-IKKε wt and HA-IKKε KD-m were induced in Flp-In 293 cells and 
phosphorylation of IRF3 at serine residue Ser396, a known IKKε substrate, was assessed via 
western blotting. IRF3 was phosphorylated in the presence of HA-IKKε wt, but expression of HA-
IKKε KD-m failed to phosphorylate IRF3, confirming of a lack of kinase activity (Figure 3.1 D). 
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Figure 3.1 – Induction of HA-tagged IKKε expression in a Flp-In 293 cell model. (A) Schematic representation of the 
Flp-In system used in 293 HEK cells. HA-tagged IKKε within a pcDNA5.5 vector is recombined into the host genome at 
FRT sites through the expression of FLP-recombinase on a secondary pOG44 vector. The constitutively expressed Tet-
R gene tetracycline repressor protein (TetR). TetR protein dimers bind the Tet Op sequence in the inducible gene 
promoter to repress transcription. Doxycycline binds TetR protein and prevents its binding to the Tet Op sequence, 
de-repressing transcription and driving HA-IKKε expression. (B) Western blot demonstrating induction of HA-IKKε or 
HA-GFP in Flp-In 293 cells. Indicated cell lines were treated with 50 ng/ml doxycycline for 16 hours, inducing 
expression of the kinase or GFP accordingly. Vinculin is shown as a loading control. (C) Schematic representation of 
the point mutation introduced into the IKKε sequence to ablate kinase domain function. (D) Western blot highlighting 
the lack of kinase activity in HA-IKKε KD-m. Indicated Flp-In 293 cell lines were treated with 50 ng/ml doxycycline for 
16 hours to induce expression of their respective gene inserts. Phosphorylation of known substrate IRF3 by IKKε at 
serine residue Ser396 (S396) is abrogated by mutation of IKKε’s kinase domain, demonstrating a lack of kinase activity. 
Vinculin is shown as a loading control. 
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3.1.2 Breast cancer cell line panel 
 
To examine the effects of IKKε on cellular metabolism in breast cancer and in a setting where, 
in comparison to the Flp-In 293 system, kinase expression was long term and established, a panel 
of nine breast cancer cell lines were selected, all with varying degrees of IKKε expression and, 
since no correlation between oncogenic activity of the kinase and breast cancer subtype has 
been observed, from a range of disease subtypes (Table 3.1).  
 
Table 3.1 – Breast cancer cell lines panel. Summary of the breast cancer cell lines used in this study, including the 
cancer type and subtype of the source disease. 
 
 
To modulate IKKε expression in the breast cancer cells, cell lines were transfected with a pool of 
4 small interfering RNA (siRNA) oligos targeting the IKBKE mRNA (which codes for IKKε). siRNA 
silences protein expression for a short period of time (typically less than 5 days) by targeting 
mRNA sequences for degradation via the RNA-Induced Silencing Complex (RISC). Assessing 
protein knockdown via western blot, it was confirmed that transfection of breast cancer cell 
lines with IKBKE-targeting siRNA suppressed kinase expression (Figure 3.2), facilitating 
comparison of cell line metabolic status before and after kinase knockdown. This therefore 
allowed characterisation of the effects of long term IKKε expression on cellular metabolism. 
 
 
Figure 3.2 – siRNA-mediated suppression of IKKε expression in a panel of breast cancer cell lines. Western blot 
demonstrating effective knockdown of IKKε in breast cancer cell lines using siRNA. Indicated cell lines were 
transfected with a pool of 4 IKBKE-targeting siRNA oligos, to suppress IKKε, or a single non-targeting control oligo to 
a final concentration of 50 nM for 72 hours. Following transfection, the efficiency of IKKε protein level knockdown 
was assessed. Vinculin is shown as a loading control. 
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When oncogenic in a subset of breast cancer cells, IKKε has been shown to be required for 
maintenance of proliferative rates195.  To determine the best cell line model for characterising 
metabolic changes, the effect of siRNA-mediated IKKε suppression on proliferation was 
evaluated to identify a cell line in which the kinase was essential for continued proliferation 
(Figure 3.3). Breast cancer cell growth upon siRNA-mediated knockdown of IKKε was assessed 
using the IncuCyte Zoom system, a live cell imaging system which incubates cells at optimal 
growth conditions to facilitate imaging over longer periods. By training the system to recognise 
cells, a mask can be applied to captured phase-contrast images (Figure 3.3 A and B) which can 
be used to determine cell confluency at defined time intervals. Tracking cell confluency over 
time at repeated time intervals therefore allows the generation of reliable growth curves and 
the measurement of proliferation. Tracking of cell proliferation upon siRNA-mediated 
suppression of IKKε in the breast cancer cell line panel revealed that kinase suppression 
significantly reduced proliferative rates of 3 out of the 8 cell lines tested; ZR-75-1, T47D and 
MCF7 (Figure 3.3 C-F). This is in partial agreement with existing literature, where suppression of 
IKKε via short hairpin RNA (shRNA) has been shown to reduce the proliferation of ZR-75-1 and 
MCF7195. However shRNA-mediated suppression of the kinase has also been shown to suppress 
proliferation of MDA-MB-231 and MDA-MB-468 cell lines213, where no effect on proliferation 
was observed according to this data. This discrepancy is likely attributable to the different 
approaches taken to suppress IKKε expression and the inherent difference between stable 
suppression of the kinase with shRNA compared to transient suppression with siRNA. Different 
knockdown efficiency of the kinase could also easily have different effects on proliferation, 
though it is difficult to compare the efficiency of knockdown between shRNA and siRNA. The 
effect of siRNA knockdown of IKKε must therefore be compared with previous findings using 
shRNA with some caution. In the context of this project, this data demonstrates that ZR-75-1, 
T47D and MCF7 breast cancer cell lines exhibit a dependency on IKKε for maintenance of 
proliferation, suggesting that IKKε is strongly oncogenic in these models. 
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Figure 3.3 – IKKε suppression reduces proliferation in a subset of breast cancer cell lines. (A and B) Representative 
images of IncuCyte cell growth tracking. Phase contrast image is captured (A) then a cell mask is applied (B) using the 
IncuCyte Zoom 2016A software to track confluency. (C) siRNA-mediated suppression of IKKε reduced proliferation in 
ZR-75-1, T47D and MCF7 breast cancer cell lines. Proliferation of indicated cell lines was tracked using the IncuCyte 
over the days following transfection with a pool of 4 IKBKE-targeting siRNA oligos, to suppress IKKε, or a single non-
targeting control oligo to a final concentration of 50 nM. Cells were washed of siRNA 16 hours post-transfection and 
placed on the IncuCyte for ongoing growth tracking. Delta confluency was calculated between 0 and 72 hours to 
identify significant changes in proliferation. n≥3 independent experiments, mean ± SEM, * p<0.05 as measured by 
two-tailed Student’s t-test. (D-F) Representative IncuCyte growth curves for single experiments in ZR-75-1 (D), T47D 
(E) and MCF7 (F) cell lines. Mean ± SD.  (G) Western blot of cells harvested at the end of IncuCyte growth tracking 
demonstrating maintenance of knockdown to the end of the experiment. Vinculin is shown as a loading control. 
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3.2 Characterisation of IKKε-dependent metabolic changes 
 
In order to determine what changes in metabolic states were induced by modulation of IKKε 
expression, labelled metabolite analysis was performed with the kind help of Dr Christian Frezza 
and Dr Sofia De Costa at the MRC cancer unit in Cambridge, UK. Labelled metabolite analysis 
allows the tracking of the utilisation of glucose-derived carbon or glutamine-derived nitrogen 
throughout the intracellular metabolic pathways by feeding cells with labelled versions of 
glucose and glutamine. Carbon atoms typically have an atomic mass of 12 (12C) and nitrogen 
atoms typically have a mass of 14 (14N). By feeding cells with a version of glucose in which the 6 
carbon atoms are replaced with 13C, or with a version of glutamine in which the nitrogen atom 
is replaced with 15N, carbon and nitrogen atoms which are heavier than usual by 1 unit of atomic 
mass are incorporated into the cellular metabolic network. As glucose and glutamine are 
subsequently metabolised within the cell, these heavier carbon and nitrogen atoms are 
incorporated into the resulting metabolites, increasing their molecular weights by a measurable 
degree proportional to the number of heavier carbon or nitrogen atoms they contain. Increases 
in metabolite mass can be detected by mass spectrometry and therefore, the heavier 
carbon/nitrogen atom can be tracked from its glucose/glutamine source to the end product, 
allowing mapping of the intracellular metabolic networks and characterisation of the utilisation 
of glucose carbon and glutamine nitrogen (Figure 3.4). 
Labelled metabolite analysis was performed in Flp-In 293 HA-IKKε wt cells and compared to 
analysis performed in Flp-In 293 HA-GFP cells. For analysis of IKKε-dependent breast cancer cells, 
T47D was selected as the optimal model as, whilst siRNA knockdown also reduced proliferation 
of ZR-75-1 and MCF7 cell lines, ZR-75-1 and MCF7 both eventually overcame IKKε knockdown 
and continued proliferation, whereas T47D showed a much greater loss of proliferation upon 
knockdown of the kinase (Figure 3.3 D-F). As with the Flp-In 293 cell models, labelled metabolite 
analysis was performed in IKBKE-targeting siRNA-transfected T47D cells and in control, non-
targeting siRNA-transfected cells. By comparing the results in Flp-In 293 cells and T47D cells 
before and after modulation of IKKε expression, it was possible to map key changes in 
intracellular metabolism which were induced or maintained by the kinase. 
To characterise IKKε-dependent changes in cellular metabolism, Dr Ruoyan Xu treated Flp-In 293 
HA-IKKε and HA-GFP cells with 50 ng/ml doxycycline for 16 hours and transfected T47D breast 
cancer cells with a pool of 4 IKBKE-targeting siRNA oligos, to suppress IKKε, or a single non-
targeting control oligo for 72 hours. Following this, metabolites were extracted and mass 
spectrometry analysis of labelled and total metabolite abundance was performed by Dr Christian 
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Frezza and Dr Sofia De Costa and characterisation of IKKε-dependent metabolic changes was 
facilitated by plotting the Z-scores for each metabolite in each individual sample in a heat map. 
Raw data from these experiments are presented as supplementary material (see supplementary 
materials: Table 7.2.) 
 
 
 
Figure 3.4 – Principal of labelled metabolite analysis. Cells are fed with a version of glucose containing 13C carbon (as 
opposed to 12C) or a version of glutamine containing or 15N nitrogen (instead of 14N). As the glucose and glutamine 
are metabolised within the cell, the heavier carbon and nitrogen atoms are incorporated into the structures of 
metabolites, generating a pool of metabolites with higher molecular weights than usual. This increase in molecular 
weight can be detected by mass spectrometry to track the utilisation of glucose-derived carbon and glutamine-
derived nitrogen throughout the cell. Labelled (13C) carbon is represented as red dots and labelled (15N) nitrogen as 
purple dots to represent how labelled atoms are incorporated throughout the intracellular metabolic network. 
 
In both the Flp-In 293 and T47D cell models, modulation of IKKε expression demonstrated 
significant metabolic effects. In the Flp-In 293 cells HA-IKKε-expressing cells exhibited 
significantly higher intracellular levels of various amino acids such as serine and glycine, a 
significant increase in intracellular glutamine levels and a significant decrease in the levels of 
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TCA metabolites such as citrate and malate compared to the levels detected in HA-GFP-
expressing cells. Concurrently, suppression of IKKε expression in T47D breast cancer cells led to 
a significant decrease in intracellular levels of multiple amino acids such as, again, serine and 
glycine, a significant decrease in glutamine levels and lactate concentration and a significant 
increase in levels of TCA metabolites like citrate, malate and fumarate (Figure 3.5 A and Figure 
3.6 A). Together, these data indicated that expression of IKKε upregulates and maintains 
intracellular concentrations of multiple amino acids and glutamine, whilst suppressing 
concentrations of TCA cycle intermediates.  
Of all the amino acids which exhibited a significant increase in IKKε-expressing cells, the 
significant increase in intracellular serine and glycine levels stood out as particularly interesting, 
given the established importance of the SBP in breast cancer304,305 (see 1.4.4.2). With this in 
mind, metabolite ion levels were examined in order to identify the source of the serine and 
glycine which was responsible for the increased intracellular concentrations observed. As each 
13C carbon atom is exactly 1 unit of atomic mass heavier than natural 12C carbon (and 15N 
nitrogen is exactly 1 unit heavier than natural 14N), the molecular weight of a metabolite will be 
increased by 1 for every labelled atom that is incorporated into its structure. Therefore, 
increases in the molecular weight of metabolites in discrete intervals of 1 atomic unit allows 
determination of how many labelled atoms are incorporated into the metabolite structure. By 
understanding how many carbons and nitrogens are donated to a protein during biosynthesis, 
it is therefore possible to distinguish between metabolites that are synthesised within the cell 
and those which are merely taken up into the cell from the extracellular environment. In the 
context of serine and glycine, serine that is produced via de novo serine biosynthesis from 
glucose incorporates 3 glucose-derived carbons into its structure and glycine incorporates 2. 
Therefore, cells that have been supplied with 13C-labelled glucose will produce a serine m+3 ion 
and a glycine m+2 ion. On the other hand, serine is also frequently obtained from the 
extracellular environment and this will not contain labelled carbon. Therefore, serine sourced 
from extracellular pools and glycine produced from such serine will only be detected at their 
regular molecular weights. Similarly, the amino group added to biosynthesised serine and 
carried over to glycine is obtained from glutamine. Therefore, it gains one nitrogen atom from 
glutamine in the process and an m+1 ion of serine and glycine will be produced in biosynthesised 
serine when cells are fed with 15N-labelled glutamine (Figure 3.4).  
Induction of IKKε in Flp-In 293 cells resulted in a significant upregulation in the levels of m+3 
labelled serine and of 15N-labelled serine in cells fed with 13C-labelled glucose and 15N-labelled 
glutamine respectively (Figure 3.5 B). Additionally, whilst serine m+3 levels could not be stably 
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detected in T47D cells, siRNA-mediated suppression of IKKε lead to a significant decrease in 
glycine m+2 ion levels in cells fed with 13C-labelled glucose and a significant decrease in levels of 
15N-labelled glycine in cells fed with 15N-labelled glutamine (Figure 3.6 B). An increase in serine 
m+3 and 15N-serine levels in glucose and glutamine-labelled analysis indicates an increase in 
serine biosynthesis activity within Flp-In 293 cells expressing HA-IKKε. Similarly, a decrease in 
glycine m+2 and 15N-glycine levels indicates a decrease in serine biosynthesis activity in IKBKE 
siRNA-transfected T47D cells. Together, these data demonstrate that IKKε expression enhances 
SBP activity in cells in which it is expressed. 
As most cancers divert glucose-derived carbon away from mitochondrial entry and TCA cycle 
utilisation, it was also intriguing to observe an IKKε-induced reduction in the levels of TCA 
metabolites like citrate, malate and fumarate. Again, examination of changes in labelled 
metabolite ion levels revealed further details about this reduction. In Flp-In 293 cells, IKKε 
expression significantly reduced citrate and malate m+2 ion levels. Furthermore, suppression of 
the kinase in T47D breast cancer cells resulted in a significant upregulation of citrate and malate 
m+2 ion levels, confirming that the kinase inhibits the formation of these m+2 ions (Figure 3.5 C 
and Figure 3.6 C). When the TCA cycle is fuelled by glucose-derived carbon, each turn of the 
cycle involves the combining of oxaloacetate from the cycle with a molecule of glucose-derived 
acetyl-CoA to regenerate citrate. Acetyl-CoA contains 2 glucose-derived carbon atoms, meaning 
that each turn of the TCA cycle involves the incorporation of 2 glucose-derived carbon atoms to 
its metabolite pool. This means that feeding of cells with 13C-labelled glucose will result in the 
generation of m+2 ions for the TCA cycle intermediates (Figure 3.4). Hence, an IKKε-mediated 
reduction in m+2 TCA metabolite ions indicates that expression of the kinase reduces the 
incorporation of glucose-derived carbon into the TCA cycle. 
It is therefore evident that IKKε dramatically alters the state of the intracellular metabolic 
network. Labelled metabolite analysis data revealed IKKε-dependent increases in lactate, 
elevated biosynthetic activity in the form of increased serine biosynthesis and reduced 
incorporation of glucose-derived carbon in the TCA cycle. It is particularly interesting to note 
that this 3-pronged change in metabolic state is characteristic of the key metabolic changes that 
frequently occur in the aerobic glycolysis phenotype of tumours. Tumours with such a metabolic 
phenotype almost always exhibit increased glycolysis with diversion of glucose-derived carbon 
away from mitochondrial pathways, increased lactate production and increased biosynthetic 
pathway activities. Consequently, this data suggests that expression of IKKε is sufficient to 
promote and maintain an aerobic glycolysis-like phenotype in Flp-In 293 cells and human breast 
cancer cells.  
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Figure 3.5 – IKKε induces an aerobic glycolysis-like phenotype in Flp-In 293 cells.  Flp-In 293 HA-IKKε and HA-GFP 
cells were treated, by Dr Ruoyan Xu, with 50 ng/ml doxycycline for 16 hours, with simultaneous addition of 13C-
labelled glucose and 15N-labelled glutamine tracer compounds for the final 14 hours. Intracellular metabolite 
abundance was measured using mass spectrometry, kindly performed by Dr Christian Frezza and Dr Sofia De Costa. 
(A) Heat map and hierarchical clustering produced by Dr Christian Frezza and Dr Sofia De Costa following analysis of 
significant changes in relative metabolite abundance in HA-IKKε-expressing Flp-In 293 cells compared to HA-GFP-
expressing cells. (B) IKKε induces serine production from glucose (serine m+3 in 13C-labelled glucose fed cells) and 
glutamine (15N-serine in 15N-labelled glutamine fed cells). (C) IKKε inhibits incorporation of glucose-derived carbon 
into the TCA cycle (citrate m+2 and malate m+2 in 13C-labelled glucose fed cells). n=5 biological replicates, mean ± 
SEM, *p<0.05 as measured by two-tailed Student’s t-test. 
A 
B 
C 
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Figure 3.6 – IKKε maintains an aerobic glycolysis-like phenotype in T47D breast cancer cells. T74D breast cancer 
cells were transfected, by Dr Ruoyan Xu, with 4 siRNA oligos targeting IKBKE mRNA, to suppress IKKε, or a single non-
targeting control oligo at 50 nM final concentration for 72 hours. Cells were fed with labelled glucose and glutamine 
tracer compounds for the final 14 hours. Intracellular abundance of metabolites was measured by mass spectrometry, 
performed by Dr Christian Frezza and Dr Sofia De Costa. (A) Heatmap and hierarchical clustering produced by Dr 
Christian Frezza and Dr Sofia De Costa following analysis of significantly changing metabolite abundance following 
siRNA-mediated IKKε suppression in T47D cells (B) IKKε silencing reduces serine and thus glycine production from 
glucose (glycine m+2 in cells fed with 13C-labelled glucose) and glutamine (15N-glycine in cells fed with 15N-labelled 
glutamine). (C) IKKε silencing promotes incorporation of glucose-derived carbon into the TCA cycle (citrate m+2 and 
malate m+2 in cells fed with 13C-labelled glucose). n≥4 biological replicates, mean ± SEM, *p<0.05 as measured by 
Student’s t-test. 
A 
B 
C 
Chapter 3. Results I: IKKε directly phosphorylates PSAT1 to promote protein stability 
111 
 
3.3 Identification of potential IKKε phosphotargets 
 
In order to understand more about how IKKε was inducing changes in cellular metabolism in the 
Flp-In 293 and breast cancer cell models, possible effector targets were sought. Given its role as 
a kinase, a phosphoproteomic analysis was performed to identify proteins that exhibited 
significant changes in phosphorylation status upon modulation of IKKε expression. To identify 
protein phosphorylations which would be altered in a linear fashion relative to the expression 
level of the kinase, 3 independent single-cell clones of Flp-In 293 HA-IKKε cells, expressing HA-
IKKε at varying degrees, were induced alongside 3 independent single-cell clones of Flp-In 293 
HA-GFP cells. Protein phosphorylation status in Flp-In 292 HA-GFP cells was used as a control to 
define a basal level of IKKε-independent phosphorylation (Figure 3.7).  
 
 
Figure 3.7 – Induction of HA-IKKε expression in 3 independent single-cell clones. Western blot demonstrating 
induction of HA-IKKε in 3 single-cell clones of Flp-In 293 HA-IKKε (wt) cells, following treatment of cells with 100 ng/ml 
doxycycline for 16 hours. 3 single-cell clones of Flp-In 293 HA-GFP cells were also treated with doxycycline as a control 
for IKKε expression. Actin is shown as a loading control. 
 
Samples were prepared for the phosphoproteomic analysis by Dr Ewa Wilcz-Villega. Flp-In 293 
HA-IKKε and HA-GFP single-cell clones were treated with doxycycline for 16 hours, after which 
cells were washed and lysed with a specialised lysis buffer containing multiple phosphatase 
inhibitors (Recipe: 8M Urea, 20 mM HEPES, 1 mM sodium orthovanadate (Na3VO4), 1 mM 
sodium fluoride (NaF), 1 mM β-Glycerol phosphate and 0.25 mM disodium diphosphate 
(Na2H2P2O7)) to maintain protein phosphorylation status within the lysate. Subsequently, 
protein phosphorylation was detected via mass spectrometry analysis in collaboration with Dr 
Pedro Cutillas and Dr Vinothini Rajeeve (Barts Cancer Institute, London, UK). Detected changes 
in protein phosphorylation were calculated as fold changes relative to the average 
phosphorylation of the protein in the 3 HA-GFP-expressing clones. 
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3.3.1 IKKε expression induces phosphorylation of serine biosynthesis enzyme PSAT1 
 
To identify bona fide IKKε phosphorylation targets, proteins identified with significant changes 
in phosphorylation status were ranked from greatest increase in phosphorylation in the 
presence of IKKε, to greatest decrease (see supplementary materials: Table 7.3). Subsequently, 
pathway analysis was applied to group identified proteins based on their primary functions and 
identify potential phosphorylation targets that might explain the observed changes in cellular 
metabolism processes. To group the proteins in this way, identified proteins were analysed 
against the Kyoto encyclopaedia of genes and genomes (KEGGS) database and discrete cellular 
functions were ranked based on the number of differentially phosphorylated proteins identified. 
As expected based on IKKε’s role in innate immunity, many of the pathways with the most 
proteins enriched for phosphorylation in the presence of IKKε are associated with the cellular 
response to infection, including pathways involved with antibiotic biosynthesis and pathways 
that respond to bacterial or viral infection. Reassuringly however, many metabolic pathways 
exhibited significant enrichment in protein phosphorylation. Such pathways included glycolysis, 
purine and carbon metabolism and most interestingly, given the increase in serine biosynthesis 
observed in IKKε-expressing cells, pathways involved in the biosynthesis of amino acids.  
Accordingly, changes in the IKKε-mediated phosphorylation of proteins associated with KEGGS 
pathway hsa01230: Biosynthesis of amino acids were represented as a heat map (Figure 3.8 B). 
 
            
Figure 3.8 – KEGGS pathway enrichment analysis of phosphoproteomic data. (A) Identification of pathways enriched 
for phosphorylation of proteins in Flp-In 293 HA-IKKε cells compared to Flp-In 293 HA-GFP control cells identified a 
significant metabolic footprint in the phosphoproteome of IKKε-expressing cells, including significant enrichment of 
protein phosphorylation in biosynthetic processes involved in amino acid production. Enriched pathways from 
differentially phosphorylated proteins were determined by Dr Pedro Cutillas and Dr Vinothini Rajeeve, using David 
Bioinformatic resources335. (B) Heat map demonstrating the log2 fold changes in relative peptide abundance in 3 IKKε-
expressing Flp-In 293 HA-IKKε single cell clones versus the average abundance in HA-GFP-expressing cells for peptides 
associated with KEGG pathway hsa01230: Biosynthesis of amino acids. Peptides are ranked by log2 fold change. 
B A 
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Closer examination of differentially phosphorylated peptides and identified phosphosites 
revealed a clear metabolic signature in Flp-In 293 HA-IKKε-expressing cells (Table 3.2). Multiple 
glycolytic enzymes were identified as more phosphorylated in the presence of IKKε including 
fructose-1,6-bisphosphate aldolase, which catalyses the conversion of fructose-1,6-
bisphosphate to dihydroxyacetone phosphate and glyceraldehyde-3-phosphate; 
triosephosphate isomerase, which catalyses the conversion of dihydroxyacetone phosphate to 
glyceraldehyde-3-phosphate; and enolase, which catalyses the conversion of 2-
phosphoglycerate to phosphoenolpyruvate (Figure 1.4). Glutamine-fructose-6-phosphate 
aminotransferase 1 (GFPT1), an enzyme which controls the flux of glucose-derived carbon into 
the hexosamine biosynthetic pathway was also identified as significantly more phosphorylated 
at Ser261 in IKKε-expressing cells. Ser 243 in a splice variant of GFPT1 is a key catalytic 
residue336,337, which corresponds to Ser261 in the full-length protein. This therefore indicates 
that IKKε might induce GFPT1 activity through Ser261 phosphorylation, implicating the kinase in 
the regulation of hexosamine biosynthesis as well as serine.  
Most interestingly however, considering the observed increase in serine biosynthesis in IKKε-
expressing cells, was the identification of significantly increased PSAT1 phosphorylation at serine 
residue Ser331. PSAT1 catalyses the second step of the SBP. Again, no function for this Ser331 
phosphosite has previously been described, but the observation that increased PSAT1 
phosphorylation was occurring in the same context as increased serine biosynthesis led to the 
hypothesis that phosphorylation of enzyme at residue Ser331 might contribute to its activity and 
that IKKε might enhance serine biosynthesis through direct or indirect PSAT1 phosphorylation. 
 
Table 3.2 – Selection of metabolic hits from phosphoproteomic analysis of HA-IKKε-expressing cells. Metabolism 
associated enzymes which were identified as significantly more or less phosphorylated at the indicated residues in 
HA-IKKε-expressing Flp-In 293 cells compared to HA-GFP controls. Phosphorylation of proteins in individual single-cell 
clones was expressed as a fold change (FC) vs the average basal phosphorylation across 3 HA-GFP-expressing single-
cell clones. Information regarding phosphosite function was obtained from the PhosphoSitePlus® database338 
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3.4 PSAT1 serine residue Ser 331 is phosphorylated in an IKKε-dependent 
manner 
 
The observation that PSAT1 Ser331 was significantly more phosphorylated in the presence of 
IKKε led to the question of whether or not the kinase was itself directly phosphorylating the 
enzyme. When comparing the established IKKε recognition motif197 with the amino acid 
sequence surrounding the identified PSAT1 phosphosite, overlap between 3 out of the 4 optimal 
residues was observed (Figure 3.9 A). This strongly indicated that the Ser331 residue on PSAT1 
could be a phospho-target of IKKε, directly phosphorylated by the kinase. To test this hypothesis, 
an in vitro kinase assay was performed using recombinant PSAT1 and either HA-IKKε wt or HA-
IKKε KD-m purified from Flp-In 293 cells via HA-pulldown. Flp-In 293 HA-IKKε wt and HA-IKKε KD-
m cell lines were treated with doxycycline for 16 hours and lysates were incubated with anti-HA 
antibody-conjugated agarose beads to bind and purify HA-IKKε from the total lysate. Purified 
kinase was then combined with recombinant PSAT1 and ATP to facilitate a phosphorylation 
reaction in vitro. Phosphorylation of recombinant PSAT1 was subsequently detected via mass 
spectrometry analysis kindly performed by Dr Pedro Cutillas and Dr Vinothini Rajeeve. 
Targeted analysis was performed to specifically search within the assay samples for peptides 
matching the profile of phosphorylated Ser331 PSAT1. Phosphorylation of the enzyme was 
detected in the in vitro kinase assay in the presence of HA-IKKε, but not in assay samples using 
HA-purified lysates where the kinase had not been induced, confirming IKKε-dependent 
phosphorylation of the enzyme. Somewhat discouragingly, phosphorylation was detected in 
samples containing HA-IKKε KD-m as well as HA-IKKε wt (Figure 3.9 B). To understand why the 
kinase dead mutant IKKε was inducing phosphorylation, the mutant’s kinase activity was 
checked. Mass spectrometry analysis revealed the wt kinase was phosphorylated at several 
sites, whereas no phosphorylation of the KD-m mutant was detected (Figure 3.9 C). Active IKKε 
typically exhibits phosphorylation of serine residue Ser172 on its own sequence, attributable to 
kinase activity-mediated auto-phosphorylation78 and whilst no Ser172 phosphorylation was 
detected with either kinase, a complete lack of any detectable phosphorylation on HA-IKKε KD-
m indicates its lack of activity. Furthermore, western blot evaluation of HA-IKKε Ser172 
phosphorylation demonstrated a complete absence of auto-phosphorylation with the kinase 
dead IKKε. HA-IKKε KD-m also exhibited an inability to phosphorylate known IKKε substrates 
such as IRF3 and p65 (Figure 3.9 D) confirming a lack of kinase activity. These data therefore 
demonstrated that phosphorylation of PSAT1 in the HA-IKKε KD-m samples was down to another 
explanation than residual kinase activity in the kinase-dead mutant. 
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The washing conditions used for the HA-pulldown were not particularly stringent (see 2.9 and 
2.10) so it was hypothesised that protein-protein interactions might have been maintained 
throughout the pulldown allowing the presence of proteins other than IKKε to be purified from 
the cell lysates, meaning other proteins might have then been present in the in vitro kinase assay 
reaction.  It was therefore hypothesised that the presence of a secondary kinase in the reaction 
might have been responsible for the observed PSAT1 phosphorylation in the HA-IKKε KD-m 
samples. To test this hypothesis, the mass spectrometry analysis was consulted to search for 
other kinases that were present in the assay and a total of 18 kinases other than IKKε were found 
to be detected in some, or all, of the other assay samples (Table 3.3). To determine whether one 
of these other kinases was a likely candidate for explaining the phosphorylation detected with 
HA-IKKε KD-m, the list of 18 kinases was filtered to highlight kinases that were detected in all of 
the samples were PSAT1 phosphorylation was detected. This left just 6 kinases from the initial 
18. A secondary filter was then applied, ruling out kinases which were detected in the lysis buffer 
blank. No organic material should have been present in this sample and therefore any kinase 
detection was likely to be a false positive. Just one kinase was left from the 18 after applying this 
secondary filter: TBK1. This was particularly interesting, as TBK1 is a fellow IKK family member 
and is known to share several phospho-targets with IKKε, including IRF3 and p65. It was 
therefore hypothesised that if IKKε could phosphorylate PSAT1, then TBK1 might be responsible 
for the phosphorylation observed in the samples containing HA-IKKε KD-m. Whilst it is possible 
that all PSAT1 phosphorylation observed could be a result of secondary kinase activity, it is 
important to note that the observed phosphorylation is, at the very least, IKKε-dependent. Even 
though other kinases, TBK1 included, were present in the samples where PSAT1 phosphorylation 
was detected, the same kinases were also present in samples where PSAT1 phosphorylation was 
not detected. Indeed, phosphorylation was only detected in samples where HA-IKKε was 
present, demonstrating a dependency on the kinase. It is possible that TBK1 can phosphorylate 
PSAT1, but it seemingly requires IKKε to do so, possibly as a TBK1/IKKε heterodimer. 
In order to attempt to distinguish which kinase in particular can phosphorylate PSAT1, an in vitro 
kinase assay was performed using recombinant PSAT1 with recombinant IKKε and recombinant 
TBK1, either alone or in combination. Unfortunately, no PSAT1 phosphorylation was detected in 
any of these samples and when using the mass spectrometry results to search for evidence of 
IKKε and TBK1 auto-phosphorylation, there was no indication of any kinase activation, 
suggesting that the lack of PSAT1 phosphorylation was attributable to kinase inactivity during 
the assay. Therefore, the furthest conclusion that can be drawn from this data is that PSAT1 
Ser331 phosphorylation does occur in an IKKε-dependent manner. However, it remains to be 
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determined whether IKKε itself, or an IKKε containing complex with a secondary kinase, such as 
TBK1, is responsible for the actual phosphorylation event. 
 
 
 
 
 
 
Figure 3.9 – PSAT1 is phosphorylated in an in vitro kinase assay in an IKKε-dependent manner. (A) IKKε’s optimal 
phosphorylation motif, as described by Hutti et al. 2006197, overlaps with the amino acid sequence surrounding PSAT1 
Ser331 at 3 out of 4 preferred residues suggesting likely direct phosphorylation by the kinase. (B) An in vitro kinase 
assay was performed using HA-tag purified IKKε wt or KD-m mutant with recombinant PSAT1. Lysates from Flp-In 293 
HA-IKKε wt or Flp-In 293 HA-IKKε KD-m cells + or – 16 hours of 100 ng/ml doxycycline treatment were subject to HA-
pulldown to purify HA-IKKε. Resulting lysates were combined with recombinant PSAT1 and ATP as indicated. Blank 
lysis buffer was used as a control and samples were run in duplicate on the mass spectrometer by Dr Pedro Cutillas 
and Dr Vinothini Rajeeve. PSAT1 Ser331 phosphorylation was detected in samples containing HA-IKKε only, indicating 
kinase-dependent phosphorylation of the enzyme. (C) Phosphorylation of IKKε, indicating kinase activity, was only 
present on HA-IKKε wt. (D) Western blot analysis of HA-IKKε wt- and HA-IKKε KD-m-expressing cells (and HA-GFP as a 
control) demonstrated lack of kinase activity in KD-m IKKε, due to lack of phosphorylation of p65 and IRF3. Indicated 
cell lines were treated with 50 ng/ml doxycycline for 16 hours then lysed and processed for western blotting. Vinculin 
is shown as a loading control. 
B D 
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3.5 Development of Flp-In 293 HA-PSAT1 phospho-mutant and -mimic cell 
lines 
 
Whilst PSAT1 Ser331 phosphorylation has been previously reported, it has only been identified 
as part of high throughput studies. Therefore, little focus had been given to either the 
phosphosite or kinases that can phosphorylate it and any potential role for the site in protein 
function remained unexplored. 
To address this, a model in which the phosphorylation status of the enzyme could be modulated 
was developed. Based on a similar model previously used to modulate the phosphorylation of 
PHGDH326, point mutagenesis was used to introduce serine > alanine or serine > glutamic acid 
mutations at the Ser331 residue of PSAT1, to inhibit or mimic phosphorylation respectively. By 
mimicking the general size, shape and chemical properties of phosphorylated and un-
phosphorylated serine residues at a neutral pH, alanine can easily represent an un-
phosphorylated serine residue and glutamic acid can potentially act as a phosphorylated serine 
residue (Figure 3.10 A). These two modifications not being serine residues means that instead 
of being subject to dynamic regulation of phosphorylation by kinases and phosphatases, they 
are permanent fixtures. Generating a PSAT1 S>A or S>E mutant therefore allows control over 
the phosphorylation status of the enzyme and evaluation of functional differences between its 
un-phosphorylated and phosphorylated states. To generate PSAT1 S>A and S>E mutants, a cDNA 
clone of the open reading frame of PSAT1 in a pGEM-T plasmid backbone was purchased from 
Sino Biological (Beijing, China) and point mutagenesis PCR was used to specifically modify the 
Ser331 residue. The resultant PSAT1 wt, PSAT1 S > A and PSAT1 S > E DNA sequences were cloned 
into the Flp-In 293 compatible pcDNA5.5 vector, adding an HA-tag to each protein in the process. 
Similar to HA-IKKε models, this allowed the generation of doxycycline inducible Flp-In 293 HA-
PSAT1 cell lines. As indicated previously, the Flp-In 293 system was an optimal model for the 
comparison of the differentially phosphorylated proteins. Inserted genes are typically integrated 
into the host genome at a single site and at the same site every time. This ensures equal 
expression of gene inserts under the control of the same promoter in different cell lines. Equal 
gene expression of mutant variants makes it easy to compare functional differences between 
alternate versions of the same protein. 
To generate new Flp-In 293 cell lines, parental Flp-In 293 cells were co-transfected with the 
desired pcDNA5.5 HA-PSAT1 plasmid and another plasmid called pOG44, which contains a gene 
encoding the enzyme Flp recombinase under the control of a constitutive promoter. 
Transfection of pOG44 into the host cell results in production of Flp recombinase. This induces 
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homologous recombination of the FRT-flanked HA-PSAT1 gene, contained within the pcDNA5.5 
plasmid, with FRT sites in the Flp-In 293 host genome. Successful recombination also introduces 
a hygromycin resistance gene to the host genome, so following transfection, successful 
integration of HA-PSAT1 genes was selected for by hygromycin treatment. This process was 
performed for each HA-PSAT1 variant and 3 independent pools of new Flp-In 293 cell lines were 
generated for each variant; Flp-In 293 HA-PSAT1 wt, Flp-In 293 HA-PSAT1 S>A and Flp-In 293 HA-
PSAT1 S>E. In each cell line, HA-PSAT1 expression was under the control of a doxycycline 
inducible promoter (Figure 3.10 B). Each pool was validated for expression of HA-PSAT1 variants 
and expression of the HA-tagged enzyme across the different pools was found to be roughly 
equal. The data presented in Figure 3.10 was obtained using cells from the first pool generated. 
These were the same cells used for experiments assessing the function of phosphorylation of 
the PSAT1 Ser331 residue.  
Induction of HA-PSAT1 wt, HA-PSAT1 S>A and HA-PSAT1 S>E in each Flp-In 293 cell line was 
validated by using quantitative real-time polymerase chain reaction (qRT-PCR) analysis to 
measure doxycycline-mediated induction of PSAT1 messenger RNA (mRNA) levels.  Treatment 
of Flp-In 293 HA-PSAT1 wt, Flp-In 293 HA-PSAT1 S>A and Flp-In 293 HA-PSAT1 S>E cells with 
doxycycline for 16 hours strongly induced PSAT1 mRNA levels (Figure 3.10 C). As expected from 
using the Flp-In 293 system, no significant difference in the induction of PSAT1 mRNA was 
observed between the different cell lines, indicating equal gene transcription. To check that the 
upregulation of mRNA levels also translated into protein expression, western blotting was used 
to validate the doxycycline-mediated induction of HA-PSAT1 protein. Treatment of Flp-In 293 
HA-PSAT1 cells with doxycycline for 16 hours led to stable induction of the protein in all 3 cell 
lines (Figure 3.10 D). Intriguingly, despite qRT-PCR analysis demonstrating equal gene 
transcription, densitometry analysis quantification of protein levels in the different Flp-In 293 
HA-PSAT1 cell lines showed differential expression of the HA-PSAT1 protein variants. Compared 
to the expression of the wt protein, HA-PSAT1 S>A protein was expressed to a significantly lower 
level and HA-PSAT1 S>E was expressed to a significantly higher level (Figure 3.10 E). Since the 
comparison of mRNA expression showed no clear differences, this suggested that the mutation 
of the PSAT1 Ser331 residue might be specifically regulating the enzyme post-translationally. 
The differential protein expression will be further discussed later (see 3.9), but regardless, the 
Flp-In 293 system was successfully used to generate 3 new cell lines that expressed wt and 
mutant versions of the PSAT1 protein when treated with doxycycline. This model was 
subsequently used to explore the functional impact of mutating the Ser331 residue for PSAT1.  
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Figure 3.10 – Induction of HA-tagged PSAT1 wt and phosphomutant/mimic variants in Flp-In 293 cells. (A) Visual 
representation of how mutation of serine to alanine or glutamic acid can physically mimic either serine or 
phosphoserine respectively. In addition to physical similarities, chemical similarities exist at physiological pH 7.4, both 
serine and alanine exhibit neutral charges whereas phosphoserine and glutamic acid are negatively charged. (B) 
Schematic representation of incorporation of HA-PSAT1 at FRT sites in the Flp-In 293 genome. (C) qRT-PCR analysis, 
measuring induction of HA-PSAT1 wt, HA-PSAT1 S>A and HA-PSAT1 S>E mRNA upon treatment of indicated Flp-In 293 
HA-PSAT1 cell lines with 50 ng/ml doxycycline for 16 hours. mRNA levels were expressed as fold changes relative to 
non-treated basal levels of PSAT1 mRNA in the corresponding cell lines and normalised to ACTB (β-Actin) mRNA. n=4 
independent experiments, mean ± SEM. No significant differences were observed using one-way ANOVA with 
Bonferroni post-hoc tests. (D) Western blot demonstrating induction of HA-PSAT1 wt, HA-PSAT1 S>A and HA-PSAT1 
S>E protein upon treatment of corresponding Flp-In 293 HA-PSAT1 cell lines with 50 ng/ml doxycycline for 16 hours. 
Vinculin is shown as loading control. (E) Densitometry analysis quantification of HA-PSAT1 protein levels expressed in 
different Flp-In 293 HA-PSAT1 mutant cell lines, normalised to vinculin protein levels. n=11 independent experiments, 
mean ± SEM, *p < 0.05 as measured by one-way ANOVA with Bonferroni post-hoc tests. 
A 
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3.6 Development of MDA-MB-453 PSAT1 wt, S>A and S>E cell lines 
 
In addition to the development of Flp-In 293 HA-PSAT1 cell lines, a breast cancer cell line 
expressing PSAT1 wt and mutant variants was also generated. To select the cell line which PSAT1 
would be introduced to, a model where the functional implications of PSAT1 mutation could be 
directly addressed was desired. To find such a model, cell growth in serine-free medium was 
assessed via IncuCyte analysis. A fully functioning SBP allows cells to survive conditions where 
external supplies of serine are lacking, as the cells can synthesise sufficient serine intracellularly 
to compensate for the external deprivation and maintain proliferation. Lack of expression of one 
or more enzymes of the SBP causes cells to lose the ability to biosynthesise serine themselves, 
triggering dependency on exogenous serine. By identifying a breast cancer cell line that failed to 
grow in serine-free medium, due to a lack of PSAT1 expression, reintroduction of PSAT1 wt or 
mutant variants could be used to assess relative mutant function by evaluating ability to rescue 
serine-free medium growth.  
To determine the ability of the breast cancer cell line panel to proliferate in serine-free medium, 
each cell line was plated in a 96-well plate and, 24 hours later, the culture medium was changed 
for either serine - medium, or serine - medium which had been reconstituted with serine to act 
as whole medium. The IncuCyte Zoom was then used to track cell growth over the following 
days. Measuring confluency at given time points and calculating changes in confluency over 72 
hours allowed detection of statistically significant changes in proliferative rates. ZR-75-1, T47D, 
MDA-MB-453, MDA-MB-231 and MCF7 cell lines all exhibited significant growth retardation 
when deprived of exogenous serine (Figure 3.11 A). Example growth curves for these cell lines 
are shown in Figure 3.11 B-F and show that although proliferative rates in ZR-75-1 and T47D 
were significantly reduced, cultures eventually grew to confluency over the course of the 
experiment. This indicated that these cell lines still featured active, albeit perhaps less efficient, 
serine biosynthesis. Contrastingly, a much stronger effect on proliferation was seen in the MDA-
MB-453, MDA-MB-231 and MCF7 cell lines, with proliferation being more or less completely 
inhibited in the absence of exogenous serine (Figure 3.11 A and D-F). The serine biosynthesis 
enzyme protein expression profile for each breast cancer cell line was then assessed to identify 
why MDA-MB-453, MDA-MB-231 and MCF7 exhibited such a reduced capacity to grow in serine-
free conditions (Figure 3.12). For MDA-MB-231, this is because the cell line lacks expression of 
the first enzyme of the pathway, PHGDH. Both MCF7 and MDA-MB-453 however, are unable to 
grow due to lack of PSAT1 expression, making them good candidate cell lines for the 
reintroduction of PSAT1. A cell line lacking endogenous PSAT1 expression represents a good 
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model for exploring the functionality of mutant PSAT1 proteins. A lack of interference of 
functional endogenous protein means exogenous PSAT1 function can be judged on its own 
merit. MDA-MB-453 was selected as the cell line to which PSAT1 would be introduced as it only 
lacked PSAT1 expression, whereas MCF7 also exhibited low levels of the PSPH protein.  
 
 
  
  
 
Figure 3.11 – Serine deprivation impairs the growth of a subset of breast cancer cell lines. Growth of breast cancer 
cell lines was measured by tracking cell confluency over time using the IncuCyte Zoom. (A) Serine deprivation 
significantly slows proliferation of ZR-75-1, T47D, MDA-MB-231, MDA-MB-453 and MCF7 breast cancer cell lines. Cell 
lines were plated in full medium which was replaced with either serine - medium, or serine - medium reconstituted 
with serine, 24 hours later. Delta confluency was calculated between 0 and 72 hours to identify statistically significant 
differences in cell proliferation. n≥4 independent experiments in all cell lines with the exception of SUM44, where 
only n=1 independent experiment was performed, mean ± SEM, * p<0.05 as measured by two-tailed Student’s t-test. 
(B-F) Representative IncuCyte growth curves from single experiments with ZR-75-1 (B), T47D (C), MDA-MB-453 (D), 
MDA-MB-231 (E) and MCF7 (F). Mean ± SD. 
A B 
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Figure 3.12 – Serine biosynthesis enzyme protein expression profile of a panel of breast cancer cell lines. Western 
blot analysis of basal PHGDH, PSAT1 and PSPH protein expression in indicated breast cancer cell lines. MDA-MB-453 
and MCF7 exhibit reduced growth in serine-deprived conditions due to a lack of PSAT1 protein. MDA-MB-231 exhibits 
reduced growth in serine-deprived conditions due to a lack of PHGDH. Vinculin is shown as a loading control. 
 
To generate MDA-MB-453 cell lines with inducible PSAT1 expression, the PSAT1 wt, PSAT1 S>A 
and PSAT1 S>E genes were cloned from the pcDNA5.5 vector into the pTRIPZ lentiviral vector, 
following which the vectors were transduced into MDA-MB-453 cells via lentiviral infection. As 
the pTRIPZ vector contains a puromycin resistance gene, successful transduction of the pTRIPZ 
PSAT1 vector was selected for using puromycin. 3 new inducible PSAT1 cell lines were therefore 
generated; MDA-MB-453 PSAT1 wt, MDA-MB-453 PSAT1 S>A and MDA-MB-453 PSAT1 S>E. 
To confirm successful transduction of inducible PSAT1 genes, the 3 MDA-MB-453 PSAT1 cell lines 
were treated with 500 ng/ml doxycycline for 16 hours and qRT-PCR was used to detect induction 
of PSAT1 mRNA levels. Treatment of all 3 MDA-MB-453 PSAT1 cell lines induced substantial fold-
increases in PSAT1 mRNA levels; roughly 75-fold, 90-fold and 55-fold increases in MDA-MB-453 
PSAT1 wt, S>A and S>E cells respectively (Figure 3.13 A). Unlike mRNA induction in Flp-In 293 
HA-PSAT1 cells, doxycycline induction of PSAT1 mRNA in the breast cancer cells resulted in 
significantly different amounts of gene transcription, with PSAT1 S>A mRNA levels induced 
significantly more than PSAT1 S>E mRNA levels. This indicated that in the MDA-MB-453 models, 
the PSAT1 genes were differentially expressed. Western blotting was subsequently used to 
evaluate PSAT1 protein induction. Doxycycline treatment induced PSAT1 protein expression in 
all three cell lines (Figure 3.13 B). However, as with the mRNA levels, densitometry analysis 
quantification of the relative PSAT1 protein levels revealed significantly different expression 
between protein variants. The PSAT1 wt protein was induced to a significantly higher level than 
either mutant variant (Figure 3.13 C). Since qRT-PCR analysis had revealed significant differences 
in PSAT1 expression at the mRNA level, densitometry analysis protein expression values were 
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normalised to mRNA levels to determine whether some of the differential expression could be 
explained by differences in gene transcription. Following normalisation, PSAT1 S>E protein levels 
showed no significant difference from PSAT1 wt protein levels, indicating the reduced protein 
induction was a result of reduced gene expression. However, PSAT1 S>A protein levels were still 
significantly lower than the wt protein levels (Figure 3.13 D). This suggested that, as in the Flp-
In 293 HA-PSAT1 model, an uncharacterised post-translational modification might be regulating 
the enzyme protein levels. Irrespective of this, stable PSAT1 protein expression in MDA-MB-453 
cells demonstrated successful generation of a breast cancer cell line where PSAT1 expression 
could be tightly controlled and generation of another model where the functional implications 
of PSAT1 Ser331 mutation could be assessed. 
 
                    
                                                                      
Figure 3.13 – Induction of PSAT1 wt and mutant variants in MDA-MB-453 cells. (A) qRT-PCR analysis measuring 
PSAT1 mRNA levels in MDA-MB-453 PSAT1 cell lines following treatment with 500 ng/ml doxycycline for 16 hours. 
mRNA levels were expressed as fold changes relative to non-treated basal levels of PSAT1 mRNA in the corresponding 
cell lines and normalised to ACTB (β-Actin) mRNA levels. n=3 independent experiments, mean ± SEM, *p<0.05 as 
measured by one-way ANOVA with Bonferroni post-hoc tests. (B) Western blot analysis demonstrating induction of 
PSAT1 wt, PSAT1 S>A and PSAT1 S>E proteins in corresponding modified MDA-MB-453 cell lines upon treatment with 
500 ng/ml doxycycline for 16 hours. Vinculin is shown as a loading control. (C) Densitometry analysis quantification 
of induced PSAT1 protein levels in MDA-MB-453 cells, normalised to vinculin. n=3 independent experiments, mean ± 
SEM, *p<0.05 as measured by one-way ANOVA with Bonferroni post-hoc tests. (D) Additional normalisation of 
densitometry analysis from (C), normalising relative protein levels to mRNA levels from (A). 
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3.7 Assessing the impact of Ser331 mutation on enzymatic activity 
 
Phosphorylation of enzymes is a frequent post-translational modification that often regulates 
enzyme activity. In order to evaluate what impact, if any, modification of the PSAT Ser331 
residue would have on enzyme activity, the wt and mutant PSAT1 proteins were assessed for 
their ability to rescue growth inhibition in serine-free medium. As previously established, MDA-
MB-453 cells fail to grow in serine-free medium, but Flp-In 293 cells express all 3 SBP enzymes 
to sufficient degrees to sustain proliferation in the absence of serine. Therefore, it was 
unsurprising to find that, when measuring growth in serine deprivation using the IncuCyte Zoom, 
parental Flp-In 293 cells continued to grow to confluency in the absence of exogenous serine, 
albeit with a significant decrease in proliferative rates (Figure 3.14). If Flp-In 293 HA-PSAT1 cells 
can sustain proliferation in serine-free medium, attempts to characterise HA-PSAT1-dependent 
growth rescue would be complicated. Therefore, a method by which Flp-In 293 proliferation in 
serine-free medium could be inhibited was sought. 
 
Figure 3.14 – Flp-In 293 cells exhibit impaired but maintained growth in serine deprived conditions. Parental Flp-In 
293 cells were plated in complete medium which, 24 hours later, was replaced with either serine - medium (Ser -) or 
serine - medium reconstituted with serine (Ser +) and growth was tracked by measurement of cell confluency over 
time using the IncuCyte Zoom. (A) Delta confluency was calculated between 0 and 72 hours to identify statistically 
significant differences in proliferative rates. n=3 independent experiments, mean ± SEM, *p<0.05 as measured by 
paired two-tailed Student’s t-test. (B) Representative IncuCyte growth curve from a single experiment with Flp-In 293 
parental cells. Mean ± SD. 
 
To inhibit the growth of Flp-In 293 cells in serine-free medium and subsequently compare the 
ability of HA-PSAT1 wt, HA-PSAT1 S>A and HA-PSAT1 S>E to rescue that growth inhibition, 
endogenous PSAT1 expression was suppressed. To achieve endogenous knockdown whilst 
maintaining inducible expression of HA-PSAT1 upon doxycycline treatment, 3 PSAT1-targeting 
siRNA oligos, which specifically targeted the non-coding sequences of the PSAT1 mRNA (which 
are absent from the HA-PSAT1 sequences), were transfected into Flp-In 293 HA-PSAT1 cells for 
72 hours. Cells were simultaneously treated with doxycycline for the final 16 hours to induce 
HA-PSAT1 in the absence of endogenous enzyme expression. To validate stable HA-PSAT1 
A B 
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induction and endogenous PSAT1 knockdown, western blotting was used. As expected, the 
transfection of non-coding targeting siRNA successfully suppressed endogenous PSAT1 
expression in all 3 Flp-In 293 HA-PSAT1 cell lines and, whilst inducible protein levels were slightly 
reduced, HA-PSAT1 wt, HA-PSAT1 S>A and HA-PSAT1 S>E proteins were all successfully induced 
with doxycycline treatment (Figure 3.15).  
 
Figure 3.15 – Stable induction of HA-PSAT1 wt and mutant variants in the absence of endogenous expression. 
Western blot demonstrating the knockdown of endogenous PSAT1 in indicated Flp-In 293 HA-PSAT1 cells by siRNA 
and induction of HA-tagged variant. Indicated cell lines were transfected with 3 siRNA oligos targeting the non-coding 
sequence of PSAT1 mRNA or a single non-targeting control oligo to a final concentration of 50 nM for 72 hours. Cells 
were simultaneously treated with 50 ng/ml doxycycline for the final 16 hours, achieving HA-tagged PSAT1 expression 
in the absence of endogenous protein. Vinculin is shown as a loading control. 
 
Suppression of endogenous PSAT1 had the desired effect on the proliferation of Flp-In 293 cells. 
Evaluating cell growth using the IncuCyte Zoom, it was found that PSAT1 siRNA had no impact 
on proliferation when serine was present in the medium, but substantially inhibited growth in 
serine deprived conditions (Figure 3.16 A), demonstrating the importance of the pathway when 
nutrient availability is compromised. With a model in place in which suppression of PSAT1 could 
inhibit the growth of Flp-In 293 cells, the ability of HA-PSAT1 to rescue growth could be assessed 
and compared between wt and mutant variants. Suppression of endogenous PSAT1 was 
confirmed to significantly reduce growth in serine-free medium in all three Flp-In 293 HA-PSAT1 
cell lines, and although doxycycline treatment had no significant proliferative effect on the cells 
when endogenous PSAT1 and exogenous serine were both present (Figure 3.16 B), the induction 
of HA-PSAT1 rescued the serine deprived growth of each cell line when endogenous PSAT1 was 
suppressed (Figure 3.16 C-E). Importantly, whilst induction of the HA-tagged enzyme resulted in 
complete growth rescue of the cells expressing either HA-PSAT1 wt or the HA-PSAT1 S>E mutant, 
cells expressing HA-PSAT1 S>A still demonstrated a significantly reduced growth over 72 hours 
compared to the siRNA control, demonstrating that the HA-PSAT1 S>A mutant could not wholly 
compensate for the absence of the endogenous enzyme. This indicated that phosphorylation of 
PSAT1 Ser331 was important for continued proliferation of cells in serine-deprived conditions. 
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Figure 3.16 – Rescue of growth of Flp-In 293 cells in serine-free medium in the absence of endogenous PSAT1 by 
HA-PSAT1 wt and mutant proteins. Flp-In 293 HA-PSAT1 cells were transfected with PSAT1 siRNA as in 3.15 and 
growth over subsequent days in either serine - medium (Ser -) or serine - medium reconstituted with serine (Ser +), 
was tracked via measurement of confluency using the IncuCyte Zoom. Delta confluency was calculated between 0 
and 72 hours to identify statistically significant differences in cell proliferation. (A) Representative IncuCyte growth 
curve from a single experiment with Flp-In 293 HA-PSAT1 wt cells. Flp-In 293 HA-PSAT1 wt cells grow at a marginally 
reduced rate in serine-free medium and knockdown of endogenous PSAT1 only inhibits growth in serine deprived 
conditions. Mean ± SD. (B) Delta confluency of control siRNA-transfected Flp-In 293 HA-PSAT1 cells with or without 
50 ng/ml doxycycline treatment. n=3 independent experiments, mean ± SEM, no significant differences were 
detected using a two-way ANOVA with Bonferroni post-hoc tests (C-E) Delta confluency of siRNA-transfected Flp-In 
293 HA-PSAT1 wt (C), HA-PSAT1 S>A (D) and HA-PSAT1 S>E (E) cells in Ser + or Ser - medium over 72 hours with or 
without 50 ng/ml doxycycline treatment. HA-PSAT1 wt and HA-PSAT1 S>E completely rescue Ser – growth diminished 
by knockdown of endogenous serine, whereas HA-PSAT1 S>A fails to fully restore growth. Control siRNA, Ser + data 
is the same data as presented as in (B) and is used here for further comparison with PSAT1 siRNA-transfected cells. 
n=3 independent experiments, mean ± SEM, *p<0.05 as measured by paired t-tests. 
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It is worth noting that, although the proliferative effect of the doxycycline-mediated induction 
of HA-PSAT1 variants in Flp-In 293 cells was assessed (Figure 3.16 B), it was only assessed in 
“basal” conditions (i.e. control siRNA-transfected cells with exogenous serine present in the 
medium). Whilst it would be interesting and informative to perform a comprehensive analysis 
of the growth of cells in the presence or absence of HA-tagged wild-type or mutant PSAT1 in all 
the conditions detailed in Figure 3.16 C-E, such an analysis could not be sufficiently performed 
here, as variability in the data prevented the identification of statistically significant differences 
when comparing more than two groups of data. Indeed, it would be important to perform 
further data collection for this experiment in the future to facilitate a more in-depth analysis. 
For the purposes of this thesis, the statistical analysis for each condition was exclusively 
performed between two groups; where endogenous PSAT1 was present (control siRNA-
transfected cells), and where it was suppressed (PSAT1 siRNA-transfected cells), facilitating the 
main aim of the experiment to compare the activity of the HA-tagged PSAT1 variants to that of 
the endogenous. 
In the MDA-MB-453 PSAT1 cell models, culturing cells in serine-free medium substantially 
impaired growth rates in all 3 cell lines. Unlike what was observed in the Flp-In 293 cells 
however, treatment of all 3 MDA-MB-453 PSAT1 cell lines with doxycycline seemed to rescue 
the growth inhibition induced by serine deprivation (Figure 3.17). This indicated that the 
enzymatic activities of PSAT1 wt, PSAT1 S>A and PSAT1 S>E in MDA-MB-453 cells were equally 
sufficient to support serine production to a level high enough to sustain growth in serine-free 
medium.  
Since the expression of HA-PSAT1 S>A in the Flp-In 293 cell model was found to be insufficient 
to rescue growth in serine-deprived conditions in the absence of endogenous serine and since 
it had previously been established that the protein expression of the HA-PSAT1 S>A mutant was 
lower than that of the wt or S>E variants upon treatment of cells with doxycycline, it was 
hypothesised that the reduced growth rescue ability of HA-PSAT1 S>A was attributable to 
reduced PSAT1 protein expression resulting in reduced overall serine production. This 
hypothesis was directly addressed by measuring the serine production from the different HA-
PSAT1 proteins using labelled metabolite analysis, allowing evaluation of the comparative 
amount of serine produced when each HA-PSAT1 mutant was expressed. As with the previous 
labelled metabolite analysis, cells were prepared by Dr Ruoyan Xu and mass spectrometry 
detection of labelled metabolites was performed by Dr Christian Frezza and Dr Sofia De Costa. 
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Figure 3.17 PSAT1 wt and mutant proteins rescue growth inhibition of MDA-MB-453 cells in serine-free medium. 
MDA-MB-453 PSAT1 cells were grown in either serine - medium (Ser -), or serine - medium reconstituted with serine 
(Ser +) and treated with 500 ng/ml doxycycline to induce PSAT1 expression. Growth with and without doxycycline 
treatment was tracked by measurement of cell confluency over time using the IncuCyte Zoom. Delta confluency was 
measured between 0 and 72 hours to identify statistically significant changes in proliferation. (A-C) Delta confluency 
of MDA-MB-453 PSAT1 wt (A), MDA-MB-453 PSAT1 S>A (B) and MDA-MB-453 PSAT1 S>E (C) cells in Ser + and Ser - 
medium over 72 hours with and without 500 ng/ml doxycycline treatment. Non-treated cell lines show diminished 
proliferation in Ser - medium, which is wholly rescued by induction of PSAT1 wt, PSAT1 S>A and PSAT1 S>E. n=3 
independent experiments, mean ± SEM, *p<0.05 as measured by paired t-tests. (D) Representative IncuCyte growth 
curves for a single experiment with MDA-MB-453 PSAT1 wt, S>A and S>E cell lines treated with doxycycline in serine-
free medium, demonstrating equivalent growth rescue. Mean ± SD. 
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As in the IncuCyte experiments, endogenous PSAT1 was suppressed in Flp-In 293 cells using non-
coding sequence-targeting siRNA oligos prior to induction of the HA-tagged PSAT1 variants and 
incubation of cells with labelled metabolites. Doxycycline-treated Flp-In 293 HA-PSAT1 cells 
were then incubated with 15N-labelled glutamine to track the incorporation of the amino group 
into phosphoserine and ultimately serine itself. This allowed evaluation of the efficiency of the 
aminotransferase reaction and therefore assessment of comparative HA-PSAT1 enzyme activity. 
To identify differences in metabolite labelling, the amount of labelled serine and glycine 
detected was calculated as a percentage of total serine and glycine. Surprisingly, whilst the HA-
PSAT1 S>A mutant variant displayed a reduced ability to rescue growth of Flp-In 293 cells in 
serine-free conditions, labelled metabolite flux analysis showed no significant differences in the 
incorporation of glutamine-derived nitrogen into serine or glycine between the different HA-
PSAT1 variants. Indeed, the proportion of synthesised serine and glycine within the cells was 
steady at about 8-10% of the total intracellular pool across each cell line. This indicated equal 
amounts of serine biosynthesis with different HA-PSAT1 variants (Figure 3.18), suggesting the 
reduced proliferation of Flp-In 293 cells expressing HA-PSAT1 S>A in serine-free conditions was 
not due to a reduction in the amount of serine produced. 
 
 
Figure 3.18 – Modulation of PSAT1 Ser331 residue has no effect on serine biosynthesis. Labelled metabolite analysis 
using Flp-In 293 HA-PSAT1 cells tracked the incorporation of 15N derived from labelled glutamine into (A) serine and 
(B) glycine, thereby measuring the efficiency of the PSAT1 reaction catalysed by the different HA-PSAT1 variants. Flp-
In 293 HA-PSAT1 cells were transfected with 3 siRNA oligos targeting the non-coding sequences of PSAT1 mRNA or a 
single non-targeting control oligo to a final concentration of 50 nM for 72 hours. Cells were treated with 50 nM 
doxycycline simultaneously for the final 48 hours, to induce expression of the respective HA-PSAT1 variant and, for 
the final 24 hours, were cultured in medium containing 15N-labelled glutamine by Dr Ruoyan Xu. Following this, 15N-
labelled metabolites were detected by mass spectrometry analysis performed by Dr Christian Frezza and Dr Sofia De 
Costa. Data is expressed as the percentage of the total metabolite concentration that is labelled, indicating the 
percent of serine and glycine within the cell containing nitrogen derived from glutamine. n=3 independent 
experiments, raw data from each independent experiment is available in supplementary Tables 7.4, 7.5 and 7.6 on 
the provided CD, mean ± SEM. No significant differences were detected using one-way ANOVA with Bonferroni post-
hoc tests. 
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This data therefore indicated that the reduced proliferation of HA-PSAT1 S>A-expressing Flp-In 
293 HA-PSAT1 cells in serine-free medium was instead attributable to an alternative, as yet 
uncharacterised role of PSAT1. Until such a role is determined, it is difficult to speculate why the 
PSAT1 S>A mutant did not demonstrate reduced growth rescue of MDA-MB-453 cells in serine-
free medium but, importantly, the lack of difference in serine production between the different 
HA-PSAT1 mutants at least demonstrates that the Ser331 residue is not a site of any distinct 
importance for the primary enzymatic activity of PSAT1. 
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3.8 Assessing the impact of Ser331 mutation on PSAT1 containing protein 
complexes 
 
As evidence suggested that the phosphorylation of PSAT1’s Ser331 site was not an important 
event for regulation of its primary enzymatic activity, attention was turned to other functional 
roles the phosphorylation of this residue might play. Characterisation of the PSAT1 crystal 
structure in Escherichia coli and Mycobacterium tuberculosis has indicated that the enzyme 
exists as a homodimer339-341 and the structure of human PSAT1, publicly available in the Protein 
Data Bank (PDB) (www.rscb.org)342 as part of the worldwide PDB (www.wwpdb.org)343, shows 
the same dimer formation (PDB ID 3E77 – Lehtio et al. Structural Genomics Consortium (SGC). 
Human phosphoserine aminotransferase in complex with PLP). Furthermore, evidence in yeast 
models demonstrating formation of a protein complex containing yeast homologs of PHGDH 
and SHMT suggests that the PSAT1 enzyme might complex with other SBP enzymes in human 
cells288. As protein phosphorylation is also known to regulate potential protein-protein 
interactions, it was hypothesised that the mutation of Ser331 on PSAT1 might impact the 
interaction of PSAT1 either with itself, or with other serine biosynthesis enzymes. 
To test this hypothesis, the Flp-In 293 HA-PSAT1 model was used. Taking advantage of the HA-
tag on the inducible PSAT1 protein, cell lysates from doxycycline-treated Flp-In 293 HA-PSAT1 
(or HA-GFP as a control) cell lines were incubated with anti-HA antibody-conjugated agarose 
beads to perform a HA-pulldown. This purified HA-PSAT1 from cell lysates. To check for protein-
protein interaction, presence of endogenous PSAT1 and other enzymes of the SBP in the pull-
down samples was evaluated using western blotting. This allowed assessment of potential 
differences in protein-protein interaction between HA-PSAT1 mutant variants (Figure 3.19). Pull-
down of HA-PSAT1 from Flp-In 293 cells resulted in strong enrichment of HA-PSAT1 in resultant 
purified lysate samples. Furthermore, interaction of HA-PSAT1 with endogenous PSAT1 was 
confirmed due to detection of endogenous PSAT1 in the pull-down samples. This indicated that 
HA-PSAT1 was dimerising with the endogenous protein. Importantly, this dimerisation did not 
appear to involve phosphorylation of the Ser331 residue. Endogenous PSAT1 appeared equally 
in the pull-down samples containing HA-PSAT1 wt, HA-PSAT1 S>A and HA-PSAT1 S>E. This 
indicated that both mutant proteins maintained endogenous dimerisation.  
Interestingly, PHGDH was also present in the pull-down assay samples, indicating that it too was 
purified from lysates via HA-PSAT1 (Figure 3.19 A). This suggested formation of a protein 
complex containing both PHGDH and PSAT1 proteins in Flp-In 293 cells and is the first indication 
of an interaction between serine biosynthesis enzymes in human cells. Similar to the interaction 
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with endogenous PSAT1, the interaction of HA-PSAT1 with PHGDH was unaffected by the 
mutation of the Ser331 residue, with PHGDH detected in the pull-down samples containing HA-
PSAT1 S>A and HA-PSAT1 S>E the same way as it was in the sample containing HA-PSAT1 wt.  
To determine whether PHGDH was directly interacting with HA-tagged PSAT1 or if it was only 
interacting with endogenous PSAT1, siRNA targeting the non-coding sequence of PSAT1 mRNA 
was used to suppress the endogenous enzyme and the pull-down was repeated with only the 
HA-variants expressed. In the absence of endogenous PSAT1, PHGDH was still purified from 
lysates during the pull-down, indicating direct interaction with the HA-tagged enzyme (Figure 
3.19 B). Collectively, this data demonstrates that, as well as enzymatic activity, phosphorylation 
of PSAT1 residue Ser331 is a post-translational modification that is entirely dispensable for 
protein-protein interactions. 
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Figure 3.19 – HA-PSAT1 wt and mutant variants interact with endogenous PSAT1 and PHGDH. Western blots from 
HA-tag pull-down purification of Flp-In 293 HA-PSAT1 cell lysates, demonstrating the protein-protein interactions of 
all variants of HA-PSAT1 with endogenous PSAT1 and PHGDH. Flp-In 293 HA-GFP control cells and Flp-In 293 HA-PSAT1 
wt, Flp-In 293 HA-PSAT1 S>A and Flp-In 293 HA-PSAT1 S>E cells were (A) treated with 50 ng/ml doxycycline for 16 
hours or (B) transfected with 3 siRNA oligos targeting the non-coding sequence of PSAT1 mRNA or a single non-
targeting control oligo to a final concentration of 50 nM for 72 hours. siRNA-transfected cells were simultaneously 
treated with 50 ng/ml doxycycline for the final 16 hours. Cells from (A) and (B) were lysed and lysates were used in 
an HA-pulldown for purification of HA-tagged proteins. Lanes 1 to 4 demonstrate the input samples and lanes 5-8 
demonstrate the purified HA-pulldown lysates. Presence of endogenous PSAT1 and PHGDH in lanes 6-8 indicate 
protein interaction with HA-PSAT1. Vinculin is shown as a loading control in the input. 
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3.9 PSAT1 Ser331 is an important residue for protein stability 
 
As phosphorylation of PSAT1 Ser331 appeared to be dispensable for both enzymatic activity and 
protein-protein interaction, attention was turned to another possible role for protein 
phosphorylation and the importance of Ser331 phosphorylation in the regulation of protein 
stability was investigated. 
Initial induction tests of the Flp-In 293 HA-PSAT1 mutant cell lines did in fact indicate a role for 
the phosphosite in protein stability when, in spite of equal expression of the wt and mutant 
variants at the mRNA level, the mutant proteins exhibited significantly different levels of protein 
expression compared to PSAT1 wt. Indeed, the PSAT1 S>E mutant protein was expressed at a 
significantly higher level than the wt and the PSAT1 S>A mutant protein was expressed to a 
significantly lower level (Figure 3.10). Similarly, initial induction of the MDA-MB-453 PSAT1 
mutant cell lines exhibited significantly lower expression of PSAT1 S>A than PSAT1 wt, in spite 
of marginally higher mRNA levels (Figure 3.13). These data seemed to indicate that the S>A 
mutant was always expressed to a lesser degree than the wt protein, which is potentially 
indicative of lower protein stability. Therefore, to evaluate comparative protein stability, a two-
fold approach was taken. Firstly, the rate of protein degradation was assessed using a pulse 
chase experiment and secondly, the comparative rate of PSAT1 induction was determined by 
performing a doxycycline-induction time course. Once again, the Flp-In 293 system is a 
particularly good system for comparison of mutant versions of the same protein as inducible 
expression is typically equal, due to the single insertion of inducible genes at the same point in 
the genome, under the same promoters. This is exhibited in the lack of significant difference in 
mRNA expression of the HA-PSAT1 variants in the Flp-In 293 cells versus the comparatively 
variable mRNA expression in MDA-MB-453 PSAT1 cells. For this reason, the Flp-In 293 HA-PSAT1 
cells were used as a more reliable model for assessing protein stability. 
A pulse chase experiment is useful for evaluating the relative stability of inducible proteins over 
time. The stimulus for induction of the protein is applied for a limited window of time in a “pulse” 
and is subsequently washed away. Representative samples are then taken at set intervals 
following the removal of the stimulus to “chase” the degradation of the protein over time as no 
more protein is induced to replace what is degraded. For this experiment in Flp-In 293 HA-PSAT1 
cells were treated with doxycycline for 16 hours and washed, then representative cell samples 
were harvested at 24-hour intervals up to 96 hours. Subsequently, a western blot was performed 
to visualise relative protein degradation and densitometry analysis was used to quantify relative 
amounts of HA-PSAT1 remaining after the initial pulse. Across the 3 HA-PSAT1 cell lines, the 
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amount of HA-PSAT1 protein remaining was always expressed as a portion of the initial induction 
of the PSAT1 variant from that cell line (i.e. starting quantities of HA-PSAT1 wt, HA-PSAT1 S>A 
and HA-PSAT1 S>E were equally defined as a value of 1.0). Quantification of the western blot 
demonstrated that whilst no significant differences were observed between the degradation 
curves of the HA-PSAT1 variants, a subtle but distinct and repeatable trend was apparent, in that 
HA-PSAT1 S>A degraded marginally faster than HA-PSAT1 wt with a half-life of roughly 32 hours 
vs the wt half-life of 38. Conversely, HA-PSAT1 S>E remained expressed for slightly longer, 
exhibiting a half-life of around 48 hours (Figure 3.20). 
 
 
                
Figure 3.20 – Mutation of PSAT1 Ser331 residue alters the protein degradation rate. Pulse chase experiment 
characterising the relative degradation rates of HA-PSAT1 wt, HA-PSAT1 S>A and HA-PSAT1 S>E proteins. 
Corresponding Flp-In 293 HA-PSAT1 cell lines were treated with 50 ng/ml doxycycline for 16 hours, which was 
subsequently washed away. Representative cell samples were harvested at 24-hour intervals up to 96 hours to track 
degradation. (A) Western blot demonstrating the degradation of HA-tagged PSAT1 after initial induction. Vinculin is 
shown as a loading control. (B and C) Densitometry analysis quantification of HA-PSAT1 protein levels at 24, 48, 72 
and 96 hours relative to initial induced level of HA-PSAT1 wt, HA-PSAT S>A and HA-PSAT1 S>E respectively. 
Comparative degradation curves (B) demonstrated marginally slower degradation of S>E mutant and faster 
degradation of S>A mutant. The average half-life (C) of S>E PSAT1 mutant was higher than that of the S>A mutant. 
n=4 independent experiments, mean ± SEM. 
 
After characterisation of HA-PSAT1 degradation, attention was turned to assessing relative rates 
of HA-PSAT1 protein induction. To evaluate induction rates, the 3 Flp-In 293 HA-PSAT1 cell lines 
were treated with doxycycline at 2 hourly intervals, up to 10 hours, to induce HA-PSAT1 protein 
at different time points and generate a curve of steadily increasing protein levels over time. As 
A 
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Chapter 3. Results I: IKKε directly phosphorylates PSAT1 to promote protein stability 
137 
 
with the pulse chase experiment, a western blot was performed to visualise the increase in HA-
PSAT1 protein levels and densitometry analysis was used to quantify the induction over the time 
scale. To quantify relative protein levels, all protein quantities were normalised to the final 
induced level of wt PSAT1 at 10 hours, which was defined as a value of 1.0. This allowed 
determination of the relative time it would take for protein levels of HA-PSAT1 S>A or HA-PSAT1 
S>E mutants to accumulate to equal levels of HA-PSAT1 wt. 
After 10 hours of doxycycline induction, HA-PSAT1 S>E levels were significantly higher than 
levels of HA-PSAT1 wt and HA-PSAT1 S>A. After just 8 hours of doxycycline induction, the HA-
PSAT1 S>E protein had accumulated to levels equivalent to that of the HA-PSAT1 wt protein after 
10 hours. This indicated that the HA-PSAT1 S>E protein accumulated faster than the wt protein. 
On the other hand, the HA-PSAT1 S>A protein failed to accumulate to levels equivalent to that 
of the HA-PSAT1 wt protein by the end of the 10-hour experiment. This data indicated that the 
HA-PSAT1 S>A protein accumulated slower than the HA-PSAT1 wt protein (Figure 3.21). 
 
 
 
 
Figure 3.21 – Mutation of PSAT1 Ser331 significantly alters HA-PSAT1 accumulation rate. Doxycycline induction time 
course characterising the relative rate of accumulation of HA-PSAT1 wt, HA-PSAT1 S>A and HA-PSAT1 S>E proteins. 
Indicated Flp-In 293 HA-PSAT1 cell lines were treated with 50 ng/ml doxycycline for 2, 4, 6, 8 or 10 hours to track HA-
tagged protein induction. (A) Western blot demonstrating the relative induction rates of the different HA-PSAT1 
variants. Vinculin is shown as a loading control. (B) Densitometry analysis quantification of HA-PSAT1 protein levels 
from all variants at all time points, relative to the quantified level of HA-PSAT1 wt at 10 hours of doxycycline induction, 
was used to visualise relative induction rates for the different HA-PSAT1 variants. HA-PSAT1 S>E mutant protein levels 
at 10 hours are significantly higher than HA-PSAT1 wt or HA-PSAT1 S>A protein levels. n=3 independent experiments, 
mean ± SEM, *p<0.05 as measured by two-way repeated measures ANOVA with Bonferroni post-hoc tests. 
A 
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Together, these data demonstrate a slower accumulation and faster degradation of the HA-
PSAT1 S>A mutant and, conversely, a faster accumulation and slower degradation of the HA-
PSAT1 S>E mutant. This supports the hypothesis that the Ser331 residue is an important residue 
for protein stability. One which, if phosphorylated, might promote stabilisation and 
accumulation of the protein.  
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3.10 Discussion 
 
This chapter described the characterisation of PSAT1 as a novel IKKε substrate, phosphorylated 
in an IKKε-dependent manner at serine residue Ser331, and detailed the experiments leading to 
the identification of Ser331 as an important serine residue for PSAT1 protein stability, thereby 
demonstrating a novel mechanism of post-translational regulation of the enzyme mediated by 
IKKε. Various transcription factors have been reported to regulate either all 3 serine biosynthesis 
enzymes at a transcriptional level, including c-Myc and NRF2315,324, or specific enzymes of the 
pathway, such as tumour suppressive kinase protein kinase  C zeta (PKCζ) which has been shown 
to suppress genetic expression of PHGDH and PSAT1326. However, very little is known about how 
the enzymes of the pathway are regulated at a post-transcriptional level. The same study 
identifying PKCζ as a regulator of PHGDH and PSAT1 gene expression also reported the PKCζ-
mediated phosphorylation of PHGDH at 2 highly conserved threonine residues (Thr57 and 
Thr78) to be an important post-translational modification that negatively regulates PHGDH’s 
enzymatic activity326, but beyond this, no other post-translational modifications known to 
regulate PHGDH function have been reported. Furthermore, nothing is currently known about 
the post-translational regulation of the other enzymes of the SBP.  
PSAT1 Ser331 phosphorylation 
Phosphoproteomic analysis, highlighting differentially phosphorylated peptides in IKKε-
expressing Flp-In 293 cells, identified PSAT1 as significantly more phosphorylated at serine 
residue Ser331 in the presence of IKKε. Using an in vitro kinase assay, PSAT1 was confirmed to 
be a target of an IKKε-dependent phosphorylation. Importantly however, whilst the in vitro 
kinase assay confirmed that phosphorylation of PSAT1 Ser331 was IKKε-dependent, it proved 
difficult to definitively confirm that IKKε was directly phosphorylating the enzyme. The 
identification of phosphorylation of PSAT1 in the samples containing HA-IKKε KD-m initially 
indicated the kinase-dead IKKε mutant had retained some residual kinase activity. However, this 
hypothesis was quickly discounted as extensive data had previously confirmed the lack of 
activity in the mutant kinase. Instead, it became evident that the presence of a secondary kinase 
in the reaction mixture had led to the phosphorylation of PSAT1 in these samples. Fortunately, 
mass spectrometry analysis of assay samples allowed identification of other kinases present and 
a list of 18 was defined (Table 3.3). The only kinase from that list that was present in all the 
samples where phosphorylation was detected and was also not detected in the control sample 
was TBK1. Notably, TBK1 is the only other kinase of the 18 which has previously been shown to 
be associated with IKKε function. It was therefore hypothesised that TBK1 was phosphorylating 
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PSAT1 in the presence of HA-IKKε KD-m. This raised the question of whether IKKε was 
phosphorylating PSAT1 at all, or if it was just required for TBK1 to phosphorylate the enzyme.  
Attempts were made to unravel this and identify which the phosphorylating kinase was by 
performing an in vitro kinase assay using recombinant IKKε and/or TBK1, but unfortunately, this 
experiment failed to re-produce PSAT1 phosphorylation due to inactivity of the recombinant 
kinases. There are various possible reasons why the recombinant kinases failed to be active, 
including lack of kinase auto-phosphorylation. A possible contributing factor is the absence of 
IKKε and TBK1 adaptor molecules and scaffolding proteins during the recombinant kinase assay, 
which could have been present when performing the HA-purified kinase assay. For example, 
IKKε is known to require K63-linked polyubiquitination for full activity, which might not have 
been present on the recombinant protein344. Another example is the scaffolding proteins that 
assist the formation of functional IKKε and TBK1 heterodimers. In order to properly dimerise, 
IKKε and TBK1 require scaffolding proteins like nucleosome assembly protein 1 (NAP1), TANK or 
similar to NAP1 TBK1 adaptor (SINTBAD) (reviewed by Chau, 200885). Such adaptors were not 
present in the recombinant kinase experiment, but notably, TANK was detected in the HA-
purified in vitro kinase assay samples. This suggests it was purified in complex with IKKε and 
indicates that combination of recombinant IKKε and TBK1 with TANK protein might facilitate the 
formation of functional dimers and be sufficient to elicit PSAT1 phosphorylation, but this would 
undoubtedly require experimental validation. If this hypothesis were true however, it would 
imply an IKKε/TBK1 heterodimer was responsible for PSAT1 phosphorylation, not either kinase 
individually. This hypothesis is in fact supported by the existing in vitro kinase assay data 
presented in this chapter. TBK1 was detected in all assay samples, which should suggest PSAT1 
would be phosphorylated if the kinase could phosphorylate it alone. Instead, PSAT1 
phosphorylation was only detected in samples were HA-IKKε and TBK1 were present 
simultaneously, suggesting an IKKε/TBK1 heterodimer is required for the phosphorylation. This 
would also be in agreement with the substantial overlap in substrates that is observed between 
the two kinases, as both IKKε and TBK1 have repeatedly been shown to phosphorylate the same 
residues on proteins, including IRF386, cRel82 and p65194. 
Phosphorylation of PSAT1 at serine residue Ser331 has previously been reported in a number of 
studies using high throughput techniques, including studies aiming to determine the 
phosphoproteome of breast cancer tissues345, lung cancer cells346 and melanoma cells347 to 
name a selection. Importantly, no pre-existing studies have attempted to characterise the 
functional relevance of phosphorylation of this residue, making the experiments described in 
this chapter the first real effort to do so. 
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PSAT1 Ser331 phosphorylation in enzyme activity 
The experiments described here support the hypothesis that PSAT1’s Ser331 residue is an 
important site for regulation of protein stability, demonstrating that, compared to the wild-type 
protein, the phospho-mimic PSAT1 S>E mutant protein showed characteristics of greater 
stability and the phospho-mutant PSAT1 S>A protein exhibited the opposite phenotype. 
Interestingly, whilst the data indicates phosphorylation of PSAT1 Ser331 promotes accumulation 
of protein levels, it appeared insufficient to alter serine biosynthesis itself. Modulation of the 
PSAT1 Ser331 residue failed to demonstrate any significant effect on the production of serine 
when serine biosynthesis was measured using labelled metabolite analysis. Despite this, it is 
difficult to completely rule out the prospect that phosphorylation of PSAT1 Ser331 might have 
some impact on enzyme activity.  Firstly, and most strikingly, previous work has detailed the 
existence of an alternate, shorter PSAT1 isoform. This isoform is lacking 46 amino acids between 
Val290 to Ser337 compared to the canonical full-length protein. Importantly, this shorter version 
of the enzyme has been shown to be substantially lacking in enzymatic activity compared to the 
dominantly expressed full-length protein348. This suggests something within this 46-amino acid 
sequence is important for enzymatic function. According to the PSAT1 entry in the 
PhosphoSitePlus® database338, multiple residues within this sequence of the protein are targets 
of post-translational modifications, including several ubiquitination and acetylation targets, but 
phosphorylation of Ser331 stands out as the second most reported modification within the 
sequence and as the only phosphorylation target in the full-length PSAT1 protein that is not 
present in the shorter sequence. It is impossible to speculate on the relative importance of other 
PSAT1 post-translational modifications without further investigation into their functions, but 
considering that the activity of PHGDH, another serine biosynthesis enzyme, has been shown to 
depend on protein phosphorylation events326, it is not unreasonable to imagine that 
phosphorylation of Ser331 might contribute to the increased activity of the full-length protein.  
It is also worth considering that Ser331 is just a solitary post-translational modification site on 
the protein. Phosphorylation of Ser331 might represent just one of several PSAT1 post-
translational modifications that serve to regulate enzyme activity. It is possible that Ser331 
phosphorylation does contribute to the regulation of PSAT1 function but cannot regulate the 
function enough on its own to significantly impact serine production. Instead Ser331 
phosphorylation might act in tandem with other phosphorylation events to modulate activity of 
the enzyme. Once again utilising information from the PhosphoSitePlus® database338, numerous 
other phosphorylation sites on PSAT1 have been described. As with Ser331 however, each of 
these sites have been characterised in studies using mass throughput techniques and no other 
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functional residues have yet been reported. It does seem unlikely however, that IKKε itself 
phosphorylates PSAT1 at any other residues. Not only was no other significant change in PSAT1 
phosphorylation detected during the phosphoproteomic analysis, but no further overlap of at 
least 3 out of 4 residues from IKKε’s optimal phosphorylation motif197 was detected in the PSAT1 
sequence. Therefore, if PSAT1 is phosphorylated at other sites, it is likely these events are IKKε-
independent.  
Another point to consider is that, although the experiments detailed here show that the residue 
is dispensable for protein-protein interactions, the phosphorylation of the residue might serve 
to alter substrate interaction dynamics and alter the affinity of PSAT1 for either 
phosphohydroxypyruvate or glutamate, thereby indirectly regulating the activity of the enzyme. 
The effect of PSAT1 Ser331 phosphorylation on substrate affinity is therefore also something 
that should be investigated.  
It is also worth recognising that the experimental conditions used to assess enzyme activity via 
labelled metabolite analysis might have served to mask detectable differences in serine 
production between HA-PSAT1 wt and HA-PSAT1 mutant variants. Although the flux analysis 
experiment showed no change in serine production upon mutation of the PSAT1 Ser331 residue, 
this experiment was performed in the presence of extracellular serine. This means that even 
though the SBP was active, the Flp-In 293 cells in which the labelled metabolite analysis was 
performed were not wholly dependent on de novo serine production for survival. It is possible 
that, in such circumstances, the amount of serine produced via PSAT1 is low enough that even 
an activity deficient variant of the enzyme could be active enough to produce the same amount 
of serine as the wild-type enzyme, thereby masking differences in mutant enzyme capacity. To 
address this limitation, it would be worth repeating the experiment in conditions where cells are 
deprived of extracellular serine, are forced to rely solely on the SBP for survival and are therefore 
utilising each of the serine biosynthesis enzymes to their maximal capacity. Considering a 
diminished ability for the HA-PSAT1 S>A mutant enzyme to rescue the growth of Flp-In 293 cells 
in serine-free medium, it is possible that differences in serine production could be observed in 
these conditions.  
PSAT1 Ser331 phosphorylation in proliferation 
Should the phosphorylation of Ser331 be entirely uninvolved in PSAT1’s role in serine 
production, the fact that the phospho-mutant HA-PSAT1 S>A protein exhibited a lesser ability to 
rescue growth of Flp-In 293 cells in serine-free medium would suggest that PSAT1 Ser331 
phosphorylation is important for an undetermined secondary function of the enzyme that 
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supports cell survival in nutrient-deprived conditions. One possibility to explore is that PSAT1 
has been shown to regulate cyclin D1 stability by indirectly inhibiting GSK3β, preventing cyclin 
D1 phosphorylation to stabilise the protein, sustaining cell cycle progression and proliferation310. 
It is possible that the marked decrease in HA-PSAT1 S>A protein levels, associated with reduced 
protein stability, is insufficient to reduce serine production, but is enough to impact inhibition 
of GSK3β, thereby reducing proliferation. Examination of the cell cycle profile, cyclin D1 stability 
and cell cycle progression markers in cells expressing the various PSAT1 mutant proteins would 
be valuable to determine the effect of PSAT1 Ser331 phosphorylation on its ability to regulate 
cyclin D1 protein stability. If phosphorylation of PSAT1 Ser331 is involved in the regulation of 
cyclin D1 and cell cycle progression, this might help explain why, in a study examining the 
phosphoproteome of different human breast cancer cases, the phosphorylation appeared to 
associate with the more aggressive triple-negative subtype of breast cancer345. 
It is worth noting that, although the HA-PSAT1 S>A mutant exhibited a reduced ability to rescue 
Flp-In 293 cell growth in serine-deprived conditions, the same diminished rescue ability was not 
observed in MDA-MB-453 cells expressing PSAT1 S>A. At this time, it is difficult to speculate why 
this might be, but it should be recognised that there are fundamental differences between the 
cell line models that might help explain the discrepancy. Primarily, the Flp-In 293 cell model is a 
cell line model which basally expresses all three serine biosynthesis enzymes and, as a result, 
can survive in serine-free conditions until endogenous PSAT1 is suppressed. MDA-MB-453 does 
not express any detectable PSAT1 protein at a basal level and therefore cannot survive without 
extracellular serine. It is therefore likely that MDA-MB-453, whilst still dependent on serine that 
it can get from the extracellular environment, has adapted to survive independently of the 
serine biosynthesis enzymes. If PSAT1 has a secondary effect on proliferation in Flp-In 293 cells, 
potentially via regulation of cyclin D1 protein stability, it stands to reason that the MDA-MB-453 
cell line, which does not express PSAT1 basally, regulates proliferation independently of PSAT1. 
As a cancer cell line, alternative mechanisms for overriding the cell cycle will likely have been 
developed. This would suggest that when PSAT1 is suddenly reintroduced upon doxycycline 
treatment of MDA-MB-453 PSAT1 cells, the enzyme serves only to facilitate the production of 
serine, allowing cells to survive in the absence of extracellular serine, but not conferring any 
secondary proliferative advantage. It could therefore be hypothesised that if phosphorylation of 
PSAT1 Ser331 is an important post-translational modification for the regulation of proliferation, 
then the modulation of this residue would have little effect in MDA-MB-453 cells. Since labelled 
metabolite analysis has indicated that the different HA-PSAT1 protein variants can synthesise 
equal amounts of serine, it would therefore be expected that the different PSAT1 variants in 
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MDA-MB-453 cells also produce equal amounts and rescue growth in serine-deprived conditions 
equally. If testing the effect of expression of HA-PSAT1 wt, HA-PSAT1 S>A or HA-PSAT1 S>E 
mutant proteins on cyclin D1 protein stability in Flp-In 293 cells, it would be interesting to test 
the effect of the mutant proteins on cyclin D1 in MDA-MB-453 cells as well, to ascertain whether 
the enzyme would have any proliferative role in the breast cancer cell line or not. 
Clinical implications of PSAT1 Ser331 phosphorylation 
With the context of breast cancer in mind, obvious questions over the pathophysiological 
relevance of IKKε-dependent PSAT1 phosphorylation in breast cancer are raised by the 
identification the Ser331 phosphosite, especially considering the lack of significant effect on 
enzymatic activity upon modulation of the phosphosite.  
As mentioned above, the reduced ability for the HA-PSAT1 S>A mutant to rescue growth in 
serine-free conditions suggest that the phosphosite is important for cell growth or survival in 
some manner. Furthermore, whilst the data presented here cannot go far enough to fully 
elucidate clear evidence of a physiological benefit to PSAT1 Ser331 phosphorylation, evidence 
in the literature base does at least suggest that the site is actively phosphorylated in a subset of 
breast cancers associated with particularly poor prognosis. As mentioned above, in a high 
throughput analysis of the phosphoproteome of multiple patient-derived breast cancer tissues, 
PSAT1 Ser331 phosphorylation was reported at a substantially higher degree in tissues coming 
from patients with a more aggressive, triple negative subtype disease345. This indicates that 
phosphorylation of the enzyme might contribute to disease progression in some, as yet 
uncharacterised, way and suggests the phosphosite might be prognostic for poor patient 
outcome.  
Interestingly, this apparent association of PSAT1 Ser331 phosphorylation with a specific breast 
cancer subtype is in contrast to the activity of IKKε in breast cancer, which has been shown to 
be oncogenic without any distinct correlation to disease subtype195. However, in spite of the 
overall lack of correlation of IKKε expression with tumour subtype, a subset of IKKε-driven triple-
negative breast cancer has been described. Termed “immunomodulatory”, this subtype of triple 
negative breast cancer is distinct, due to an activated JAK/STAT cytokine signalling network 
which has been shown to be driven by IKKε expression213. Therefore, whilst expression of the 
kinase itself shows no clear correlation with breast cancer subtype, it is clear that IKKε activity 
is associated with certain subsets of triple negative classified tumours. This activity might be 
responsible for the increased PSAT1 Ser331 phosphorylation observed in patients with tumours 
exhibiting the triple-negative phenotype. 
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IKKε-dependent phosphorylation of other serine biosynthesis enzymes 
The question remains as to whether IKKε’s post-translational regulation of the serine 
biosynthesis enzymes is limited to PSAT1, or if the other enzymes are potential substrates. 
Current evidence suggests the answer to this question is that IKKε specifically acts on PSAT1, 
since neither PHGDH nor PSPH phosphorylation was detected in the phosphoproteomic analysis 
performed in the early stages of this project. Searching for potential IKKε phosphosites in the 
PHGDH and PSPH sequences using IKKε’s optimal phosphorylation motif197 and looking for at 
least 3 out of 4 overlapping residues, did identify residues in both PHGDH and PSPH that 
matched the sequence targeted by the kinase, namely PHGDH serine residue Ser166 and PSPH 
serine residue Ser114. Whilst this does suggesting phosphorylation might be possible, according 
to information contained within the PHGDH and PSPH entries in the PhosphoSitePlus 
database338, neither of these sites have ever been previously reported as phosphorylated. This 
raises a question over whether these residues would even be phosphorylatable in vivo at all and 
suggests that neither of these proteins could be legitimate IKKε substrates in the way PSAT1 is. 
This would imply that the regulation of the SBP by IKKε is centred specifically around the second 
enzyme of the pathway. This would be in accordance with the fact that, despite PHGDH being 
the subject of genetic amplification in breast cancer304,305, the ability for PSAT1 to generate 
glutamine-derived α-KG to fuel the TCA cycle means it provides more direct growth benefits to 
tumours than PHGDH305. 
Given the importance of the donation of serine-derived carbon to one-carbon metabolism in 
cancer for the maintenance of redox balance, it would also be important to address whether 
SHMT, the enzyme catalysing the catabolism of serine to glycine and the donation of serine-
derived carbon to the one-carbon cycle, might also be a target of IKKε phosphorylation. Again, 
no SHMT phosphopeptide was detected in the phosphoproteomic analysis, but overlap of the 
optimal IKKε motif with the sequence of either SHMT isoform (SHMT1 catalyses the reaction in 
the cytosol and SHMT2 catalyses the reaction in the mitochondria) revealed three potential IKKε 
target sites on SHMT1; Ser164, Ser169 and Ser473 and five potential sites on SHMT2; Ser5, 
Ser187, Ser192, Ser322 and Ser470. Of these identified residues, SHMT1 Ser169 and SHMT2 Ser5 
and Ser192 all demonstrated overlap of 4 out of 4 possible residues from the optimal recognition 
motif, demonstrating a strong potential for phosphorylation of these residues by IKKε. However, 
as with PHGDH and PSPH, most of these identified potential phosphosites have not been 
previously reported. Only SHMT2 Ser470 having been reported in a single study using mass-
throughput analysis techniques349. Especially considering the lack of identified phosphopeptide 
for any other serine related enzyme, it therefore seems likely that PSAT1 is the only serine 
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biosynthesis enzyme subject to IKKε-dependent phosphorylation. To confirm this hypothesis 
however, it would be important to perform further in vitro kinase assays to definitively rule out 
IKKε-dependent phosphorylation of the other enzymes. 
Phosphorylation of other metabolic proteins by IKKε 
In addition to the finding of PSAT1 Ser331 phosphorylation in IKKε-expressing cells, several other 
metabolic proteins were identified to be significantly more phosphorylated in the presence of 
kinase expression. These enzymes included glycolytic enzymes fructose bisphosphate aldolase 
at serine residue Ser46, gamma enolase at residue Ser40 and triosephosphate isomerase at 
residues Ser58 and Ser273. Phosphorylation of fructose bisphosphate aldolase Ser46, gamma 
enolase Ser40 and triosephosphate isomerase Ser58 residues have all been previously reported 
in the PhosphoSitePlus® database338, but as before, only in mass-throughput studies. 
Interestingly, no previous reports have been made regarding triosephosphate isomerase Ser273. 
Therefore, the finding of IKKε-dependent increased phosphorylation is possibly the first 
identification of this phosphosite. Again, whether phosphorylation of this site would have any 
functional role is a question that is yet to be answered. It is worth noting that Ser46 of fructose 
bisphosphate aldolase, Ser40 of gamma enolase and Ser273 of triosephosphate isomerase are 
all conserved residues in mouse and rat protein sequences. Whether this implies any further 
importance to a residue for protein function is arguable, but conservation of a residue across 
species at least suggests it is possible that these residues are important for the function of these 
enzymes and that IKKε might promote glycolytic activity by phosphorylating them. 
The identification of 3 glycolysis enzymes exhibiting increased phosphorylation in the presence 
of IKKε expression clearly indicates the potential for the kinase to play a role in glycolysis. This is 
in agreement with previous findings demonstrating a link between IKKε and the upregulation of 
glycolytic rates. In dendritic cells, IKKε promotes a metabolic shift to aerobic glycolysis upon 
early activation of the cells106 and in pancreatic cancer cells, an IKKε dependent-shift to aerobic 
glycolysis has been shown to sustain cellular proliferation189. In dendritic cells, this shift has been 
reported to be initiated by AKT-dependent phosphorylation of glycolytic enzyme hexokinase II, 
which is associated with localisation of the enzyme to the mitochondria where it can directly use 
mitochondrial ATP to maximise its enzymatic efficiency, boosting the glycolytic rate. In 
pancreatic cancer cells, IKKε-mediated metabolic regulation has been shown to be attributable 
to the activation of an AKT-dependent phosphorylation cascade which results in stabilisation 
and nuclear retention of c-Myc, thereby promoting proliferation and glycolysis-related gene 
expression. This action is dependent on the phosphorylation of GSK3β at serine residue Ser9, 
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which inhibits the GSK3β-mediated phosphorylation of c-Myc that promotes its nuclear export. 
Intriguingly, the induction of the aerobic glycolysis phenotype observed in the Flp-In 293 HA-
IKKε cells appears independent of both of these described mechanisms, as investigation of the 
phosphoproteomic analysis detected no significant changes in hexokinase II, GSK3β or c-Myc 
phosphorylation in the IKKε-expressing cells. Whilst the lack of changes in phosphorylation 
status of these proteins would need to be experimentally validated, using western blotting or 
similar techniques, the phosphoproteomic analysis at least indicates a lack of involvement of 
these mechanisms in IKKε-driven metabolic reprogramming in Flp-In 293 HA-IKKε cells. 
Consequently, this suggests that the kinase-dependent rewiring of cellular metabolism occurs 
via a previously uncharacterised mechanism in this particular system. 
The phosphoproteomic analysis also demonstrated significantly increased phosphorylation of 
GFPT1, the enzyme controlling the flow of glucose-derived carbon into the hexosamine 
biosynthesis pathway, at serine residue Ser261. Phosphorylation of GFPT1 Ser261 has been 
linked to the induction of GFPT1 enzymatic activity, as the site corresponds to key catalytic 
residue Ser243 in a splice variant of the enzyme336,337. Increased phosphorylation of this residue 
in IKKε-expressing cells therefore suggests IKKε might promote hexosamine biosynthesis. Other 
enzymes of the hexosamine biosynthesis pathway, such as UDP-N-acetylhexosamine 
pyrophosphorylase (UAP1) and GFPT isoenzyme 2 (GFPT2), have been shown to be 
overexpressed in prostate cancer and support disease development by promoting epithelial-
mesenchymal transition and protecting against endoplasmic reticulum stress350,351. At the same 
time, the hexosamine biosynthesis pathway has also been shown to act in a tumour suppressive 
fashion in a subset of prostate cancers352. It is therefore unclear what role, if any, the 
hexosamine biosynthesis pathway might play in a breast cancer setting, but whether or not IKKε 
is capable of inducing activity of pathway is certainly an avenue worth exploring. Unfortunately, 
the performed labelled metabolite analysis failed to detect any metabolite products from the 
hexosamine biosynthesis pathway so, from the current metabolomics data available, it is 
difficult to assess the effect that the kinase might have on the pathway without further research. 
Phosphorylation of other non-metabolic proteins by IKKε 
From a non-metabolic standpoint, the phosphoproteomic analysis also revealed significantly 
decreased phosphorylation of YAP1 at serine residue Ser61 and significantly increased 
phosphorylation of histone deacetylase 2 (HDAC2) at residue Ser394 in IKKε-expressing cells. 
Both of these events are notable. Phosphorylation of YAP1 Ser61 has been shown to contribute 
to the inhibition of pro-proliferative, oncogenic Hippo pathway signalling. Whilst it should be 
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noted that phosphorylation of YAP1 Ser61 alone is insufficient to inhibit Hippo pathway 
oncogenesis353, decreased phosphorylation of this residue in IKKε-expressing cells suggests that 
the kinase might at least contribute to the maintenance of a YAP1-dependent oncogenic signal 
to promote cancer development. In agreement with this, IKKε has been previously linked to 
cancer development through YAP1 in gliomas, where the kinase has been shown to stabilise 
YAP1 by decreasing phosphorylation of YAP1 Ser127. This increases YAP1 transcriptional activity 
which initiates a feedback loop, reinforcing kinase expression through suppression of IKKε-
targeting microRNA miR-let-7b/i173. Identification of IKKε-dependent decreased YAP1 Ser61 
phosphorylation in the phosphoproteomic analysis therefore supports the findings in gliomas, 
demonstrating a close regulation of Hippo pathway oncogenic activity by the kinase through the 
regulation of YAP1 protein stability. 
Phosphorylation of HDAC2 Ser394 is also an event which can be linked to cancer development. 
Phosphorylation of this residue has been shown to be important for HDAC2 enzyme activity354 
and HDAC2 overexpression correlates with tumour aggressiveness in breast cancer355. 
Accordingly, HDAC2 has been shown to contribute to breast cancer development by indirectly 
upregulating DNA-damage response genes like RAD51 through the suppression of microRNA’s 
that inhibit such genes356. The increased phosphorylation of HDAC2 by IKKε therefore implies 
that the kinase might also contribute to cancer development through the promotion of HDAC2 
activity, which has not previously been considered as part of the kinases oncogenic potential. 
PHGDH/PSAT1 dimer formation in human cell lines 
Finally, although it has been mentioned earlier that the PSAT1 Ser331 residue was shown to be 
inessential for the dimerisation of HA-PSAT1 with endogenous PSAT1 or the interaction of PSAT1 
with PHGDH, the data presented in this chapter demonstrating the interaction of PSAT1 
interaction with PHGDH represent the first characterisation of a PHGDH/PSAT1 protein-protein 
interaction in human cell lines. Indeed, in yeast, the yeast homologs of the serine biosynthesis 
enzymes Ser33 and Ser3 (isoforms of PHGDH) and Shm2 (SHMT) have been shown to interact in 
a protein complex called SESAME with yeast homologs of PKM2 and SAM synthetases, but no 
such interactions have as yet been detailed in human cells. It is unlikely that the protein complex 
observed in the pull-down assay is representative of a human variant of the SESAME complex, 
since attempts to probe for PKM2 and SHMT demonstrated no pull-down of those enzymes and 
Ser1 (the yeast homolog of PSAT1) was absent from the SESAME complex. This suggests the 
interaction observed might represent an as yet uncharacterised complex that contains PHGDH 
and PSAT1. Other proteins present in such a complex could be identified using mass 
Chapter 3. Results I: IKKε directly phosphorylates PSAT1 to promote protein stability 
149 
 
spectrometry analysis of HA-pulldown samples and could help elucidate what kind of protein 
complex is formed, or indicate what its potential function might be. 
Concluding remarks 
In summary, this chapter has detailed efforts to characterise the IKKε-dependent metabolic 
phenotype in both a Flp-In 293 system and a more physiological breast cancer cell line model. 
The kinase was found to significantly increase intracellular serine biosynthesis, a particularly 
important pathway for rapidly proliferating cells. Consequently, IKKε was shown to be required 
for the phosphorylation of serine enzyme PSAT1 at a residue that regulates protein stability. As 
the kinase therefore potentially promotes PSAT1 protein accumulation, the effects of IKKε 
expression of the serine biosynthesis enzyme protein levels were next explored. The results of 
such experiments are described in the next chapter. 
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4.1 IKKε regulates serine biosynthesis enzyme protein levels in Flp-In 293 cells 
and breast cancer cell lines 
 
The findings of the previous chapter detailed a mechanism through which PSAT1, upon 
phosphorylation at serine residue Ser331 in an IKKε-dependent manner, was stabilised at the 
protein level, leading to faster accumulation and slower degradation of the protein. It was 
therefore hypothesised that modulation of IKKε expression in Flp-In 293 HA-IKKε cells or human 
breast cancer cell lines might directly impact the serine biosynthesis enzyme and lead to 
upregulation of the PSAT1 protein. To test this hypothesis, Flp-In 293 HA-IKKε and Flp-In 293 HA-
GFP cells were treated with doxycycline for 16 hours, inducing HA-tagged kinase expression or 
HA-tagged GFP as a control. The potential impact of HA-IKKε induction on the protein levels of 
PSAT1 and other serine biosynthesis enzymes was subsequently assessed via western blotting 
(Figure 4.1). 
 
 
Figure 4.1 – Induction of HA-IKKε in Flp-In 293 cells upregulates PSAT1 and PSPH protein levels. Western blot 
demonstrating effect of IKKε expression on serine biosynthesis enzyme protein levels in Flp-In 293 cells. Indicated Flp-
In 293 cell lines were treated with 50 ng/ml doxycycline for 16 hours inducing HA-GFP or HA-IKKε. PSAT1 and PSPH 
protein levels were upregulated upon induction of HA-IKKε expression. Vinculin is shown as a loading control. 
 
Treatment of Flp-In 293 HA-IKKε cells with doxycycline led to upregulation of PSAT1, whereas 
doxycycline treatment of Flp-In 293 HA-GFP cells had no impact of the enzyme’s protein levels, 
confirming that induction of IKKε leads to upregulation of PSAT1 in Flp-In 293 cells. This 
suggested that the kinase might be phosphorylating and stabilising the enzyme in Flp-In 293 
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cells, as was hypothesised. Surprisingly, whilst PHGDH protein levels were unaffected by 
induction of IKKε, PSPH protein levels were upregulated, similar to PSAT1, by expression of the 
kinase. This indicated that upregulation of the serine biosynthesis enzymes might not be limited 
to the PSAT1 enzyme and, since the phosphoproteomic analysis did not indicate that IKKε 
induced PSPH phosphorylation, might not be solely attributable to substrate phosphorylation. 
Since PSPH protein levels were unexpectedly found to be upregulated by expression of IKKε, it 
was also questioned whether SHMT, the enzyme that catalyses the breakdown of serine to 
glycine and regulates the entry of serine-derived carbon into the one-carbon cycle, might be 
regulated by the kinase as well. Specifically, it was wondered whether SHMT2, the mitochondrial 
isoform of the enzyme and the isoform that has been more frequently linked to cancer 
progression due to its role in maintaining redox balance320,357-359, might be regulated. To 
investigate this, protein levels of SHMT2 upon doxycycline treatment of Flp-In 293 HA-GFP or 
HA-IKKε cells were investigated via western blotting, using the same samples from Figure 4.1. 
Treatment of Flp-In 293 HA-GFP or HA-IKKε cells with doxycycline had no effect on the protein 
levels of SHMT2 (Figure 4.2), demonstrating that the kinase does not regulate the enzyme. This 
demonstrated that IKKε-mediated protein regulation of enzymes related to serine biosynthesis 
in Flp-In 293 cells is limited to PSAT1 and PSPH. 
 
 
Figure 4.2 – Induction of HA-IKKε expression in Flp-In 293 cells has no effect on SHMT2 protein levels. Western blot 
indicating SHMT2 protein levels in indicated Flp-In 293 cells upon treatment with 50 ng/ml doxycycline for 16 hours. 
No change in SHMT2 protein levels was observed upon HA-IKKε induction. Vinculin is shown as a loading control. 
 
To determine whether IKKε was regulating PSAT1 and PSPH protein levels in a more 
physiological model, the panel of 9 breast cancer cell lines was transfected with a pool of IKBKE-
targeting siRNA oligos, to suppress IKKε, or a non-targeting control siRNA oligo for 72 hours. 
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Following transfection, serine biosynthesis enzyme protein levels were evaluated via western 
blotting (Figure 4.3). Subsequently, protein levels were quantified using densitometry analysis 
in order to determine changes IKKε-mediated in serine biosynthesis enzyme protein expression 
(Figure 4.4). 
 
 
Figure 4.3 – siRNA-mediated suppression of IKKε in breast cancer cell lines reduces serine biosynthesis enzyme 
protein levels. Western blot of IKKε and serine biosynthesis enzyme protein levels following transfection of indicated 
breast cancer cell lines with IKBKE-targeting siRNA. Indicated breast cancer cell lines were transfected with a pool of 
4 IKBKE-targeting siRNA oligos, to suppress IKKε, or a single non-targeting control oligo to a final concentration of 50 
nM for 72 hours. Quantification of protein levels is shown in Figure 4.4. Vinculin is shown as a loading control. 
 
In agreement with the findings in Flp-In 293 cells, siRNA-mediated suppression of IKKε 
expression significantly reduced PSAT1 protein levels in 5 out of 9 breast cancer cell lines tested. 
Of the remaining cell lines, only MDA-MB-231 failed to show any significant change in PSAT1 
protein levels, as MDA-MB-453, MCF7 and SUM44 do not basally express the protein to any 
detectable level. Additionally, significant decreases in PHGDH and PSPH protein levels were 
detected in the ZR-75-1 and MDA-MB-468 cell lines. Together, this data validates evidence in 
Flp-In 293 cells of IKKε-mediated regulation of the protein levels of the serine biosynthesis 
enzymes. Furthermore, demonstration of a significant IKKε-mediated regulation of serine 
biosynthesis enzymes in human breast cancer cells supports the hypothesis that the kinase 
regulates serine biosynthesis enzymes in human breast tumours. Importantly, PSAT1 represents 
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a key focal point of regulation of the pathway by IKKε, being repeatedly regulated by the kinase 
across multiple cell lines, potentially reflecting the fact that it is phosphorylated in an IKKε-
dependent manner. 
 
 
 
 
Figure 4.4 – Quantification of reduction in serine biosynthesis enzyme protein levels in breast cancer cell lines upon 
transfection of IKBKE siRNA. Densitometry quantification analysis of (A) PHGDH, (B) PSAT1 and (C) PSPH protein 
levels upon transfection of indicated breast cancer cell lines with IKBKE-targeting siRNA and subsequent suppression 
of IKKε protein. PSAT1 protein levels were significantly reduced by IKKε siRNA transfection in all breast cancer cell 
lines where it is expressed, with the exception of MDA-MB-231. PHGDH and PSPH protein levels were significantly 
reduced by suppression of the kinase in ZR-75-1 and MDA-MB-468 cell lines. Serine enzyme densitometry per sample 
was quantified as a percentage of total protein densitometry and normalised to vinculin. n≥3 independent 
experiments, mean ± SEM, *p<0.05 as measured by paired t-test. 
A 
B 
C 
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4.2 IKKε regulates serine biosynthesis enzyme transcription 
 
Whilst the regulation of the PSAT1 protein by IKKε was expected, due to results from the 
previous chapter demonstrating that phosphorylation of the enzyme in an IKKε-dependent 
manner resulted in protein stabilisation, the findings that expression of the kinase regulated 
protein levels of PSPH in Flp-In 293 HA-IKKε cells and PHGDH and PSPH in ZR-75-1 and MDA-MB-
468 breast cancer cell lines were unexpected. As previously discussed, existing evidence 
suggested that IKKε-mediated phosphorylation of PHGDH and PSPH is unlikely, suggesting a 
mechanism of regulation for the enzymes other than substrate phosphorylation. Therefore, the 
effect of IKKε expression on the transcription of the serine biosynthesis enzymes was evaluated. 
Flp-In 293 HA-IKKε and Flp-In 293 HA-GFP cells were treated with doxycycline for 16 hours to 
induce HA-IKKε or HA-GFP respectively. mRNA levels of PHGDH, PSAT1 and PSPH were 
subsequently measured using qRT-PCR. Changes in serine biosynthesis enzyme transcript levels 
were evaluated as fold changes versus basal levels in untreated Flp-In 293 HA-GFP samples. As 
expected, treatment of Flp-In 293 HA-GFP cells with doxycycline had no effect on the mRNA 
levels of the serine biosynthesis enzymes. However, treatment of Flp-In 293 HA-IKKε cells with 
doxycycline significantly upregulated mRNA levels of all three serine biosynthesis enzymes, 
indicating that IKKε regulates PHGDH, PSAT1 and PSPH at a transcriptional level, in addition to 
the post-translational regulation of the PSAT1 protein via phosphorylation (Figure 4.5). 
 
 
Figure 4.5 – Induction of HA-IKKε in Flp-In 293 cells upregulates serine biosynthesis enzyme mRNA levels. qRT-PCR 
analysis measuring PHGDH, PSAT1 and PSPH mRNA levels upon treatment of Flp-In 293 cells with 50 ng/ml 
doxycycline for 16 hours. Doxycycline treatment of Flp-In 293 HA-IKKε, but not Flp-In 293 HA-GFP cells significantly 
upregulated PHGDH, PSAT1 and PSPH mRNA levels. mRNA levels are presented as relative fold change values from 
HA-GFP non-treated samples and normalised to ACTB (β-Actin) mRNA levels. n=4 independent experiments, mean ± 
SEM, *p<0.05 as measured by two-way ANOVA with Bonferroni post-hoc tests. 
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To determine whether the upregulation of serine biosynthesis enzyme transcript levels was a 
result of increased IKKε kinase activity in doxycycline-treated cells, the effect of induction of HA-
IKKε wt and HA-IKKε KD-m, a mutant variant of the kinase featuring a K38A point mutation in 
the protein kinase domain that ablates kinase activity (Figure 3.1), on PSAT1 mRNA was assessed 
and compared. Whilst induction of HA-IKKε wt led to a significant increase in PSAT1 mRNA levels 
as before, induction of HA-IKKε KD-m, failed to elicit the same upregulation (Figure 4.6). This 
demonstrated that upregulation of the serine biosynthesis enzymes upon doxycycline treatment 
of Flp-In 293 HA-IKKε cells was a consequence of elevated IKKε kinase activity in the cells, 
suggested that the transcriptional upregulation of the enzymes was a result of kinase activity-
dependent IKKε downstream signalling. 
 
 
Figure 4.6 – Transcriptional upregulation of PSAT1 mRNA requires IKKε kinase activity. qRT-PCR analysis of PSAT1 
mRNA levels in Flp-In 293 HA-GFP, HA-IKKε wt or HA-IKKε KD-m cell lines upon treatment with 50 ng/ml doxycycline 
for 16 hours. PSAT1 mRNA levels are expressed as a fold change versus basal mRNA levels in non-treated cells. 
Induction of HA-IKKε wt but not HA-IKKε KD-m significantly upregulated PSAT1 mRNA levels, demonstrating 
dependency on IKKε kinase activity for transcriptional regulation of serine biosynthesis enzymes. PSAT1 mRNA levels 
are normalised to ACTB (β-Actin) mRNA levels. n=3 independent experiments, mean ± SEM, *p<0.05 as measured by 
two-way ANOVA with Bonferroni post-hoc tests. 
 
Given the hypothesised involvement of fellow IKK family member and close IKKε relation TBK1 
in the phosphorylation of PSAT1, it was questioned whether the kinase might also be involved 
in IKKε-mediated transcriptional regulation of the serine biosynthesis enzymes. To address this 
question, TBK1-targeting siRNA was used to facilitate induction of HA-IKKε in Flp-In 293 cells in 
the absence of TBK1. Flp-In 293 HA-IKKε cells were transfected with a pool of siRNA oligos 
targeting TBK1 mRNA, to suppress TBK1, or a non-targeting control oligo for 72 hours. Cells were 
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simultaneously treated with doxycycline for the final 16 hours to induce HA-IKKε without the 
interference of TBK1. 
Induction of HA-IKKε in TBK1 silenced Flp-In 293 cells resulted in upregulation of PSAT1 and PSPH 
proteins to a level roughly equivalent to what was observed in cells where TBK1 had not been 
suppressed (Figure 4.7 A). Similarly, at the transcript level, there was no significant difference in 
IKKε-driven PSAT1 mRNA upregulation in cells transfected with TBK1 siRNA compared to cells 
transfected with control siRNA (Figure 4.7 B). Suppression of TBK1 also had no clear effect on 
basal PSAT1 mRNA levels or PHGDH, PSAT1 and PSPH protein levels, indicating that the IKK-
related kinase has no role in maintaining the expression of the enzymes of the SBP. Together, 
these data demonstrate that, whilst seemingly involved in the phosphorylation of PSAT1, TBK1 
is inessential for IKKε-mediated upregulation of serine biosynthesis enzyme transcription and 
protein levels in Flp-In 293 cells. This also indicates that upregulation of serine biosynthesis 
enzymes is not a function shared by both non-canonical IKK’s, but is instead a unique activity of 
IKKε. 
To determine whether IKKε was also regulating serine biosynthesis enzyme transcription in 
breast cancer cells, kinase expression was silenced in the panel of 9 breast cancer cell lines by 
using siRNA as before (see 4.1). Following siRNA transfection, PHGDH, PSAT1 and PSPH mRNA 
levels in IKBKE siRNA-transfected cells were compared to mRNA levels in control siRNA-
transfected cells to identify any IKKε-mediated effect on serine biosynthesis enzyme 
transcription (Figure 4.8).  
In line with what was observed at the protein level, siRNA-mediated IKKε silencing in breast 
cancer cell lines significantly reduced PSAT1 mRNA levels in the majority of cell lines tested. Of 
the cell lines where IKBKE siRNA reduced PSAT1 protein levels, only PSAT1 mRNA levels in Cal120 
failed to show a corresponding reduction in response to IKKε suppression. Whilst not significant, 
the PHGDH mRNA levels in ZR-75-1 and MDA-MB-468 cells also showed a trend of reduction 
upon IKKε silencing, which is in agreement with the significant reduction observed in PHGDH 
protein levels observed in these cell lines when the kinase was suppressed. Similarly, PSPH 
mRNA levels showed a trend of IKKε siRNA-mediated reduction in MDA-MB-468 cells. No clear 
trend was observed for PSPH mRNA in ZR-75-1 cells however, despite the significant reduction 
in protein levels observed upon kinase suppression in that cell line. This suggests that, in this cell 
line, PSPH might be regulated by an IKKε-dependent post-translational mechanism rather than 
regulation at a transcriptional level. Interestingly, whilst not significant (although this is more 
than likely due to the limited analytical power of the one-sample t-test required to measure 
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statistical differences in fold changes between two samples), a strong increase in PHGDH, PSAT1 
and PSPH mRNA levels was observed in MDA-MB-231 cell. Although this did not appear to 
translate to any clear increasing trend in serine enzyme protein levels, this does suggest that in 
MDA-MB-231 cells, IKKε suppresses the transcription of the enzymes of the serine biosynthesis 
pathway rather than promoting it. 
 
 
 
Figure 4.7 – IKKε-mediated regulation of serine biosynthesis enzymes is independent of TBK1. Flp-In 293 HA-IKKε 
cells were transfected with a pool of 4 siRNA oligos targeting TBK1 or a single non-targeting control oligo at a final 
concentration of 50 nM for 72 hours. In the final 16 hours, 50 ng/ml doxycycline was added to the cells to induce HA-
IKKε expression in the absence of TBK1. (A) Western blot demonstrating the effective knockdown of TBK1 protein 
levels and the effect HA-IKKε induction on PSAT1 and PSPH protein levels in the presence and absence of TBK1. HA-
IKKε still upregulated PSAT1 and PSPH in cells where TBK1 expression was suppressed. Vinculin is shown as a loading 
control. (B) qRT-PCR analysis of PSAT1 mRNA levels upon the induction of HA-IKKε in Flp-In 293 HA-IKKε cells 
transfected with either control or TBK1 siRNA. mRNA levels were expressed as fold changes versus non-treated, 
control siRNA-transfected cells and normalised to ACTB (β-Actin) mRNA levels. n=3 independent experiments, mean 
± SEM, *p<0.05 as measured by two-way ANOVA with Bonferroni post-hoc tests.  
A 
B 
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Figure 4.8 – Suppression of IKKε expression in select breast cancer cell lines significantly reduces serine biosynthesis 
enzyme mRNA levels. qRT-PCR analysis of PHGDH, PSAT1 and PSPH mRNA levels in indicated breast cancer cell lines 
following suppression of IKKε. Cells were transfected with a pool of 4 siRNA oligos targeting IKBKE, to suppress IKKε, 
or a single non-targeting control oligo to a final concentration of 50 nM for 72 hours, following which PHGDH, PSAT1 
and PSPH mRNA levels were measured by qRT-PCR. mRNA levels in IKBKE siRNA-transfected cells were presented as 
a fold change versus basal levels in control siRNA-transfected cells and normalised to ACTB (β-Actin) mRNA levels. 
PSAT1 mRNA levels were significantly reduced in ZR-75-1, T47D, MDA-MB-468, MCF7 and HCC1143 cell lines. PHGDH 
mRNA levels were significantly reduced in MCF7 cells. n≥3 independent experiments, mean ± SEM, *p<0.05 as 
measured by one-sample t-test comparing fold change values to a hypothetical mean of 1.0. 
 
In order to confirm that the observed reduction in serine biosynthesis enzyme protein and 
mRNA levels was a consequence of IKKε suppression and not a result of an off-target effect of a 
particular siRNA oligo, the pool of four oligos used to knock down the kinase was deconvoluted 
in ZR-75-1, T47D and MDA-MB-468 cells. siRNA oligos were transfected individually to identify 
any unusual effects that might occur with one oligo but not the other three. When used as an 
oligo pool, each individual oligo was used at a concentration of 12.5 nM, making the total 
concentration of the siRNA oligo pool 50 nM. When used individually, the concentration at which 
each siRNA oligo was transfected was increased to 50 nM to match the total concentration 
present in the siRNA oligo pool and keep transfection concentrations consistent. Cells were 
transfected with siRNA oligo pools or single oligos for 72 hours and subsequently, knockdown of 
IKKε was confirmed via western blotting. The consequences of IKKε silencing on PSAT1 protein 
and mRNA level were also assessed using western blotting and qRT-PCR respectively. 
Transfecting each oligo individually suppressed IKKε protein levels generally equally across the 
three cell lines used for the pool deconvolution. Suppression of IKKε through individual 
transfection of three out of the four oligos used in the pool had similar effects on PSAT1 protein 
levels, reducing expression of the enzyme. Only one oligo (oligo #6) consistently failed to induce 
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a downregulation of PSAT1 protein levels as a result of transfection (Figure 4.9 A). When 
evaluating the effect of individual oligos on PSAT1 mRNA levels, similar results were observed. 
In ZR-75-1 cells, two of the four oligos used reduced PSAT1 mRNA levels.  In T47D cells, three of 
the oligos reduced mRNA levels and, in MDA-MB-468 cells, all four oligos reduced PSAT1 mRNA 
levels (Figure 4.9 B-D). This indicated that the observed transcriptional downregulation of the 
serine biosynthesis enzymes in breast cancer cells transfected with IKBKE-targeting siRNA was 
dependent specifically on IKKε silencing and was not an off-target effect of one particular siRNA 
oligo used. 
Together, these data demonstrate that induction of HA-IKKε induces expression of serine 
biosynthesis enzymes at a transcriptional level in Flp-In 293 cells and that this mRNA induction 
corresponds to a protein level induction for PSAT1 and PSPH. This also suggests that PHGDH is 
regulated post-translationally in Flp-In 293 cells in a manner different to PSAT1 and PSPH. These 
data also provide evidence that expression of IKKε maintains the expression of serine 
biosynthesis enzymes in a panel of breast cancer cell lines. Taken together, these data reveal 
that IKKε is a central regulator of the enzymes of the serine biosynthesis pathway in Flp-In 293 
and human breast cancer cells. 
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Figure 4.9 – IKBKE siRNA oligo pool deconvolution. ZR-75-1, T47D and MDA-MB-468 breast cancer cell lines were 
transfected for 72 hours with either a pool of 4 IKBKE-targeting siRNA oligos or a single IKBKE-targeting siRNA oligo, 
to suppress IKKε expression, or a single non-targeting control oligo to a final concentration of 50 nM for 72 hours. (A) 
Western blot demonstrating the knockdown of IKKε and PSAT1 protein suppression by the siRNA oligo pool or single 
oligos. Vinculin is shown as a loading control. (B-D) qRT-PCR analysis of PHGDH, PSAT1 and PSPH mRNA levels in (B) 
ZR-75-1, (C) T47D and (D) MDA-MB-468 breast cancer cell lines following suppression of IKKε with either single IKBKE-
targeting siRNA oligos or a combined pool of 4 oligos. mRNA levels in IKBKE siRNA-transfected cells were presented 
as a fold change versus basal levels in control siRNA-transfected cells and normalised to ACTB (β-Actin) mRNA levels. 
PSAT1 mRNA levels were consistently reduced by IKBKE siRNA oligos 7 and 9, and by oligo 8 in 2 out of 3 cell lines 
tested. n=2 independent experiments. 
 
A 
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4.3 Expression of IKKε adaptor proteins in Flp-In 293 and breast cancer cells 
 
Whilst PHGDH, PSAT1 and PSPH mRNA and PSAT1 and PSPH proteins were upregulated by 
induction of HA-IKKε in doxycycline-treated Flp-In 293 cells, this pattern of regulation was not 
consistent across the panel of breast cancer cell lines. Some cell lines, like T47D, exhibited just 
significant downregulation of PSAT1 mRNA and PSAT1 protein upon transfection of IKKε siRNA, 
whereas some cell lines, such as MDA-MB-468, showed significant reductions in all three 
enzyme protein levels and PSAT1 mRNA, with a trend of reduction in PHGDH and PSPH mRNA, 
suggesting regulation of all three enzymes together. The reason for this discrepancy between 
cell lines was unclear, however it is known that IKKε requires specific adaptor proteins to carry 
out its signalling activities and different conformations of these adaptor proteins can affect the 
kind of signalling that the kinase induces85. It was therefore questioned whether different 
adaptor protein expression between cell lines might explain the differential regulation of the 
serine biosynthesis enzymes that was observed. 
To address this question, the expression of 4 main non-canonical IKK adaptor proteins; 
optineurin, SINTBAD, NAP1 and TANK, was assessed via western blotting in non-treated and 
doxycycline-treated Flp-In 293 HA-GFP and Flp-In 293 HA-IKKε cells and the control siRNA-
transfected breast cancer cell line samples from Figure 4.3, as control siRNA transfection was 
represented the “basal” state in both that experiment and in the labelled metabolite analysis 
experiment described in chapter 3 (see 3.2). This allowed evaluation of the expression profile of 
IKKε adaptors in conditions where serine biosynthesis was known to be elevated and serine 
biosynthesis enzyme levels were known to be increased. 
All four adaptor proteins were expressed in Flp-In 293 cells but, more intriguingly, treatment of 
Flp-In 293 HA-IKKε cells with doxycycline and subsequent induction of HA-IKKε resulted in a 
marginal upward shift in the detected protein bands for SINTBAD, NAP1 and TANK (Figure 4.10). 
Whilst it would require further experimental validation, such a shift is typically indicative of 
protein phosphorylation, suggesting that these three adaptors are phosphorylated when IKKε is 
induced. Whether this implies that the specific adaptor complex that forms in Flp-In 293 cells 
upon induction of HA-IKKε is one that involves SINTBAD, NAP1 and TANK but not optineurin, 
remains to be seen, but it is certainly possible that interaction with these three adaptor proteins 
is required for the induction of serine biosynthesis enzyme mRNA and PSAT1 and PSPH protein 
in Flp-In 293 cells. 
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Figure 4.10 – Expression of IKKε adaptor proteins in Flp-In 293 cells. Western blot demonstrating the expression of 
known IKKε adaptor proteins optineurin, SINTBAD, NAP1 and TANK in Flp-In 293 HA-GFP and Flp-In 293 HA-IKKε cells. 
Cells were treated with 50 ng/ml doxycycline for 16 hours as indicated. Minor shift in molecular weight of SINTBAD, 
NAP1 and TANK protein bands in doxycycline-treated Flp-In 293 HA-IKKε cells is potentially indicative of increased 
phosphorylation. Vinculin is shown as a loading control. 
 
Unfortunately, examining the expression profiles of adaptor proteins in breast cancer cell lines 
by western blotting failed to provide any explanation for the variable nature of serine 
biosynthesis enzyme regulation in the cell lines. Between cell lines where IKKε either regulates 
no serine enzyme proteins (MDA-MB-231), just PSAT1 (such as T47D), or multiple serine 
biosynthesis enzymes (such as MDA-MB-468) no clearly observable pattern of adaptor 
expression was detected (Figure 4.11). This therefore made it difficult to draw conclusions about 
the involvement of specific adaptor proteins in the regulation of serine biosynthesis enzymes by 
IKKε in the context of breast cancer cell lines. Furthermore, no minor size shifts were observed 
in any of the proteins in this experiment, making it difficult to even hypothesise which adaptors 
are more likely to be involved than others. 
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Figure 4.11 – Expression of IKKε adaptor proteins in the panel of human breast cancer cell lines. Western blot 
demonstrating the expression pattern of the four IKKε adaptor proteins across the panel of human breast cancer cell 
lines. Samples for each indicated cell line were the same samples which were transfected with a single non-targeting 
control oligo at a final concentration of 50 nM for 72 hours from Figure 4.3, to represent the expression of adaptor 
proteins in “basal” conditions from this experiment. Each cell line appears to express the four adaptors in a unique 
pattern. Notably, Cal120 and HCC1143 express little to no detectable levels of SINTBAD, NAP1 or TANK. Vinculin is 
shown as a loading control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4. Results II: IKKε transcriptionally regulates serine biosynthesis enzymes 
165 
 
4.4 Activation of canonical IKKε signalling pathways in IKKε-expressing cells 
 
Since induction of IKKε in Flp-In 293 HA-IKKε cells was seen to transcriptionally upregulate the 
enzymes of the serine biosynthesis pathway and, correspondingly, kinase silencing in breast 
cancer cell lines suppressed mRNA levels of serine biosynthesis enzymes, the mechanism by 
which the kinase induced the transcriptional regulation necessary to upregulate the enzymes 
was investigated. The established downstream signalling pathways of IKKε (discussed in 1.2.3.2) 
involve the activation of 2 major intracellular transcriptional programmes, induced by the IKKε-
mediated activation of NF-κB and IFNβ signalling. Therefore, it was hypothesised that activation 
of one of these transcriptional programmes might be responsible for the upregulation of 
PHGDH, PSAT1 and PSPH mRNA levels upon IKKε induction. Before testing this hypothesis, the 
activation of canonical IKKε downstream signalling pathways in doxycycline-treated Flp-In 293 
HA-IKKε cells was confirmed by western blotting for key markers of NF-κB and IFNβ pathway 
activation. 
Whilst IKKε is not capable of inducing IκBα-degradation and canonical activation of NF-κB alone, 
due its inability to phosphorylate both serine residues necessary for proteasomal degradation79, 
the kinase is capable of directly phosphorylating select NF-κB subunits to regulate transcriptional 
activity independently of IκBα degradation. For instance, IKKε can directly phosphorylate p65 at 
serine residues Ser468 and Ser536 to promote p65 transactivation activity83,194 independently 
of canonical NF-κB activation. Therefore, IKKε induction of NF-κB signalling was evaluated by 
immunoblotting for p65 and phosphorylation of p65 at residue Ser468. To assess IKKε-mediated 
induction of IFNβ signalling, phosphorylation of IRF3 at serine residue Ser396, a site directly 
phosphorylated by IKKε to induce dimerisation, nuclear translocation and transcriptional 
activity90, was evaluated by western blotting. The subsequent activation of downstream 
JAK/STAT signalling, necessary for induction of the IFNβ-dependent transcriptional response, 
was also assessed by immunoblotting for the phosphorylation of STAT1 at tyrosine residue 
Tyr701, a site whose phosphorylation is indicative of STAT1 activation360. 
Flp-In 293 HA-GFP or Flp-In 293 HA-IKKε cells were treated with doxycycline for 16 hours to 
induce HA-GFP and HA-IKKε expression respectively. Following treatment, the selected markers 
of NF-κB and IFNβ pathway activation were subsequently detected via western blotting (Figure 
4.12). Treatment of the Flp-In 293 HA-IKKε cells, but not Flp-In 293 HA-GFP cells, with 
doxycycline resulted in increased phosphorylation of p65 at serine residue Ser468, indicative of 
increased p65 transcriptional activity in cells expressing HA-IKKε. Similarly, phosphorylation of 
IRF3 Ser396 and STAT1 Tyr701 phosphorylation was increased in doxycycline-treated Flp-In 293 
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HA-IKKε cells but not Flp-In 293 HA-GFP cells, indicating an HA-IKKε-dependent increase in IRF3 
activation and JAK/STAT signalling pathway activity respectively. Together, this data 
demonstrates the activation of canonical IKKε signalling pathways upon its induction in Flp-In 
293 cells. 
 
 
Figure 4.12 – Induction of NF-κB and IFNβ signalling in Flp-In 293 HA-IKKε cells. Western blot analysis of NF-κB and 
IFNβ pathway activation in Flp-In 293 HA-GFP and Flp-in 293 HA-IKKε cells treated with 50 ng/ml doxycycline for 16 
hours. Phosphorylation of p65 at serine residue Ser468 (S468) was used as a readout for NF-κB pathway activation, 
and phosphorylation of IRF3 at Ser396 (S396) and STAT1 at tyrosine residue Tyr701 (Y701) as a readout for IFNβ 
signalling activation. Induction of HA-IKKε but not HA-GFP induced phosphorylation of p65, IRF3 and STAT1 indicating 
activation of NF-κB and IFNβ signalling. Vinculin is shown as a loading control. 
 
Activation of canonical IKKε signalling pathways was also assessed in the panel of 9 human 
breast cancer cell lines, by using western blotting to evaluate the basal phosphorylation status 
of p65 Ser468, IRF3 Ser396 and STAT1 Tyr701.  Control siRNA-transfected samples from Figure 
4.3 were used again here, as the activation of IKKε-mediated signalling pathways in conditions 
where the expression of serine biosynthesis enzymes were elevated compared to IKKε siRNA-
transfected cells was to be investigated. Phosphorylation status of p65, IRF3 and STAT1 in the 
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breast cancer cell lines was compared to the induced level of phosphorylation of the proteins 
that was observed in Flp-In 293 HA-IKKε cells upon doxycycline treatment, as a positive control 
for immunoblot detection of protein phosphorylation (Figure 4.13). Phosphorylation of p65 at 
serine residue Ser468 was detected to varying degrees in all breast cancer cell lines with the 
exception of SUM44 indicating variable activation of NF-κB signalling. In contrast, no clear 
phosphorylation of IRF3 was detected in any of the breast cancer cell lines. Some cell lines tested 
demonstrated phosphorylation of STAT1 at Tyr 701, but considering the lack of detectable IRF3 
phosphorylation upstream, it seems likely that this phosphorylation is attributable to factors 
other than the activation of JAK/STAT signalling by IKKε rather than it being representative of 
active IFNβ signalling. This data suggests that although initial induction of the kinase in Flp-In 
293 cells results in strong activation of both branches of IKKε signalling, in breast cancer, where 
IKKε expression is established and constitutive, the kinase primarily signals via NF-κB only in 
terms of recognised downstream signalling. This is in agreement with data presented by Boehm 
et al. upon initial identification of IKKε as a transforming kinase, where activation of IRF3 and 
IFNβ signalling was shown to be dispensable for IKKε’s oncogenic activity195. 
 
 
Figure 4.13 – Basal activation of NF-κB and IFNβ signalling in human breast cancer cell lines. Western blot 
demonstrating the basal phosphorylation of p65 Ser468 (S468), IRF3 Ser396 (S396) and STAT1 Tyr701 (Y701) as a 
readout for activation of NF-κB and IFNβ signalling. Samples for each indicated cell line were the same samples which 
were transfected with a single non-targeting control oligo at a final concentration of 50 nM for 72 hours from Figure 
4.3, to represent the “basal” activation of signalling pathways in this experiment. Vinculin is shown as a loading 
control. 
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4.5 Evaluating the effect of IKKε on serine enzyme expression in a model of 
IKKε-driven transformation 
 
As initial induction of the kinase in Flp-In 293 cells was found to significantly upregulate the 
serine biosynthesis enzymes and IKKε-mediated regulation of the enzymes was observed in 
breast cancer cell lines, it was questioned whether the regulation of serine biosynthesis might 
occur in the early stages of IKKε-mediated cellular transformation and whether regulation of the 
serine enzymes might contribute to the early stages of IKKε-driven tumour formation. To test 
this, a model where IKKε expression induced transformation was required. IKKε was originally 
identified as a transforming kinase in 2007 but, importantly, was only shown to induce cellular 
transformation in the presence of a constitutively active form of MEK (MEKDD)195. The Flp-In 293 
HA-IKKε cell model used to explore the effect of the kinase on metabolism does not feature 
constitutively active MEK and, accordingly, proliferation of doxycycline-treated Flp-In 293 HA-
IKKε cells slows over the first 12 hours of induction compared to the doxycycline-treated Flp-In 
293 HA-GFP cells (Figure 4.14), as expression of the kinase alone is insufficient for 
transformation. This effect was likely attributable to the activation of IFNβ signalling, which 
culminates in the activation of cytotoxic signals as part of the innate immune response, but 
regardless prevented the evaluation of the effect of IKKε expression on PHGDH, PSAT1 and PSPH 
in transformation using the Flp-In 293 HA-IKKε model.  
 
        
Figure 4.14 – Induction of HA-IKKε in Flp-In 293 cells induces proliferation arrest. Comparison of growth of non-
treated Flp-In 293 HA-IKKε cells and cells treated with 50 ng/ml doxycycline over 12 hours was assessed by measuring 
cell confluency at 0, 6 and 12 hours following the addition of doxycycline using the IncuCyte Zoom. Despite equal 
confluency at 0 hours, confluency of doxycycline-treated Flp-In HA-IKKε cells after 12 hours of treatment is reduced 
compared to the confluency of non-treated Flp-In 293 HA-IKKε cells, indicating a decreasing proliferative rate. n=9 
independent experiments. 
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In the same study which identified IKKε as a transforming kinase, a cell line model termed “HA1E-
M” was developed, in which HEK293 cells expressed hTERT, SV40 LT and ST, and featured 
constitutively active MEKDD. The addition of IKKε expression to these cells was therefore enough 
to render the cells oncogenic and a cell line expressing IKKε was developed as a transformed line 
(HA1E-M F-IKKε) for comparison to the IKKε-lacking HA1E-M cell line. These HA1E-M and HA1E-
M F-IKKε cell lines represent a model in which expression of the kinase is sufficient to tip the 
scales in favour of oncogenic cellular transformation. Since induction of IKKε in Flp-In 293 cells, 
which are themselves a modified version of the HEK293 cell line, resulted in induction of serine 
biosynthesis enzymes transcriptionally without transformation, and suppression of the kinase in 
select transformed breast cancer cells reduced transcription of PSAT1, it was questioned 
whether expression of IKKε would also induce serine biosynthesis enzyme regulation in HA1E-M 
F-IKKε cells when it was transforming. To answer this question, basal expression of PHGDH, 
PSAT1 and PSPH protein was assessed and compared between HA1E-M and HA1E-M F-IKKε cells 
using western blotting. Additionally, basal PSAT1 mRNA levels were compared between the two 
cell lines using qRT-PCR. IKKε expression in HA1E-M F-IKKε cells was also suppressed by 
transfecting cells with a pool of IKBKE-targeting siRNA oligos for 72 hours, after which serine 
biosynthesis enzyme protein expression was evaluated using western blotting to determine the 
effect of modulating established kinase expression in this alternate HEK293 cell model. 
Surprisingly, no difference in PHGDH, PSAT1 or PSPH protein expression was observed between 
the HA1E-M and HA1E-M F-IKKε cell lines. In agreement with this, no significant difference in 
PSAT1 mRNA levels was detected between the two cell lines either, despite clear expression of 
the kinase in the HA1E-M F-IKKε cells. Similarly, siRNA-mediated silencing of IKKε in HA1E-M F-
IKKε cells showed no significant reduction in the protein of any of the serine biosynthesis 
enzymes (Figure 4.15). This data therefore demonstrated that IKKε was not regulating serine 
biosynthesis enzyme expression in the HA1E-M F-IKKε cell model.  
To understand why regulation of serine biosynthesis enzymes might not have been observed in 
these cells, the activation of IKKε-mediated downstream signalling was evaluated. As before, 
activation of canonical IKKε downstream signalling pathways was confirmed by investigating key 
markers of pathway activation, including phosphorylation of p65 at serine residue Ser468 as an 
indicator of NF-κB activity, and phosphorylation of IRF3 and STAT1 at serine residue Ser396 and 
tyrosine residue Tyr701 respectively as markers for IFNβ signalling (see 4.4). These markers for 
the activation of IKKε’s downstream signalling were assessed in the HA1E-M and HA1E-M F-IKKε 
cell lines in basal conditions using western blotting and compared to levels of pathway activation 
resulting from induction of HA-IKKε in Flp-In 293 cells following doxycycline treatment. 
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Figure 4.15 – Serine biosynthesis enzymes are not regulated by IKKε in HA1E-M and HA1E-M F-IKKε cells. (A) HA1E-
M and HA1E-M F-IKKε cells were cultured and lysed for western blot analysis of basal protein levels of IKKε, PHGDH, 
PSAT1 and PSPH. No difference between PHGDH, PSAT1 and PSPH protein levels were observed between the 2 cell 
lines. (B) qRT-PCR analysis of PSAT1 mRNA levels in HA1E-M F-IKKε cells relative to levels in HA1E-M cells. PSAT1 
mRNA levels were normalised to ACTB (β-Actin) mRNA levels. n=3 independent experiments, mean ± SEM. No 
significant differences were detected using a one sample t-test, comparing values to a hypothetical mean of 1.0. (C) 
Western blot analysis of HA1E-M F-IKKε cells transfected with a pool of 4 IKBKE-targeting siRNA oligos, to suppress 
IKKε, or a single non-targeting control oligo to a final concentration of 50 nM for 72 hours allowed assessment of the 
effect of kinase suppression on serine biosynthesis enzymes. No difference between PHGDH, PSAT1 and PSPH protein 
levels was detected between cells in which IKKε was silenced and cells transfected with control, non-targeting siRNA. 
A B 
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Unexpectedly, no signs of signalling activity downstream of the kinase were detected in these 
HA1E-M F-IKKε cells (Figure 4.16). No phosphorylation of either p65 residue Ser468 or IRF3 
residue Ser396 was detected. Furthermore, whilst some phosphorylation of STAT1 Tyr701 was 
observed, no clear difference between phosphorylation was seen in the IKKε-expressing HA1E-
M F-IKKε cells versus the HA1E-M cells, suggesting that the STAT1 phosphorylation detected in 
these cell line models was IKKε-independent. IKKε itself was found to exhibit no detectable 
phosphorylation of serine residue Ser172 when expressed in HA1E-M F-IKKε cells either. As 
previously mentioned, phosphorylation of IKKε residue Ser172 is highly indicative of kinase 
activity and is auto-phosphorylated by the kinase itself when active. Together, this data 
therefore indicates that the kinase expressed in these HA1E-M F-IKKε cells is not inducing 
activation of any established signalling pathway downstream of IKKε, due to inactivity of the 
kinase itself. This explains the lack of regulation of the serine biosynthesis enzymes in this 
cellular model, as this requires active kinase activity as has previously been demonstrated in this 
chapter (Figure 4.6). 
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Figure 4.16 – IKKε signalling appears to be inactive in these HA1E-M F-IKKε cells. Western blot analysis of NF-κB and 
IFNβ signalling pathway activation in HA1E-M and HA1E-M F-IKKε cells compared to Flp-In 293 HA-IKKε cells treated 
with 50 ng/ml doxycycline for 16 hours. Phosphorylation of p65 Ser468 was used as a readout for NF-κB activation 
and phosphorylation of IRF3 Ser396 and STAT1 Tyr701 was used as a readout for IFNβ signalling. Despite expression 
of IKKε in HA1E-M F-IKKε cells, no indication of canonical IKKε signalling was detected, indicating inactive kinase 
signalling. Vinculin is shown as a loading control. 
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4.6 IKKε-mediated serine biosynthesis enzyme regulation is independent of 
autocrine/paracrine IFNβ signalling 
 
Since the primary function of the kinase involves the induction of IFNβ signalling and the 
activation of an IFNβ-mediated transcriptional programme, attempts to understand the IKKε-
mediated transcriptional regulation of PHGDH, PSAT1 and PSPH first focussed on investigating 
the role of IFNβ signalling. Despite the fact that the no clear evidence of IFNβ-mediated signalling 
was observed in the panel of breast cancer cell lines, the pathway was strongly activated in the 
Flp-In 293 HA-IKKε cells upon induction of the kinase. Considering the effect on the serine 
biosynthesis enzymes was so broad in the Flp-In 293 cells, it was questioned whether the 
observed transcriptional upregulation of the enzymes could be attributable to the activation of 
an IFNβ-mediated transcriptional programme. Interferon signalling involves the secretion of 
IFNβ from activated cells, where upon it activates the interferon receptor (IFNAR) on the cell 
surface in an autocrine or paracrine manner. Therefore, to address the involvement of IFNβ 
signalling in IKKε’s regulation of the serine biosynthesis enzymes, this IFNβ signalling loop was 
targeted using multiple techniques. 
Firstly, the activation of the IFNAR in response to IFNβ was inhibited using a competitive binding 
antibody specific to the receptor. This blocked the binding of IFNβ to the receptor, thereby 
inhibiting the activation of the JAK/STAT signalling cascade and preventing the activation of the 
IFNβ-mediated transcriptional programme. Flp-In 293 HA-IKKε or Flp-In 293 HA-GFP cells were 
pre-treated with the IFNAR blocking antibody for 2 hours prior to 16 hours of doxycycline 
treatment to induce HA-IKKε or HA-GFP respectively. Following doxycycline treatment, the 
induction of PSAT1 and PSPH protein levels was assessed using western blotting and PHGDH, 
PSAT1 and PSPH mRNA by qRT-PCR. mRNA levels in IFNAR pre-treated cells were compared to 
the level of induction in Flp-In 293 HA-IKKε cells upon doxycycline treatment without IFNAR 
treatment as was shown in Figure 4.5, as the IFNAR pre-treated samples were run in parallel 
with those samples as part of the same experiment. 
Inhibition of IFNAR activation by pre-treatment with the IFNAR blocking antibody reduced the 
phosphorylation of STAT1 Tyr701 in the presence of IKKε expression, indicating a reduction of 
JAK/STAT signalling activation, which is in accordance with functional inhibition of the IFNAR. 
Induction of HA-IKKε in the presence of the IFNAR blocking antibody exhibited the same level of 
PSAT1 and PSPH protein induction as induction of the kinase without the blocking antibody. 
Similarly, no significant difference in the induction of PHGDH, PSAT1 and PSPH mRNA levels was 
detected between the doxycycline-treated and IFNAR-pre-treated Flp-In 293 HA-IKKε cells and 
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those cells not treated with the blocking antibody (Figure 4.17). This data demonstrated that 
although the IFNAR blocking antibody successfully inhibited the activation of the JAK/STAT 
signalling cascade in response to IKKε expression, the blocking of IFNAR activation had no 
inhibitory effect on the induction of serine biosynthesis enzymes. This therefore indicated that 
the transcriptional regulation of PHGDH, PSAT1 and PSPH by IKKε is independent of the IFNβ 
stimulated transcriptional programme. 
 
   
Figure 4.17 – IKKε-mediated upregulation of serine biosynthesis enzymes is independent of IFNAR activation. Flp-
In 293 HA-GFP and HA-IKKε cells were treated with 3.75 µg/ml IFNAR blocking antibody for 2 hours, after which 50 
ng/ml doxycycline was added for 16 hours to induce HA-GFP or HA-IKKε whilst blocking IFNAR activation. (A) Western 
blotting analysis of PSAT1 and PSPH protein upregulation upon blocking of IFNAR activation. Decreased 
phosphorylation of STAT1 Tyr 701 (Y701) in response to IKKε induction in IFNAR treated cells indicates successfully 
reduced IFNAR activation. PSAT1 and PSPH proteins were upregulated by IKKε even when IFNAR activation was 
blocked. (B) qRT-PCR analysis of PHGDH, PSAT1 and PSPH mRNA levels upon treatment of Flp-In 293 HA-IKKε cells 
with 50 ng/ml doxycycline for 16 hours with or without IFNAR blocking antibody pre-treatment. mRNA levels are 
normalised relative to non-treated basal levels in Flp-In 293 HA-GFP cells and compared to mRNA levels in 
doxycycline-treated Flp-In 293 HA-IKKε cells from Figure 4.5, of which the α-IFNAR pre-treated samples were run as 
part of the same experiment. mRNA levels were normalised to ACTB (β-Actin) mRNA levels. No significant difference 
was detected between PHGDH, PSAT1 or PSPH mRNA levels in doxycycline-treated Flp-In 293 HA-IKKε cells and 
doxycycline-treated Flp-In 293 HA-IKKε cells pre-treated with the IFNAR blocking antibody, as measured by two-way 
ANOVA with Bonferroni post-hoc tests. n=4 independent experiments, mean ± SEM. 
 
Whilst JAK/STAT mediated IFNβ transcriptional regulation was therefore concluded to be 
uninvolved in the regulation of serine biosynthesis enzymes by IKKε, it was questioned whether 
the kinase might induce another endocrine signalling loop to regulate serine enzyme 
A B 
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transcription. The involvement of cytokine secretion in this process was therefore addressed 
using a conditioned medium experiment. Flp-In 293 HA-GFP and Flp-In 293 HA-IKKε cells were 
treated with doxycycline for 16 hours to induce HA-GFP and HA-IKKε expression respectively and 
allow secretion of cytokines released from the Flp-In 293 cells into the culture medium. The 
medium from these cells was subsequently collected, filtered to remove any cell contaminants 
and applied to receiving Flp-In 293 HA-GFP cells for 24 hours. As the medium from HA-IKKε cells 
contained IKKε-dependent cytokines, applying the medium to Flp-In 293 cells would therefore 
replicate the downstream cytokine-mediated signalling induced by the kinase in the Flp-In 293 
HA-GFP cells without requiring the expression of IKKε. This then allowed evaluation of the role 
of an endocrine signalling loop in the regulation of serine biosynthesis enzymes by IKKε. 
Since other signalling pathways are less well defined, activation of IKKε-driven cytokine signalling 
was confirmed by evaluating the phosphorylation of STAT1 at tyrosine residue Tyr701 using 
western blotting as a readout for IFNβ signalling activation (Figure 4.18). In accordance with the 
secretion of IFNβ by IKKε-expressing cells, application of medium conditioned by doxycycline-
treated Flp-In 293 HA-IKKε cells induced phosphorylation of STAT1 at tyrosine residue Tyr701. 
This indicated IFNβ-dependent activation of the IFNAR and the JAK/STAT signalling cascade and 
confirmed the presence of IKKε-dependent cytokines capable of endocrine signalling in the 
conditioned medium. However, even though IKKε-dependent cytokine signalling was induced in 
Flp-In HA-GFP cells upon application of the conditioned medium, the conditioned medium had 
no effect on the protein levels of either PSAT1 or PSPH. This therefore suggested that regulation 
of serine biosynthesis enzymes in Flp-In 293 HA-IKKε cells was independent of a cytokine 
endocrine signalling loop.  
IKKε has also been shown to function downstream of cytokine signalling pathways as well as 
upstream. For instance, in the activation of the JAK/STAT signalling cascade, IKKε regulates the 
initial activation of the pathway through phosphorylation of IRF3, but also regulates the pathway 
downstream of IFNAR activation through the direct phosphorylation of STAT1 at serine residue 
Ser708, which promotes ISGF3 formation and can enhance the induction of interferon 
stimulated genes (ISGs), as well as control the induction of an IKKε-dependent subtype of 
ISGs99,102. It was therefore noted that Flp-In 293 HA-GFP cells do not basally express IKKε, 
meaning that cytokine signalling pathways in which IKKε plays upstream and downstream rolls 
might not be properly activated. It was questioned whether regulation of serine biosynthesis 
enzymes might be regulated by such a cytokine signalling pathway. To address this question, 
medium conditioned by doxycycline-treated Flp-In 293 HA-IKKε cells was applied to breast 
cancer cell lines ZR-75-1 and T47D which express IKKε basally. 
Chapter 4. Results II: IKKε transcriptionally regulates serine biosynthesis enzymes 
176 
 
 
Figure 4.18 – IKKε-mediated upregulation of serine biosynthesis enzymes in Flp-In 293 cells is independent of 
endocrine signalling. Flp-In 293 HA-GFP or HA-IKKε cells were treated with 50 ng/ml doxycycline for 16 hours. The 
culture medium from those cells was subsequently collected, filtered and applied to receiving Flp-In 293 HA-GFP cells 
for 24 hours, to activate cytokine signalling in HA-GFP cells mediated by cytokines secreted from HA-GFP- or HA-IKKε-
expressing cells. Phosphorylation of STAT1 Tyr701 and p65 Ser468 indicates IFNβ and NF-κB activation respectively. 
Activation of IFNβ signalling in particular is indicative of active cytokine signalling in receiving cells. Receiving cells 
were also treated with 50 ng/ml doxycycline for 24 hours to control for the presence of doxycycline in the conditioned 
medium. No upregulation of serine biosynthesis enzymes was detected in cells cultured with Flp-In 293 HA-IKKε 
conditioned medium. Vinculin is shown as a loading control. 
 
As with Flp-In 293 HA-GFP cells, application conditioned medium to both ZR-75-1 and T47D cells 
induced phosphorylation of STAT1, indicating activation of cytokine induced signalling in the 
form of JAK/STAT signalling. However, even with the presence of basal IKKε expression in the 
breast cancer cells lines, and therefore the potential for the contribution of the kinase to 
downstream signalling, application of conditioned medium failed to upregulate PSAT1 or PSPH 
proteins in either ZR-75-1 or T47D cell lines (Figure 4.19 and Figure 4.20). Together, this data 
demonstrated that the regulation of serine biosynthesis enzymes by IKKε was wholly 
independent of an endocrine signalling loop and the secretion of cytokines. 
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Figure 4.19 – IKKε-mediated upregulation of serine biosynthesis enzymes in ZR-75-1 cells is independent of 
endocrine signalling. Flp-In 293 HA-GFP and Flp-In 293 HA-IKKε conditioned medium was prepared as in Figure 4.18 
and applied to receiving ZR-75-1 breast cancer cells for 24 hours. As before, induction of STAT1 Tyr701 
phosphorylation indicated active cytokine signalling in receiving cells. Despite activation of cytokine signalling, no 
upregulation of serine biosynthesis enzymes was detected in ZR-75-1 breast cancer cells cultured with Flp-In 293 HA-
IKKε conditioned medium. ZR-75-1 cells were also treated with 50 ng/ml doxycycline for 24 hours, controlling for the 
presence of doxycycline in the conditioned medium. Vinculin is shown as a loading control. 
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Figure 4.20 – IKKε-mediated upregulation of serine biosynthesis enzymes in T47D cells is independent of endocrine 
signalling. Medium conditioned by doxycycline-treated Flp-In 293 HA-GFP and Flp-In 293 HA-IKKε was prepared as in 
Figure 4.18 and applied to T47D breast cancer cells for 24 hours to induce cytokine signalling. STAT1 Tyr701 
phosphorylation confirmed active cytokine signalling in T47D cells. No upregulation of serine biosynthesis enzymes 
was detected in T47D breast cancer cells cultured with Flp-In 293 HA-IKKε conditioned medium. In addition to 
treatment with Flp-In 293 cell conditioned medium, T47D cells were also treated with 50 ng/ml doxycycline for 24 
hours to control for doxycycline in the conditioned medium. Vinculin is shown as a loading control. 
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4.7 Induction of serine biosynthesis enzymes by IKKε is independent of p65 
and IRF3 signalling 
 
Although the regulation of serine biosynthesis enzymes was found to be independent of a 
cytokine controlled endocrine signalling network, it was still uncertain whether IKKε-mediated 
phosphorylation of its canonical targets; IRF3 and NF-κB subunits like p65, was important for the 
regulation of serine biosynthesis enzymes transcriptionally. Therefore, this was directly 
addressed through the siRNA-mediated suppression of IRF3 and p65. 
Flp-In 293 HA-GFP and Flp-In 293 HA-IKKε cells were transfected with single siRNA oligos 
targeting either RELA or IRF3 mRNA, to suppress p65 an IRF3 protein expression respectively, or 
a non-targeting control oligo for 72 hours. For the final 16 hours, doxycycline was added to the 
siRNA-transfected cells to induce HA-GFP or HA-IKKε in the absence of p65 or IRF3 protein 
expression. Subsequently, knockdown of p65 and IRF3 protein levels was validated via western 
blotting and induction of PHGDH, PSAT1 and PSPH mRNA levels was evaluated using qRT-PCR 
(Figure 4.21). 
Western blotting showed that transfection of RELA and IRF3-targeting siRNA resulted in 
effective knockdown of p65 and IRF3 proteins respectively and demonstrated induction of HA-
IKKε protein upon doxycycline treatment in the absence of p65 and IRF3 (Figure 4.21 A). This 
allowed evaluation of the role of canonical IKKε signalling pathways in the upregulation of 
PHGDH, PSAT1 and PSPH mRNA levels (Figure 4.21 B, C and D). Consistent with previous findings, 
qRT-PCR analysis of serine biosynthesis enzyme mRNA levels demonstrated that doxycycline 
treatment of control siRNA-transfected Flp-In 293 HA-IKKε cells resulted in an upregulation of 
PHGDH, PSAT1 and PSPH mRNA levels. Notably, suppression of p65 and IRF3 protein levels 
appeared to slightly downregulate basal mRNA levels of the enzymes, suggesting that NF-κB and 
IFNβ signalling may play a minor role in maintaining the basal expression of PHGDH, PSAT1 and 
PSPH mRNA.  
Importantly however, doxycycline treatment of Flp-In 293 HA-IKKε cells in which p65 and IRF3 
protein levels had been suppressed via siRNA-mediated knockdown still resulted in an 
upregulation of the SBP enzyme mRNA levels. Comparing the fold-change in mRNA levels in 
doxycycline-treated RELA or IRF3-targeting siRNA-transfected cells with the fold-change in 
control siRNA-transfected cells revealed relatively consistent levels of doxycycline-dependent 
induction for all three SBP enzyme mRNA’s. This data therefore demonstrates that, although 
both p65 and IRF3 may be involved in maintaining basal expression of the serine biosynthesis 
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enzymes, neither transcription factor is required for the IKKε-mediated upregulation of PHGDH, 
PSAT1 or PSPH mRNA levels that is observed upon doxycycline treatment of Flp-In 293 HA-IKKε 
cells. By extension, this indicates that the IKKε-dependent transcriptional regulation of the 
serine biosynthesis enzymes is independent of both NF-κB and IFNβ signalling. 
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Figure 4.21 – Transcriptional upregulation of serine biosynthesis enzymes by IKKε is independent of p65 or IRF3. 
Flp-In 293 HA-IKKε cells were transfected with single siRNA oligos targeting RELA or IRF3 mRNA, to suppress p65 and 
IRF3 protein levels respectively, or a non-targeting control oligo at a final concentration of 50 nM for 72 hours. 50 
ng/ml doxycycline was added for the final 16 hours to induce HA-IKKε expression in the absence of p65 or IRF3 protein 
expression. (A) Western blot analysis demonstrating the knockdown of p65 and IRF3 proteins following transfection 
of Flp-In 293 HA-IKKε cells with RELA- and IRF3-targeting siRNA. Vinculin is shown as a loading control. (B-D) qRT-PCR 
analysis of (A) PHGDH, (B) PSAT1 and (C) PSPH mRNA levels in RELA- or IRF3-targeting siRNA-transfected Flp-In 293 
HA-IKKε cells upon treatment with 50 ng/ml doxycycline for 16 hours. Serine biosynthesis enzyme mRNA levels in 
RELA or IRF3 siRNA-transfected cells were calculated as fold differences versus enzyme levels in non-treated, control 
siRNA-transfected cells and normalised to ACTB (β-Actin) mRNA. No statistically significant difference was detected 
between said conditions when measured using a two-way ANOVA with Bonferroni post-hoc tests. n=3 independent 
experiments, mean ± SEM. 
B C 
D 
A 
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4.8 Discussion 
 
Following the findings detailed in chapter 3, demonstrating that serine biosynthesis enzyme 
PSAT1 is phosphorylated at serine residue Ser331 in an IKKε-dependent manner and that this 
phosphorylation promoted PSAT1 protein stability, this chapter set out to investigate whether 
modulation of IKKε expression in Flp-In 293 HA-IKKε or human breast cancer cells could lead to 
the corresponding modulation of PSAT1 protein levels. Consistently with IKKε-mediated 
phosphorylation increasing PSAT1 protein stability, it was found that induction of HA-IKKε in Flp-
In 293 cells led to the upregulation of the PSAT1 protein and suppression of IKKε in the panel of 
breast cancer cell lines resulted in a decrease in PSAT1 protein levels in all PSAT1-expressing cell 
lines tested with only one exception (MDA-MB-231). Interestingly however, upregulation of 
PSPH in doxycycline-treated Flp-In 293 HA-IKKε cells and downregulation of PHGDH and PSPH 
proteins in IKKε siRNA-transfected ZR-75-1 and MDA-MB-468 breast cancer cell lines was also 
observed alongside PSAT1 regulation. Since the hypothesis for PSAT1 protein regulation 
involved the IKKε-dependent phosphorylation of the enzyme increasing protein stability, 
observing regulation of other serine biosynthesis enzymes by the kinase was somewhat 
surprising, since evidence pointed to the fact that neither PHGDH nor PSPH would be 
phosphorylated by the kinase (see 3.10).  
Transcriptional regulation of PHGDH, PSAT1 and PSPH by IKKε 
The regulation of other serine biosynthesis enzymes by IKKε led to the question of whether 
regulation of the enzymes was occurring at a transcriptional level. It was subsequently identified 
that induction of HA-IKKε expression in Flp-In 293 cells led to a transcriptional upregulation of 
PHGDH, PSAT1 and PSPH expression and, similarly, transcriptional regulation of the enzymes by 
the kinase was observed in breast cancer cell lines as well. This demonstrated that, in addition 
to the regulation of the pathway through post-translational regulation of the PSAT1 protein, 
IKKε regulated the serine biosynthesis pathway at a transcriptional level by upregulating mRNA 
levels of the pathway enzymes. 
The finding that, in Flp-In 293 cells at least, the enzymes of the pathway were all regulated 
transcriptionally, even when only PSAT1 and PSPH were regulated at the protein level, was 
partially unexpected, though consistent with what is already known about transcriptional 
regulators of the serine biosynthesis enzymes, as many regulate the enzymes all together as a 
full set, including TGFβ361, c-Myc315 and ATF4324,362. The fact that all three enzymes were 
regulated transcriptionally, whereas only two proteins were regulated however, suggests that 
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IKKε regulates the serine biosynthesis enzymes at two distinct levels. Transcriptionally, to 
promote mRNA production, and at a translational level, either preventing mRNA translation of 
PHGDH/promoting mRNA translation of PSAT1 and PSPH or degrading PHGDH 
protein/stabilising PSAT1 and PSPH proteins post-translationally. Although this work has already 
shown how IKKε can post-translationally modify PSAT1 to promote protein stability, it is difficult 
to speculate about post-transcriptional regulation of the other enzymes at this stage, since very 
little is currently known about the regulation of PHGDH or PSPH proteins. 
Phosphorylation vs. transcriptional regulation 
A key question is, if IKKε regulates PSAT1 protein stability through phosphorylation and PSAT1 
transcription through upregulation of mRNA levels, which of these two regulatory processes 
contributes more to the overall upregulation of the PSAT1 protein, and which is more important 
for the enhanced serine biosynthesis observed in HA-IKKε-expressing Flp-In 293 cells? Whilst it 
is admittedly difficult to definitively answer this question without further investigation, evidence 
does suggest that the transcriptional regulation contributes to a greater extent than the 
phosphorylation of the protein. Whereas increased gene expression of serine enzymes is well 
known to boost serine biosynthesis304,305,324, changing PSAT1 phosphorylation status appeared 
to have no discernible impact on production of serine intracellularly, as evidenced by the 
labelled metabolite analysis performed with Flp-In 293 HA-PSAT1 wt, S>A and S>E mutants (see 
3.7). The possibility that phosphorylation of PSAT1 Ser331 could still contribute to enzymatic 
activity despite the findings from the labelled metabolite analysis has been discussed extensively 
in chapter 3 (see 3.10), but in the context of IKKε-mediated upregulation of serine biosynthesis 
activity, the data presented throughout this thesis certainly appear to indicate that the increased 
serine production observed in HA-IKKε-expressing cells is a consequence of IKKε’s effect on the 
serine biosynthesis pathway as a whole and the upregulation of PHGDH, PSAT1 and PSPH 
transcription, rather than the phosphorylation of PSAT1. 
It is possible that, whilst increasing protein stability, the phosphorylation of PSAT1 in Flp-In 293 
cells is not sufficient to induce accumulation of PSAT1 protein levels to a degree necessary for 
an observable increase in serine biosynthesis in the same way that transcriptional upregulation 
is. Evidence from the in vitro kinase assay described in chapter 3 (see 3.4) suggests that TBK1 
can phosphorylate PSAT1 Ser331 in the presence of a kinase-dead mutant variant of IKKε (IKKε 
KD-m). It would therefore be expected that if PSAT1 is phosphorylated in Flp-In 293 cells 
expressing HA-IKKε wt, then it would also be phosphorylated in Flp-In 293 cells expressing HA-
IKKε KD-m. If the phosphorylation alone was sufficient to induce protein accumulation, this 
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would mean that the induction of HA-IKKε in KD-m would result in upregulation of PSAT1. 
Instead, induction of HA-IKKε KD-m in Flp-In 293 cells, which has no effect on serine biosynthesis 
enzyme mRNA levels, failed to upregulate PSAT1 protein levels. This therefore provides further 
evidence of the fact that upregulation of PSAT1 protein by IKKε in Flp-In 293 cells requires a 
corresponding upregulation of PSAT1 mRNA. As with the lack of the effect of mutation of the 
PSAT1 Ser 331 residue on serine biosynthesis, this suggests that transcriptional regulation of 
PSAT1 by the kinase is a far more crucial aspect of IKKε’s ability to increase intracellular serine 
production than the phosphorylation of PSAT1. 
Unequal regulation of serine biosynthesis enzymes across cell lines 
Another major question is, why are the serine biosynthesis enzymes not regulated equally across 
all the cell lines tested? Whilst all three enzymes were regulated at the transcriptional level in 
Flp-In 293 cells, things were less consistent in the breast cancer cell lines. Transcriptional 
regulation of PSAT1 alone was commonly observed and only MCF7 showed a significant 
reduction in any other serine biosynthesis enzyme mRNA levels (PHGDH in this instance), whilst 
other cell lines like MDA-MB-468 simply showed a trend of reduction of other enzymes.  
It was hypothesised that the regulation of the enzymes might require availability of a specific 
conformation of IKKε adaptor proteins. In Flp-In 293 cells, evidence suggested that induction of 
HA-IKKε led to possible phosphorylation of SINTBAD, NAP1 and TANK adaptor proteins, as 
protein bands exhibited characteristic phosphoshifts when examined by western blotting. In 
addition to this, TANK was detected within the in vitro kinase assay samples (see 3.4), having 
likely been purified as part of the HA-IKKε pulldown through interaction with the kinase, 
demonstrating that at least one of these three adaptors formed a stable interaction with IKKε. 
This indicated that interaction of IKKε with TANK and potentially with SINTBAD and NAP1 
occurred in Flp-In 293 HA-IKKε cells upon induction of the kinase and suggested that this 
particular conformation of adaptor proteins might facilitate the signalling activity that induced 
the serine biosynthesis enzymes. When searching for evidence of this in breast cancer cell lines, 
as an explanation for the differential regulation of serine biosynthesis enzymes between cell 
lines, no clear pattern of expression of these adaptor proteins was observable, even amongst 
the breast cancer cell lines where more than just PSAT1 appeared to be regulated by the kinase 
(although this experiment did offer hints as to why IKKε might regulate mitochondrial function 
in some breast cancer cell lines but not others (see 5.2 and 5.7)). Indeed, cell lines like T47D 
expressed all the adaptor proteins, yet only PSAT1 was regulated. MDA-MB-468 expressed high 
levels of TANK protein and seemed to regulate all three enzymes similar to what was observed 
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in Flp-In 293 cells. However, ZR-75-1, MDA-MB-453 and SUM44 also expressed high levels of 
TANK and failed to show consistent regulation of PHGDH, PSAT1 and PSPH transcriptionally. The 
explanation for why some enzymes are regulated by the kinase in some breast cancer cell lines 
but not others remains unfortunately elusive. 
Negative transcriptional regulation of serine biosynthesis enzymes by IKKε in MDA-MB-231 
One point of interest with regards to the IKKε-mediated regulation of serine biosynthesis 
enzymes in breast cancer is the apparent negative regulation of PHGDH, PSAT1 and PSPH mRNA 
levels by the kinase in the MDA-MB-231 breast cancer cell line. The serine biosynthesis pathway 
is not of any particular functional relevance in the MDA-MB-231 cell line, as it is not fully active 
due to a lack of PHGDH protein expression. These cells therefore cannot synthesise their own 
serine and, accordingly, cannot survive in serine-free medium (see 3.6). Nevertheless, even if 
the whole pathway is not hugely important for the cell line, growth benefits could still be offered 
via the contribution of the PSAT1 reaction to the incorporation of glutamine-derived carbon in 
the TCA cycle. It is therefore interesting that the upregulation of serine biosynthesis enzyme 
mRNA levels upon siRNA-mediated suppression of IKKε suggests that the kinase might actively 
be suppressing PHGDH, PSAT1 and PSPH mRNA levels in MDA-MB-231 cells.  
Considering the importance of the serine biosynthesis pathway in breast cancer, this might 
suggest that IKKε is instead acting in a tumour suppressive role in this cell line. Although this 
would be surprising for a kinase that, till now, had previously only been linked to tumour 
formation, other IKK’s have been demonstrated to have tumour suppressive roles in the past, 
including IKKα’s role in inhibiting the formation and progression of squamous cell carcinoma135-
137 and the controversial role of IKKβ in mesenchymal cells in the development of colitis-
associated cancer (CAC) where expression of IKKβ has been shown to play both tumour 
promoting and tumour suppressive roles139,140 (see 1.3.1). It is therefore not entirely impossible 
to hypothesise a scenario where IKKε might also act unexpectedly in a tumour suppressive 
fashion. Evidence at least supports the hypothesis that IKKε is not driving the proliferation of 
MDA-MB-231 cells by the fact that suppression of the IKKε in MDA-MB-231 cells failed to inhibit 
proliferative rate (Figure 3.3), indicating that that the cell line does not require expression of the 
kinase for proliferation. On the other hand, suppression of the kinase also did not result in an 
increase in proliferative rates, indicating that IKKε is not necessarily restricting the growth of the 
cell line either. From a functional standpoint, this negative regulation of PHGDH, PSAT1 and 
PSPH mRNA levels by IKKε in MDA-MB-231 does not translate through to the protein levels 
(Figure 4.4), indicating that some uncharacterised mechanism maintains protein expression in 
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the face of mRNA downregulation by IKKε. Considering that modulation of IKKε in MDA-MB-231 
has no bearing on proliferation, it appears likely that the effect of kinase modulation on the 
serine biosynthesis enzymes in this setting is inconsequential. Nevertheless, the fact that the 
effect of kinase suppression in this singular cell line is so different is notable and would be worth 
investigating further. 
Lack of IKKε-mediated serine biosynthesis enzyme regulation in HA1E-M cells 
In addition to identifying transcriptional regulation of the serine biosynthesis enzymes by IKKε 
in Flp-In 293 and breast cancer cell lines, a model in which the kinase was directly inducing 
cellular transformation was used to investigate whether the serine enzymes were regulated by 
IKKε in the early stages of oncogenic transformation.  
The model was one defined by Boehm et al. in 2007, in the same study wherein IKKε was 
identified as a transforming kinase195, and is a HEK293 cell line system expressing hTERT, SV40 
LT and ST and a constitutively active version of MEKDD. Termed “HA1E-M”, the addition of IKKε 
expression to this model is sufficient to tip the balance of cellular transformation in favour of 
oncogenesis. When the effect of IKKε expression on serine biosynthesis enzymes in this model 
was investigated, it was done so by comparing the expression of PHGDH, PSAT1 and PSPH 
proteins in HA1E-M cells to expression in a stable IKKε-expressing equivalent cell line; HA1E-M 
F-IKKε. The expression of serine biosynthesis enzymes in the HA1E-M F-IKKε cells was also 
compared to their expression in HA1E-M F-IKKε cells wherein IKKε had been suppressed using 
siRNA. In both comparisons, no clear reproducible change in enzyme protein levels was 
detected, suggesting no IKKε-dependent regulation of the enzymes was occurring in this cell 
model. Surprisingly, this was found to be explainable by an unexpected lack of established IKKε 
signalling in these cell lines. No phosphorylation of known IKKε targets p65, IRF3 or STAT1 was 
found to occur in an IKKε-dependent manner and auto-phosphorylation of the kinase, indicative 
of kinase activity, could not be detected in the HA1E-M F-IKKε cells. The kinase expressed in 
these particular HA1E-M cells therefore appeared inactive, despite IKKε providing the cells with 
the ability to grow in an anchorage-independent manner. An explanation for the apparent lack 
of kinase activation remains elusive. It is possible that, over time in culture, the cells have 
adapted to the constant presence of the kinase and no longer exhibit the same key markers of 
downstream pathway activation as those that are observed upon the short-term induction of 
the kinase in the doxycycline-treated Flp-In 293 cells. Alternatively, the wrong markers may have 
been examined. Phosphorylation of p65 at Ser468 by IKKε has indeed been shown to facilitate 
regulation of NF-κB signalling83, but when confirming activation of the pathway by the kinase in 
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HA1E-M cells, Boehm et al. demonstrated that expression of IKKε reduced cytoplasmic levels of 
both IκBα and NF-κB subunit p50 and increased nuclear localisation of NF-κB p50195. In addition 
to phosphorylation of p65 Ser468, these readouts should be evaluated in the HA1E-M and HA1E-
M F-IKKε cells used in this project to properly confirm whether the kinase is indeed activating 
NF-κB signalling in these cells. 
To attempt to recapitulate the short-term activation of the kinase observed in doxycycline-
treated Flp-In 293 cells, it would be worth mimicking the physiological activation of the kinase 
by treating HA1E-M F-IKKε cells with toll-like receptor (TLR) agonists LPS or Poly(I:C). This would 
stimulate TLR activation and its downstream signalling to provide an activating signal for IKKε 
and therefore allow potential evaluation of the role of short-term activated IKKε in regulating 
the serine biosynthesis enzymes in the HA1E-M cell model. Importantly however, the activation 
of TLR’s does not exclusively activate IKKε. A variety of signalling pathways are activated in 
response to receptor activation, meaning such an experiment might not be sufficient to 
conclude on the specific role of IKKε. Instead, a different HA1E-M cell line model could prove 
more useful in this regard. In the same 2007 study, several IKKε-expressing HA1E-M cell lines 
were created, including a version containing a myristoylated, constitutively active kinase. By 
comparing the expression of the serine biosynthesis enzymes in the myristoylated-IKKε-
expressing cells, where Boehm et al. have already shown that the kinase induces NF-κB 
activation and is therefore active and signalling195, to the HA1E-M cells without IKKε and even to 
HA1E-M F-IKKε cells with the inactive kinase, it would be possible to definitively conclude 
whether PHGDH, PSAT1 or PSPH are regulated by IKKε in the HA1E-M cell model or not.  
In spite of the lack of PHGDH, PSAT1 and PSPH regulation by IKKε in the HA1E-M F-IKKε cells, it 
is worth noting that experiments performed by another member of the Bianchi lab, Dr Ewa 
Wilcz-Villega, have successfully offered some insight into the role of serine biosynthesis in IKKε-
driven cellular transformation. Dr Wilcz-Villega has found that mimicking the inflammatory 
conditions found in a tumour microenvironment by treating MCF-10A cells with medium 
conditioned by patient-derived M1 and M2 macrophages induces IKKε expression and promotes 
the transformation of cells as measured by an increased ability for cells to grow in an anchorage-
independent manner in a soft agar colony formation assay. In the context of serine biosynthesis, 
this effect was effectively blocked by the addition of recently described PHGDH inhibitor, NCT-
502363, to the cells, thus indicating that the serine biosynthesis pathway is an important 
contributor to the IKKε-driven acquisition of transformed properties. The role of serine 
biosynthesis in this model of IKKε-mediated transformation is therefore something that should 
be investigated further. 
Chapter 4. Results II: IKKε transcriptionally regulates serine biosynthesis enzymes 
188 
 
Canonical IKKε-signalling pathways are dispensable for regulation of serine biosynthesis 
As well as identifying the transcriptional regulation of the serine biosynthesis enzymes by IKKε, 
the other major finding of this chapter is that said regulation is independent of established IKKε 
signalling and the NF-κB and IFNβ pathways. This was surprising, given that the major 
transcriptional programmes that IKKε is known to induce as part of its main functions involve 
both NF-κB and IFNβ signalling, but is significant in the context of the project and the therapeutic 
options it might present for breast cancer patients. Herein is evidence for a breast cancer 
oncogene regulating the activity of a pathway that has been extensively linked to breast cancer 
development independently of the NF-κB pathway. As discussed in chapter 1 (see 1.3.3.1), 
therapeutic targeting of NF-κB activation remains a poor strategy for therapeutic intervention 
in IKKε-driven breast cancers. Whilst the kinase has been primarily linked to breast cancer 
through both the induction of IκBα degradation and canonical NF-κB activation192,195 and the 
activation of NF-κB independently of IκBα degradation via direct phosphorylation of NF-κB 
subunits82,194, other NF-κB-independent mechanisms of IKKε-mediated oncogenesis have been 
described. Such mechanisms include the direct promotion of the stabilisation of YAP1 in 
gliomas173, the phosphorylation and inhibition of FOXO3a in lung cancers177 and in breast cancer, 
the induction of expression of a truncated ERα, ERα-36, in ER negative breast cancers that 
induces cyclin D1 and c-Myc211,212. The NF-κB independent regulation of serine biosynthesis 
enzymes to promote serine biosynthesis might therefore represent a novel NF-κB independent 
mechanism by which IKKε expression can promote cell growth and cancer development and 
provide a host of new therapeutic targets for drug development.  
IKKε, serine biosynthesis and oxidative stress in breast cancer 
Whether or not the upregulation of the serine biosynthesis pathway actively contributes to 
IKKε’s ability to support breast cancer development remains to be seen. However, some indirect 
evidence from the labelled metabolite analysis described in chapter 3 (see 3.2) does suggest that 
the upregulation of PHGDH, PSAT1 and PSPH by IKKε could indeed benefit rapidly proliferating 
cancer cells.  
One of the primary ways that increased serine biosynthesis can support rapid proliferation and 
cancer development is by contributing to the maintenance of intracellular redox balance. Serine 
is catabolised to glycine by SHMT, which removes a carbon unit from serine and donates it to 
the one-carbon cycle, an important by-product of which is NADPH to support the production of 
key cellular anti-oxidant glutathione320.  Although SHMT2, the mitochondrial isoform of SHMT 
that primarily facilitates this process and the isoform that has been most linked with cancer 
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progression320,357-359, showed no significant upregulation at the protein level upon induction of 
HA-IKKε in Flp-In 293 cells, evidence from the labelled metabolite analysis suggests that 
expression of IKKε does promote anti-oxidant production in breast cancer cells. It was found 
that suppression of IKKε in T47D cells reduced intracellular glutathione levels (Figure 3.6). This 
therefore suggests that upregulation of IKKε in breast cancer contributes to the maintenance of 
glutathione levels within the cells and that the kinase might help to maintain intracellular redox 
balance. Considering IKKε upregulated serine biosynthesis in T47D cells, this IKKε-dependent 
increase in cellular glutathione levels could be explained via an increase in the flux of serine-
derived carbon into one-carbon metabolism. Indeed, even if SHMT2 itself is not regulated by the 
kinase, increased serine biosynthesis can increase the flow of glucose-derived carbons towards 
glycine, thereby increasing the contribution of glucose-derived carbon into the one-carbon 
metabolic cycles and facilitating the maintenance of redox balance through glutathione 
reduction. With this in mind, it would be prudent to evaluate the effect of IKKε suppression in 
T47D breast cancer cells on intracellular ROS levels, as this would allow evaluation of whether 
the kinase does indeed provide such a mechanism for ROS detoxification in this context. 
Concluding remarks 
The data presented in this chapter follows up on the work from the previous chapter, in which 
the phosphorylation of PSAT1 in an IKKε-dependent manner was shown to promote protein 
stability, by providing evidence that expression of IKKε in Flp-In 293 HA-IKKε cells and a panel of 
human breast cancer cell lines upregulates PSAT1 protein levels. Unexpectedly, in addition to 
PSAT1, other serine biosynthesis enzymes were found to be regulated by the kinase, indicating 
that regulation of the enzymes was not solely attributable to substrate phosphorylation. This 
subsequently led to the finding that IKKε regulates serine biosynthesis enzymes at a 
transcriptional level to enhance serine production. Importantly, the transcriptional regulation of 
PHGDH, PSAT1 and PSPH mRNA levels by IKKε was found to be independent of the kinases 
known functions in NF-κB and IFNβ signalling, suggesting that expression of the kinase in Flp-In 
293 cells and breast cancer cell lines activates other, previously uncharacterised transcriptional 
programmes. What this transcriptional programme might be, what the transcription factor 
responsible for its activation is and how the kinase induces that transcription factor were the 
next major questions to be asked. Efforts to answer these questions are therefore described in 
the next chapter. 
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Chapter 5 
Results  
IKKε regulates serine biosynthesis enzymes via mitochondrial inhibition 
 
Disclaimer: Whilst such instances are clearly indicated previously in the materials and 
methods and again in the following text and figure legends, the data demonstrating the effect 
of IKKε on oxygen consumption rate (presented in Figures 5.1 and 5.2) were acquired by Dr 
Ruoyan Xu. Similarly, the samples sent for assessment of IKKε’s effect on mitochondrial 
membrane potential via TMRM staining with collaborator Professor Gyorgy Szabadkai at 
University College London, London, UK were prepared with the assistance of Dr Ruoyan Xu, 
who prepared the samples for the experiment presented in Figure 5.3 (samples for the 
experiment presented in Figure 5.6 were prepared by the author). These data were included 
with the intention to provide context for the work examining the role of ATF4 in IKKε-
mediated regulation of the serine biosynthesis enzymes, as the changes in OCR provided the 
key reason for investigating ATF4.  
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5.1 Identification of potential serine biosynthesis enzyme-regulating 
transcription factors 
 
The results described in the previous chapter provided evidence for the transcriptional 
upregulation of serine biosynthesis enzymes by IKKε. Experiments performed in Flp-In 293 HA-
IKKε cells, wherein p65 or IRF3 proteins were suppressed using siRNA targeting RELA and IRF3 
mRNA respectively to inhibit canonical NF-κB or IFNβ activation, found that the transcriptional 
upregulation of PHGDH, PSAT1 and PSPH mRNA in response to induction of HA-IKKε was wholly 
independent of the kinases established NF-κB- or IFNβ-mediated signalling. Therefore, the 
regulation of serine enzymes by IKKε was deemed to be via alternative signalling activities.  
In order to identify other potential transcription factors capable of upregulating PHGDH, PSAT1 
and PSPH mRNA in response to induction of HA-IKKε in doxycycline-treated Flp-In 293 cells, a 
two-pronged approach was taken. Firstly, a promoter analysis was performed to identify 
transcription factor binding sites in the promoter regions of the serine biosynthesis enzyme 
genes. Simultaneously, existing literature was searched to identify transcription factors which 
had been previously been reported to induce PHGDH, PSAT1 and PSPH expression. 
The promoter analysis was performed in collaboration with Professor Claude Chelala and Dr Ai 
Nagano (Barts Cancer Institute, London, UK) and studied the peak Histone H3 methylation 
regions upstream of the PHGDH, PSAT1 and PSPH genes, searching for potential transcription 
factor binding sites. Since a transcription factor that regulates all three enzymes in HA-IKKε-
expressing Flp-In 293 cells was sought, the lists of identified transcription factors with potential 
binding sites in each gene promoter were subsequently compared to highlight common factors 
between the three genes. The resulting list was then cross-referenced with the literature base 
to identify factors that might be regulated upon induction of the kinase (Table 5.1). 
Several transcription factors with predicted binding sites in the promoter regions of all three 
serine biosynthesis enzyme genes were identified as having potential links to IKKε. These factors 
therefore represented possible candidates for regulating the serine biosynthesis enzymes in 
response to induction of the kinase. Such factors included members of the ccaat-enhancer-
binding protein (C/EBP) family C/EBPβ and C/EBPδ and transcription factor specificity protein 1 
(SP1), all of which have been shown to be activated by IKKε364-366. Importantly, the links between 
these factors and IKKε all involve or require p65 and active NF-κB signalling to some degree364,366. 
Similarly, E1A-associated protein p300 (EP300), a histone acetyltransferase which can bind to 
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IRF3 to drive transcription can be linked to IKKε through IKKε’s ability to induce nuclear 
translocation of IRF3367,368.  
Unfortunately, the fact that the links between IKKε and these transcription factors all depended 
on the activity of p65 or IRF3 demonstrated that none of them were likely to be responsible for 
the observed transcriptional regulation of the serine biosynthesis enzymes. Indeed, the previous 
chapter confirmed that neither p65 nor IRF3 were essential for the upregulation of PHGDH, 
PSAT1 or PSPH mRNA upon induction of HA-IKKε in Flp-In 293 cells. This means that transcription 
factors which depend on p65 or IRF3 could not be involved, as such factors would have been 
unable to function upon the knockdown of p65 or IRF3 and enzyme induction would have been 
inhibited as a result. That this was not the outcome therefore indicates that the responsible 
transcription factor must function independently of p65 or IRF3. Consequently, none of the 
transcription factors identified in the promoter analysis were deemed to be suitable candidates 
to explain the observed phenotype and instead, attention was turned back to the existing 
literature, to identify transcription factors that had previously been shown to be regulators of 
PHGDH, PSAT1 and PSPH expression. 
From a literature search, it was apparent that two major transcription factors, which were 
absent from the promoter analysis, have been reported to induce transcription of the three 
serine biosynthesis enzymes. Firstly, c-Myc has been shown upregulate PHGDH, PSAT1 and PSPH 
mRNA levels (and SHMT1 and SHMT2 mRNA as well) in tumours driven by the oncogene and 
accordingly, ChIP-qPCR analysis has demonstrated the binding of c-Myc to enhancer regions in 
the PHGDH, PSAT1 and PSPH genes315,369. Secondly, ATF4, a key stress-responding transcription 
factor, has been reported to be a master regulator of serine biosynthesis having repeatedly been 
shown to transcriptionally upregulate serine biosynthesis enzyme mRNA levels in mouse cell 
lines, drosophila and in human cancer cells and, in agreement with this, has been shown to 
upregulate the enzymes downstream of NRF2 to support glutathione and nucleotide production 
in NSCLC324,370-372.  
The absence of c-Myc and ATF4 from the promoter analysis suggested that the analysis that was 
performed was incomplete, that it was likely not searching the full promoter sequences for the 
three genes and was therefore unlikely to be detecting all the possible transcription factor 
binding sites. Nevertheless, c-Myc and ATF4 represented promising candidates for the 
regulation of the pathway by IKKε. Indeed, IKKε has been shown to promote c-Myc nuclear 
translocation via activation of AKT to promote an aerobic glycolysis phenotype and support 
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pancreatic cancer growth189, demonstrating a strong link between the kinase and c-Myc in the 
context of cellular metabolism. 
Before investigating the role of c-Myc however, the results of the labelled metabolite analysis 
were recalled (Figures 3.5 and 3.6). When mapping the metabolic response to modulation of 
IKKε in Flp-In 293 cells and T47D breast cancer cells, it was concluded that the kinase was 
inducing an aerobic glycolysis-like state, with an increase in anabolic biosynthesis (in the form 
of increased serine biosynthesis), an increase in lactate production and a decrease in the 
incorporation of glucose-derived carbon in the intermediates of the TCA cycle. Reduced entry of 
glucose-derived carbon into the mitochondria and the TCA cycle is one of the key features of 
classical aerobic glycolysis and is one of the main reasons why cancer cells do not display typical 
mitochondrial respiration via OXPHOS.  
That IKKε was regulating mitochondrial metabolism was interesting. The kinase has been 
previously demonstrated to associate with the mitochondria through interaction with 
mitochondrial antiviral-signaling (MAVS) protein373 and a previous study examining the effect of 
IKKε on cellular metabolism in dendritic cells demonstrated that the kinase can induce aerobic 
glycolysis by promoting the interaction of glycolytic enzyme hexokinase II with the 
mitochondria106. More importantly, as this project has demonstrated, IKKε regulates serine 
biosynthesis activity, inducing expression of serine biosynthesis enzymes in both Flp-In 293 cells 
and breast cancer cells. This is particularly notable, as regulation of mitochondrial function has 
recently been linked with the regulation of serine biosynthesis activity via ATF4. A 2016 study 
by Bao et al. identified that mitochondrial dysfunction, triggered by a reduction in mitochondrial 
DNA and OXPHOS membrane complex expression, induced a retrograde mitochondria-to-
nucleus signalling axis mediated by ATF4, which resulted in the transcriptional upregulation of 
PHGDH, PSAT1 and PSPH and the enhancement of serine biosynthesis activity to support one-
carbon metabolism362.  
Since the labelled metabolite analysis demonstrated that IKKε inhibited the mitochondrial 
uptake of glucose-derived carbon, it was therefore speculated that if the effect of the kinase on 
the mitochondria was sufficient to inhibit mitochondrial function, then the upregulation of 
PHGDH, PSAT1 and PSPH mRNA levels could be a result of the same ATF4-mediated retrograde 
mitochondria-to-nucleus signalling. To address this, the question of whether expression of IKKε 
led to an inhibition of mitochondrial function was first investigated. 
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Table 5.1 – List of transcription factors with predicted binding sites in PHGDH, PSAT1 and PSPH promoter regions. 
Promoter analysis performed in collaboration with Professor Claude Chelala and Dr Ai Nagano to identify potential 
transcription factor binding sites in the promoter regions of serine biosynthesis enzyme genes. Using data from the 
ENCODE project374, the analysis was performed by searching for transcription factor binding sites located in regions 
of peak Histone H3 lysine 4 methylation (H3K4me3) near PHGDH, PSAT1 and PSPH gene start positions. Previous 
links of transcription factors to IKKε, as identified via a literature search, are indicated.  
 
Transcription 
Factor 
 
Link to IKKε 
C/EBPβ Activation and nuclear translocation induced by IKKε binding365 
C/EBPδ DNA binding activity induced by IKKε in response to LPS stimulation364 
CHD2  
E2F1  
E2F4  
EP300 Binds to IRF3 via an IRF3 binding domain (IBiD) to drive transcription367,368 
MAZ  
NFYB  
PHF8  
RCOR1  
REST  
RFX5  
SIN3AK20  
SP1 Induced by p52 in response to poly(I:C)-mediated IKKε activation366 
TAF1  
TBP  
ZBTB33  
ZNF143  
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5.2 IKKε inhibits mitochondrial function 
 
In cells undergoing classical aerobic respiration, the TCA cycle fuels the electron transport chain 
(ETC), which is used to produce ATP in large quantities for energy storage. The final stages of the 
ETC involve the consumption of oxygen as an acceptor of the electrons passed along the 
intermembrane complexes (Figure 1.5). Therefore, in order to determine the effect of IKKε on 
classical mitochondrial function, cellular oxygen consumption rate (OCR) was measured by Dr 
Ruoyan Xu. In Flp-In 293 cells, the effect of induction of the kinase upon OCR was measured 
using Oroboros high resolution respirometry analysis. In breast cancer cell lines, the effect of 
siRNA-mediated suppression of IKKε on cellular OCR was measured using Seahorse extracellular 
flux analysis. 
Flp-In 293 HA-IKKε wt or Flp-In 293 HA-IKKε KD-m cells were used to assess the effect of IKKε 
kinase activity on mitochondrial function. Cells were treated with doxycycline for 16 hours to 
induce kinase expression, following which OCR was measured in both non-treated and 
doxycycline-treated cells to compare cellular oxygen consumption before and after IKKε 
induction (Figure 5.1). 
 
 
Figure 5.1 – Induction of HA-IKKε wt in Flp-In 293 cells reduces cellular oxygen consumption. Oroboros high 
resolution respirometry analysis of basal oxygen consumption in non-treated Flp-In 293 HA-IKKε wt or Flp-In 293 HA-
IKKε KD-m cells compared to cells treated with 50 ng/ml doxycycline for 16 hours. Oxygen consumption values of 
doxycycline-treated cells were normalised to non-treated cells. IKKε reduces cellular oxygen consumption in a kinase 
activity-dependent manner. Experiment performed by Dr Ruoyan Xu. n≥3 independent experiments, mean ± SEM, 
*p<0.05 as measured by two-way ANOVA with Bonferroni post-hoc tests. 
 
Treatment of Flp-In 293 HA-IKKε wt cells with doxycycline significantly reduced OCR. Conversely, 
doxycycline treatment of Flp-In 293 HA-IKKε KD-m cells failed to induce any significant change 
in cellular OCR. This indicated that expression of HA-IKKε induces a particular signalling axis 
which reduces cellular OCR in a kinase-dependent manner. 
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To determine whether IKKε was affecting OCR in human breast cancer cell lines, siRNA was used 
to suppress kinase expression as in previous experiments. Cells were plated and transfected with 
a pool of siRNA oligos targeting IKBKE mRNA, to suppress IKKε, or a single non-targeting control 
oligo for 72 hours. Following kinase knockdown, OCR was measured using Seahorse extracellular 
flux analysis to determine IKKε-dependent changes in oxygen consumption (Figure 5.2). Whilst 
basal OCR was of primary interest to this project, other parameters, such as maximal and spare 
respiratory capacity were also measured for each cell line upon IKKε suppression. 
Representative data for these parameters is presented for each cell line in the supplementary 
material (see supplementary materials: Figure 7.1).  
Suppression of the kinase in breast cancer cells led to significant increases in OCR in 6 out of the 
9 cell lines tested, indicating that IKKε suppresses cellular oxygen consumption in a subset of 
breast cancer cell lines. This supports the findings in Flp-In 293 cells upon induction of the kinase 
and together, these data demonstrate that IKKε significantly impairs mitochondrial oxygen 
consumption. 
 
Figure 5.2 – Suppression of IKKε increases cellular oxygen consumption in a subset of breast cancer cell lines. 
Seahorse extracellular flux analysis of basal oxygen consumption rate in IKBKE siRNA-transfected breast cancer cell 
lines. Indicated cell lines were transfected with a pool of 4 siRNA oligos targeting IKBKE mRNA, to suppress IKKε, or a 
single non-targeting control oligo at a final concentration of 50 nM. 24 hours post-transfection, cells were trypsinised 
and re-plated into a Seahorse plate and 48 hours later, OCR was measured using the Seahorse XF96 analyser. All OCR 
values were normalised to the protein concentration of each sample well (measured by a BCA assay), then additionally 
normalised to the OCR in cells transfected with non-targeting control siRNA. IKKε suppression significantly increased 
OCR in 6 out of the 9 cell lines tested. Experiment performed by Dr Ruoyan Xu. n≥3 independent experiments, mean 
± SEM, *p,0.05 as measured by paired, two-tailed Student’s t-test. 
 
In addition to evaluating the kinases effect on OCR, the effect of IKKε on mitochondrial activity 
was also investigated by measuring mitochondrial membrane potential. Active mitochondria 
feature a strong negatively charged polarity across the inner mitochondrial membrane due to 
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the function of the electron transport chain. As the activity decreases, the membrane 
depolarises. This change in polarity can therefore be exploited to measure mitochondrial 
activity, by staining cells with tetramethylrhodamine, methyl ester (TMRM), a positively charged 
dye that accumulates in mitochondria proportionally to the membrane potential. TMRM dye 
does not accumulate in inactive mitochondria with a depolarised membrane, therefore meaning 
that dye intensity correlates with mitochondrial activity. This experiment was also performed by 
Dr Ruoyan Xu, in collaboration with Professor Gyorgy Szabadkai (University College London, 
London, UK), who measured TMRM staining intensity in cells using the ImageXpress Micro XL 
High-Content Imaging system. 
Flp-In 293 HA-IKKε wt or Flp-In 293 HA-IKKε KD-m cells were plated, treated with doxycycline for 
16 hours to induce kinase expression and subsequently stained with TMRM dye to evaluate 
mitochondrial activity (Figure 5.3).  
Similar to the analysis of OCR upon induction of HA-IKKε, treatment of Flp-In 293 HA-IKKε wt 
cells with doxycycline for 16 hours significantly reduced TMRM staining intensity, whereas 
doxycycline treatment of Flp-In 293 HA-IKKε KD-m cells failed to induce any significant change 
in staining intensity. This, in agreement with findings on IKKε’s effect on cellular oxygen 
consumption, demonstrated that IKKε inhibits mitochondrial activity in a manner dependent on 
kinase activity. Additionally, this confirms that the IKKε-dependent reduction in OCR is 
attributable to the inhibition of mitochondrial activity and the suppression of the electron 
transport chain. 
 
Figure 5.3 – Induction of HA-IKKε wt in Flp-In 293 cells reduces mitochondrial membrane potential. 
Tetramethylrhodamine, methyl ester (TMRM) staining analysis of mitochondrial membrane potential as a readout for 
mitochondrial activity in non-treated Flp-In 293 HA-IKKε wt or Flp-In 293 HA-IKKε KD-m cells compared to cells treated 
with 50 ng/ml doxycycline for 16 hours. Staining intensity was measured using the ImageXpress Micro XL High-
Content Imaging system and intensity in doxycycline-treated cells was normalised to that of non-treated cells. IKKε 
significantly reduces mitochondrial sequestration of TMRM dye in a kinase-dependent manner, indicating a significant 
reduction in mitochondrial membrane potential and therefore, mitochondrial activity. Experiment performed by Dr 
Ruoyan Xu in collaboration with Professor Gyorgy Szabadkai. n≥3 independent experiments, mean ±SEM, *p<0.05 as 
measured by two-way ANOVA with Bonferroni post-hoc tests. 
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5.3 IKKε controls glucose-carbon entry into the TCA cycle via PDHA1 
 
As previously mentioned, data from the labelled metabolite analysis demonstrated that IKKε-
expressing cells exhibited reduced incorporation of glucose-derived carbon into the TCA cycle. 
In order to confirm whether the reduction in mitochondrial respiration induced by the kinase 
was attributable to this diversion of substrate away from the TCA cycle it was questioned how 
exactly the kinase was preventing the mitochondrial uptake of glucose-derived carbon.  
To identify potential effectors of IKKε’s effect on the mitochondria, the results of the 
phosphoproteomic analysis, identifying proteins exhibiting significant changes in 
phosphorylation in HA-IKKε-expressing Flp-In 293 cells, were recalled (Table 3.2). Several 
metabolic proteins were identified as significantly more phosphorylated when IKKε was 
expressed, including PSAT1 as described in chapter 3. In the context of mitochondrial inhibition 
however, it was particularly intriguing to find that pyruvate dehydrogenase E1 component 
subunit alpha (PDHA1) was significantly more phosphorylated at serine residue Ser232 in HA-
IKKε-expressing cells. Phosphorylation of PDHA1 at Ser232 inhibits the activity of the 
enzyme375,376. That this residue was significantly more phosphorylated in IKKε-expressing cells 
indicates that the kinase inhibits PDHA1 activity.  
PDHA1 is a central component of the pyruvate dehydrogenase complex, which catalyses the 
conversion of pyruvate to acetyl-CoA for entry into the mitochondrial TCA cycle. In essence, the 
enzyme complex is the gatekeeper for the entry of glucose-derived carbon into the TCA cycle. 
IKKε inducing an inhibitory phosphorylation of an essential subunit of the complex could explain 
the decrease of glucose-derived carbon in the TCA cycle and the reduced mitochondrial function 
in kinase-expressing cells. However, overlap of IKKε’s optimal phosphorylation motif197 with the 
PDHA1 sequence surrounding Ser232 exhibited no overlap in residues other than the requisite 
phosphorylated serine (Figure 5.4). This, combined with the fact that PDHA1 is a mitochondrial 
protein inaccessible to the kinase, indicated that PDHA1 Ser232 is not a direct substrate of IKKε. 
  
 
 
Figure 5.4 – PDHA1 is likely not a direct substrate of IKKε. IKKε’s optimal phosphorylation motif as described by Hutti 
et al. 2006197 compared with the amino acid sequence surrounding the PDHA1 Ser232 residue, identified as 
significantly more phosphorylated in IKKε-expressing cells. With the exception of the serine residue, no overlap of 
residues was detected between IKKε’s optimally recognised sequence and the PDHA1 sequence, indicating that 
PDHA1 is unlikely to be an IKKε substrate. 
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This suggested that, rather than direct phosphorylation similar to phosphorylation of PSAT1 
Ser331 by IKKε, the kinase induced PDHA1 Ser232 phosphorylation indirectly through the 
activation of a signalling cascade. To attempt to validate the detected IKKε-dependent 
phosphorylation of the enzyme, western blotting was used to evaluate PDHA1 Ser232 
phosphorylation levels in Flp-In 293 HA-IKKε cells upon treatment with doxycycline (Figure 5.5).  
No clear difference in PDHA1 Ser232 phosphorylation was observed between non-treated and 
doxycycline-treated cells via western blot. This was confirmed by densitometry quantification 
analysis of the blot, performed by normalising total PDHA1 and p-PDHA1 (Ser232) protein levels 
to vinculin, to account for differences in loading, followed by normalisation of phosphorylated 
protein levels to total protein levels, to account for any changes in PDHA1 expression that might 
be induced by IKKε. The fact that no differences in Ser232 phosphorylation were observed upon 
treatment of Flp-In 293 HA-IKKε cells with doxycycline indicated that the kinase was unable to 
induce stable phosphorylation of PDHA1. It is worth noting however, that kinase 
phosphorylations are often highly transient events, meaning it is possible that IKKε does induce 
PDHA1 Ser232 phosphorylation, but that it does so in a dynamic manner that is difficult to detect 
via western blotting. Therefore, alternative methods of evaluating the role of PDHA1 in IKKε-
mediated mitochondrial inhibition were used. 
 
                  
Figure 5.5 – Induction of HA-IKKε in Flp-In 293 cells has no impact on levels of stable PDHA1 phosphorylation. (A) 
Western blot analysis of total PDHA1 protein levels and PDHA1 Ser232 (S232) phosphorylation in either non-treated 
Flp-In 293 HA-IKKε cells or cells treated with 100 ng/ml doxycycline for 16 hours to induce kinase expression. Vinculin 
is shown as a loading control. (B) Densitometry quantification analysis of PDHA1 Ser232 phosphorylation levels in 
doxycycline-treated cells versus non-treated cells. Total PDHA1 and p-PDHA1 Ser232 densitometry per sample was 
quantified as a percentage of total protein densitometry and normalised to vinculin, then p-PDHA1 Ser232 
densitometry was further normalised to total PDHA1. PDHA1 Ser232 phosphorylation was unchanged by induction of 
HA-IKKε with doxycycline. n=3 independent experiments, mean ± SEM. No significant differences were detected when 
measured using a paired, two-tailed Student’s t-test. 
A B 
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To better clarify the role of PDHA1 in IKKε-mediated mitochondrial regulation in Flp-In 293 cells, 
pyruvate dehydrogenase complex activity was forcibly induced in the presence of IKKε induction 
through treatment of Flp-In 293 HA-IKKε cells with dichloroacetate (DCA). Phosphorylation of 
PDHA1 at serine residue Ser232 is typically controlled by a kinase called pyruvate dehydrogenase 
kinase (PDK) which phosphorylates the enzyme to inhibit the pyruvate dehydrogenase 
complex377. DCA can activate PDHA1 by inhibiting PDK378. Therefore, treatment of HA-IKKε-
expressing Flp-In 293 cells with DCA should prevent IKKε’s effect on the mitochondria, if it is 
mediated by inhibition of PDHA1, by maintaining activation of the enzyme in the presence of 
the kinase. The effect of combined treatment of Flp-In 293 HA-GFP or Flp-In 293 HA-IKKε cells 
with DCA and doxycycline on mitochondrial activity was evaluated using TMRM staining with 
the help of Professor Gyorgy Szabadkai (Figure 5.6). 
In agreement with previous data, treatment of Flp-In 293 HA-IKKε cells, but not Flp-In 293 HA-
GFP cells, with doxycycline significantly reduced TMRM staining intensity within the cells, 
confirming an IKKε-dependent inhibition of mitochondrial activity. Importantly, whilst 
treatment of either Flp-In 293 HA-GFP or Flp-In 293 HA-IKKε cells with DCA alone had no 
significant impact on TMRM intensity, combined treatment of Flp-In 293 HA-IKKε cells with DCA 
and doxycycline completely abolished the kinase-dependent decrease in TMRM staining. This 
indicated that the reduction in mitochondrial activity by the HA-IKKε was mediated through 
inhibition of the activity of the pyruvate dehydrogenase complex and that this phenotype was 
rescuable with therapeutic intervention. 
Together, these data confirm that, as indicated by the labelled metabolite analysis, IKKε 
supports an aerobic glycolysis-like phenotype by having an inhibitory effect on the mitochondria, 
reducing mitochondrial respiration as measured by oxygen consumption and membrane 
potential. This inhibition is controlled by the IKKε-dependent inhibition of pyruvate 
dehydrogenase activity, resulting in an inhibition of the conversion of pyruvate to acetyl-CoA 
and the uptake of glucose-derived carbon to the mitochondria. This therefore explains the 
reduction in glucose-derived carbon incorporation in TCA cycle metabolites observed in the 
labelled metabolite analysis performed in IKKε-expressing cells (see 3.2).  
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Figure 5.6 – DCA pre-treatment rescues HA-IKKε-mediated inhibition of the mitochondria in Flp-In 293 cells. TMRM 
staining analysis of mitochondrial membrane potential in Flp-In 293 HA-GFP or Flp-In 293 HA-IKKε cells treated with 
50 ng/ml doxycycline, 50 mM DCA or a combination of doxycycline and DCA for 16 hours. Staining intensity was 
measured using the ImageXpress Micro XL High-Content Imaging system and intensity in doxycycline, DCA or 
doxycycline and DCA-treated cells was normalised to the intensity in non-treated Flp-In 293 HA-IKKε cells. Neither 
doxycycline nor DCA had any significant impact on TMRM staining intensity in Flp-In 293 HA-GFP cells. Treatment of 
Flp-In 293 HA-IKKε cells with doxycycline for 16 hours significantly reduced TMRM staining intensity as before, 
consistent with decreased mitochondrial activity, but combination of doxycycline treatment with DCA prevented this 
HA-IKKε-dependent decrease, indicating that the kinase blocks mitochondrial function through reversible inhibition 
of the pyruvate dehydrogenase complex. Experiment performed in collaboration with Professor Gyorgy Szabadkai. 
n=3 independent experiments, mean ± SEM, *p<0.05 as measured by two-way ANOVA with Bonferroni post-hoc tests. 
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5.4 IKKε-mediated transcriptional upregulation of PHGDH, PSAT1 and PSPH in 
Flp-In 293 cells requires ATF4 
 
As previously mentioned, mitochondrial dysfunction has previously been demonstrated to 
upregulate the enzymes of the serine biosynthesis pathway via ATF4-mediated retrograde 
mitochondria-to-nucleus signalling362. Confirmation that the IKKε-induced reduction in 
mitochondrial utilisation of glucose-derived carbon is accompanied by a reduction in 
mitochondrial function suggested that the expression of the kinase would be sufficient to 
activate the same ATF4-mediated retrograde signalling axis. It was therefore hypothesised that 
IKKε’s effect on the enzymes of the serine biosynthesis pathway was mediated by ATF4. 
Accordingly, the involvement of the transcription factor on IKKε-mediated upregulation of 
PHGDH, PSAT1 and PSPH mRNA levels was investigated.  
Flp-In 293 HA-IKKε cells were transfected with a single ATF4-targeting siRNA oligo or a non-
targeting control oligo for 72 hours, with doxycycline being added for the final 16 hours. This 
allowed the induction of the kinase in the absence of ATF4 expression and therefore evaluation 
of the role that ATF4 plays in the IKKε-mediated transcriptional regulation of the serine 
biosynthesis enzymes (Figure 5.7). The data shown is using single oligo suppression of ATF4, but 
the experiment was also repeated with a pool of 4 ATF4-targeting siRNA oligos to control for off-
target effects. 
The first observation that was noted was that treatment of Flp-In 293 HA-IKKε cells with 
doxycycline resulted in an increase in overall ATF4 protein levels. Whilst total protein levels of a 
transcription factor do not necessarily correlate with transcriptional activity, meaning an 
increase in ATF4 protein levels may not be indicative of increased activity, this at least indicated 
some regulation of the transcription factor by the kinase. Furthermore, transfection of the siRNA 
oligo effectively suppressed ATF4 protein levels which could not then be rescued by induction 
of the kinase. More interestingly, whereas induction of HA-IKKε successfully increased PSAT1 
and PSPH protein levels and significantly upregulated PHGDH, PSAT1 and PSPH mRNA levels as 
expected in the control siRNA-transfected cells, the transfection of cells with ATF4 targeting 
siRNA not only reduced basal levels of PHGDH, PSAT1 and PSPH protein and mRNA, but also 
completely abrogated IKKε’s ability to induce the enzymes at a protein or mRNA level. This 
indicated that the observed upregulation of serine biosynthesis enzymes in IKKε-expressing cells 
was mediated by ATF4-dependent transcriptional upregulation of the enzyme mRNA levels. 
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Figure 5.7 – HA-IKKε-mediated upregulation of serine biosynthesis enzymes in Flp-In 293 cells requires ATF4. Flp-In 
293 HA-IKKε cells were transfected with a single ATF4-targeting siRNA oligo, to suppress the transcription factor, or a 
non-targeting control oligo at a final concentration of 50 nM for 72 hours. 50 ng/ml doxycycline was added for the 
final 16 hours to induce HA-IKKε in the absence of ATF4. (A) Western blot analysis demonstrating upregulation of 
ATF4 protein levels upon treatment of Flp-In 293 HA-IKKε cells with doxycycline and effective suppression of ATF4 
protein following transfection of ATF4 siRNA. (B) Western blot analysis examining the effect of doxycycline treatment 
on PHGDH, PSAT1 and PSPH protein levels in Flp-In 293 HA-IKKε cells where ATF4 is suppressed using siRNA. 
Doxycycline induces PSAT1 and PSPH protein upregulation as expected upon induction of IKKε, but suppression of 
ATF4 decreases basal PHGDH, PSAT1 and PSPH protein level and prevents HA-IKKε-mediated upregulation of PSAT1 
and PSPH upon doxycycline treatment. Vinculin is shown as a loading control. (C) qRT-PCR analysis of the effect of 
doxycycline on serine biosynthesis enzyme mRNA levels in Flp-In 293 HA-IKKε cells transfected with ATF4 siRNA. As 
before, doxycycline significantly upregulates PHGDH, PSAT1 and PSPH mRNA levels in control siRNA transfected cells, 
but suppression of ATF4 inhibits HA-IKKε-mediated upregulation of enzyme mRNA levels. These data indicate ATF4 
controls HA-IKKε-driven upregulation of serine biosynthesis enzymes. mRNA levels are presented as relative fold 
change values versus non-treated, control siRNA-transfected samples and normalised to ACTB (β-Actin) mRNA levels. 
n=4 independent experiments, mean ± SEM, *p<0.05 as measured by two-way ANOVA with Bonferroni post-hoc tests. 
 
A B 
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Together, these data confirm that the IKKε-mediated transcriptional regulation of serine 
biosynthesis enzymes in doxycycline-treated Flp-In 293 HA-IKKε cells is in fact a consequence of 
the effect of IKKε on the mitochondria. As determined earlier, expression of IKKε blocks the 
uptake of glucose-derived carbon into the TCA cycle and, as a consequence, mitochondrial 
OXPHOS is impaired. The inhibition of mitochondrial function is evidently sufficient to activate 
ATF4-mediated retrograde mitochondria-to-nucleus signalling, inducing transcriptional 
upregulation of the enzymes of the serine biosynthesis pathway. 
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5.5 ATF4 maintains serine biosynthesis enzyme expression in human breast 
cancer cell lines 
 
As upregulation of the serine biosynthesis enzymes by HA-IKKε in Flp-In 293 cells was found to 
be mediated by ATF4, the role of this transcription factor in IKKε-mediated regulation of the 
enzymes in human breast cancer cell lines was also assessed.  
Since mitochondrial dysfunction was found to be the driving force behind IKKε-mediated 
upregulation of PHGDH, PSAT1 and PSPH in Flp-In 293 cells, it was hypothesised that the 
upregulation of the enzymes was occurring via a similar mechanism in breast cancer cell lines 
where the kinase also inhibited cellular oxygen consumption. Therefore, the effect of siRNA-
mediated suppression of ATF4 on PHGDH, PSAT1 and PSPH mRNA levels was investigated in ZR-
75-1, T47D and MDA-MB-468 cell lines. These are cell lines where IKKε regulated the expression 
of one or more serine biosynthesis enzymes whilst also regulating OCR (see 4.1, 4.2 and 5.2), 
suggesting activation of ATF4 was responsible for the transcriptional upregulation of the 
enzymes in these cells. It was thus hypothesised that suppression of ATF4 in ZR-75-1, T47D and 
MDA-MB-468 cells would have the same effect on the expression of PHGDH, PSAT1 and PSPH 
mRNA as suppression of IKKε did.  
Breast cancer cell lines were transfected with a single ATF4-targeting siRNA oligo or a non-
targeting control oligo for 72 hours, following which the effect of transcription factor knockdown 
on PHGDH, PSAT1 and PSPH mRNA was assessed using qRT-PCR. These experiments were 
performed with the assistance of Miss Sheila Olendo Barasa, a master’s degree student under 
supervision in the lab. 
The effect of ATF4 suppression on the serine biosynthesis enzymes was much broader than the 
effect of IKKε suppression. Knockdown of ATF4 had a very general suppressive effect on all of 
the serine biosynthesis enzymes, significantly downregulating both PHGDH and PSAT1 mRNA 
levels in ZR-75-1, T47D and MDA-MB-468 cells and PSPH in T47D cells (Figure 5.8 A). This is in 
contrast to the effect of IKKε knockdown in these cells, which primarily resulted in the significant 
downregulation of PSAT1 mRNA with no consistent impact on PHGDH or PSPH mRNA (Figure 
4.8). To ascertain whether this broad effect was limited to just the selected cell lines, the effect 
of siRNA-mediated suppression of ATF4 was validated in all of the other cell lines of the panel. 
Confirming what was seen in ZR-75-1, T47D and MDA-MB-468, ATF4 knockdown in the other 
breast cancer cell lines resulted in substantial downregulation of mRNA levels of all three serine 
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biosynthesis enzymes in all cell lines except Cal120 and HCC1143, where PSPH mRNA levels 
stayed mostly unaffected (see supplementary materials: Figure 7.2).  
To determine whether this broad pattern of regulation would translate to the enzyme protein 
levels, western blotting was used to assess the effect of ATF4 knockdown on PHGDH, PSAT1 and 
PSPH protein levels in breast cancer cell lines. As before, this was primarily assessed in ZR-75-1, 
T47D and MDA-MB-468 cells, but this for this experiment, the effect of knockdown on the 
enzyme protein levels was also evaluated in MDA-MB-231, as the only PSAT1-expressing cell line 
where IKKε inhibited OCR but did not upregulate PSAT1, and HCC1143, as a cell line where IKKε 
regulated PSAT1 but had no effect on OCR. As with the qRT-PCR experiments, these experiments 
were performed with the assistance of Miss Sheila Olendo Barasa. 
Akin to the findings at the mRNA level, ATF4 suppression broadly and consistently 
downregulated the protein levels of all three enzymes in all the cell lines tested, even in MDA-
MB-231 and HCC1143 (Figure 5.8 B). Comparatively, suppression of IKKε led to a consistent 
reduction in PSAT1 protein levels in all PSAT1-expressing cell lines (except MDA-MB-231), but 
had no consistent effect on the other enzymes of the pathway (Figures 4.3 and 4.4). This 
reduction in PHGDH, PSAT1 and PSPH protein levels upon ATF4 knockdown was also validated 
in all other cell lines within the panel, further demonstrating the ubiquitous role of the 
transcription factor (see supplementary materials: Figure 7.3). Transcription factor knockdown 
was also assessed across the full panel of cell lines at the same time. 
Together, these data confirm that ATF4 plays a much broader role in the regulation of PHGDH, 
PSAT1 and PSPH in breast cancer cell lines than IKKε does, and demonstrates ATF4’s status as a 
master regulator of serine biosynthesis. In line with the fact that IKKε is just one of many factors 
capable of regulating ATF4 activity, it was unlikely that identical effects would be observed upon 
suppression of IKKε or ATF4. Indeed, these data highlight that IKKε’s ability to regulate the serine 
biosynthesis enzymes in breast cancer cell lines is far more specific to PSAT1 than the ability of 
ATF4, and indicate that, as expected based on previous findings of the role of ATF4 in 
cancer324,372,379, the transcription factor is likely frequently regulated independently of IKKε. 
Nevertheless, these data do confirm that ATF4 is an active regulator of the serine biosynthesis 
enzymes in the panel of breast cancer cell lines. This therefore maintains the possibility that, in 
cell lines where IKKε regulates mitochondrial function, the serine biosynthesis enzymes could 
theoretically be induced via the same ATF4-mediated retrograde signalling through which the 
kinase seems to regulate the enzymes in Flp-In 293 cells.  
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Figure 5.8 – ATF4 is an active master regulator of serine biosynthesis enzyme expression in human breast cancer 
cell lines. Indicated breast cancer cell lines were transfected with a single ATF4-targeting siRNA oligo or a non-
targeting control oligo, at a final concentration of 50 nM for 72 hours. ATF4 suppression downregulated serine 
biosynthesis enzyme proteins and mRNA levels in all cell lines tested. (A) qRT-PCR analysis of PHGDH, PSAT1 and PSPH 
mRNA levels in ZR-75-1, T47D and MDA-MB-468 breast cancer cell lines following ATF4 suppression. mRNA levels are 
presented as relative fold changes compared to control siRNA transfected cells and normalised to ACTB (β-Actin) 
mRNA levels. n=3 independent experiments, mean ± SEM, *p<0.05 as measured by one-sample t-test comparing fold 
change values to a hypothetical mean of 1.0. (B) Western blot analysis of PHGDH, PSAT1 and PSPH protein levels in 
ATF4 siRNA transfected ZR-75-1, MDA-MB-468, MDA-MB-231, T47D or HCC1143 breast cancer cells compared to cells 
transfected with control siRNA. Vinculin is shown as a loading control. 
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5.6 DCA inhibits IKKε-mediated upregulation of serine biosynthesis enzymes 
 
As the IKKε-mediated regulation of serine biosynthesis enzymes in Flp-In 293 cells was found to 
be attributable to the mitochondrial dysfunction that results from the inhibition of pyruvate 
dehydrogenase and the corresponding reduction in the uptake of glucose-derived carbon to the 
mitochondria, it was questioned whether forced re-activation of pyruvate dehydrogenase would 
block the IKKε-mediated upregulation of serine biosynthesis enzymes. Treatment of Flp-In 293 
HA-IKKε cells with DCA was previously found to be capable of preventing the mitochondrial 
inhibition induced by IKKε (see 5.2), so it was therefore hypothesised that if treatment with DCA 
reversed the mitochondrial inhibition, it would also prevent the IKKε-driven upregulation of the 
serine biosynthesis enzymes. 
To test this hypothesis, Flp-In 293 HA-IKKε cells were plated and treated with doxycycline, DCA, 
or a combination of both doxycycline and DCA for 16 hours. This allowed induction of the kinase 
whilst activating mitochondrial uptake of glucose-derived carbon. Induction of PSAT1 mRNA was 
subsequently assessed using qRT-PCR (Figure 5.9). 
Surprisingly, it was found that treatment of Flp-In 293 HA-IKKε cells with DCA alone upregulated 
PSAT1 mRNA similar to treatment of cells with doxycycline. This suggested that, instead of 
mitochondrial inhibition being required to activate ATF4, any modulation of mitochondrial 
function, positive or negative, might be sufficient to activate the retrograde signalling necessary 
to upregulate the serine biosynthesis enzymes. Importantly, the combination of DCA and 
doxycycline treatment had no synergistic effect on PSAT1 mRNA levels. Instead, the level of 
induction that was observed with the combined treatment of Flp-In 293 HA-IKKε cells with 
doxycycline and DCA was similar to the level of induction observed when cells were treated with 
just doxycycline or DCA alone. This indicated that, when Flp-In 293 HA-IKKε cells were treated 
with DCA, the activation of pyruvate dehydrogenase was at least blocking IKKε-dependent 
increases in enzyme mRNA levels.  
Since DCA alone upregulated PSAT1 transcription, it was questioned whether the activation of 
pyruvate dehydrogenase was inducing the same retrograde mitochondria-to-nucleus signalling 
that IKKε does. Therefore, to address this, a western blot was performed to evaluate the protein 
levels of the ATF4 transcription factor, PHGDH, PSAT1 and PSPH in Flp-In 293 HA-GFP or Flp-In 
293 HA-IKKε cells upon treatment with doxycycline, DCA, or a combination of both compounds 
for 16 hours (Figure 5.10 A). Subsequently, the protein levels of ATF4, PSAT1 and PSPH in these 
conditions were measured using densitometry quantification analysis (Figure 5.10 B-D).  
Chapter 5. Results III: IKKε regulates serine biosynthesis enzymes via mitochondrial inhibition 
209 
 
 
Figure 5.9 – DCA upregulates PSAT1 mRNA levels independently but prevents further upregulation by IKKε. qRT-
PCR analysis of PSAT1 mRNA levels in Flp-In 293 HA-IKKε cells treated with 50 ng/ml doxycycline and 50 mM DCA as 
indicated for 16 hours. mRNA levels are presented as fold change values versus non-treated control samples and 
normalised to ACTB (β-Actin) mRNA levels. Doxycycline upregulated PSAT1 mRNA as expected but, surprisingly, so 
did DCA treatment alone. No additive effect was observed in the combined treatment, indicating that the mechanism 
by which the two treatments induced PSAT1 mRNA were the same. Since DCA acts by modulation of mitochondrial 
activity, this supports the hypothesis that IKKε upregulates PSAT1 mRNA via regulation of the mitochondria as well. 
n=5 independent experiments, mean ± SEM. 
 
Western blotting quantification revealed that DCA treatment induced upregulation of ATF4 
protein levels, similar to induction of IKKε (Figure 5.10 B). This therefore indicated that DCA was 
activating ATF4-mediated mitochondria-to-nucleus retrograde signalling, as predicted based on 
the observed upregulation of PSAT1 mRNA levels following treatment of Flp-In 293 HA-IKKε cells 
with DCA. This seemingly confirmed the hypothesis that, rather than only being activated upon 
inhibition of the mitochondria, such signalling could potentially be activated by any modulation 
of mitochondrial function.  
Importantly, in support of the findings at the PSAT1 mRNA level, although induction of IKKε 
upregulated PSAT1 and PSPH proteins as expected, induction of the kinase alongside DCA 
treatment had no additive effect of upregulation of the enzymes (Figure 5.10 C and D). If DCA 
was regulating expression of the serine biosynthesis enzymes through modulation of 
mitochondrial activity and IKKε was inducing the enzymes via an alternate mechanism, then it 
would be expected that a combination of DCA treatment and doxycycline-mediated HA-IKKε 
induction would have a synergistic effect on the expression of the serine biosynthesis enzymes. 
In this instance, mRNA and protein levels would be expected to rise to a greater level following 
combined DCA and doxycycline treatment than with either treatment individually. That there is 
no additive effect at either the mRNA or protein level indicates that both treatments trigger the 
upregulation of the enzymes via the same mechanism. These data therefore further support the 
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hypothesis that regulation of PHGDH, PSAT1 and PSPH by HA-IKKε in Flp-In 293 cells occurs via 
regulation of mitochondrial activity and induction of ATF4.  
Interestingly, despite a lack of additive effect of the combination treatment on the serine 
biosynthesis enzymes, an additive effect was observed in terms of ATF4 protein induction. This 
suggests that the induction of ATF4 by IKKε and by DCA occur via different mechanisms. 
Importantly, the increased levels of ATF4 in the combined doxycycline and DCA-treated cells do 
not appear to reflect an increase in transcriptional activity compared to the single treatment 
conditions. Indeed, despite higher levels of ATF4 protein, the expression of the serine 
biosynthesis enzymes is not further increased, suggesting that the ATF4 protein induced by the 
combined treatment is less active overall than the protein induced by induction of IKKε or 
treatment with DCA alone. Potential explanations for this are discussed later (see 5.7).  
Together, these data support the hypothesis that the transcriptional upregulation of serine 
biosynthesis enzymes is a direct consequence of mitochondrial inhibition by the kinase, 
mediated by the inhibition of the conversion of pyruvate to acetyl-CoA, the resulting 
mitochondrial dysfunction and the consequential activation of ATF4-mediated gene 
transcription. 
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Figure 5.10 – DCA upregulates serine biosynthesis enzyme protein levels independently, but prevents further 
upregulation of PSAT1 and PSPH by IKKε. (A) Western blot analysis of the effect of doxycycline and DCA on PHGDH, 
PSAT1, PSPH and ATF4 protein levels in Flp-In 293 HA-GFP or Flp-In 293 HA-IKKε cells. Cells were treated with 50 ng/ml 
doxycycline and 50 mM DCA as indicated for 16 hours. Vinculin is shown as a loading control. (B-D) Densitometry 
quantification analysis of ATF4 (B), PSAT1 (C) and PSPH (D) protein levels in Flp-In 293 HA-IKKε cells. Protein 
densitometry per sample was quantified as a percentage of total protein densitometry and normalised to vinculin. 
Treatment of cells with doxycycline upregulated ATF4, PSAT1 and PSPH protein levels in agreement with previous 
findings. DCA also upregulated PSAT1 and PSPH protein levels alone, supporting findings at the PSAT1 mRNA level. 
This is potentially attributable to a significant increase in ATF4 protein levels upon DCA treatment. No additive effect 
of doxycycline and DCA was observed with PSAT1 and PSPH proteins, but ATF4 protein levels were significantly higher 
in the cells treated with both compounds combined than in cells treated with either compound individually. n=4 
independent experiments, mean ± SEM, *p<0.05 as measured by two-way ANOVA with Bonferroni post-hoc tests. 
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5.7 Discussion 
 
After chapter 4 described the finding that induction of HA-IKKε in Flp-In 293 cells not only 
upregulated PSAT1 protein levels, as was expected based on the hypothesis that IKKε-
dependent phosphorylation would increase protein stability, but also upregulated PSPH protein 
levels and transcriptionally upregulated PHGDH, PSAT1 and PSPH, it became clear that the 
kinase was broadly affecting the activity of the serine biosynthesis pathway via a mechanism 
independent of substrate phosphorylation. Importantly, this mechanism was also shown to be 
independent of “classical” IKKε signalling activities, with NF-κB subunit p65 and IFNβ signalling 
factor IRF3 both being found to be inessential for the transcriptional upregulation of serine 
biosynthesis enzymes. It was therefore evident that the kinase was regulating the serine 
biosynthesis pathway transcriptionally via a previously uncharacterised mechanism. This 
chapter described the efforts undergone to identify this mechanism and a transcription factor 
responsible for the upregulation of PHGDH, PSAT1 and PSPH expression. 
IKKε-mediated mitochondrial inhibition 
Recent studies have described the interaction of IKKε with the mitochondria to varying degrees, 
either promoting the association of secondary enzymes with the organelle106, or interacting with 
it itself373. As labelled metabolite analysis had identified an IKKε-dependent decrease in the 
incorporation of glucose-derived carbon in TCA cycle metabolites, it was hypothesised that the 
kinase was actively inhibiting mitochondrial function in addition to the upregulation of serine 
biosynthesis activity.  
It was found that IKKε inhibited the uptake of glucose-derived carbon in the mitochondria by 
blocking the conversion of pyruvate to acetyl-CoA, which in turn decreased mitochondrial 
OXPHOS. What currently remains unclear, is how exactly the kinase exerts its effect on the 
mitochondria. Considering that the inhibitory effect can be blocked by treatment with DCA, 
which induces activation of pyruvate dehydrogenase, the regulation of mitochondrial function 
by IKKε appears to involve the inhibition of pyruvate dehydrogenase activity. In favour of this 
hypothesis, PDHA1, a central subunit of the pyruvate dehydrogenase complex, was identified as 
part of the phosphoproteomic described in chapter 3 (see 3.3) to be significantly more 
phosphorylated in IKKε-expressing cells at serine residue Ser232. Phosphorylation of PDHA1 at 
Ser232 is known to be a site linked with inactivity of the enzyme375,376, therefore suggesting that 
IKKε inhibits pyruvate dehydrogenase complex activity through inducting the phosphorylation 
of PDHA1. Overlap of IKKε’s optimal phosphorylation recognition motif197 with the amino acid 
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sequence surrounding the PDHA1 Ser232 phosphosite showed little sequence matching, 
indicating that PDHA1 is unlikely to be a direct substrate of the kinase.  
Pyruvate dehydrogenase complex subunits are typically phosphorylated by members of the 
pyruvate dehydrogenase kinase family, and PDHA1 Ser232 is usually phosphorylated by 
pyruvate dehydrogenase kinase 1 (PDK1), though it is possible other kinases could also 
phosphorylate the residue376. Considering that IKKε’s inhibition of the mitochondria was 
completely rescued by treatment of cells with DCA, a PDK1 inhibitor380, it is possible that the 
kinase inhibits PDHA1 by activating PDK1. PDK1 is known to be activated by high levels of acetyl-
CoA and ATP and, conversely, be inhibited by high levels of pyruvate and ADP, but has also been 
shown to be activated by phosphorylation at threonine residue Thr338 by mitochondria-
translocated phosphoglycerate kinase 1 (PGK1)381 and at residue Thr346 by AKT382. PGK1 can be 
translocated to the mitochondria by EGFR activation, which has been shown to activate IKKε in 
non-small cell lung cancer383 and it is well characterised that IKKε can activate AKT directly384. 
Therefore, whilst PDK1 phosphorylation was unable to be detected in IKKε-expressing cells via 
the phosphoproteomic analysis, it is possible that IKKε could activate PDK1 by indirectly inducing 
Thr338 or Thr346 phosphorylation, thereby promoting the inactivation of PDHA1 and pyruvate 
dehydrogenase activity. It would therefore be worth evaluating the effect of IKKε on the activity 
of PDK1 in future work to either confirm or deny this hypothesis.  
IKKε significantly regulated mitochondrial activity and OCR in Flp-In 293 cells and in 6 out of 9 
breast cancer cell lines tested and, although not significant, a trend of upregulated OCR upon 
IKKε suppression in the SUM44 cell line was also observed. Only the Cal120 and HCC1143 cell 
lines showed no change in OCR upon siRNA-mediated suppression of IKKε. When trying to 
consider why these cell lines might be different, the activation of IKKε canonical signalling was 
first considered. As reported in chapter 4 (see 4.4 and Figure 4.13) none of the breast cancer cell 
lines tested demonstrated phosphorylation of IRF3 suggesting that, in accordance with findings 
that signalling via IRF3 is dispensable for IKKε-driven transformation195, IFNβ signalling was 
inactivated in breast cancer. Cal120 and HCC1143 did show evidence of STAT1 phosphorylation, 
but so did MDA-MB-453 and MDA-MB-468 which feature OCR regulation upon IKKε suppression, 
suggesting that the absence of OCR regulation in Cal120 and HCC1143 is independent of STAT1 
phosphorylation. Similarly, p65 was phosphorylated in all breast cancer cell lines tested with the 
exception of SUM44 indicating that presence or absence of NF-κB activation would not explain 
the differential regulation of OCR between cell lines either. Together this demonstrated that the 
regulation of OCR in breast cancer cell lines was independent of activation of canonical IKKε 
signalling. Interestingly, assessing the expression of established IKKε adaptor proteins in the 
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panel of breast cancer cell lines offered some insight as to why Cal120 and HCC1143 might be 
different to the other cell lines tested. In HA-IKKε-expressing Flp-In 293 cells, evaluation of 
adaptor protein expression indicated that IKKε adaptor proteins SINTBAD, NAP1 and TANK were 
potentially phosphorylated, suggesting that these proteins might be acting as IKKε adaptors for 
signalling in those cells (see 4.3 and Figure 4.10). When looking at the expression profile of kinase 
adaptors in the breast cancer cell line panel, Cal120 and HCC1143 cells were found to express 
little to no SINTBAD, NAP1 or TANK, whereas the rest of the cell lines expressed all of the known 
adaptors (Figure 4.11). If the IKKε-mediated signalling that results in regulation of OCR requires 
the formation of a protein complex of IKKε with SINTBAD, NAP1 and/or TANK adaptor proteins, 
then the absence of these proteins in Cal120 and HCC1143 could explain the lack of effect of the 
kinase on OCR in these cell lines. It would therefore be interesting to test whether reintroduction 
of these adaptor proteins to Cal120 and HCC1143 cells could recapitulate IKKε’s effect on OCR. 
IKKε-mediated regulation of serine biosynthesis via ATF4 
Irrespective of the mechanism, induction of IKKε in Flp-In 293 cells inhibits mitochondrial oxygen 
consumption and by extension mitochondrial activity by inhibiting the conversion of pyruvate 
to acetyl-CoA, thereby blocking the entry of glucose-derived carbon to the TCA cycle. 
Mitochondrial dysfunction has been shown to induce the activation of ATF4, which is believed 
to be a response to altered cellular redox balance and the oxidative stress that occurs upon the 
inhibition of the electron transport chain362. Indeed, the transcription factor has been shown to 
be crucial for the cellular response to redox imbalance. It is also activated as part of the 
integrated stress response to endoplasmic reticulum stress, specifically enhancing glutathione 
synthesis to maintain intracellular redox balance385. Disruption in mitochondrial activity induces 
an ATF4-mediated mitochondria-to-nucleus retrograde signalling axis that upregulates the 
serine biosynthesis enzymes362. The upregulated serine biosynthesis enzymes help maintain 
redox balance by providing cells with a mechanism by which glucose-derived carbon can be 
easily diverted into one-carbon metabolism in order to support production of reduced 
glutathione320. Accordingly, data described in this chapter demonstrated that IKKε upregulated 
enzymes of the serine biosynthesis pathway in an ATF4-dependent manner, indicating the 
mitochondrial dysfunction induced by the kinase is responsible for the transcriptional 
upregulation of the serine biosynthesis enzymes.  
This demonstrates a much broader mechanism of regulation of serine biosynthesis by IKKε than 
the specific upregulation of PSAT1 through IKKε-dependent phosphorylation. With this in mind, 
and to further discuss a point debated in chapter 4 (see 4.8), it is necessary to consider the 
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relative importance of PSAT1 phosphorylation versus transcriptional regulation in the overall 
IKKε-driven upregulation of enzyme expression and serine biosynthesis. The data presented 
here in Figure 5.7 supports the conclusion reached in the previous chapter that transcriptional 
regulation supersedes protein phosphorylation for overall upregulation of the PSAT1 protein. 
Whilst suppression of ATF4 in Flp-In 293 HA-IKKε cells completely abolished IKKε’s ability to 
upregulate PSAT1 and PSPH protein levels and PHGDH, PSAT1 and PSPH mRNA levels, IKKε 
kinase activity was unaffected in these conditions, meaning PSAT1 should still be 
phosphorylated in an IKKε-dependent manner. The fact that no protein upregulation was 
observed therefore indicates that transcriptional regulation of the enzymes plays a more 
significant role in the regulation of total protein levels and that the primary regulation of serine 
biosynthesis by IKKε comes from the ATF4-mediated upregulation of gene transcription as a 
consequence of mitochondrial inhibition. 
Interestingly, the data presented in Figure 5.9 and Figure 5.10 in this chapter seemingly indicate 
that ATF4 signalling is not solely induced by mitochondrial dysfunction, but rather by any 
modulation of mitochondrial activity. Treatment of both Flp-In 293 HA-GFP and Flp-In 293 HA-
IKKε cells with mitochondrial activator DCA for 16 hours not only induced upregulation of ATF4 
protein levels themselves, but also PSAT1 mRNA levels, indicating that ATF4 transcriptional 
activity is induced as well. Notably, it is not clear what effect DCA treatment has on redox 
homeostasis within the cells over the course of 16 hours of treatment. One possible explanation 
is that, rather than ATF4 being activated by an increase in mitochondrial activity, DCA is 
unexpectedly inducing a mitochondrial stress response despite enhancing mitochondrial 
activity. DCA treatment and the resulting hyperactivation of the pyruvate dehydrogenase 
complex might lead to rapid depletion of available fuel and therefore lead to the activation of a 
stress response and ATF4 due to a lack of mitochondrial substrate availability. This could explain 
why the transcription factor was activated when, theoretically, mitochondrial function was 
maximised. Measuring intracellular ROS levels upon treatment of cells with DCA could help 
determine the effect of the compound on redox balance and ascertain how DCA is activating 
ATF4 signalling. 
The data in Figure 5.10 and Figure 5.7 indicate that induction of HA-IKKε in Flp-In 293 HA-IKKε 
also upregulates ATF4 protein levels. Whilst total protein levels of a transcription factor do not 
necessarily correlate with its transcriptional activity, this at least indicated that the transcription 
factor was regulated by the kinase and the characteristic increase in PHGDH, PSAT1 and PSPH 
mRNA levels upon induction of the kinase obviously supports the hypothesis that IKKε increases 
ATF4 transcriptional activity. Interestingly, whilst this data represents the first explicit 
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connection of IKKε with the induction of ATF4 transcriptional activity, the transcription factor 
has been indirectly linked with IKKε before, when it was found that the activation of TLR4 
signalling in human monocytes, following treatment with LPS, activated ATF4 and induced its 
nuclear translocation, wherein it promoted the induction and secretion of key inflammatory 
cytokines like IL-6386. Whilst this activity was determined to be mediated by the TLR4-
recruitment of MyD88 and the resulting activation of c-Jun N-terminal kinases (JNK), activation 
of toll-like receptors by LPS stimulation also induces IKKε and IKKε signalling activities88. The data 
presented here therefore represent a secondary mechanism by which activation of innate 
immune response signalling can promote the activation of ATF4 and, considering the role the 
transcription factor plays in serine biosynthesis, further emphasises the link between immunity 
and metabolism. 
Intriguingly, our data suggest that IKKε might induce ATF4 protein levels via two alternative 
mechanisms. The evidence presented in this chapter demonstrates the induction of ATF4 
protein levels and transcriptional activity as a result of IKKε-mediated mitochondrial inhibition. 
However, as previously discussed, DCA also induced ATF4 protein upregulation and 
transcriptional activity. Given DCA’s mechanism of action, DCA-mediated upregulation of ATF4 
almost certainly occurs via mitochondrial regulation. It would be expected then, that if induction 
of IKKε and treatment of cells with DCA both induced ATF4 transcriptional activity via regulation 
of mitochondrial activity, a combination of DCA treatment and induction of IKKε would have no 
additive effect on ATF4 protein levels or transcriptional activity. As Figure 5.9 and Figure 5.10 
demonstrate, even though ATF4 transcriptional activity in combined DCA treatment and IKKε 
induction conditions appears equal, ATF4 protein levels are surprisingly significantly higher in 
cells treated with DCA and doxycycline together compared to cells treated with either 
compound individually. This additive effect on ATF4 protein levels suggests that induction of 
IKKε and treatment of cells with DCA induce ATF4 protein levels via two distinct mechanisms. 
This suggests that, although IKKε may upregulate ATF4 protein levels via regulation of 
mitochondrial activity, the kinase might also upregulate the transcription factor via a second, 
undetermined mechanism. It does however appear that if this hypothesis is proven correct, this 
unknown second mechanism is insufficient to induce activation of ATF4. As mentioned above, 
despite the additive effect on total protein levels, no additive effect on PSAT1 mRNA or PSAT1 
and PSPH protein was observed, suggesting ATF4 transcriptional activity was equal between 
conditions. This suggests that the additional ATF4 protein induced in the combined treatment 
condition was transcriptionally inactive. Further investigation would be necessary to identify 
whether IKKε was capable of upregulating ATF4 this way or not, but this would help explain why 
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when IKKε is induced but the mitochondria remain active, the protein levels of ATF4 can increase 
without an observable increase in transcription of the serine biosynthesis enzymes. 
IKKε and ATF4 in breast cancer 
Whilst the role of ATF4 in IKKε-mediated upregulation of serine biosynthesis enzymes in Flp-In 
293 cells appears conclusive, the role that the transcription factor plays in IKKε’s regulation of 
the enzymes in breast cancer remains less clear. The data presented in Figure 5.8 and 
supplementary Figures 7.1 and 7.2 demonstrate that the transcription factor is indeed 
maintaining expression of the enzymes in breast cancer and previous studies have also 
demonstrated a role for it in both lung cancer and breast cancer324,387. However, the consistency 
with which ATF4 was found to be regulating the enzymes across multiple cell lines demonstrated 
that it is activated far more broadly in breast cancer cell lines than just in cell lines where IKKε 
regulates the mitochondria. Based on the findings in Flp-In 293 HA-IKKε cells it would be 
expected that, wherever IKKε regulated cellular OCR, the expression of all three serine 
biosynthesis enzymes would be downregulated upon suppression of the kinase. Instead, in 
certain cell lines, suppression of the kinase only regulated PSAT1 mRNA and PSAT1 protein levels 
(Figure 4.4 and Figure 4.8). Additionally, PSAT1 mRNA was also regulated in the HCC1143 cell 
line, where no effect on OCR was observed. Contrastingly, ATF4 suppression frequently 
downregulated mRNA and protein levels of all three enzymes in all of the breast cancer cell lines 
tested. Active ATF4 signalling in the panel of breast cancer cell lines suggests that IKKε does have 
the potential to act via ATF4 in cell lines where it regulates the mitochondria, but perhaps 
instead of IKKε expression leading to an induction of ATF4 activity as is seen in Flp-In 293 cells, 
which would lead to the regulation of all three serine biosynthesis enzymes, IKKε might just 
modify pre-existing ATF4 transcriptional activity in breast cancer cells to upregulate PSAT1, 
similar to how the kinase modifies STAT1 transcriptional activity to promote the activation of 
additional IKKε-dependent STAT1 target genes99. This is consistent with the fact that ATF4 is not 
solely regulated by IKK in cancer, with the kinase instead being just one of many factors known 
to induce ATF4 transcriptional activity324,372,379.  
It is also likely that IKKε-mediated regulation of serine biosynthesis enzymes across numerous 
breast cancer cell lines cannot be simply pinned down to the activity of a single transcription 
factor. Whilst the role of NF-κB and IFNβ signalling in the regulation of serine biosynthesis in Flp-
In 293 cells has been shown to be minimal, the roles of these signalling pathways and resulting 
transcriptional programmes should be properly assessed in breast cancer cell lines. Whilst 
preliminary experiments have indicated a similarly inessential role for NF-κB signalling in breast 
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cancer cells, the role of IRF3 and IFNβ signalling is less clear, sometimes appearing to be partially 
involved, sometimes appearing to have no role. Given that experiments investigating the 
activation of IFNβ signalling in the breast cancer cell line panel indicated that the pathway is 
inactive in the cell lines used, it seems contradictory to suggest that siRNA-mediated suppression 
of IRF3 would have any impact on these cell lines, but further validation of the roles of both the 
NF-κB and IFNβ signalling pathways may allow some clarification of the role that ATF4 and other 
IKKε downstream targets play in the regulation of serine biosynthesis in breast cancer. 
Activation of alternative transcription factors by IKKε in breast cancer 
It would also be worth further exploring additional transcription factors that might be involved 
in breast cancer cell lines. Whilst the promoter analysis that was performed and described at 
the start of this chapter (see 5.1) highlighted other transcription factors that might regulate 
PHGDH, PSAT1 and PSPH together, none of these potential factors were deemed to be suitable 
candidates for the regulation of the enzymes in Flp-In 293 cells. Links between IKKε and C/EBPβ, 
C/EBPδ, SP1 and EP300 all required the involvement of NF-κB subunit p65 or IFNβ-signalling 
factor IRF3364-368. Since neither NF-κB or IFNβ signalling were found to be necessary for the 
regulation of the serine biosynthesis enzymes by IKKε in Flp-In 293 cells, the role of these 
transcription factors in those cells was considered to likely be minor compared to ATF4. 
However, given the lack of clarity of the role of ATF4 in the regulation of serine biosynthesis 
enzymes by IKKε in breast cancer cells, it would be prudent to revisit some of these other 
potential transcription factors to re-assess their involvement. Additionally, in light of findings in 
pancreatic cancer demonstrating that IKKε-driven metabolic reprogramming in a Myc-
dependent manner promotes proliferation189 the involvement of c-Myc in IKKε-mediated 
upregulation of PHGDH, PSAT1 and PSPH mRNA should also be examined. 
Concluding remarks 
To summarise, the data presented in this final results chapter expands on the findings from the 
labelled metabolite analysis experiment described in chapter 3, detailing how IKKε regulates 
mitochondrial function to promote a phenotype akin to aerobic glycolysis within Flp-In 293 cells 
and breast cancer cell lines. Following the findings regarding the inessential nature of IKKε’s 
canonical NF-κB and IFNβ signalling activities in the kinases ability to enhance serine 
biosynthesis, it was found that IKKε’s inhibitory effect on the mitochondria induced the 
activation of an ATF4-mediated retrograde mitochondria-to-nucleus signalling axis which in turn 
upregulates PHGDH, PSAT1 and PSPH, demonstrating how the kinases effect on anabolic serine 
metabolism is a key consequence of its effect on the mitochondria. 
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6.1 Overview 
 
Although identified as a major breast cancer oncogene in 2007, amplified and overexpressed in 
around 30% of human breast cancer cases195, therapeutic options for targeting and treating 
IKKε-driven cancers remain limited by the fact that the primary mechanism of oncogenesis in 
breast cancer is attributed to aberrant activation of NF-κB. The impracticalities of targeting NF-
κB signalling for therapeutic intervention in cancer have been discussed previously (see 1.3.3.1) 
and given the ubiquitous nature of NF-κB signalling in tissues, prolonged inhibition can have 
severely detrimental effects, including immunosuppression. Furthermore, attempts to develop 
NF-κB inhibitors for cancer therapy have thus far yielded few promising compounds. This means 
that in order to effectively treat IKKε-driven breast cancers, a greater understanding of the full 
scope of IKKε’s oncogenic potential is required and alternative therapeutic targets must be 
identified so that the cancer can be treated without inhibiting NF-κB. 
IKKε regulates cellular metabolism in breast cancer cells 
Cellular metabolism is frequently and dramatically altered in most human cancers, with classical 
oxidative phosphorylation being suppressed in favour of aerobic glycolysis. In aerobic glycolysis, 
glycolytic rates and lactate production are substantially increased and glucose-derived carbon is 
diverted away from the mitochondria and the TCA cycle in favour of its utilisation in biosynthetic 
pathways. Various oncogenes and cancer promoting processes have previously been shown to 
be master regulators of cellular metabolism. For example; c-Myc is known to increase the 
expression of glucose transporters and glycolytic enzymes, increase lactate production and 
promote glutaminolysis264-266,268,269; HIF1α has been shown to upregulate glucose transporters, 
glycolytic enzymes and lactate dehydrogenase to enhance glycolysis and also upregulates PDK 
to inhibit mitochondrial metabolism222-224,250-253 and finally; tumour suppressor p53 reportedly 
inhibits glycolysis by suppressing glucose transporters and upregulating TP53-induced glycolysis 
and apoptosis regulator (TIGAR), which subsequently suppresses fructose-2,6-bisphosphate 
protein levels and lowers glycolytic rate, and promotes OXPHOS by upregulating synthesis of 
cytochrome c oxidase 2 (SCO2) to increase cytochrome c oxidase protein293,294,388. The data 
presented in this thesis propose IKKε, a central player in the innate immune response86-88,99,102 
and transforming kinase, involved in the oncogenic activation of NF-κB signalling192,194,195, as an 
oncogenic kinase capable of regulating cellular metabolism via target protein phosphorylation 
equally as substantially as major oncogenic transcription factors like c-Myc and HIF1α, which 
modulate metabolism via regulation of gene expression.  
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Previous work has identified roles for other members of the IKK family of kinases in the 
regulation of cellular metabolism. As per p53’s role as a tumour suppressor and a suppressor of 
aerobic glycolysis, loss of p53 was found to increase kinase activities of IKKα and IKKβ and, as a 
result, increase NF-κB activation, which subsequently increased the rate of glycolysis and 
upregulated glucose transporter GLUT3389. Similarly, in B-cell lymphomas, IKKβ-driven activation 
of NF-κB was found to be required for the localisation of glucose transporter GLUT1 to the cell 
surface390, further demonstrating the promotion of glycolytic metabolism by IKKβ and the 
activation of the canonical NF-κB pathway. Conversely, IKK and NF-κB activation can also 
promote oxidative phosphorylation over aerobic glycolysis. Recent studies have demonstrated 
that IKKβ facilitates cancer cell adaptation to glutamine depravation, phosphorylating and 
inhibiting PFKFB3 to down-regulate aerobic glycolysis when glutamine sources are limited391 
and, in muscle cells, IKKα has been reported to promote oxidative metabolism by inducing 
mitochondrial biogenesis via the activation of the non-canonical NF-κB pathway and 
upregulation of peroxisome proliferator-activated receptor-gamma (PPAR-γ) coactivator-1 beta 
(PGC1-β)392. Along a similar line, p65-mediated NF-κB signalling in MEFs has been reported to 
actively promote oxidative phosphorylation in response to glucose starvation by 
transcriptionally upregulating the expression of SCO2 via p53393. These studies demonstrate how 
the activation of canonical IKK’s and NF-κB signalling can both promote or limit an aerobic 
glycolysis phenotype in a context-dependent manner. 
Whilst the regulation of aerobic glycolysis by canonical IKK’s has been shown to involve positive 
or negative regulation, recent years have also the non-canonical IKK’s TBK1 and IKKε increasingly 
linked to the regulation of cellular metabolism specifically through the promotion of aerobic 
glycolysis. TBK1 has been shown to be involved in the metabolic response to obesity. Both IKKε 
and TBK1 kinase activity is significantly increased in the adipocytes of obese mice on high fat 
diets104 and mice with an adipocyte-specific knockout of TBK1 failed to become obese when fed 
with a high-fat diet due to substantial increases in oxygen consumption and energy expenditure 
in white adipose tissue. This indicated that TBK1 suppressed mitochondrial respiration. Indeed, 
the kinase has subsequently been shown to suppress mitochondrial respiration by inactivating 
AMPK-induced mitochondrial biogenesis394. Although IKKε and TBK1 share some overlap in 
phosphorylation targets and signalling activities, it remains to be seen whether the regulation 
of AMPK activity is unique to TBK1’s functional capacity or not. More relevant to this project 
therefore, is how previous work has demonstrated a strong link between IKKε and aerobic 
glycolysis.  
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In dendritic cells, proper cellular activation was shown to require an early metabolic switch to 
aerobic glycolysis that is dependent on TBK1 and IKKε. In this context, the kinases promote the 
association of glycolytic enzyme hexokinase II with the mitochondria, facilitating direct use of 
mitochondrial ATP and thereby enhancing the glycolytic rate106. Furthermore, whilst it remains 
to be seen whether TBK1 would regulate cellular metabolism in a cancer setting, IKKε has been 
clearly shown to promote aerobic glycolysis in pancreatic cancer, where the kinase induces an 
AKT/GSK3β/c-Myc phosphorylation cascade that culminates in nuclear translocation of c-Myc 
and c-Myc-dependent induction of an aerobic glycolysis phenotype189. The non-canonical IKK’s 
have therefore been shown to regulate cellular metabolism via multiple distinct mechanisms. 
IKKε in particular promotes aerobic glycolysis both via direct interaction with a glycolytic enzyme 
and indirectly via the activation of oncogenic c-Myc, demonstrating that the kinase regulates 
cellular metabolism in a versatile manner. Intriguingly, the data presented within this thesis 
propose a novel alternate mechanism of IKKε-mediated metabolic regulation. This thesis 
presents a 2-pronged mechanism, through which the kinase inhibits mitochondrial respiratory 
activity and induces cellular biosynthetic activity to promote an aerobic glycolysis-like metabolic 
state. 
Labelled metabolite analysis was used to identify key IKKε-dependent changes in the metabolic 
state of HEK cells and breast cancer cells. It was found that the kinase had 2 major effects. 
Specifically, a reduction in the incorporation of glucose-derived carbon in TCA-cycle metabolites 
and an increase in the incorporation of glucose-derived carbon in amino-acids serine and 
glycine. This indicated that expression of IKKε was inhibiting classical respiratory mitochondrial 
function and increasing the de novo biosynthesis of serine. Using a combination of oroboros, 
seahorse extracellular flux analysis and TMRM mitochondrial staining in cells, the kinase was 
confirmed to reduce mitochondrial respiration. A phosphoproteomic analysis, identifying 
significantly more or less phosphorylated proteins in IKKε-expressing HEK cells, was performed 
to identify a potential mechanism for IKKε’s metabolic regulation. This data suggested the kinase 
was inhibiting mitochondrial activity by indirectly inducing an inhibitory phosphorylation of 
PDHA1, the central gatekeeper for the entry of glucose-derived carbon into the TCA cycle. 
Treatment of IKKε-expressing cells with DCA, a pyruvate dehydrogenase activator, successfully 
reversed IKKε-induced mitochondrial inhibition, thereby confirming that the kinase inhibits the 
mitochondrial uptake of glucose-derived carbon via the blocking of pyruvate dehydrogenase 
activity. Given that IKKε is capable of directly activating AKT384, which has been shown in 
previous work to be able to phosphorylate and activate PDK1 to indirectly inhibit pyruvate 
dehydrogenase382, it is likely that the kinase inhibits pyruvate dehydrogenase via the 
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phosphorylation and activation of AKT. This hypothesis requires further experimental validation, 
but regardless, even though IKKε has previously been linked to the regulation of oxygen 
consumption in high-fat diet fed mice103, in cancer, previous links between IKKε and metabolism 
have primarily demonstrated the focussed effect of the kinase on a single glycolytic enzyme106, 
or demonstrated that the kinase regulated glycolysis independently of any effect on 
mitochondrial oxygen consumption189. This makes the data presented here the first indication 
in cancer cells that, in addition to enhancing glycolytic reactions, the kinase also promotes 
aerobic glycolysis by suppressing mitochondrial respiration.  
IKKε upregulates serine biosynthesis via mitochondrial inhibition and ATF4 
The other major effect of IKKε on the intracellular metabolic state that was observed during the 
labelled metabolite analysis was a significant increase in the incorporation of glucose-derived 
carbon in amino acids serine and glycine, indicative of an increase in serine biosynthesis from 
glucose. The serine biosynthesis pathway branches from the mainline glycolytic reactions as 
PHGDH converts 3-phosphoglycerate to phosphohydroxypyruvate. PSAT1 and PSPH 
subsequently catalyse the addition of an amino group and the removal of a phospho group 
respectively to produce serine (Figure 1.9). Previous work has identified PHGDH as an oncogene, 
subject to a recurrent genetic amplification in ER- breast cancer and melanoma304,305. 
Accordingly, the serine biosynthesis pathway is of particular importance for rapidly proliferating 
cells and cancer cells for two key reasons.  
Firstly, in aerobic glycolysis, glucose-derived carbon is diverted from the mitochondria, 
preventing replenishment of TCA cycle intermediates and OXPHOS. Since, in addition to its role 
in mitochondrial respiration, the TCA cycle is important for various biosynthetic reactions, it is 
beneficial for proliferating cells to maintain TCA intermediate levels in the absence of glucose-
derived carbon incorporation. The primary alternate source of carbon in many cancers is 
glutamine. The second reaction of the serine biosynthesis pathway, catalysed by PSAT1, 
transfers an amino group from glutamine-derived glutamate to phosphohydroxypyruvate 
leaving TCA intermediate α-KG and producing phosphoserine respectively. The production of α-
KG via the PSAT1 reaction means that serine biosynthesis can therefore contribute to the fuelling 
of the TCA cycle with glutamine-derived carbon. Indeed, the serine biosynthesis pathway has 
been shown to account for a substantial proportion of glutamine anaplerosis (TCA cycle 
refuelling) in breast cancer305. Secondly, the break-down of serine to glycine involves the 
donation of one-carbon units to one-carbon metabolism, which is well known to help maintain 
redox balance and supports nucleotide production and DNA methylation in cancer320,322,323,395.  
Chapter 6. Discussion 
224 
 
Outside of the genetic amplification of PHGDH, multiple transcription factors, proteins and 
enzymes have been shown to induce upregulation of the serine biosynthesis enzymes in cancer 
including c-Myc315, ATF4324,387, p73325 and PKCζ326. Expression of IKKε in HEK and breast cancer 
cells was found to transcriptionally upregulate serine biosynthesis enzymes, accounting for the 
increased serine biosynthesis observed in cells expressing the kinase. Therefore, a transcription 
factor that induced the enzymes in response to IKKε expression was sought. Mitochondrial 
dysfunction has been previously reported to induce ATF4-mediated retrograde mitochondria-
to-nucleus signalling to upregulate serine biosynthesis enzymes362 and accordingly, the 
upregulation of serine biosynthesis enzymes was found to require ATF4 expression, indicating 
that the enzymes were regulated as a consequence of mitochondrial inhibition. 
ATF4 has been repeatedly linked to activation of the serine biosynthesis enzymes in previous 
work. The transcription factor has been shown to be upregulated by NRF2396, which itself can be 
activated downstream of K-Ras to induce ATF4397. Accordingly, in lung cancer, activation of NRF2 
has been shown to induce transcriptional upregulation of the serine biosynthesis enzymes via 
activation of ATF4324. Similarly, in ER- breast cancer, ATF4 was recently reported to be essential 
for the transcriptional upregulation of PSAT1, which was necessary to drive cell proliferation 
through the regulation of cyclin D1 protein stability387, although, in this setting, the mechanism 
behind the activation of ATF4 was not characterised. This thesis presents the hypothesis that 
IKKε is an indirect activator of ATF4 in breast cancer, demonstrating a previously uncharacterised 
mechanism of ATF4 activation and presenting the kinase as a novel regulator of serine 
biosynthesis enzyme expression in cancer. 
PSAT1 is phosphorylated in an IKKε-dependent manner to promote protein stability 
During the phosphoproteomic analysis of differentially phosphorylated proteins in IKKε-
expressing cells, PSAT1 was also identified as significantly more phosphorylated at serine residue 
Ser331. The enzyme was subsequently confirmed to be phosphorylated at this residue in a 
manner dependent on IKKε using an in vitro kinase assay. Studies using high-throughput 
techniques to analyse the phosphoproteome of cells had previously reported phosphorylation 
of the residue345-347,349,398-402, but no known previous work had characterised the relevance of the 
phosphosite for enzyme function. Generating a model of mutated PSAT1 proteins in which 
residue Ser331 was mutated to mimic (S>E, phosphomimic) or inhibit phosphorylation (S>A, 
phosphomutant)326, possible effects of PSAT1 Ser331 phosphorylation on enzyme function were 
assessed, examining serine production, protein-protein interactions and protein stability. The 
Ser331 residue was found to be an important residue for protein stability, with subtle but 
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measurable differences in protein stability being observed between phosphomimic and 
phosphomutant PSAT1 using pulse chase and induction time course assays. This study marks, 
not only the first investigation into the functional relevance of phosphorylation of the PSAT1 
Ser331 residue, but also represents the first known characterisation of any post-translational 
modification that regulates the function of the enzyme. As overexpression of PSAT1 has been 
shown to promote cancer growth309,310,312, it seems likely that phosphorylation of PSAT1 by IKKε 
could represent a mechanism by which the kinase can increase PSAT1 protein levels and 
promote cell proliferation. Whilst a lack of validated tools for detection of PSAT1 
phosphorylation have limited the chance to detect phosphorylation in breast cancer cell lines, 
the data presented here provides some evidence for this phosphorylation event occurring. 
Specifically, suppression of IKKε in the Cal120 breast cancer cell line led to a significant decrease 
in PSAT1 protein levels without a corresponding decrease in mRNA levels, indicating post-
translational regulation. IKKε-dependent phosphorylation of PSAT1 Ser331 modifying protein 
stability therefore represents a strong candidate to explain increased protein levels in the 
presence of IKKε-expression in this cell line. Additionally, whilst phosphorylation of PSAT1 
Ser331 in breast cancer cell lines was not directly examined as part of this work, previous work 
has detected phosphorylation of the enzyme in human breast cancer tissues, confirming that it 
occurs in a cancer context. Analysis of the phosphoproteome of 77 breast cancer samples 
spanning different disease subtypes found greater PSAT1 Ser331 phosphorylation in samples 
coming from a triple-negative breast tumour345. This indicates that the phosphorylation of PSAT1 
Ser331 correlates with a more aggressive tumour subtype and worse prognosis, implying that 
phosphorylation of this residue in an IKKε-dependent manner might contribute to poor disease 
outcome. 
Together, the data presented in this thesis present IKKε as a master regulator of cell metabolism 
in both HEK cells and breast cancer cell lines, capable of inducing profound changes to 
intracellular metabolic networks. Through the inhibition of mitochondrial respiration, 
attributable to indirect inhibition of pyruvate dehydrogenase activity; the upregulation of serine 
biosynthesis activity, as a consequence of mitochondrial inhibition and finally; the direct 
regulation of PSAT1 phosphorylation to promote protein stability, the kinase induces a 
metabolic state in which mitochondrial OXPHOS is reduced, whilst biosynthetic processes are 
increased. This combined with an increase in lactate secretion as observed by labelled 
metabolite analysis indicate that IKKε shifts the metabolic state of cells towards a phenotype 
that bears striking similarities to classical aerobic glycolysis, presenting metabolic regulation as 
a possible mechanism of IKKε-driven oncogenesis in breast cancer. 
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6.2 Future work 
 
One of the main ambitions of this project was to identify an NF-κB-independent mechanism of 
IKKε-mediated oncogenesis. In this thesis, the effect of the kinase on intracellular metabolism 
has been investigated and a dual mechanism of upregulation of serine biosynthesis activity has 
been described. The serine biosynthesis pathway is a particularly important pathway in cancers 
for reasons extensively described throughout this thesis, but a major outstanding question from 
this project is whether the mechanism described here, where IKKε regulates mitochondrial 
metabolism and consequently serine biosynthesis, is in fact of importance to the progression of 
human breast cancer or not. Specifically, it remains to be seen whether the IKKε-mediated 
upregulation of serine biosynthesis forms a part of IKKε’s oncogenic potential and important 
future experiments are required to begin to answer this question.  
Identifying IKKε-mediated regulation of PSAT1 in human cancer cases 
In breast cancer cell lines, the primary effect of IKKε expression on the serine biosynthesis 
pathway appears to focus on the upregulation of PSAT1, either transcriptionally or post-
translationally. This is of particular interest as, unlike PHGDH, the enzyme has not previously 
been indicated to be the subject of genetic amplification, instead relying on the action of other 
oncogenic transcription factors like Myc to be upregulated in cancer. In fact, when performing 
preliminary immunohistochemical staining of PSAT1 in patient tissue, it seems that overall 
expression of PSAT1 in any breast tissue is rather low, which is also supported by data in the 
human protein atlas, which shows no detectable PSAT1 expression in normal breast tissue and 
relatively low expression in breast cancer tissue compared to other cancer types403,404. It is 
possible that in cancer tissues where expression is higher, IKKε is responsible.  
Notably, the same preliminary immunohistochemical staining indicates that PSAT1 expression 
in breast tumour tissue might correlate with inflammation of the tumour microenvironment. 
Considering that data from Dr Ewa Wilcz-Villega, a fellow lab member, demonstrates induction 
of IKKε in MCF-10A cells by macrophage conditioned medium, this could indicate that induction 
of IKKε in breast tissue as a result of inflammation represents a mechanism by which the serine 
biosynthesis enzyme is upregulated in human breast tissue. Similarly, it is worth acknowledging 
that bioinformatic biclustering analysis of the METABRIC dataset405, kindly performed by 
Professor Gyorgy Szabadkai (University College London, London, UK), revealed that PSAT1 
expression correlated with IKKε expression when stratifying tumours based on mitochondrial 
gene expression. This indicated that in tumours where mitochondrial function is impaired, IKKε 
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might be regulating the expression of the enzyme. Indeed, further work must be done to 
evaluate the link between IKKε and PSAT1 in patients. The aforementioned 
immunohistochemical staining of PSAT1 is a good place to start in this regard, as staining the 
same tissue samples for IKKε will allow identification of the presence of any correlation between 
the kinase and PSAT1 within the tissues. Furthermore, applying similar sample stratifications 
and biclustering analysis to other large cancer gene expression datasets, such as the breast 
cancer dataset within The Cancer Genome Atlas (TCGA)406,407, would be prudent, to help try and 
identify a link between IKKε and the enzyme in larger numbers of patients. 
Identifying a function for IKKε-mediated regulation of serine biosynthesis in cancer 
PSAT1 has previously been found to be important for breast cancer progression both as part of 
the serine biosynthesis pathway and as an independent enzyme. For example, as has been 
previously discussed, the aminotransferase reaction that PSAT1 catalyses during its primary 
function in serine biosynthesis is beneficial to cancer cells as it provides a mechanism for 
glutamine anaplerosis of the TCA cycle. This allows cells to replenish TCA intermediates in the 
absence of glucose-derived carbon entry and allows the continuation of the biosynthetic 
reactions that use TCA metabolites as precursors. Accordingly, many cancers rely on the 
utilisation of glutamine to refuel TCA cycle intermediates227 and exhibit glutamine addiction and 
susceptibility to glutaminolysis inhibition234,235. Indeed, although the overall contribution of 
PSAT1 to TCA cycle anaplerosis remains open for debate, findings from Possemato et al. have 
demonstrated that, in breast cancer cell lines where PHGDH is genetically amplified, suppression 
of PHGDH has little impact on intracellular serine levels, but does significantly impair the 
production of α-KG from glutamine305, which indicates that the contribution of PSAT1 to 
anaplerosis is not an insubstantial one. Whilst labelled metabolite analysis was performed in 
IKKε-expressing cells using 13C-labelled glucose and 15N-labelled nitrogen, these experiments 
have been unable to provide substantial information regarding the contribution of glutamine-
derived carbon to the TCA cycle in the presence of IKKε. In order to properly address the effect 
that the kinase has on glutamine TCA anaplerosis, it would be important to perform labelled 
metabolite analysis using 13C-labelled glutamine, as this would allow measurement of the 
incorporation of glutamine-derived carbon into TCA cycle intermediates. 
Upregulation of serine biosynthesis also allows cells to overcome a major obstacle that arises as 
tumour size increases. As a tumour expands beyond the limits of oxygen perfusion from the 
existing vasculature, hypoxic regions begin to emerge. Whilst induction of hypoxia is well 
established to be beneficial for tumour cells, promoting aerobic glycolysis and inducing other 
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pro-proliferative factors like VEGF (see 1.4.3.1), hypoxic conditions can have adverse effects on 
tumour cells, specifically through the induction of oxidative stress and redox imbalance. In 
hypoxia, oxygen is unavailable as a terminal electron acceptor of the electron transport chain in 
the mitochondria. As a result, electrons in the chain will form reactive oxygen species (ROS)408 
that can induce cell death if left unaddressed. Induction of HIF1 transcriptional activity promotes 
the activation of genes that assist in the detoxification of ROS. One such example of these genes 
is SHMT2320, the mitochondrial isoform of SHMT that catalyses the breakdown of serine to 
glycine. Serine catabolism actively supports cells at risk of ROS associated toxicity, as its 
conversion to glycine involves the removal of a one-carbon unit. This one-carbon unit is donated 
to one-carbon metabolism and directly contributes to the production of NADPH to support the 
reduction of glutathione to help detoxify ROS. Accordingly, suppression of SHMT2, thereby 
inhibiting serine catabolism has been reported to induce cell death in hypoxic neuroblastoma 
cell lines and reduce xenograft tumour formation in vivo320. As IKKε has been shown to 
upregulate serine biosynthesis and, specifically, the flux of glucose-derived carbon towards 
serine, it stands to reason that increases in synthesised serine by the kinase can benefit breast 
cancer progression by increasing the flux of glucose-derived carbon into the one-carbon pool. 
From a non-serine biosynthesis stand-point, the enzyme has been shown to enhance cell 
proliferation through the activation of GSK-3β and subsequent stabilisation of cyclin D1 to drive 
cell cycle progression in both non-small cell lung cancer and ER- breast cancer310,387. Therefore, 
the upregulation of PSAT1 by IKKε could, at least theoretically, directly support cell growth in 
aerobic glycolysis like-conditions. The lack of basal PSAT1 expression initially suggests the MDA-
MB-453 PSAT1 cell line model would be useful for investigating the role of the enzyme and its 
IKKε-dependent phosphorylation in the regulation of cyclin D1 protein stability in breast cancer. 
However, as has already been discussed, the lack of basal expression of PSAT1 might prevent 
any proliferative effect of the enzyme being detected in this context (see 3.10). Therefore, to 
evaluate the effect that IKKε could have on PSAT1’s ability to regulate cyclin D1 stability, it would 
be more useful to begin by examining the effect of modulation of kinase expression on cyclin D1 
protein levels in both Flp-In 293 cells and breast cancer cell lines, particularly in ZR-75-1 and 
T47D breast cancer cells, where siRNA-mediated suppression of IKKε is known to both 
significantly reduce proliferative rates (see 3.1.2) and PSAT1 expression (see 4.1 and 4.2). 
Considering the ways that serine biosynthesis and specifically PSAT1 upregulation can therefore 
directly contribute to cancer progression, it certainly seems unlikely that IKKε would consistently 
upregulate PSAT1 in breast cancer cell lines without it providing any growth advantage to those 
cells. From a broader perspective than the possible investigative paths mentioned above, it 
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would first be useful to address the importance of PSAT1 in the growth of IKKε-expressing breast 
cancers, using siRNA to suppress enzyme expression and evaluating the effects on proliferation 
using the IncuCyte. This would help to identify which of these cell lines are dependent on PSAT1 
for proliferation and therefore indicate whether upregulation of the enzyme by IKKε could be 
supporting their growth or not. Further to this, the importance of PSAT1 in transformation and 
tumour formation could also be assessed, using the doxycycline-inducible MDA-MB-453 PSAT1 
mutant cell lines to examine the importance of PSAT1 in anchorage independent growth via a 
soft agar colony formation assay, or in tumour formation via a xenograft mouse model. It is 
worth keeping in mind however, that MDA-MB-453 cells are already transformed independently 
of PSAT1. Therefore, an alternative, perhaps more appropriate approach to investigate the role 
of PSAT1 in transformation might be to ectopically express the enzyme in untransformed breast 
epithelial cell line MCF-10A. Previous experiments have demonstrated that ectopic expression 
of PHGDH in MCF-10A is sufficient to induce transformed characteristics in the cells when grown 
in 3D cultures304. It would be interesting to evaluate the effect of PSAT1 expression in MCF-10A 
cells using a similar model. Additionally, introduction of both wt and S>A or S>E PSAT1 mutant 
variants into MCF-10A cells might also allow evaluation of the importance of the PSAT1 Ser331 
phosphosite in transformation.  
Alternatively, the HA1E-M model could be utilised to assess the role of the serine biosynthesis 
enzymes in IKKε-mediated transformation. When characterising IKKε as a transforming kinase, 
Boehm et al. used HA1E-M cells expressing a myristoylated form of IKKε (myr-IKKε) in a soft agar 
colony formation assay. They found that cells expressing myr-IKKε formed significantly more and 
larger colonies than cells expressing an empty vector195. Whilst the HA1E-M F-IKKε cells used 
within this project failed to show any significant regulation of the serine biosynthesis enzymes 
by the kinase, this was concluded to be a result of an inactive kinase within those cells. 
Therefore, it is possible that the constitutively active IKKε variant in the HA1E-M myr-IKKε cell 
line would exhibit kinase-mediated regulation of the serine biosynthesis enzymes. Should this 
be the case, the soft agar colony formation assay could be repeated whilst using siRNA, shRNA 
or even CRISPR/Cas9 technology to suppress PSAT1 expression. This would therefore allow 
evaluation of the importance of the enzyme and de novo serine synthesis in IKKε-mediated 
transformation. 
Considering the main function of the serine biosynthesis pathway is to synthesise serine, it 
would also be interesting to investigate how modulation of IKKε expression would affect the 
ability of cell lines to grow in serine-free medium. Cell lines like MDA-MB-468 demonstrate both 
an IKKε-dependent regulation of the expression of serine biosynthesis enzymes and an ability to 
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maintain more or less equivalent growth rate in whole medium and serine-free medium. 
Evaluation of how suppression of IKKε would impact the ability of such cell lines to grow in serine 
deprived conditions would indicate whether the regulation of the pathway by the kinase would 
provide cells with a greater ability to tolerate nutrient-depleted conditions common to the 
regions of tumours with poor vasculature. In line with the SBPs ability to protect against redox 
imbalance, it would also be beneficial to evaluate levels of ROS in IKKε-expressing Flp-In 293 
cells or breast cancer cells where a kinase-dependent reduction in OCR is observed. This would 
help determine whether inhibition of the mitochondria by IKKε is sufficient to induce redox 
imbalance. Following this, measuring ROS levels whilst suppressing PSAT1 could help 
demonstrate whether the regulation of serine biosynthesis levels protected breast cancer cells 
from oxidative stress induced by IKKε-mediated inhibition of the mitochondria.  
Whilst it may prove difficult to untangle the involvement of IKKε-mediated regulation of serine 
biosynthesis from the other mechanisms by which the kinase has already been demonstrated to 
support cell growth (see 1.3.3) such experiments could at least begin to indicate whether the 
regulation of metabolism is simply a side effect of IKKε expression in cancer, or is a driving force 
of disease progression in its own right. 
Does regulation of serine biosynthesis contribute to other functions of IKKε? 
It would also be beneficial to investigate potential roles for the pathway in other known 
functions of the kinase without cancer in mind. For instance, it has been previously mentioned 
how regulation of metabolism by the kinase is crucial for the activation of dendritic cells106. Even 
though the mechanism of metabolic regulation in dendritic cells appears to be different to the 
one described here, it is worth questioning whether the kinase still regulates serine biosynthesis 
in this context and, if so, what role the pathway might play in the process of antigen 
presentation.  
Furthermore, is the pathway important for the primary function of the kinase in the activation 
of the innate immune response? Findings detailed in chapter 4 demonstrated that activation of 
IRF3 and IFNβ signalling is dispensable for the regulation of serine biosynthesis enzymes by the 
kinase, but it would be interesting to investigate whether the enzymes themselves are important 
for the proper activation of IFNβ signalling. Excitingly, preliminary data as offered some 
indication that serine biosynthesis might be important for endocrine IFNβ signalling. An 
experiment was performed in which conditioned medium was collected from doxycycline-
treated Flp-In 293 HA-IKKε cells in which siRNA was used to suppress PSAT1. The conditioned 
medium was then applied to T47D cells and the resulting activation of IFNβ signalling was 
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evaluated via western blotting (see supplementary materials: Figure 7.4). Medium from Flp-In 
293 HA-IKKε cells where PSAT1 was present induced activation of the JAK/STAT signalling 
pathway, a key downstream pathway in IFNβ signalling to a greater extent than medium from 
cells where PSAT1 had been suppressed, as measured by western blot analysis of STAT1 Tyr701 
phosphorylation. This indicates that the serine biosynthesis pathway is important for proper 
secretion of IFNβ from cells upon the activation of innate immune signalling and suggests a role 
for the pathway in IKKε-mediated cytokine secretion. It is possible that the role of serine in 
protein and nucleotide production makes the serine biosynthesis pathway important for initial 
cytokine production, but the exact reason for this phenotype remains to be determined. 
Irrespectively, this finding raises fascinating questions with potentially wide-reaching 
implications. Is the serine biosynthesis pathway important for all mechanisms of cytokine 
secretion? Would suppression of the pathway limit the effectiveness of an immune response? 
Further investigation would be prudent to better clarify the role of the pathway in cytokine 
production and secretion to help to begin to answer such questions. 
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6.3 Therapeutic implications 
 
Should upregulation of serine biosynthesis be found to be important for IKKε-driven 
oncogenesis, it presents a handful of exciting potential therapeutic targets.  
Glutaminase inhibitors 
Focussing on the fact that elevated serine biosynthesis could facilitate glutamine anaplerosis in 
the face of IKKε’s inhibitory effect on mitochondrial utilisation of glucose-derived carbon, it 
would be unsurprising if IKKε-expressing cells were using glutamine to a greater extent and were 
dependent on it for the replenishment of TCA cycle metabolites. Glutamine consumption could 
be easily measured in IKKε-expressing cells and future experiments can also examine the growth 
of these cells in glutamine-deprived medium to help to elucidate whether the kinase induces 
glutamine dependency in addition to inhibiting mitochondrial utilisation of glucose-derived 
carbon. Should a hypothesis of IKKε-mediated increased glutamine consumption and 
dependency be proven correct, this would suggest that cells expressing the kinase could be more 
susceptible to inhibition of glutaminolysis, using glutaminase inhibitors such as BPTES, which has 
previously shown efficacy in Myc-driven, glutamine-dependent tumours409-412; CB-839, which 
has demonstrated efficacy in triple negative breast cancer cell lines413 and is currently in clinical 
trials; or recently described UPGL00004, which has been reported to exhibit greater stability 
than BPTES and CB-839 and has been demonstrated to inhibit the proliferation of triple negative 
breast cancer cell lines and suppress xenograft breast tumour formation in a mouse model414,415.  
If IKKε-driven cancers do indeed exhibit glutamine dependency, then inhibition of glutaminolysis 
through the targeted inhibition of glutaminase could be expected to be therapeutically effective. 
The sensitivity of IKKε-expressing cell lines to such an inhibitor could be easily assessed using a 
combination of the IncuCyte system and IC50 assays, which would help indicate the therapeutic 
potential of inhibiting glutaminolysis to target IKKε-driven cancer.  
Importantly, the fact that glutaminase inhibitors like CB-839 and UPGL00004 have demonstrated 
efficacy in triple-negative breast cancer cell lines is particularly interesting413,414. This is the same 
subtype where it is indicated that PSAT1 Ser331 phosphorylation occurs to a greater extent345. 
Whilst data described in chapter 3 indicates that the phosphorylation of PSAT1 Ser331 has no 
discernible effect on its enzymatic activity, the possibility that, despite the findings of the flux 
analysis, phosphorylation of the enzyme can in fact still impact its activity has been extensively 
discussed, as has the possibility that the phosphorylation might alter substrate affinity (see 
3.10). It is possible that phosphorylation of PSAT1 Ser331 improves its ability to metabolise 
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glutamate in some way. Should this be the case, this suggests that, in cancers where IKKε might 
be phosphorylating PSAT1, the kinase might be inducing glutamine dependency and such 
cancers would benefit from inhibition of glutaminolysis.  
Whilst glutaminase inhibitors would successfully inhibit TCA cycle anaplerosis, the use of such 
compounds would not necessarily prevent the serine biosynthesis pathway from continuing to 
support tumour growth via its contribution to one-carbon metabolism. Therefore, rather than 
targeting glutaminolysis individually, targeting of the serine biosynthesis pathway as a whole 
would likely prove more successful, negatively impacting glutamine anaplerosis whilst 
simultaneously removing a major mechanism by which cells adapt to oxidative stress. The 
combined inhibition of these 2 major cancer-promoting processes could therefore potentially 
be highly effective.  
PHGDH inhibitors 
Several therapeutic strategies for the targeting of serine biosynthesis in cancer exist. Firstly, 
several groups have recently described the identification of novel PHGDH inhibitors. Mullarky et 
al. identified CBR-5884, from a screen of 800,000 compounds, as a non-competitive inhibitor of 
PHGDH and demonstrated both its ability to inhibit serine biosynthesis and its efficacy in 
inhibiting the proliferation of breast cancer cells with high serine biosynthesis activity416. Almost 
simultaneously, a separate study from Pacold et al. described the inhibitors NCT-502 and NCT-
503. These inhibitors were shown to be effective at inhibiting serine biosynthesis both in vitro 
in breast cancer cell lines and in vivo in xenograft mouse models. Surprisingly, NCT-503 was 
found to not only impact the incorporation of glucose-derived carbon into the one-carbon pool, 
but also reduced the incorporation of carbon from exogenous serine as well, indicating that 
inhibition of the serine biosynthesis pathway also prevented the proper utilisation of exogenous 
serine363. Shortly following, a third study, from Wang et al. reported the discovery of PHGDH 
specific allosteric inhibitors PKUMDL-WQ-2101 and PKUMDL-WQ-2201, demonstrating strong 
efficacy of these compounds in PHGDH-dependent breast cancer cell lines like MDA-MB-468 and 
in xenograft mouse models using the same cell line417.  
These inhibitors stand as promising compounds both for the investigation of the role of the 
serine biosynthesis pathway in new contexts and for the treatment of cancers with upregulated 
serine biosynthesis activity. For example, CBR-5884 has been used to demonstrate the 
importance of serine biosynthesis in protecting Müller glial cells against oxidative stress418 and 
NCT-503 has been used to reduce pulmonary fibrosis in an in vivo mouse model419, 
demonstrating a previously uncharacterised role for the pathway in the retina and in lung tissue 
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scarring respectively. Furthermore, in clear cell renal cell carcinoma, where constitutive 
activation of HIF is an important part of the pathogenesis of the disease, PHGDH and serine 
biosynthesis has been shown to allow cells to overcome HIF2α inhibition and both NCT-503 and 
CBR-5884 have been demonstrated to reduce cellular proliferation and xenograft formation in 
clear cell renal cell carcinomas which are growing independently of HIF2α420. 
No inhibitors of either PSAT1 or PSPH have been described to date, possibly due to the fact that, 
compared to PHGDH, roles for PSAT1 and PSPH in cancer have only recently been identified, but 
also because, unlike production of NADH by PHGDH, PSAT1 and PSPH do not produce easily 
measurable by-products, which makes it difficult to measure the activity of these enzymes. 
Nevertheless, inhibition of PHGDH should sufficiently cut off the progression of serine 
biosynthesis at its earliest stage, thereby reducing substrate availability for PSAT1 and thus 
preventing it from contributing to glutaminolysis. Indeed, as previously mentioned, suppression 
of PHGDH expression has been shown to dramatically reduce the incorporation of glutamine-
derived α-KG into the TCA cycle in cells with elevated serine biosynthesis activity305, 
demonstrating how chemical inhibition of PHGDH could effectively inhibit glutamine 
anaplerosis.  
However, whilst inhibition of serine production can block the contribution of glucose derived 
carbon to the one-carbon pool, this does not necessarily block the involvement of exogenous 
serine. Despite findings from Pacold et al. suggesting that inhibition of de novo serine synthesis 
can also reduce the donation of carbon derived from exogenous serine to the one-carbon 
pool363, it is not clear whether this inhibition would be enough to completely diminish the redox 
balancing effect of serine for patient treatment. Therefore, strategies inhibiting serine 
catabolism must also be examined.  
Dietary serine deprivation 
To counter the involvement of exogenous serine, a serine and glycine-free diet has been 
proposed, designed to limit the SHMT-mediated conversion between the 2 amino acids. This 
strategy would obviously prove particularly effective in targeting cells lacking the ability to 
synthesise serine intracellularly, such as breast tumours like the one from which the MDA-MB-
231 cell line was derived. These cells lack PHGDH expression and, as demonstrated in chapter 3, 
cannot survive in serine-free medium due to an inability to synthesise their own serine. A serine 
and glycine-free diet has been shown to be effective in p53-deficient xenograft tumour models, 
where removal of exogenous serine forces cells to rely on serine biosynthesis and lack of p53 
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prevents remodelling of metabolism to upregulate serine biosynthesis, thereby preventing cells 
from adapting to serine deprivation and triggering cell death as a result of oxidative stress421.  
Importantly however, deprivation of serine has also recently been shown to induce 
mitochondrial fragmentation attributable to disruption of mitochondrial fatty acid 
metabolism422. Whilst this experiment was performed in HCT-116 colon cancer cells, therefore 
demonstrating the potential efficacy of such a diet in cancer, it is currently unclear what effect 
serine deprivation would have on normal cells and whether the systemic nature of restricting 
serine in the diet would have potentially damaging off-target effects. Indeed, dietary serine 
deprivation has recently been shown to limit effector T-cell expansion in a mouse model infected 
by Listeria monocytogenes423 indicating that a serine/glycine free diet might have a negative 
impact on a patient’s immune capabilities. Furthermore, dietary intervention has also been 
shown to be less successful in circumstances where other factors can upregulate serine 
biosynthesis enzymes. For example, although efficacy has been observed in Myc-driven 
lymphomas, where serine biosynthesis enzymes could theoretically be upregulated, dietary 
restriction of serine and glycine was concurrently found to be less effective in K-Ras-driven 
pancreatic and intestinal mouse tumour models, where activation of K-Ras was explicitly shown 
to upregulate serine biosynthesis enzymes322. This calls into question the effectiveness of such 
a therapeutic regime in IKKε-driven breast cancers, where the kinase can upregulate serine 
biosynthesis enzymes and increase pathway activity.  
In this circumstance, specifically blocking serine catabolism through the use of SHMT inhibitors 
may be a more suitable option. Along this line, several SHMT inhibitors have been characterised. 
Antifolate drug lometrexol has been found to inhibit the enzyme424 and recent years have seen 
the emergence of small molecule inhibitors of both SHMT isoforms. In 2015, compounds capable 
of targeting the protozoan isoforms of the enzyme were described425 and subsequently, human 
SHMT isoform inhibitors have been described using the protozoan inhibitors as a basis426. These 
compounds have been demonstrated to inhibit HCT-116 cell growth and were found to be 
particularly effective inhibitors of diffuse large B-cell lymphoma proliferation 
Combining diet and inhibitor 
Again, whilst these strategies targeting serine catabolism are promising, there is an issue. Whilst 
pharmaceutical inhibition of PHGDH with a small molecule inhibitor fails to account for the 
involvement of exogenous serine in tumour development, the removal of exogenous serine and 
inhibition of serine catabolism fail to account for the fact that unhindered serine biosynthesis 
can still contribute to glutamine anaplerosis. For this reason, it seems that the most effective 
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therapeutic strategy would involve a combination approach, in which a serine-free diet is 
maintained, depriving cells of exogenous serine and forcing them to rely on the serine 
biosynthesis pathway, whilst simultaneous treatment with a targeted inhibitor of PHGDH is 
administered to completely block de novo serine production within cells. This combined therapy 
should successfully prevent the donation of one-carbon units to redox balancing mechanisms, 
whilst also inhibiting glutamine anaplerosis. The resulting redox imbalance and reduction in TCA 
cycle biosynthetic activity should be sufficiently toxic in cancer cells.  
Indeed, the efficacy of a combination of a serine/glycine free diet with metformin, an inhibitor 
of cellular anti-oxidant response, has already been evaluated and shown to have additive 
efficacy over either therapy alone322, demonstrating how the  effectiveness of a serine and 
glycine-free diet can be improved in combination with a secondary compound. It would be 
important to recognise that maintaining a serine-free diet would also put healthy cells into a 
state of dependency on de novo serine biosynthesis, therefore the delivery mechanism of the 
inhibitor drug should be carefully considered, as systemic delivery would likely result in 
substantial off target toxicity, but if that obstacle can be overcome, a combined therapy could 
prove to be a highly successful and useful tool for the targeting of both IKKε-driven tumours, as 
well as other tumours with elevated serine biosynthesis. 
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6.4 Concluding remarks 
 
Ultimately, this thesis has taken the observation that IKKε regulates overall cellular metabolism 
and serine biosynthesis and identified a two-pronged regulatory mechanism by which the 
enzymes of the serine biosynthesis pathway can be regulated in breast cancer. Firstly, by direct 
substrate phosphorylation of PSAT1, the second pathway enzyme, to promote protein stability 
and possibly support proliferation and secondly, transcriptional upregulation of the enzymes by 
ATF4 following IKKε-mediated inhibition of the mitochondria. The importance of the serine 
biosynthesis pathway in cancer, particularly breast cancer, suggests that the upregulation of the 
pathway by IKKε might be a key part of IKKε’s oncogenic activities. Whilst work remains to be 
done before conclusions can be properly drawn on this hypothesis, it is important to recognise 
that if IKKε-mediated regulation of serine biosynthesis is indeed important for IKKε-driven breast 
cancer progression, the fact that both regulatory mechanisms are independent of IKKε’s 
canonical roles in NF-κB and IFNβ signalling promises to open up exciting new therapeutic 
options for the treatment of IKKε-driven breast cancer. 
 
 
Figure 6.1 – Summary scheme. Schematic demonstrating the model proposed by this thesis, by which IKKε regulates 
intracellular metabolism. IKKε is proposed to directly inhibit mitochondrial function in cells in which it is expressed 
via inhibition of mitochondrial substrate uptake through the inhibitory phosphorylation of PDHA1. The subsequent 
inhibition of the pyruvate dehydrogenase complex (PDHC) reduces mitochondrial oxygen consumption, respiratory 
TCA cycle function and mitochondrial membrane potential. Consequently, a mitochondria-to-nucleus retrograde 
signalling pathway, mediated by the transcription factor ATF4, upregulates the expression of genes associated with 
the serine biosynthesis pathway to promote cell adaptation to mitochondrial inhibition. In parallel, IKKε directly 
regulates the serine biosynthesis pathway through the direct phosphorylation of PSAT1, leading to increased protein 
stability which potentially supports increased pathway activity. Together, these two parallel mechanisms serve to 
promote a cellular metabolic state akin to aerobic glycolysis (decreased mitochondrial respiration and increased 
biosynthesis in the form of serine production). This represents a previously uncharacterised function of the kinase 
and a potential mechanism by which the kinase could support breast cancer progression.
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For IncuCyte-based growth tracking and measurement of cell confluency as a readout for cell 
proliferation, different processing definitions within the Zoom 2016B software (Essen 
Bioscience) were set up for each cell line. The parameters for each cell line’s processing 
definition are detailed in Table 7.1 
 
Table 7.1 – Processing definition parameters for the measurement of cell line confluency using the IncuCyte Zoom 
and Zoom 2016B software. 
   Filters 
  Cleanup Area (µm2) Eccentricity 
Cell Line 
Segmentation 
Adjustment 
Hole Fill 
(µm2) 
Adjust Size 
(pixels) Min Max Min Max 
Flp-In 293 0.9 0 0 500 - - - 
ZR-75-1 1.1 100 0 350 - - - 
T47D 0.9 0 0 300 - - 0.9915 
MDA-MB-453 1.1 200 0 400 - - - 
MDA-MB-468 1.4 50 -1 200 - - - 
MDA-MB-231 0.8 0 0 300 - - 0.9900 
MCF7 1 0 0 300 - - 0.9950 
Cal120 1.2 0 0 300 - - 0.9900 
HCC1143 2 0 0 250 - - 0.9900 
SUM44 1.1 0 0 100 - - - 
 
 
Heatmap and hierarchical clustering of significantly changing metabolite concentrations in 
doxycycline-treated Flp-In 293 HA-GFP and Flp-In 293 HA-IKKε cells or in IKBKE-targeting siRNA-
transfected T47D cells as measured by labelled metabolite analysis using U-13C6-D-glucose are 
presented in Figures 3.5 and 3.6 respectively. The raw data from Dr Christian Frezza and Dr Sofia 
De Costa (MRC Cancer Unit, Cambridge, UK) and full details of total metabolite and 13C- or 15N-
labelled metabolite concentrations detected in the experiments are provided in Table 7.2, 
included on the CD provided with this thesis. 
Similarly, KEGGS pathway enrichment analysis of significantly differentially phosphorylated 
peptides in HA-IKKε-expressing Flp-In 293 cell clones compared to HA-GFP-expressing cells was 
presented in Figure 3.8 as a summary of the phosphoproteomic analysis and the selection of 
metabolic proteins with significantly altered phosphorylation status was presented in Table 3.2.  
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Figure 7.1 – Representative OCR curves demonstrating effect of siRNA-mediated suppression of IKKε on the 
mitochondrial respiratory profile of breast cancer cell lines. (A) Schematic demonstrating a breakdown of how the 
Seahorse XFe96 and addition of Oligomycin, FCCP, Rotenone and Antimycin A facilitates the characterisation of the 
mitochondrial respiratory profile of cellular samples, measuring basal, coupled, uncoupled and reserved respiratory 
capacities. (B-J) Representative OCR curves from single experiments examining the effect of siRNA-mediated 
suppression of IKKε on the mitochondrial respiratory profiles of ZR-75-1 (B), T47D (C), MDA-MB-453 (D), MDA-MB-
468 (E), MDA-MB-231 (F), MCF7 (G), Cal120 (H), HCC1143 (I) and SUM44 (J) cells. Repeated OCR measurements were 
taken at 5-minute intervals, mean ± SD. Compiled data is presented in Figure 5.2, displaying data from at least 3 
independent experiments per cell line. 
A B 
C D 
E F 
G H 
I J 
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The raw phosphoproteomic analysis data, detailing the log fold changes in phosphorylation of 
detected proteins and a heat map of significant changes, provided by Dr Pedro Cutillas and Dr 
Vinothini Rajeeve (Barts Cancer Institute, London, UK) following mass spectrometry analysis, is 
provided in Table 7.3 on the included CD. 
The comparison of the relative enrichment of 15N-serine and 15N-glycine between Flp-In 293 cells 
expressing HA-PSAT1 wt, HA-PSAT1 S>A or HA-PSAT1 S>E was presented in Figure 3.18. The raw 
data from Dr Christian Frezza and Dr Sofia De Costa, detailing the peak area values from mass 
spectrometry analysis of total and labelled metabolites in three independent repeats are 
provided in Tables 7.4, 7.5 and 7.6 for each repeat. These tables are provided on the included 
CD. In each file, a sheet with the raw peak area data for each detected metabolite is 
accompanied by a sheet analysing the percentage of the total metabolite pool comprised by the 
detected 15N-labelled ions for each metabolite. 
In chapter 5, experiments were described in which the Seahorse XFe96 was used to measure 
IKKε-mediated changes in cellular oxygen consumption rate (OCR). The data presented in Figure 
5.2 shows the effect of siRNA-mediated suppression of IKKε on basal OCR in a panel of 9 breast 
cancer cell lines. Analysis of cellular OCR using the Seahorse XFe96 uses various drugs to fully 
map the mitochondrial functional capacity; Oligomycin inhibits ATP synthase to characterise 
coupled oxygen consumption associated with mitochondrial ATP production, Carbonyl cyanide 
4-(trifluoromethoxy)phenylhydrazone (FCCP) is an uncoupling agent that allows measurement 
of the maximum and reserve respiratory capacity of the mitochondria, and Rotenone and 
Antimycin A completely block the mitochondrial electron transport chain, thereby completely 
crashing mitochondrial respiratory capacity to determine the non-mitochondrial oxygen 
consumption of the cell (Figure 7.1 A). Although only the effect of IKKε on basal OCR was of 
interest for this project, the effect of the kinase on these other metabolic parameters was 
measured at the same time by Dr Ruoyan Xu. Representative Seahorse XFe96 OCR profile curves 
generated by Dr Xu are provided in Figure 7.1 B-J).  
Also in chapter 5, ATF4-targeting siRNA was used to suppress expression of the transcription 
factor in Flp-In 293 cells and a panel of breast cancer cell lines (see 5.4 and 5.5). In breast cancer 
cell lines, suppression of ATF4 significantly downregulated PHGDH and PSAT1 in ZR-75-1, T47D 
and MDA-MB-468 cell lines and PSPH in T47D cells (Figure 5.8 A). To validate that this broad 
effect was not limited to just the selected cell lines tested, the effect of ATF4 knockdown on 
serine biosynthesis enzyme transcription was validated in all other cell lines of the panel. As with 
ZR-75-1, T47D and MDA-MB-468, ATF4 knockdown substantially downregulated PHGDH, PSAT1 
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and PSPH mRNA levels in all other breast cancer cell lines within the panel with the exception of 
Cal120 and HCC1143, where PSPH mRNA levels were unaffected by knockdown of the 
transcription factor (Figure 7.2). The same broad effect was observed at the protein level in 
select cell lines (Figure 5.8 B) and this was also validated in all other cell lines of the panel. Similar 
to analysis of enzyme transcription, ATF4 knockdown consistently suppressed PHGDH, PSAT1 
and PSPH proteins in every cell line (Figure 7.3). Together these data demonstrated ATF4’s status 
as a master regulator of serine biosynthesis enzyme expression in breast cancer.  
Notably, whilst effective knockdown of the transcription factor was validated via western blot 
in Flp-In 293 cells (Figure 5.7 A), attempts to validate the knockdown in the breast cancer cell 
line panel were less successful (Figure 7.3). Many cell lines appeared to give different unspecific 
bands when using the ATF4 antibody used in Flp-In 293 cells (Cell Signaling - #11815). A band 
corresponding to the size of band detected and validated in Flp-In 293 cells was detected in 
MDA-MB-453, MDA-MB-468 and MDA-MB-231 cells where ATF4-targeting siRNA effectively 
depleted the band intensity, confirming knockdown of the transcription factor, but other cell 
lines exhibited varying patterns of unspecific antibody binding, making it difficult to conclude on 
the effectiveness of knockdown in these contexts. qRT-PCR analysis of ATF4 mRNA levels would 
help resolve this issue, but given that PHGDH, PSAT1 and PSPH are all confirmed downstream 
transcriptional targets of ATF4, corresponding suppression of the serine biosynthesis enzymes, 
which occurred in all cell lines transfected with ATF4-targeting siRNA was accepted as sufficient 
indication of effective suppression of the transcription factor in breast cancer cells. 
  
 
Figure 7.2 – siRNA-mediated ATF4 suppression broadly regulates serine biosynthesis enzyme transcription in all 
breast cancer cell lines. qRT-PCR analysis of PHGDH, PSAT1 and PSPH mRNA levels in breast cancer cell lines 
transfected with a single ATF4-targeting siRNA oligo or a non-targeting control oligo at a final concentration of 50 nM 
for 72 hours. mRNA levels are presented as relative fold changes versus control siRNA transfected cells and normalised 
to ACTB (β-Actin) mRNA levels. Suppression of ATF4 recurrently suppressed PHGDH and PSAT1 mRNA levels in all cell 
lines tested, and frequently suppressed PSPH mRNA levels. n=1 independent experiment per cell line. 
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Finally, chapter 6 discussed the potential role for IKKε-mediated regulation of serine 
biosynthesis in the kinases primary function activating IRF3 and IFNβ signalling in the innate 
immune system (see 6.2). A preliminary experiment investigating such a role was performed 
which indicated that the serine biosynthesis pathway is important for IKKε-mediated IFNβ 
secretion. Medium conditioned by Flp-In 293 cells expressing HA-IKKε in which PSAT1 was 
suppressed using siRNA (Figure 7.4 A) was applied to T47D cells and the activation of the IFNβ-
mediated JAK/STAT signalling pathway was evaluated in receiving cells by western blot analysis 
of STAT1 Tyr701 phosphorylation (Figure 7.4 B). It was observed that medium conditioned by 
Flp-In 293 HA-IKKε cells where PSAT1 was suppressed induced less STAT1 Tyr 701 
phosphorylation than medium conditioned by cells in which PSAT1 was still expressed, indicating 
that the serine biosynthesis pathway is important for IKKε-mediated IFNβ secretion and that 
upregulation of the serine biosynthesis pathway by IKKε might serve to support cytokine 
secretion in the innate immune system. 
 
 
Figure 7.3 – siRNA-mediated suppression of ATF4 reduces serine biosynthesis enzyme protein levels in all breast 
cancer cell lines. Western blot of ATF4 and serine biosynthesis enzyme protein levels following transfection of 
indicated breast cancer cell lines with ATF4-targeting siRNA. Indicated breast cancer cell lines were transfected with 
a pool of 4 ATF4-targeting siRNA oligos, to suppress the transcription factor, or a single non-targeting control oligo to 
a final concentration of 50 nM for 72 hours. Effective knockdown was only validated in MDA-MB-453, MDA-MB-468 
and MDA-MB-231 cell lines, being the only cell lines to clearly display bands corresponding to the band validated in 
Flp-In 293 cells (Figure 5.7 A), but transfection of siRNA resulted in reduction in PHGDH, PSAT1 and PSPH protein 
levels in most cell lines, indicative of ATF4 knockdown. Vinculin is shown as a loading control. 
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Figure 7.4 – Serine biosynthesis enzyme PSAT1 is important for IKKε-mediated IFNβ secretion. Analysis of STAT1 
Tyr701 (Y701) phosphorylation in T47D cells following application of conditioned medium for 2 hours. (A) Medium 
was conditioned for 16 hours by Flp-In 293 HA-IKKε cells transfected with a pool of 4 PSAT1-targeting siRNA oligos or 
a single non-targeting control oligo to a final concentration of 50 nM for 72 hours and treated with 50 ng/ml 
doxycycline for the final 16 hours. PSAT1 suppression in medium-conditioning cells is demonstrated by western 
blotting. (B) Conditioned medium was filtered through a 0.22 µm pore-size filter and applied to receiving T47D cells 
for 2 hours. Activation of IFNβ-mediated JAK/STAT signalling was evaluated by western blot detection of relative 
STAT1 Tyr701 phosphorylation levels. Suppression of PSAT1 in medium-conditioning cells substantially reduced the 
phosphorylation of STAT1 Tyr701 in receiving cells, indicating that the enzyme is important for proper IFNβ secretion. 
Vinculin is shown as a loading control. 
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